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Abstract
Mapping a Functional Cancer Genome Atlas
Ryan Dz-Wei Chow
2021
Over the past decade, tremendous resources have been devoted to sequencing the
genomes of patient cancers. But while the molecular portraits of cancer are now in higher
resolution than ever before, it has remained challenging to derive clinically actionable insights
from these data. A central issue is that tumor genome sequencing often can only tell us what
mutations are present, not which ones are functionally important. Towards this end, I sought to
build an improved toolkit for functional cancer genomics, with the overarching goal of creating
experimental platforms that are practical, scalable, and flexible.
In collaboration with several colleagues, I developed autochthonous AAV-mediated
CRISPR/Cas9 screens to quantitatively interrogate the contributions of specific mutations
towards tumorigenesis in the murine liver and brain. Importantly, this experimental system is
well suited for studies in tumor immunology, as it preserves the native tissue microenvironment
in the context of an immunocompetent host. I subsequently utilized the AAV-CRISPR tumor
model to further investigate the genetic determinants of response to PD-1 checkpoint blockade
immunotherapy. In addition to recovering known regulators of immunotherapy response, I found
that deficiency of the histone modifier KMT2D sensitizes diverse tumor types to immune
checkpoint blockade by promoting the generation of immunogenic neoantigens.
I further sought to comprehensively dissect the genetic regulation of anti-tumor immunity
responses from both sides of the aisle, interrogating the immune cells that react against tumors as
well as the cancer cells themselves. As a foray into the roles of noncoding RNAs in anti-tumor
immunity, I mapped the landscape of sdRNAs expressed in human cancers, finding numerous

transcripts that are associated with signatures of anti-tumor immune infiltration and survival
across multiple cancer types. My colleagues and I also performed genome-scale CRISPR screens
in primary CD8+ T cells to identify genetic regulators of T cell degranulation and tumor
infiltration. These studies identified that Dhx37 knockout enhances NF-kB signaling in CD8+ T
cells, leading to enhanced anti-tumor function in vitro and in vivo.
Using genome-scale CRISPR activation (CRISPRa) screens, I further sought to identify
genes that could promote tumorigenesis in immunocompetent hosts when overexpressed. In
pursuing this line of study, my colleagues and I unexpectedly found that CRISPRa could be
repurposed as a new immunotherapy modality, an approach we termed MAEGI (multiplexed
activation of endogenous genes as immunotherapy). By delivering CRISPRa systems through
AAVs to forcibly overexpress mutated genes directly in tumors, MAEGI enhanced immune
recognition of tumor neoantigens, thereby eliciting robust and long-lasting anti-tumor immunity.
The CRISPR screens employed in the aforementioned studies have an important
limitation, however. Cancers arise from the sequential acquisition of genetic or epigenetic
alterations, and the unique combinations of these alterations can interact in complex ways. To
more precisely study these genetic interactions, I established a strategy for in vivo combinatorial
knockout screening using massively-parallel CRISPR-Cas12a array profiling. I applied this
technique to pinpoint mutation combinations that synergistically promote lung metastasis,
demonstrating the utility of this technology to dissect genetic interactions in cancer. Finally, I
devised a method for programmable sequential mutagenesis by combining CRISPR-Cas12a
arrays with Cre recombination cassettes. I employed this approach to model the stepwise
acquisition of resistance mutations against immunotherapy, thus providing a controlled
experimental system for exploring strategies to overcome immunotherapy resistance.
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§ CHAPTER 1: INTRODUCTION

1.1: Genetic mutations as the substrate of evolution
As the blueprint for cellular life, DNA encodes all of the necessary information for an
organism to develop and thrive. One would naturally expect the DNA replication machinery in
cells to be of exquisitely high fidelity. Indeed, whereas DNA polymerases exhibit an intrinsic
error rate of about 10-4 to 10-5 in vitro, a variety of safeguarding mechanisms exist in living cells
to correct the vast majority of these errors, leading to error rates on the order of 10-8 to 10-10 1.
Even still, with the diploid human genome clocking in at 6.2 x 109 bases 2,3, there is a nontrivial
probability that an error will occur each time a cell divides and replicates its DNA 4.
The consequences of these errors, known as mutations, can span the entire gamut from
inconsequential to lethal. In the setting of harsh competition for limited resources and mates,
individuals with mutations that provide a competitive advantage will be better equipped to
survive and reproduce, leading to further propagation of their genetic alterations. For instance,
mutations in the HMGA2 gene led to a progressive decrease in the beak sizes of Galapagos
finches, enabling unrestricted access to new food sources that were free of competition from
larger-beaked finches 5. Over millennia, the accumulation of such genetic changes can eventually
lead to the generation of entirely new species. Mutations are therefore the substrate of evolution.
However, the core processes underlying evolution – the accumulation of genetic changes
that lead to increased fitness in a competitive environment – also operate at smaller scales than
the level of organisms and species 6. Evolutionary forces analogously act on individual cells in
the timescale of human lifetimes, where cells that have acquired advantageous mutations can
gradually outcompete their neighboring cells

7–9

. Recent studies utilizing genetic sequencing in

noncancerous tissues have revealed dramatic age-associated expansions of discrete cell clones
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carrying mutations in cancer-associated genes 10–18. With the acquisition of additional mutations
that bypass the normal safeguards against uncontrolled cell growth, malignant transformation
may eventually occur 19–21.
The process of progressive mutation and selection accelerates as the cancer grows, in
large part due to the genomic instability that is characteristic of many cancers

22

. The tumor-

initiating cell clone subsequently develops into a mosaic of different mutant subclones that
compete for limited nutrients and space. Surveillance by the immune system exerts yet another
layer of selection, pruning tumor cells with mutant proteins that are readily recognized and
eliminated by immune cells 23–25. In turn, the process of metastasis imposes yet another selective
pressure and evolutionary bottleneck, with only a fraction of the tumor cells successfully seeding
distant tissues and establishing new tumors

26,27

. As a consequence of these varied selective

forces, the evolutionary history of a cancer is not a single trajectory, but rather an amalgamation
of several branches from a common initiating cell 28,29.

1.2: Genetic sequencing to reveal the evolutionary trajectories of tumors
Tumor profiling studies have illuminated the molecular underpinnings of cancer at a
higher resolution than ever before. Large-scale consortium projects such as PCAWG (PanCancer Analysis of Whole Genomes), TRACERx (TRAcking Cancer Evolution through
therapy), ICGC (International Cancer Genome Consortium), and TCGA (The Cancer Genome
Atlas) have devoted tremendous resources towards sequencing the genomes of diverse cancer
types

30–33

. By examining recurrently mutated genes across thousands of patients, multiple

studies have converged on a core set of oncogenes (genes that promote tumorigenesis) and tumor
suppressors (genes that normally restrain tumorigenesis) that drive the development of cancer
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21,34–36

. For instance, gain-of-function mutations in KRAS are nearly universal in patients with

pancreatic adenocarcinoma

37

and present in about one third of patients with lung

adenocarcinoma 38. But while the identification of recurrently mutated genes can be informative
for revealing the signaling pathways that are implicated in a cancer type, it is essential to
remember that each individual tumor possesses its own unique repertoire of mutations, which
can interact in complex ways to shape the behavior of the tumor 39,40.
By analyzing the mutations present in a tumor (particularly when multiple regions of a
tumor are sampled), it is possible to generate detailed reconstructions of tumor evolutionary
paths, to the point of mapping out the order of specific mutational events that led to the current
state of the tumor

41–46

. An intriguing observation from these tumor evolutionary studies is that

mutations in certain genes consistently occur early in cancer progression, while others tend to
occur at later stages

47,48

. This concept of stereotypical, sequential mutation acquisition was set

forth many decades earlier by Bert Vogelstein and colleagues, in the context of stepwise colon
tumorigenesis

49

. Nevertheless, the order of mutation acquisition can still vary widely from

patient to patient, potentially with clinically relevant consequences

42,50–52

. Thus, it is crucial to

study not just the combinations of mutations that are present in tumors, but also their
evolutionary trajectories – that is, the “permutations” of mutations, analogous to the mathematic
concepts of combinations versus permutations.

1.3: Impact of tumor sequencing on clinical decision-making
One important application of the increasingly widespread use of tumor sequencing is that
patients with certain drug-targetable mutations can be readily stratified for precision-targeted
therapies

53

. While many cancer-causing mutations are not directly amenable to pharmacologic

manipulation 54, a subset of cancer-driving genes can be inhibited in a relatively precise manner,
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often through small molecule drugs or blocking antibodies
therapies include blocking antibodies against HER2/ERBB2

55–61
62

. Key examples of targeted

, a growth receptor which is

highly expressed in a subset of breast cancer patients, and small molecule inhibitors of EGFR 63¸
a growth receptor that becomes aberrantly active in a fraction of lung cancer patients. Since
normal tissues are anticipated to be less dependent on the mutant signaling pathways that drive
the growth of the tumor, targeted therapies can severely cripple the growth of the cancer while
leaving normal cells mostly unaffected 64.
However, many challenges still remain before the promise of precision cancer therapy
can be realized. Chief among these is the limited number of cancer drivers that currently have
effective drugs. In fact, it was recently estimated that only 8.33% of all U.S. cancer patients are
eligible for a genome-targeted therapy; 4.90% of all patients ultimately derive clinical benefit
from such therapies 65. Though the limited reach of genome-targeted therapies certainly reflects
the difficulty of drug discovery, part of the issue stems from the “me-too” mentality that is
pervasive in the pharmaceutical industry 66. Rather than pursuing novel drug targets that would
be impactful in a new subset of patients that do not currently benefit from genome-targeted
therapies, pharmaceutical companies frequently devote their resources towards developing drugs
against established targets that already have an effective therapy available.
Another major issue with precision cancer therapies is the phenomenon of acquired
resistance. While precision therapies have remarkably high response rates initially, the vast
majority of patients will eventually develop resistance and progress within months of initiating
treatment

67,68

. In light of the above discussion recontextualizing cancer as an evolutionary

process, these observations of acquired drug resistance are not particularly surprising. Given
sufficient mutational substrate (i.e. a genetically diverse pool of tumor cells), applying the strong
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selective pressure of a genome-targeted therapy will inevitably lead to the selective outgrowth of
tumor cells that have acquired mechanisms to bypass their dependency on the targeted cancer
driver 69,70.
Finally, although a tumor may have mutations in a known cancer driver, the functional
significance of a specific mutation is often unclear. While certain amino acid residues are
recurrently mutated across patients and have robust experimental data to support their pathogenic
nature, many other mutations occur in less well-studied regions of a protein, leading to
ambiguities in their interpretation

71,72

. Accordingly, such mutations are termed “variants of

uncertain significance” in the sequencing reports returned by cancer sequencing panels 73. In the
event that a patient has a variant of uncertain significance in a targetable cancer gene, current
guidelines from the American College of Medical Genetics advise against altering clinical
management 73.

1.4: Experimental approaches to interrogate genetic drivers of cancer
Recent technological advances have provided new approaches for experimentally
interrogating novel or poorly characterized mutations in a highly scalable manner. In particular,
clustered regularly interspersed palindromic repeat (CRISPR) technologies have enabled
programmable editing of the genome

74–77

. CRISPR-associated protein 9 (Cas9) is an enzyme

that generates double-stranded breaks on specific DNA sites when complexed with targeting
RNAs called guide RNAs (gRNAs). As these double-stranded DNA breaks are usually repaired
in an error-prone manner, Cas9 endonuclease activity will often lead to the generation of
mutations in the targeted DNA locus

78

. Importantly, the targeting specificity of Cas9 is

10

essentially determined by the sequence of the gRNA; by changing the sequence of the gRNA,
Cas9 can be retargeted to generate mutations in different areas of the genome.
Given the modular and programmable nature of CRISPR systems, they are amenable to
high-throughput screening approaches. By introducing a library of gRNAs targeting distinct
genomic sites into cells expressing Cas9, it is possible to simultaneously assay thousands of
distinct mutations in a single experiment

79,80

. This approach, termed CRISPR screening, has

been applied to diverse research questions, ranging from genetic suppressors of tumor metastasis
81

and drivers of cancer therapy resistance 82, to host regulators of SARS-CoV-2 entry 83–86.
A number of studies have utilized CRISPR-based genome editing strategies to precisely

install thousands of different variants in parallel, facilitating functional studies of variants of
uncertain significance. For instance, by coupling CRISPR mutagenesis with massively-parallel
homology-directed repair, thousands of distinct mutations in the cancer predisposition gene
BRCA1 have been characterized, an important step towards comprehensive interpretation of the
BRCA1 variants observed in patients, many of which are currently classified as variants of
uncertain significance

87,88

. Similarly, by pairing CRISPR machinery with nucleotide base

modifiers, studies have investigated the functional impact of variants in several DNA damage
repair genes, an important step towards identifying specific patients that are more likely to
benefit from targeted cancer therapies such as olaparib 89,90.
Here, I summarize my efforts utilizing CRISPR technologies to better understand the
interactions among genes, cancers, and the immune system.
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Opinion

Cancer CRISPR Screens In Vivo
Ryan D. Chow1,2,3 and Sidi Chen1,2,3,4,5,6,7,*
Clustered regularly interspaced short palindromic repeats (CRISPR) screening
is a powerful toolset for investigating diverse biological processes. Most
CRISPR screens to date have been performed with in vitro cultures or cellular
transplant models. To interrogate cancer in animal models that more closely
recapitulate the human disease, autochthonous direct in vivo CRISPR screens
have recently been developed that can identify causative drivers in the native
tissue microenvironment. By empowering multiplexed mutagenesis in fully
immunocompetent animals, direct in vivo CRISPR screens enable the rapid
generation of patient-speciﬁc avatars that can guide precision medicine. This
Opinion article discusses the current status of in vivo CRISPR screens in cancer
and offers perspectives on future applications.

Highlights
In vivo CRISPR screens enable highthroughput interrogation of complex
processes in cancer.
Direct autochthonous models recapitulate human cancer by maintaining
the native microenvironment.
Direct in vivo CRISPR technologies
can empower patient-speciﬁc cancer
modeling for precision medicine.

CRISPR-Mediated Genome Editing Meets the Complexity of the Cancer
Genome
Over the past decade, tremendous efforts have been devoted to proﬁling patient cancers.
Multi-institutional consortia such as The Cancer Genome Atlas have now proﬁled over 10 000
tumors, generating petabytes of high-dimensional data that illuminate the complexities of
several cancer types [1]. Although the molecular portraits of cancer are now in higher resolution
than ever before, the path to clinical translation for many cancer types remains largely
unexplored.
The central issue is that cancer genomics can inform what mutations are present, but has
limited power to indicate which ones are functionally important [2,3]. Individual tumors often
have hundreds, if not thousands, of molecular aberrations. While some of these alterations are
found in well-established oncogenes (see Glossary) and tumor suppressors, many novel
aberrations occur in previously uncharacterized or even unannotated regions, making it difﬁcult
to reliably discern whether they are actually driving the progression of a given cancer. Furthermore, different patients can present with unique combinations of these various mutations that
can drastically inﬂuence a cancer’s growth pattern, tendency to metastasize, and susceptibility
to therapy.
CRISPR-mediated genome editing has become a powerful tool in cancer biology due to its
programmability and ﬂexibility [4]. In addition to its canonical use for targeted gene knockouts
[5,6], CRISPR has been reengineered for a variety of purposes including transcriptional
activation [7,8], transcriptional repression [9], histone modiﬁcation [10], base editing [11,12],
DNA methylation [13–15], and genome architecture manipulation [16]. Following in the footsteps of RNAi screens, the modularity of CRISPR has naturally lent itself to high-throughput
screening approaches [17]. By designing custom libraries of single-guide RNAs (sgRNAs),
one can simultaneously screen large collections of genomic elements (coding genes, regulatory
elements such as enhancers, noncoding RNAs, or other noncoding features) in a given
biological context [18]. Here we review the development and application of in vivo CRISPR
screens.

Trends in Cancer, May 2018, Vol. 4, No. 5
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In Vivo CRISPR Screens to Interrogate the Complexities of Cancer

CRISPR screens were ﬁrst developed by using pooled sgRNA libraries to target all annotated
genes in the human genome [19,20]. High-throughput, and particularly genome-wide, CRISPR
screens combine the power of forward genetics and reverse genetics. Such approaches offer
an unbiased yet precisely targeted method of identifying genes that contribute to a phenotype,
such as cancer progression. Compared with random mutagenesis, CRISPR screens use
customized sgRNA libraries, while simultaneously preserving the ‘randomness’ during selection. Unlike RNAi screens, CRISPR generates precise mutations or complete knockouts
instead of partial gene knockdown or silencing, which has been shown to facilitate higher
between-construct concordance and lower off-target rates [21,22]. CRISPR screens have thus
become the state-of-the-art approach for the discovery of genetic drivers and phenotypic
modulators in many biological contexts.
In cancer, CRISPR screens have been performed to identify genes involved in a wide variety of
processes [23], including regulators of drug resistance [24–28], synergistic and synthetic
lethal interactions [29,30], regulators of PD-L1 expression [31], and essential genes [32–34]
(Figure 1). While in vitro studies are valuable for identifying cell-intrinsic properties of cancer cells
and potential therapeutic windows (Figure 2A, Key Figure), they cannot address problems
involving complex interactions between multiple cell types that reﬂect the bona ﬁde nature of
cancer as an organ, instead of a collection of isolated tumor cells [35]. As highlighted by recent
advances in cancer immunotherapy, the microenvironmental milieu is constantly engaged in
conversation with tumor cells, with signiﬁcant clinical consequences [36–40]. To more faithfully

TransformaƟon

Metastasis

Angiogenesis

Drug resistance

In vivo CRISPR
screening

Genome instability

Metabolic
reprogramming

Immune evasion

InhibiƟon
of apoptosis

Figure 1. Functional Cancer Genomics with In Vivo Clustered Regularly Interspaced Short Palindromic
Repeats (CRISPR) Screening. In vivo CRISPR screening is a powerful, ﬂexible tool to dissect important processes in
cancer. Genome-wide CRISPR screens have illuminated novel regulators of metastasis, malignant transformation,
immune evasion, and drug resistance. Moving forward, in vivo CRISPR screens may improve our understanding of other
processes, such as angiogenesis, genome instability, and metabolic programming.
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Glossarya
Cas9: an endonuclease that is
directed to speciﬁc sites in the
genome by CRISPR spacers, where
it induces double-stranded breaks in
the target DNA.
Clustered regularly interspaced
short palindromic repeats
(CRISPR): segments of prokaryotic
DNA containing short repetitions of
base sequences. Each repetition is
followed by short segments of
‘spacer DNA’ from previous
exposures to a bacteriophage virus
or plasmid. The CRISPR–Cas system
is a prokaryotic immune system that
confers resistance to foreign genetic
elements such as those present in
plasmids and phages. Cas proteins
use the CRISPR spacers to
recognize and cut these exogenous
genetic elements in a manner
analogous to RNAi in eukaryotic
organisms. By delivering the Cas9
nuclease and appropriate guide
RNAs (gRNAs) into a cell, the cell’s
genome can be cut at a desired
location, allowing existing genes to
be removed and/or new ones added.
CRISPR-associated
endonuclease in Prevotella and
Francisella 1 (Cpf1): also known as
Cas12a; a CRISPR-guided
endonuclease that can be utilized for
targeted genome editing in diverse
species. Unlike Cas9, Cpf1 does not
require a tracrRNA for DNA
cleavage, and has the capability to
autonomously process crRNA
arrays.
CRISPR RNA (crRNA): the short
RNA sequence that directly guides
CRISPR nucleases to target sites in
the genome that is independent of
the scaffold sequence present in fulllength sgRNAs.
dCas9: catalytically dead Cas9
nuclease that cannot generate
double-stranded breaks in DNA;
commonly tethered to other proteins
to enable programmable targeting of
the tethered enzymes.
Double-knockout CRISPR screen:
a CRISPR screen in which two
genes are simultaneously
interrogated rather than a single
gene.
Driver mutation: a mutation that is
causally implicated in oncogenesis. It
confers a growth advantage on the

recapitulate the human disease for enhanced translational accuracy, it is essential to investigate
these phenomena in vivo where cancers can develop in the context of a tissue
microenvironment.
To date, virtually all in vivo CRISPR screens have aimed to investigate phenotypes of cancer,
directly demonstrating the power and simplicity of this technology in oncology. The ﬁrst in vivo
CRISPR screen investigated annotated genes in the mammalian genome and their potential to
promote tumor growth and metastasis when mutagenized [41]. In this study, the authors
introduced a genome-wide sgRNA library into a non-metastatic cancer cell line. The poolmutagenized cell library was then subcutaneously transplanted into the back skin of nude mice
and monitored for metastasis to the lung. By sequencing the sgRNAs present in the metastases, the authors identiﬁed and subsequently validated a panel of hits from the initial screen that
functionally drove lung metastasis. Multiple in vivo CRISPR screens have since been performed
to identify tumor suppressors [42–44], oncogenes [45], synthetically lethal genes [46], and
regulators of cancer immunotherapy, in both two-cell type (2-CT) coculture systems [47] and
transplant tumor models [48], among others. A common thread in these studies is their twostep workﬂow: the sgRNA library is ﬁrst introduced to cells in culture, followed by transplantation into mice to assess phenotypes in vivo. After a selection phase (e.g., expression of a
reporter, outgrowth of a tumor, resistance to therapy), the cells are sequenced to identify
enriched and/or depleted sgRNAs (Figure 2B).

Limitations of Transplant-Based In Vivo CRISPR Screens
By virtue of them having a microenvironment, compared with in vitro CRISPR screens, it is
anticipated that in vivo studies more faithfully model carcinogenesis as it occurs in humans.
However, transplant-based in vivo screens have signiﬁcant limitations. First, introducing large
numbers of cancer cells into mice clearly does not resemble the normal process of tumorigenesis. Second, transplantations are commonly performed subcutaneously, rather than
orthotopically in the relevant organs. In addition, immunodeﬁcient mice are often used to
promote the grafting efﬁciency of the mutagenized cell library, limiting the applicability of these
models for investigation of cancer–immune interactions. Moreover, the engraftment efﬁciency
of transferred cells can vary from cell line to cell line and from host to host. Furthermore, there
exist multiple cellular bottlenecks of tumor evolution in vivo, such as the circulation limit during
the metastasis cascade. Finally, the native organ microenvironment places numerous constraints on transplanted cells even in orthotopic settings. These limitations can affect the
preclinical utility of cancer-cell transplant-based in vivo CRISPR screens.

Direct In Vivo CRISPR Screens to More Faithfully Recapitulate Human
Cancers
To better model the natural context of cancer as it occurs in humans, the following features can
provide guiding principles for more accurate in vivo CRISPR screens in cancer: (i) the tumors
being modeled derive from the endogenous target tissue; (ii) the immune system remains intact;
and (iii) the corresponding tissue microenvironment is preserved. These challenges can be
overcome by directly mutagenizing target tissues in vivo rather than using a transplant
approach.
A number of studies have demonstrated efﬁcient CRISPR-mediated in vivo mutagenesis
directly at the target organ site. In the liver, hydrodynamic injection of sgRNA-containing
plasmids into the tail veins of Cas9 mice was sufﬁcient to induce multiplexed mutagenesis
in hepatocytes [49], while in the lung intratracheal delivery of sgRNA-carrying lentiviruses was
able to induce mutagenesis directly in Cas9-expressing lung epithelial cells [50]. Through the
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use of adenoassociated viruses (AAVs), direct mutagenesis in the mouse brain was also shown
to be feasible [51]. Because Cas9 and other genome-editing RNA-guided nucleases (RGNs)
are large proteins, generation of Cas9 transgenic animals [52–54] simpliﬁes the delivery of
CRISPR components and facilitates direct in vivo mutagenesis.
Extending on these direct in vivo CRISPR techniques, autochthonous CRISPR screens of
varying scales have now been performed in a few organ systems (Figure 2C). Hydrodynamic
injection of plasmids with sgRNA and Cas9 expression cassettes ﬂanked by Sleeping Beauty
(SB) inverted repeats, along with a SB-transposase vector, has been utilized to screen ten
sgRNAs for their ability to induce CRISPR-mediated tumorigenesis in a KrasG12D-sensitized
mouse liver [55]. As another approach, lentiviral pools were utilized to screen 11 sgRNAs for
their ability to drive lung tumorigenesis in Cre-driven Cas9 mice [56]. Finally, stereotaxic delivery
of an AAV sgRNA library directly into the mouse brain efﬁciently induced glioblastomas that
recapitulate the pathologic features of the human disease [57], which enabled direct and
quantitative assessment of the tumorigenicity of 280 sgRNAs targeting 56 genes. Of note, the
relative mutant frequencies of these genes in the AAV-based model signiﬁcantly correlated with
the mutant frequencies observed in human glioblastoma cohorts. Delivery of AAV-CRISPR
sgRNA pools intravenously followed by captured sequencing using customized probesets [57]
or molecular inversion probe sequencing [58] allows autochthonous mapping of causative
functional variants directly in the targeted genomic loci, as demonstrated in the brain [57] and
liver [58]. Facilitated by the high efﬁciency of AAV-mediated transduction, various signiﬁcantly
co-occurring pairs were identiﬁed, thereby pinpointing synergistic driver pairs in tumorigenesis.
Nevertheless, direct in vivo approaches have their share of limitations. Optimal technical
parameters that are easily achievable in in vitro or cell line transplant settings (i.e., ‘indirect’
in vivo), such as library size, coverage, and multiplicity of infection (MOI), are much more
challenging with a direct in vivo approach. Therefore, the size of a sgRNA library must be
controlled to ensure adequate coverage in vivo. With an oversized library, random sampling
errors from low viral transduction rates will invariably lead to many spurious positive and
negative ‘hits’. Other key constraints include the number of tumor-originating cells in the
native organ, the accessibility of such cells due to the complexity of cellular organization in
endogenous tissues, uncharacterized or unknown cell–cell interactions, the viral transduction
efﬁciency, and immune rejection. To this end, it is worth noting that AAV-mediated approaches
have the major advantage of higher-titer, higher direct in vivo transduction efﬁciencies and
provoke minimal immune reactions [57], thus enabling larger CRISPR libraries to be screened
more efﬁciently in an autochthonous setting. Since AAVs usually do not integrate into the
genome, the relative abundance of sgRNAs in tumors cannot be ascertained by sgRNA
cassette sequencing as is commonly done for lentivirus-based screens. Instead, the AAVmediated approach requires capture sequencing of the sgRNA target regions to functionally
extract the mutational signatures of the tumors.

Direct In Vivo CRISPR Pooled Mutagenesis Technologies for Precision
Medicine
With further improvements and modiﬁcations, we envision that direct in vivo CRISPR screens
could be widely applied in multiple facets of precision medicine. Using the genomic information
from a patient’s tumor, a personalized CRISPR library could be readily designed to directly
generate disease mimics, or cancers encompassing the same set of mutations, to investigate
the behaviors of those mutations in mice (Figure 3A). As a proof of principle, high-titer AAV
libraries have been successfully used to infect single cells at high MOI in vivo, leading to
genetically complex tumors with several mutations [57,58]. This ‘mouse avatar’ approach
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would enable robust enumeration of the tumorigenic potential of each mutation present in a
patient’s tumor. More importantly, rapid generation of such disease mimics allows robust
therapeutic testing of approved or novel treatments in genetically matched tumors. This type of
approach could then be utilized to predict the outcomes of treatments in patients and
potentially anticipate which speciﬁc tumors would exhibit sensitivity or resistance to
chemo-, targeted, or immune therapies, and thus be leveraged for prioritization of therapies.
It was recently demonstrated that patient-derived tumor xenografts (PDXs) adopt evolutionary
courses divergent from the human primary tumor [59]. While this effect is likely to be due in large
part to intrinsic differences between mice and humans, a key contributing factor may lie in the
method, as xenografts generally require immunodeﬁcient hosts for successful engraftment.
The development and application of humanized mice [60] has helped to bridge this gap in part,
particularly with regard to innate immunity, although complete humanization of the full immune
system remains to be seen. By contrast, direct in vivo models are designed to originate from the
autochthonous tissue site in fully immunocompetent mice. For these reasons, we anticipate
that direct in vivo CRISPR screens will more faithfully recapitulate the behavior and evolutionary
course of human cancers.
Intratumoral heterogeneity is increasingly being recognized as an important feature of human
cancers, potentially contributing to drug resistance and relapse [61,62]. In addition to cell-type
heterogeneity and microenvironmental variations, intratumoral heterogeneity is often characterized by distinct subclonal mutation signatures that differentially inﬂuence cellular behavior
[63]. To this end, AAV-mediated direct in vivo CRISPR screens are particularly well equipped to
model the heterogeneity present in human cancers. As demonstrated in the brain and liver,
AAV-CRISPR approaches can rapidly create genetically complex multiclonal tumors in individual mice [57,58]. This immense heterogeneity inherent to AAV-mediated CRISPR screens
could be exploited to investigate clonal dynamics in tumors, serving as a discovery platform for
how tumor subclones interact in controlled experimental settings in otherwise wild-type
organisms.

Outstanding Questions
Does a corresponding CRISPR-engineered mouse avatar mimic the drug
response of a genetically matched
tumor from a patient?
Can in vivo CRISPR screens be effectively leveraged for the study of complex genetic interactions in cancer?
How can direct in vivo CRISPR
screens be efﬁciently coupled with
other high-throughput approaches
such as single-cell sequencing and
high-content imaging to enable the
dissection of highly heterogeneous
cancers?
Can direct in vivo CRISPR screens be
utilized to deduce mutations that are
associated with sensitivity to immunotherapy as well as those conferring
primary or acquired resistance?
How can in vivo CRISPR screens be
effectively used in immune cells to
identify novel regulators of the tumor
microenvironment?

Concluding Remarks
Recent development and applications of in vivo CRISPR screens have showcased their power
for unbiased identiﬁcation of functional genetic elements. Particularly, direct in vivo CRISPR
screens offer a high-throughput strategy to interrogate candidate genes for their ability to drive
tumorigenesis from the autochthonous tissue. Unlike in vitro or transplant-based approaches,
direct in vivo CRISPR studies retain the endogenous tissue microenvironment and can be
performed in fully immunocompetent animals at high efﬁciency. Future studies will need to
explicitly evaluate whether direct in vivo CRISPR models better recapitulate human disease (see
Outstanding Questions). A key experiment would be to compare the in vivo evolutionary
trajectory of a primary patient tumor and the corresponding mouse avatar, with or without
therapeutic selection pressure.
The design philosophy behind most CRISPR screens is to study the effects of single-gene
mutations on a desired phenotype. However, many biological processes are driven by interactions between multiple genes. In cancer, the precise combinations of mutations in individual
autochthonous target organ site instead of in culture. Lentiviral and adenoassociated virus (AAV) approaches have both been successfully used for multiplexed direct in
vivo mutagenesis. Intravenous, intracranial, and intratracheal viral injections can drive tumorigenesis from the liver, brain, and lung, respectively. Since AAVs do not
integrate into the genome, capture sequencing must be performed to read out the results of the screen (i.e., highly abundant indel variants).

354

Trends in Cancer, May 2018, Vol. 4, No. 5

17

(A)

Personalized mouse avatars
Control
Drug 1

Tumpr burden

AAV

Drug 2
Drug 3
Time

PaƟent mutaƟon signatures

(B)

Personalized
sgRNA library

Direct in vivo
mouse avatar

PrioriƟzaƟon of
therapeuƟc candidates

Higher-dimensional screens
Double knockout
5v
3v
cr1 DR cr2
Triple knockout
3v
5v
cr1 DR cr2 DR cr3
n-tuple knockout
5v
cr1 DR cr2

DR crN

3v

Cpf1 mulƟ-KO
crRNA arrays
(C)

MulƟ-KO crRNA
array library

MulƟ-KO viral pool

Direct in vivo
mulƟ-KO screen

GeneraƟon and dissecƟon of tumor heterogeneity
AAV

DNA

RNA
MicroŇuidic chip

GeneraƟon of complex
autochthonous tumors
(D)

Single-cell analysis of
CRISPR-induced tumors

Capture sequencing
and RNA sequencing

In situ clonal analysis of autochthonous tumors

GeneraƟon of complex
autochthonous tumors

MulƟplexed in situ hybridizaƟon
for sgRNAs on tumor secƟons

In situ clonal analysis and
phenotype–genotype matching

(See figure legend at the bottom of the next page.)
Trends in Cancer, May 2018, Vol. 4, No. 5

18

355

tumors can lead to strikingly diverse behaviors, inﬂuencing tumor aggressiveness and clinical
response. In this regard, in vivo CRISPR screens can be readily applied to identify phenotypic
modulators on speciﬁc sensitized backgrounds. For instance, direct in vivo CRISPR screens
could be used to identify factors that inﬂuence the metastatic properties of mutant Kras-driven
tumors. An exciting avenue for further work is the adaptation of CRISPR-associated endonuclease in Prevotella and Francisella 1 (Cpf1) [64,65] to in vivo cancer modeling. Like
Cas9, the Cpf1 RGN can be used for precisely targeted genome editing, yet it has unique
multiplexing capabilities due to its independence from a tracrRNA [64,65]. Cpf1 has just begun
to emerge for higher-dimensional genetic screening of tumor growth and metastasis in
vivo [66] and remains to be more broadly applied for other aspects of cancer. The development
of this technology would enable high-dimensional screening of different mutation combinations, potentially leading to the identiﬁcation of novel synergistic or synthetically lethal genetic
interactions in cancer (Figure 3B).
Additionally, the application of dCas9-activator mice could enable the functional identiﬁcation
of oncogenes directly in vivo, providing an orthogonal perspective to preexisting tumor
suppressor screens [67]. Similarly, mice engineered to express CRISPR-targeted base editors
might offer an approach to screen speciﬁc point mutations that drive tumorigenesis from the
autochthonous tissue. It would also be interesting to apply single-cell RNA-seq (scRNA-seq) to
tumors generated by direct in vivo CRISPR screens [68–70]. Together, these technologies
would enable the creation and subsequent dissection of cancer heterogeneity at ultrahigh
resolution (Figure 3C). To further provide spatial information, multiplexed ﬂuorescent in situ
hybridization (MERFISH) [71] could potentially be adapted for the purpose of sequencing
sgRNA pools directly in tissue sections. These data would allow matched comparisons
between CRISPR-induced mutational signatures and histopathological phenotypes
(Figure 3D).
Finally, direct in vivo CRISPR screens can be readily applied for studies in cancer immunity, as
these models are fully functional in immunocompetent animals. A key question on the forefront
of immunooncology is to understand why only a fraction of patients respond to immunotherapy,
such as checkpoint inhibitors. Multiplexed AAV-CRISPR screens could be applied in the
context of checkpoint blockade to deduce which mutations are associated with sensitivity
to immunotherapy, as well as those conferring primary or acquired resistance. With further
technological development, direct in vivo screens on primary immune cell populations may also
become feasible, allowing high-throughput interrogation of factors that regulate immune
responses against tumors.
As these technologies continue to develop and mature, they can be adapted for personalized
cancer modeling and tumor driver proﬁling as well as the identiﬁcation of novel and relevant
therapeutic targets. Emerging new technologies such as direct in vivo CRISPR screens
continue to transform oncology discovery.
Figure 3. Applications and Extensions of Direct In Vivo Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screens. (A) Direct in
vivo CRISPR screens can be readily used to generate personalized mouse avatars. CRISPR libraries can be customized to the mutations present in a given patient’s
tumor. Following autochthonous mutagenesis, therapeutic candidates can be evaluated using the mouse avatars, informing clinical decision-making. (B) Higherdimensional screens (i.e., double, triple, n-tuple knockouts) using CRISPR-associated endonuclease in Prevotella and Francisella 1 (CRISPR–Cpf1) offer an elegant,
high-throughput approach to investigate genetic interactions. Such studies could uncover synergistic driver mutations and synthetically lethal combinations, which
may help to inform patient prognostication and to identify novel therapeutic vulnerabilities. (C) Direct in vivo CRISPR mutagenesis drives the formation of genetically
complex, multiclonal tumors. Coupled with single-cell capture sequencing and RNA-seq, direct in vivo CRISPR screens offer a powerful approach for the generation
and subsequent dissection of tumor heterogeneity. (D) In vivo CRISPR screens thus far have lacked spatial resolution, as single-guide RNA (sgRNA) sequencing and/or
capture sequencing is performed on genomic DNA extracted from dissociated cell suspensions. By combining direct in vivo CRISPR mutagenesis with multiplexed in
situ hybridization, it may be feasible to perform clonal analysis and phenotype–genotype matching on tissue sections.
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§ CHAPTER 2: DIRECT IN VIVO CRISPR SCREENS TO INTERROGATE TUMOR
SUPPRESSORS IN THE NATIVE TISSUE MICROENVIRONMENT

2.1: AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in
glioblastoma
In this study, we sought to adapt CRISPR screening to study genetic regulators of brain
tumorigenesis, directly in the native brain microenvironment

91

. Unlike other CRISPR screens

that involve genetic manipulation of cancer cell lines, followed by transplantation into recipient
mice, we hypothesized that an autochthonous in vivo CRISPR screen approach would more
faithfully mimic the process of tumorigenesis as it occurs in humans 92.
This line of investigation was initially conceived by my advisor Dr. Sidi Chen and our
collaborator Dr. Randall Platt. The study was performed in close collaboration with several
colleagues, including Chris Guzman, Guangchuan Wang, and Florian Schmidt. My primary role
in this study was the development of integrative analytical approaches to parse the complex
genetic sequencing data resulting from multiplexed CRISPR perturbations in the mouse brain. I
was also responsible for preparing the manuscript text and figures, together with Dr. Sidi Chen.
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AAV-mediated direct in vivo CRISPR screen identifies
functional suppressors in glioblastoma
Ryan D Chow1–3,17 , Christopher D Guzman1,2,4–6,17, Guangchuan Wang1,2,17, Florian Schmidt7,8,17,
Mark W Youngblood1,3,9,18, Lupeng Ye1,2,18, Youssef Errami1,2, Matthew B Dong1–3, Michael A Martinez1,2,
Sensen Zhang1,2, Paul Renauer1,2,4, Kaya Bilguvar1,10, Murat Gunel1,3,9,10, Phillip A Sharp11,12, Feng Zhang13,14,
Randall J Platt7,8 & Sidi Chen1–5,15,16
A causative understanding of genetic factors that regulate glioblastoma pathogenesis is of central importance. Here we developed
an adeno-associated virus–mediated, autochthonous genetic CRISPR screen in glioblastoma. Stereotaxic delivery of a virus
library targeting genes commonly mutated in human cancers into the brains of conditional-Cas9 mice resulted in tumors
that recapitulate human glioblastoma. Capture sequencing revealed diverse mutational profiles across tumors. The mutation
frequencies in mice correlated with those in two independent patient cohorts. Co-mutation analysis identified co-occurring driver
combinations such as B2m–Nf1, Mll3–Nf1 and Zc3h13–Rb1, which were subsequently validated using AAV minipools. Distinct
from Nf1-mutant tumors, Rb1-mutant tumors are undifferentiated and aberrantly express homeobox gene clusters. The addition
of Zc3h13 or Pten mutations altered the gene expression profiles of Rb1 mutants, rendering them more resistant to
temozolomide. Our study provides a functional landscape of gliomagenesis suppressors in vivo.
Glioblastoma (glioblastoma multiforme, GBM) is one of the deadliest cancers1. Current standard of care fails to cure the vast majority
of patients with this disease1–3, leaving them a median survival time
of 12.2 to 18.2 months4–7. The first genome atlas of GBM uncovered 453 validated nonsilent somatic mutations in 223 unique genes,
which were further refined to a total of 71 significantly mutated
genes (SMGs)8. Subsequent integrative genomic analyses revealed
comprehensive mutational landscapes in GBM, uncovering 21 to 75
SMGs across multiple different cohorts of patients8–13. Many of these
newly discovered genes have never been characterized in GBM; thus,
their functional roles in gliomagenesis remain largely unknown9,10.
Further complicating the interpretation of causality, mutations can
occur in novel combinations across individual patients, leading to
drastically different pathological features, prognoses and therapeutic
responses3,14–16. Thus, a deeper functional understanding of gliomagenesis and a quantitative measurement of phenotypic effects across
various combinations of drivers are both of central importance.
To date, no study of which we are aware has comprehensively and
combinatorially investigated which of the mutations identified in
human patients can indeed functionally drive GBM from normal cells
in the brain9. Key barriers include accurate delivery; precise genome

manipulation; efficient, massively parallel perturbation; and unbiased,
high-sensitivity quantitative readout, all of which must be achieved
simultaneously in the native brain microenvironment. We overcame
these challenges through an AAV-mediated direct in vivo autochthonous CRISPR screen in the brain of fully immunocompetent mice,
coupled with capture sequencing to achieve an ultradeep readout of
all functional variants. With these data, we identified multiple drivers
and co-occurring drivers, and subsequently we validated a set of such
combinations. Transcriptome profiling of mouse GBMs with precisely
controlled driver combinations revealed distinct expression signatures
between genotypes and in response to temozolomide (TMZ) treatment.
Using this approach, we mapped the functional landscape of GBM
suppressors in the native microenvironment of the mouse brain.
RESULTS
Stereotaxic injection of an AAV-CRISPR library drives robust
gliomagenesis
To directly test the function of putative SMGs in the mouse brain, we
set out to develop a direct in vivo autochthonous screening strategy,
which necessitates pooled mutagenesis of normal cells directly in the
native organ and subsequent deconvolution of mutant phenotypes.
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Figure 1 Autochthonous brain tumorigenesis induced by an AAV-mediated CRISPR library. (a) Schematics of direct in vivo AAV-CRISPR GBM
screen design. Top: AAV-mTSG library design, synthesis and production. Bottom: stereotaxic injection of AAV library and subsequent analysis. HPF,
hippocampus; LV, lateral ventricle. (b) MRI sections show brain tumors in AAV-mTSG injected mice but not in PBS- or AAV-vector-injected mice. Matching
sections are shown. Arrowheads indicate brain tumors. Scale bar, 5 mm. (c) MRI-based volumetric quantification of time-matched tumor size o s.e.m.
Two-tailed Welch’s t test, t17 = 2.62, P = 0.018, mTSG vs. vector or PBS (PBS, n = 2 mice; vector, n = 6; mTSG, n = 18). (d) Kaplan-Meier curves for
overall survival (OS) of mice injected with PBS (n = 5), AAV-vector (n = 24) or AAV-mTSG library (n = 56). OS for PBS and vector groups are both 100%;
the curves are dashed and slightly offset for visibility; dpi, days postinjection. Log-rank (LR) test, P < 2.20 × 10−16, mTSG vs. vector or PBS.

Because GBM is a disease originating from astrocytes, we generated
an AAV-CRISPR vector that encodes Cre recombinase under a glial
fibrillary acidic protein (GFAP) promoter, resulting in conditional
expression of Cas9 and GFP in astrocytes when injected into a
conditional Rosa26-LSL-Cas9-GFP mouse (LSL-Cas9 mouse; Online
Methods and Supplementary Fig. 1a). The vector also contains an
sgRNA targeting Trp53, initially intended to generate co-mutational
Trp53 knockouts that might exhibit genome instability and thus be
sensitized to tumorigenesis17–21. Local viral delivery into the brain
restricts the number of transducible cells, and cancer genomes
generally consist of dozens to hundreds of SMGs22–25. With these
considerations in mind, we designed an sgRNA library (a mousehomolog tumor suppressor gene (mTSG) library) targeting the mouse
homologs of top-ranked pan-cancer SMGs (Online Methods), plus
seven genes with essential molecular functions that we initially
considered as internal controls (Fig. 1a and Supplementary Table 1).
We pool-synthesized all sgRNAs, cloned them into the AAV-CRISPR
vector at greater than 100× coverage and deep-sequenced the library
to ensure all sgRNAs were fully covered and represented with a
tight lognormal distribution (99% within two orders of magnitude;
Fig. 1a and Supplementary Fig. 1b). We generated high-titer AAVs
(> 1 × 1012 viral particles per mL) from the plasmid that contained
the mTSG library (AAV-mTSG), as well as an empty vector (AAVvector; Fig. 1a). We then stereotaxically injected AAV-mTSG, AAVvector or phosphate-buffered saline (PBS) into the lateral ventricle
(n = 40 mice) or hippocampus (n = 16 mice) in the brains of LSLCas9 mice (Online Methods). We scanned the brains of these mice
by MRI 4 months postinjection and found that half (9 of 18 = 50%)
1330

of AAV-mTSG library-transduced animals had developed brain
tumors at this time point, whereas none of the AAV-vector-injected
or PBS-injected animals had tumors detectable by MRI (Fig. 1b,
Supplementary Fig. 1e and Supplementary Table 2). Quantification
of tumor volumes showed that AAV-mTSG-transduced mice had average tumor volumes of 70.2 mm3 (including animals without tumors)
or 140.3 mm3 (excluding animals without a tumor; two-tailed Welch’s
t test, t17 = 2.62, P = 0.018, all mTSG mice versus vector or PBS;
Fig. 1c and Supplementary Table 2). These data suggested that the
AAV-mTSG library robustly initiated tumorigenesis in the brains of
LSL-Cas9 mice.
We analyzed the overall survival of a cohort of LSL-Cas9 mice injected
with AAV-mTSG, AAV-vector or PBS (Supplementary Table 3).
In this screen, injection location did not affect the rate of tumor development as reflected by overall survival (two-sided Mann-Whitney U test
of hippocampus versus lateral ventricle, P = 0.054; Supplementary
Table 3) and thus were considered as one group (AAV-mTSG).
For the AAV-mTSG-transduced group, the first three animals
died 84 days postinjection, 90% of animals did not survive 176 d
and all 56 AAV-mTSG-transduced animals reached their survival
endpoints within 299 d (i.e., died or had a poor body condition score
(BCS) < 2 and thus were euthanized; Fig. 1d and Supplementary
Table 3). The median survival time of the AAV-mTSG group was 129 d
(95% confidence interval = 111–159 d; Fig. 1d), consistent with the
presence of tumors in half of the mice at 4 months by MRI. In contrast, all 24 AAV-vector-injected and all 5 PBS-injected animals survived the duration of the study and maintained good body condition
(BCS = 5; log-rank test, P < 2.2 × 10−16, mTSG versus vector or PBS;
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Figure 2 AAV-mTSG-induced brain tumors recapitulate pathological
features of GBM. (a) Top row: representative hematoxylin and eosin (H&E)stained brain sections from PBS-, AAV-vector- and AAV-mTSG-injected mice.
Arrowheads indicate brain tumors. Scale bar, 1 mm. Bottom four rows:
representative images of brain sections from PBS-, AAV-vectorand AAV-mTSG-injected mice stained with Cas9, GFP, GFAP and Ki67
immunohistochemistry (IHC). Cas9 IHC, red arrowheads indicate
Cas9+ cells; GFP IHC, red arrowheads indicate GFP+ cells; GFAP IHC,
representative GFAP+ astrocytes in PBS-, AAV-vector- and AAV-mTSGinjected mice (blue arrows), as well as representative cancer cells in
AAV-mTSG-injected mice (red arrowheads); Ki67 IHC, arrowheads indicate
representative proliferative cells, which are mostly in tumors (AAV-mTSG)
or scattered in tumor-adjacent brain regions (AAV-mTSG). Scale bar,
0.25 mm. (b) Quantification of tumor sizes o s.e.m. found in H&E brain
sections from PBS-, AAV-vector- and AAV-mTSG-injected mice. Two-tailed
Welch’s t test, t10 = 3.97, P = 0.003, mTSG vs. vector or PBS (PBS,
n = 3; vector, n = 7; mTSG, n = 11). (c) Representative higher
magnification H&E images showing pathological features of AAV-mTSGinduced brain tumors. Clockwise from top left: yellow arrowheads, giant
aneuploid cells with pleomorphic nuclei; blue arrows, endothelial cells
and angiogenesis; green arrows, hemorrhagic regions; black arrowheads,
necrotic regions. Similar features were observed in human GBM
patient sections from Yale glioma tissue bank (Supplementary Fig. 3).
Scale bar, 0.5 mm.

Targeted-capture sequencing reveals diverse mutational
profiles across tumors
Because AAVs usually do not integrate into the genome, direct
sequencing of the targeted regions was needed to determine which
mutations were in each tumor. To map the molecular landscape
of these brain tumors, we designed a probe set (mTSG-Amplicon
probes) covering the target regions of all library sgRNAs (Online
Methods and Supplementary Table 5). We used these probes to
perform targeted-capture sequencing for whole-brain and liver samples (as a control organ not being directly transduced) in a cohort of
NATURE NEUROSCIENCE

PBS

H&E

log-rank test, P = 1, vector versus PBS; Fig. 1d), suggesting Trp53
knockout alone does not lead to gliomagenesis. For the vast majority
(96.4% or 54 of 56) of AAV-mTSG-injected mice, macrocephaly was
observed at the survival endpoint (Supplementary Fig. 1c), suggesting that they had developed brain tumors. On the contrary, macrocephaly was observed in none of the AAV-vector-injected (0 of 24) or
PBS-injected (0 of 5) mice during the study (two-tailed Fisher’s exact
test, P < 1 × 105, mTSG versus vector or PBS; P = 1, vector versus PBS).
These data indicate that the brain tumors induced by the AAV-mTSG
viral library were typically lethal.
We observed that AAV-mTSG mice had GFP+ masses that
deformed their brains (100% or 6 of 6; Fig. 2a and Supplementary
Fig. 1d). AAV-vector mice had diffuse GFP+ regions in the brain
with fully normal morphology, suggesting that these were AAVtransduced cells expressing Cas9-GFP induced by Cre expression
and that had not become tumors (n = 2; Fig. 2a and Supplementary
Fig. 1d). PBS-injected or uninjected mice had no detectable GFP
expression even at long exposure (n = 3; Supplementary Fig. 1d).
Immunohistochemistry analysis showed that AAV-mTSG induced
tumors stained positive for Cas9 and GFP, consistent with them
having arisen from cells with activation of Cas9-GFP expression
(Fig. 2a). These tumors were also positive for GFAP, an astrocytic
marker (Fig. 2a), and for Ki67, a proliferation marker (Fig. 2a).
AAV-vector-transduced brains stained positive for Cas9 and GFP in
a subset of cells at the injection site (Fig. 2a), but these cells were not
proliferative (Ki67–) and did not have tumor-like pathological features
(Fig. 2a). PBS-injected mice stained negative for Cas9, GFP and Ki67
(Fig. 2a). Endpoint histopathology showed that the vast majority of
AAV-mTSG mice developed brain tumors (10 of 11 = 91%), whereas
none of the AAV-vector (0 of 7 = 0%) or PBS (0 of 3 = 0%) mice
had detectable tumors (two-tailed Fisher’s exact test: P = 0.0003,
mTSG versus vector; P = 0.011, mTSG versus PBS; Fig. 2a,b and
Supplementary Table 4). The mean endpoint tumor size, as measured
by area in brain sections, for the AAV-mTSG group was 13.9 mm 2,
compared to 0 mm2 in the two control groups (two-tailed Welch’s
t test, t10 = 3.97, P = 0.003, mTSG versus vector or PBS; Fig. 2b). Brain
tumors in AAV-mTSG mice showed pathological features of dense
cellular structure with proliferative spindles, nuclear aneuploidy
and pleomorphism, giant cells, regions of necrosis, angiogenesis and
hemorrhage (Fig. 2c), all of which are hallmark features of human
GBM2. Clinical features such as deformation of the brain, invasion,
loss of neuronal bundles, necrosis and hemorrhage were further corroborated by special staining methods such as Luxol fast blue–cresyl
violet, Wright Giemsa, Masson and Alcian blue periodic acid–Schiff
(Supplementary Fig. 2). We investigated a panel of human GBM
clinical samples from the Yale Brain Tumor Program (http://medicine.yale.edu/braintumorresearch/) and confirmed the observation
of these pathological features (Supplementary Fig. 3a,b). These data
suggest that the AAV-mTSG library-induced autochthonous brain
tumors recapitulated features of human GBM.

AAV-mTSG-, AAV-vector- and PBS-injected mice (n = 25, 3 and 4
brain samples, respectively; Supplementary Table 6). We captured
277 of 278 (99.6%) unique sgRNA target regions for all samples from
this experiment, the exception being Arid1a-sg5 (due to the unavailability of qualified regions in capture probe design). Across all 41
brain and liver samples, the average of mean coverage across all probes
was 19,405 o 180 s.e.m. (Supplementary Table 7). We analyzed the
mutant variants at the predicted cutting sites of the 277 successfully

25

1331

ARTICLES

c
Sum variant frequency (%)

Brain
Liver

10 20 30
mTSG brain 10
variant frequency (%)
Vector

mTSG

0

20 40 60 80
mTSG brain 24
variant frequency (%)

PBS

Vector

r

mTSG

e

PBS

mTSG brain

60
40

sgRNAs

20

25
09
14
08
03
24
11
12
13
15
18
19
22
23
04
17
02
20
10
16
21
05
06
01
07

15
10
5
0

–50 –40 –30 –20 –10 0
Deletion size (bp)

Mean variant
frequency (%)

r

0

80

0

2

Li
ve

0

4

log2 rpm

Sequence

6

Br
ai
n

mTSG brain 19

61.4
16.0
10.1
4.5
3.1
1.5
1.5
1.2
0.4
0.2
0.2
%

P = 6.03 10–5
8

Li
ve

100

P = 5.96  10–5

10

Br
ai
n

100

d

Rb1-sg2
Gata3-sg2
Trp53-sg4
Tgfbr2-sg3
Zc3h13-sg5
B2m-sg5
Pten-sg3
Mll2-sg3
Apc-sg1
Nf1-sg2
Bcor-sg1
Kdm5c-sg4
Rnf43-sg1
Smad4-sg1
Pcna-sg1
Cdkn1b-sg2
Ep300-sg2
Cdkn1b-sg4
Arid2-sg1
Arid2-sg2
Pten-sg4
Zc3h13-sg2
Notch1-sg1
Mll3-sg4
Setd2-sg4
Setd2-sg5
Rpl22-sg3
Mll2-sg5
Pik3r1-sg4
Mll3-sg3
Vhl-sg3
B2m-sg3
Npm1-sg5
Cic-sg3

Pik3r1-sg1
Smad4-sg1
Trp53-sg4
Pten-sg3
Atrx-sg3
Cdkn1b-sg2
Pik3r1-sg5
Mll2-sg3
Apc-sg1
Cdkn1b-sg3
Stag2-sg1
Pten-sg2
Stag2-sg3
B2m-sg5
Notch1-sg1
Map3k1-sg1

r

Vector PBS

3

Li
ve

b

PAM

Br
ai
n

Mll2 sgRNA 4

5

Mean variant frequency (%)

a

10

20 30 40 50
Insertion size (bp)

0 5 10 15 20
Mean variant
frequency (%)

10
8
6
4
2
0

Samples

Figure 3 Targeted-capture sequencing of sgRNA sites in AAV-mTSG-induced mouse GBM. (a) Indel variants observed at the genomic region targeted
by Mll2 sgRNA-4 in representative PBS-, AAV-vector- and AAV-mTSG-injected mouse brain samples. (b) Bar plots of variant frequencies in significantly
mutated sgRNA target regions from two representative AAV-mTSG-injected mouse brain samples. (c) Heat map of variant frequency across all targeted
capture samples (n = 41). Rows denote individual sgRNAs, while columns correspond to samples from mice stereotaxically injected with PBS,
AAV-vector or AAV-mTSG. The liver was considered an off-target organ and thus was used as a background control. Of note, one liver sample contains
modest levels of indels. Bar plots of the mean variant frequencies for each sgRNA (right, orange bars) and each sample (bottom, purple bars) are shown.
(d) Dot plot of mean variant frequency o s.e.m., grouped by treatment condition and tissue type. AAV-mTSG-injected brains had significantly higher
mean variant frequencies (2.087 o 0.429, n = 25) compared to vector (0.005 o 0.001, n = 3) or PBS (0.003 o 0.001, n = 4) injected brains
(two-tailed Welch’s t test, t24 = 4.85 and t24= 4.86, P = 6.03 × 10−5 and P = 5.96 × 10−5 for mTSG vs. vector and mTSG vs. PBS, respectively). In
AAV-mTSG-injected mice, mean variant frequencies of brains (2.087 o 0.429) were significantly higher than those of livers (0.309 o 0.261, n = 4;
t21.48 = 3.54, P = 0.002). (e) Indel size distribution for all filtered variants in each mTSG brain sample (n = 25).

captured unique sgRNAs across all samples (Online Methods and
Supplementary Table 8). At the single-sgRNA level, for example,
at the predicted cutting site of sgRNA-4 (sg4) in the Mll2 locus
(also known as Kmt2d), various insertions and deletions (indels)
were detected in AAV-mTSG but not AAV-vector or PBS mice
(Fig. 3a). As gliomagenesis takes multiple months in mice (Fig. 1d),
we surveyed three mice at 3.5 weeks postinjection and performed
capture sequencing to reveal early mutation profiles, as an approximation for in vivo sgRNA cutting efficiency (Supplementary Fig. 4a,b
and Supplementary Table 9). We found that even lower-efficiency
sgRNAs could end up being highly enriched in the process of tumorigenesis if the mutations they generated were strongly oncogenic
(Fig. 3b,c and Supplementary Fig. 4c). After removing germline variants, we determined whether the regions flanking each sgRNA target
site would be classified as significantly mutated sgRNA sites (SMSs;
1332

Online Methods and Supplementary Table 10). We implemented
a false-discovery rate (FDR) approach based on the 12 PBS/vector
samples (FDR < 1/12, or 8.33%) as well as a flat 5% variant-frequency
cutoff, and we confirmed that the choice of alternative cutoffs did
not alter the final SMS calls (Supplementary Fig. 6a). With these
criteria, we observed a diverse mutational landscape across most mice
that were capture-sequenced (Fig. 3b,c, Supplementary Fig. 5 and
Supplementary Table 11). As an example, one AAV-mTSG mouse
(mTSG brain 10) had significant mutations at the predicted cutting
sites of 16 of 277 captured gene-targeting sgRNAs in the mTSG library,
covering 12 significantly mutated genes (mouse SMGs, or mSMGs;
Fig. 3b). A second example (mTSG brain 24) showed a more diverse
mutational profile (34 SMSs for 26 mSMGs; Fig. 3b). The raw indel
frequencies were also summed across all detected variants for each
sgRNA target site in each sample, revealing a highly diverse pattern
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Figure 4 Integrative analysis of functional mutations in driving tumorigenesis. (a) Gene-level mutational landscape of AAV-mTSG induced primary
mouse GBM. Top: bar plots of the total number of significantly mutated genes identified in each AAV-mTSG sample. Center: tile chart depicting the
mutational landscape of primary brain samples from LSL-Cas9 mice injected with the AAV-mTSG library (n = 25), AAV-vector (n = 3) or PBS (n = 4).
Genes are grouped and colored according to their functional classifications as noted in the top-right legend. Right: bar plots of the percentage of GBM
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plots describing the types of indels observed in each sample, colored according to the bottom-right legend. (b,c) Comparative cancer genomics in GBM
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based on their functional classification (as in a). (b) Mutant frequencies in AAV-mTSG-treated mouse brain samples correlated with patients in the TCGA
GBM dataset (Pearson correlation R = 0.402, P = 0.002). (c) Mutant frequencies in AAV-mTSG-treated mouse brain samples correlated with patients in
the Yale glioma dataset (Yale Glio; Pearson correlation R = 0.318, P = 0.028).
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of variant frequencies generated by this sgRNA pool (Fig. 3c and
Supplementary Table 10). Comparing brain samples between treatment groups, AAV-mTSG-injected brains had significantly higher
mean variant frequencies (2.087 o 0.429 s.e.m., n = 25) compared to
vector-injected (0.005 o 0.001, n = 3) or PBS-injected (0.003 o 0.001,
n = 4) brains (two-tailed Welch’s t test, t24 = 4.85 and t24= 4.86,
P = 6.03 × 10−5 and P = 5.96 × 10−5 for mTSG versus vector and
mTSG versus PBS, respectively; Fig. 3c,d). Comparing targeted
versus nontargeted organs in AAV-mTSG-injected mice, the mean
variant frequencies of brains (2.087 o 0.429, n = 25) were significantly higher than those of livers (0.309 o 0.261, n = 4; two-tailed
Welch’s t test, t21.48 = 3.54, P = 0.002; Fig. 3c,d). The predominant
indels were deletions for virtually all samples, and most insertions
at SMS sites were 1 bp in size (Fig. 3e and Supplementary Table 8).
We identified distinct variant-frequency clusters of sgRNA-induced
indels that may serve as an approximation to the clonality of these
tumors (Online Methods). From this analysis, we found that only
2 of 22 of the brains had single-cluster tumors, with the majority
(20 of 22) comprising multiple clusters (Supplementary Fig. 6b).
These data demonstrate on-target, pooled genome editing in the
brain at a library scale, stochastically generating loss-of-function
mutations in native glial cells and priming them for selection
during gliomagenesis.
We next summarized the mutational data from the SMS level to the
mSMG level (Supplementary Table 12) and created an oncomap of
all mTSG brain samples (Fig. 4a). Across all mice with mSMGs (23
of 25), the detected variants were predominantly frameshift indels
(frameshift reads per total variant fraction > 60% in 22 of 23 mice)
compared to non-frameshift indels, splicing indels and intronic indels
(Fig. 4a, bottom panel). Unexpectedly, all 56 genes had at least one
associated SMS, and eight of them (Pten, Map2k4, B2m, Pcna, Cic,
Setd2, Gata3 and Apc) had all 5 SMSs (Fig. 4a). The mSMGs encode
functionally diverse categories of proteins, including cell death or cell
cycle regulators, immunological regulators, DNA repair and replication regulators, transcriptional repressors, epigenetic regulators,
transcription factors, cadherin type proteins and ubiquitin ligases
(Fig. 4a). Many of the genes were significantly mutated in 20% to 50%
of mice, with most of the epigenetic regulators in this range, such as
Arid1b, Mll3, Setd2, Mll2, Kdm5c, Kdm6a, Arid2 and Ctcf (Fig. 4a),
highlighting the role of epigenetic regulators in brain tumorigenesis.
Notably, B2m, a core component of major histocompatibility complex
(MHC) class I that is essential for antigen presentation, appeared as
the second most frequently mutated gene (19 of 25 = 76% of mice;
Fig. 4a). This analysis revealed, in a quantitative manner, the relative
phenotypic strength of specific loss-of-function mutations in driving
gliomagenesis in vivo.
We compared the mutational frequencies in mice to the variant frequencies of their homologous genes in human GBM with
their frequencies of nonsilent mutation and deletion. For these 56
genes, the mutation frequencies in mouse GBMs (an end-product
of pooled mutagenesis and in vivo gliomagenesis) significantly
correlated with the mutation frequencies in patients with GBM in
The Cancer Genome Atlas (TCGA) (Pearson correlation R = 0.402,
P = 2.1 × 10−3; Fig. 4b and Supplementary Table 13). To further
investigate this correlation, we used the clinical cancer genomics
data of a cohort of patients (Yale Glio) from the Yale Brain Tumor
Program, a source independent of TCGA (Supplementary Tables
14 and 15). Collectively, the mouse mutation frequencies again
significantly correlated with those in human patients (R = 0.318,
P = 0.0277; Fig. 4c and Supplementary Table 16). These data suggest
that the AAV-CRISPR autochthonous GBM mouse model revealed a
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quantitative phenotypic profile of tumor suppressors reflecting the
genomic landscape of human GBM patients.
Co-mutation analysis identifies frequently co-occurring driver
combinations
To generate an unbiased map of co-drivers, we calculated the cooccurrence rate of double mutations for each gene pair (Fig. 5a,b,
Online Methods and Supplementary Table 17). This analysis showed
that 76 gene pairs out of a total of 1,540 possible pairs were statistically significant in terms of co-occurrence (hypergeometric test,
FDR adjusted q < 0.05). The Nf1+Pten pair emerged as the top pair
(co-occurrence rate = 18 of 21 = 85.7%, hypergeometric test, P = 7.53 ×
10−8; Fig. 5a–c). Notably, several previously undocumented combinations emerged, such as Kdm5c+Gata3 (co-occurrence rate = 77.8%,
hypergeometric test, P = 6.04 × 10−6) and B2m+Pik3r1 (70.0%,
P = 2.28 × 10−5; Fig. 5a–c). In addition, we performed correlation
analysis of summed mutant frequencies for each pair of genes across
all mice (Fig. 5d,e, Online Methods and Supplementary Table 18).
We found that 22.9% (352 of 1,540) of the gene pairs were positively correlated (Spearman correlation > 0, FDR adjusted q < 0.05;
Fig. 5d,e). The most significantly correlated gene pair was again
Nf1+Pten (Spearman correlation r = 0.861, P = 3.34 × 10−8; Fig. 5d–f
and Supplementary Table 18), along with other representative pairs
such as Cdkn2a+Ctcf (correlation r= 0.792, P = 2.41 × 10−6; Fig. 5g),
B2m+Notch1 (correlation r = 0.789, P = 2.82 × 10−6) and Apc+Pik3r1
(correlation r= 0.774, P = 5.77 × 10−6; Fig. 5d,e). Exclusion of
Trp53 revealed largely identical results for the remaining genes
(Supplementary Fig. 7a,b). Of note, a subset of the significantly
co-occurring pairs were also found to be co-mutated in human GBM,
including RB1+TP53, PTEN+RB1, RASA1+STK11, B2M+MAP2K4,
PTEN+STAG2, CDKN1B+TP53 and CDKN1B+NF1 (Supplementary
Fig. 7c,d). These data revealed the co-occurrence and correlation relationships of specific mutations during glioblastoma progression in vivo.
Minipool validation of individual drivers and combinations
We went on to test several of the highly represented individual drivers or combinations using an sgRNA minipool validation approach
(Fig. 6a and Online Methods). All of the uninjected (n = 2), EYFP
(n = 4) and empty-vector (n = 3) mice survived and maintained good
body condition for the whole duration of the study. Control mice
examined 4–11 months after treatment were devoid of any observable tumors by histology analysis (Fig. 6b, Supplementary Fig. 8 and
Supplementary Table 19), again indicating that without mutagenesis,
or with Trp53 disruption alone, LSL-Cas9 mice did not develop brain
tumors. In contrast, within 11 months postinjection, 50% (4 of 8)
of mice receiving AAVs containing Nf1 sgRNA minipool developed
macrocephaly, poor BCS and tumors (compared to all 9 control mice;
two-tailed Fisher’s exact test, P = 0.029). All mice receiving Nf1;Pten
(9 of 9, 100%, P = 4.11 × 10−5) and Nf1;B2m minipools (4 of 4, 100%,
P = 0.0014) developed macrocephaly, poor BCS and large tumors
(Fig. 6c and Supplementary Table 19). Notably, mice receiving
Nf1;B2m minipools had significantly worse survival times than
mice receiving Nf1 minipools alone (P = 0.0067; Supplementary
Fig. 9a), implying that loss of antigen presentation in cancer cells
likely accelerates GBM progression in immunocompetent mice. All
mice receiving Rb1, Rb1;Pten or Rb1;Zc3h13 minipools (3 of 3, 100%,
P = 0.0045 for all three groups) developed macrocephaly, poor BCS
and large tumors (Fig. 6d and Supplementary Table 19). For the
same duration of study (maximum 11 months), smaller fractions
of mice receiving the AAV sgRNA minipools targeting Arid1b;Nf1
(4 of 9), Mll3;Nf1 (2 of 5), Mll2 (2 of 10), Cic (1 of 5), Cic;Pten
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(1 of 4), Setd2 (1 of 5) and Gata3;Mll3 (1 of 5) developed tumors
(Supplementary Table 19). Collectively, half (40 of 80, or 50%) of
the mice receiving AAV sgRNA minipools targeting any of the single

a

genes or gene pairs developed brain tumors within 11 months (collective validation versus all controls, two-tailed Fisher’s exact test,
P = 0.004). These data indicated that mutating these individual genes
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Figure 5 Co-mutation analysis uncovers synergistic gene pairs in GBM. (a) Top left: heat map of pairwise mutational co-occurrence rates. Bottom-right:
heat map of −log10 P values by hypergeometric test for statistical co-occurrence. (b) Scatterplot of the co-occurrence rate of each gene pair, plotted
against −log10 P values. (c) Venn diagrams showing representative strongly co-occurring mutated gene pairs such as Kdm5c and Gata3 (co-occurrence
rate = 77.8%, hypergeometric test, P = 6.04 × 10−6), B2m and Pik3r1 (70.0%, P = 2.28 × 10−5), and Nf1 and Pten (85.7%, P = 7.53 × 10−8).
(d) Top-left: heat map of the pairwise Spearman correlation of variant frequency for each gene, summed across sgRNAs. Bottom right: heat map of
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only four currently approved drugs for this disease (Online Methods
and Fig. 8a). Drug-response phenotyping showed that Zc3h13 lossof-function rendered Rb1 cells significantly more resistant to 1 mM
TMZ, similarly to Pten loss-of-function (two-tailed t test, t4 = 31.32
and t4 = 23.51, P = 6.20 × 10−6 and P = 1.94 × 10−5, for Rb1;Pten
versus Rb1 and Rb1;Zc3h13 versus Rb1, respectively; Fig. 8b).
These differences were also observed with 2 mM TMZ (t4 = 50.69
and t4 = 38.10, P = 9.06 × 10−7 and P = 2.84 × 10−6, for Rb1;Pten
versus Rb1 and Rb1;Zc3h13 versus Rb1, respectively; Fig. 8c).
Given the differential responses among these three genotypes, we performed mRNA-seq to profile the transcriptome of these mutant cells
treated with TMZ as compared to dimethyl sulfoxide (DMSO)-treated
controls (Supplementary Tables 20 and 21). Differential expression
analyses of TMZ- and DMSO-treated cells from each of the three
genotypes revealed systematic changes in gene expression (Fig. 8d–f
and Supplementary Tables 25–27). Collectively, the differentially
expressed genes in the TMZ versus DMSO comparisons uncovered
the transcriptomic differences between genotypes in response to TMZ
treatment (Fig. 8g).
Of the genes that were significantly reduced upon TMZ treatment in
each group, a total of 69 genes were shared among all three genotypes
(Fig. 8h and Supplementary Table 28), indicating that these genes
are a common transcriptional response to TMZ. As Rb1;Zc3h13 and
Rb1;Pten cells exhibited greater survival fractions with TMZ treatment
when compared to Rb1 cells, we identified 37 genes that were significantly reduced upon TMZ treatment in Rb1;Zc3h13 and Rb1;Pten cells
but not in Rb1 cells (Fig. 8h and Supplementary Table 28). As for the
genes that were significantly induced by TMZ, a total of 42 genes were
common in all three genotypes (Fig. 8i and Supplementary Table
29), representing a shared TMZ-induced gene signature. Notably, we
identified 60 genes that were upregulated upon TMZ treatment in
Rb1;Zc3h13 and Rb1;Pten cells but not in Rb1 cells. These included
Arl6ip1, which encodes a protein that has been shown to suppress
cisplatin-induced apoptosis in cancer cells26, and Cd274 (also known
as PD-L1), which encodes the ligand for an inhibitory receptor, PD-1,
that is currently a major focus of investigation in cancer immunotherapy27. Taken together, the transcriptomic analyses provide unbiased
molecular signatures underlying the increased TMZ-resistance upon
Zc3h13 or Pten mutations in Rb1-mutant glioma cells, suggesting that
the precise combinations of mutational drivers present in individual
GBMs directly influence therapeutic responses.

or combinations in combination with Trp53 causes GBM in fully
immunocompetent animals.
Notably, brain tumors with Nf1 mutations displayed highly polymorphic pathological features, with diverse fibroblastic cell morphologies, regions of necrosis and large hemorrhages (Fig. 6c) yet
were almost always GFAP+ (Supplementary Fig. 8). In sharp contrast,
tumors with Rb1 mutations were composed of round cells with dense
nuclei, frequently with proliferative spindles and giant cells with massive nuclear aneuploidy and pleomorphism but rarely with regions of
necrosis or large-area hemorrhage (Fig. 6d), and they often contained
mixtures of GFAP+ and GFAP– cells (Supplementary Fig. 8).
Transcriptomic characterization of tumors with differing
mutational backgrounds
We then investigated the molecular underpinnings of gliomagenesis
driven by different combinations of drivers (Fig. 7a and Supplementary
Fig. 9b). We performed mRNA-seq to profile the transcriptome
of these mutant glioma cells (Nf1, Nf1;Mll3, Rb1 and Rb1;Zc3h13;
n = 3 cell replicates each) (Supplementary Tables 20 and 21).
Comparing Nf1-mutant and Rb1-mutant cells, we found that 616
genes were more highly expressed in Rb1 cells (Benjamini-Hochberg
adjusted P < 0.05 and log fold change q 1), while 982 genes were more
highly expressed in Nf1 cells (Fig. 7b and Supplementary Table 22).
Gene ontology analysis of the genes associated with higher expression
in Nf1-mutant cells revealed multiple enriched categories (BenjaminiHochberg adjusted P < 0.05), including extracellular region, biological
adhesion, neuron differentiation, hormone metabolic process, cell
motion and cell–cell signaling (Fig. 7c). Gene ontology analysis of the
genes associated with higher expression in Rb1-mutant cells revealed
a distinct set of enriched categories (adjusted P < 0.05), which unexpectedly included regionalization, anterior–posterior pattern formation, transcription factor activity, embryonic morphogenesis, cell
adhesion, extracellular matrix, neuron differentiation and GTPase
regulator activity (Fig. 7d). Strikingly, a total of 13 homeobox genes
were among the top-40 upregulated genes in Rb1 mutants.
To understand the direct effect of additional mutations on the
transcriptome of these cells, we next compared Nf1;Mll3 to Nf1 cells
and Rb1;Zc3h13 to Rb1 cells. We found that 522 genes were upregulated in Nf1;Mll3 compared to Nf1 cells, while 175 were downregulated (Fig. 7e and Supplementary Table 23). Gene ontology analysis
of the upregulated genes in Nf1;Mll3 cells revealed enrichment of
extracellular matrix, EGF-like region, biological adhesion, calciumion binding, tube development and growth factor binding (Fig. 7f).
Comparing Rb1;Zc3h13 to Rb1 cells revealed 703 upregulated and
166 downregulated genes (Fig. 7g and Supplementary Table 24).
Rb1;Zc3h13-high genes were enriched in categories such as extracellular matrix, immune response, cell adhesion, 2-5-oligoadenylate
synthetase, cell morphogenesis, GTPase activity, cell motion and vasculature development (Fig. 7h). Collectively, these findings indicate
that the addition of an Mll3 mutation significantly alters the transcriptome of Nf1-mutant cells, as does the addition of a Zc3h13 mutation
on Rb1-mutant cells.

DISCUSSION
A systematic phenotypic picture of which genetic factors and combinations are necessary or sufficient to drive tumorigenesis in the brain
is critical to better understanding GBM. To answer these questions, it
is critical to directly test the hypotheses gleaned from cancer genomics in a controlled experimental setting to find causative genes and to
quantitatively measure their phenotypes in vivo. Determining whether
these alterations are bona fide driver mutations requires direct in vivo
testing and has historically been performed using cell lines or genetically engineered mouse models28. Development and applications of
pioneering mouse models of GBM have led to profound progress in
our understanding of tumor initiation, stem cell populations, progression and therapeutic responses of GBM driven by a variety of important mutations29–40. Recently, the CRISPR system41–43 has been used
to directly mutate oncogenes and tumor suppressor genes in somatic
cells for modeling genetic events in various cancer types (reviewed
in ref. 44). We now demonstrate high-throughput gene editing for
multiplexed autochthonous GBM models in fully immunocompetent mice. Our study provides a massively parallel view of tumor

Secondary mutations influence the transcriptome and
engender chemotherapeutic resistance
As GBM remains a very challenging cancer type to treat, understanding the molecular changes underlying drug response is important. We
thus performed drug-treatment RNA-seq experiments to investigate
the transcriptome responses of AAV-CRISPR-induced GBM cells
(Rb1, Rb1;Pten and Rb1;Zc3h13) to TMZ, a chemotherapeutic with
significant, albeit small, survival benefit for GBM patients, among the
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suppressors in vivo, revealing the relative selective strength of mutations in these genes when competing in the brain, as well as the driver
variations between individuals. As CRISPR targeting might lead to
off-target effects at other loci, we performed exome sequencing for a
subset of the mTSG brain samples. This dataset revealed an unbiased
measurement of other coding mutations (Supplementary Fig. 7e and
Supplementary Tables 30 and 31). These mutations might be caused by
off-target effects of CRISPR/Cas9, rare AAV integrations45 or by
the unstable genomes of GBM cells, especially those with p53 loss20,
throughout tumorigenesis.
Across all genes tested, the mutation frequencies in this highly complex mouse model of GBM significantly correlated with the mutation
frequencies in human patients from two large independent cohorts
(TCGA and Yale Glio), suggesting the clinical relevance of the findings. Several of the novel mSMGs highly enriched in this mouse study
have also been associated with GBM in the clinical setting, such as
B2M, CIC, MLL2, MLL3, SETD2, ZC3H13 and ARID1B11,46–49.
Because differences in driver mutations can dramatically affect treatment efficacies in preclinical animal models and in human patients50,
a functional understanding of cancer drivers is therefore essential for
precision medicine.
We also performed a lentiCRISPR direct in vivo screen in GBM, using
the same mTSG library (Online Methods, Supplementary Table 32
and Supplementary Fig. 9c,d). We found that the AAV-mTSG CRISPR
library resulted in more robust gliomagenesis in vivo compared to
lentiCRISPR mTSG, in terms of latency (death of first animal, 84 versus
200 d), survival (median survival, 4 versus 10 months) and penetrance
(100% versus 67%). However, AAVs usually do not integrate into the
genome, except under certain circumstances (low rate of integration at
AAVS1 locus)45. Thus, AAV-encoded transgenes such as exogenously
supplied sgRNAs do not replicate as cells divide during tumor progression,
limiting the readout of the mTSG library by PCR amplification of
the sgRNA cassette itself. Instead, we achieved successful readout of
driver mutations by sequencing the predicted sgRNA cutting sites
using ultradeep targeted-captured sequencing. A key advantage of this
approach is the ability to perform high-throughput mutagenesis in an
autochthonous model of GBM, in which tumors directly evolve from
normal cells at the organ site in situ in immunocompetent mice, without
cellular transplantation. This platform can be readily extended to study
other types of cancer for tumor progression, as well as therapeutic
responses in vivo. Taken together, our study provides a systematic and
unbiased molecular landscape of functional tumor suppressors in an
autochthonous mouse model of GBM, opening new paths for highthroughput analysis of cancer genetics directly in vivo.
METHODS
Methods, including statements of data availability and any associated
accession codes and references, are available in the online version of
the paper.
Note: Any Supplementary Information and Source Data files are available in the
online version of the paper.
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Plasmid library representation was read out by barcoded Illumina sequencing as
described above, with primers customized to the vectors. The lentiCRISPR GBM
plasmid vector (lentivector) and library (lenti-mTSG) were subjected to high-titer
lentivirus production and purification. Briefly, HEK293FT cells (ThermoFisher)
were transiently transfected with transfer (lentivector or lenti-mTSG) and
packaging (psPAX and pMD2.G) plasmids using PEI or Lipofectamine.
Each replicate consist of five 80% confluent HEK293FT cells in 15-cm tissue culture dishes or T-175 flasks (Corning). Multiple replicates were pooled to enhance
production yield. Approximately 48 h post-transfection, virus-containing media
was collected and purified via sucrose gradient ultracentrifugation at q 30,000
rpm for 2–3 h. The supernatant was discarded, and the pellet was dried and
resuspended with 100 ML sterile PBS in 4 °C overnight. Virus was titered by viral
protein p24 ELISA (RnD). The experiments in Supplementary Figure 9 were
done using the EFS version of the vector.

Design, synthesis and cloning of the mTSG library. Briefly, pan-cancer mutation data from 15 cancer types were retrieved from The Cancer Genome Atlas
(TCGA portal) via cBioPortal51 and Synapse (https://www.synapse.org). SMGs
were calculated similar to previously described methods22–25. Known oncogenes
were excluded and only known or predicted tumor suppressor genes (TSGs) were
included. The top 50 TSGs were chosen, and their mouse homologs (mTSG)
were retrieved from mouse genome informatics (MGI; http://www.informatics.
jax.org). A total of 49 mTSGs were found. A total of seven known housekeeping
genes were initially chosen as internal controls. We designed sgRNAs against
these 56 genes using a previously described method52,53 with our custom scripts.
Five sgRNAs were chosen for each gene, plus eight nontargeting controls (NTCs),
for a total of 288 sgRNAs in the mTSG library. There were two sets of duplicate
sgRNAs, Cdkn2a-sg2 / Cdkn2a-sg5, and Rpl22-sg4 / Rpl22-sg5, leaving a total of
286 unique sgRNAs.

Animal work statements. All animal work was performed under the guidelines of Yale University Institutional Animal Care and Use Committee (IACUC)
and Massachusetts Institute of Technology Committee for Animal Care (CAC),
with approved protocols (Chen-2015-20068, Zhang-0414-024-17, and Sharp0914-091-17), and was consistent with the Guide for Care and Use of Laboratory
Animals, National Research Council, 1996 (Institutional Animal Welfare
Assurance No. A-3125-01).

Design, cloning of an AAV-CRISPR GBM vector and mTSG sgRNA library
cloning. An AAV-CRISPR vector was designed for astrocyte-specific genome
editing. This vector contains a cassette specifically expressing Cre recombinase
under the control of a GFAP promoter for conditional induction of Cas9 expression in brain astrocytes when delivered to LSL-Cas9 mice54. Two sgRNA cassettes
were built in this vector, one encoding an sgRNA targeting Trp53, the most frequently mutated gene in cancer22,23,25, and the other an empty sgRNA cassette
(double SapI sites for sgRNA cloning) enabling flexible targeting of genes of
interest in either an individual or a pooled manner. The vector was generated by
gBlock gene fragment synthesis (IDT) followed by Gibson assembly (NEB). The
mTSG libraries were generated by oligonucleotide synthesis, pooled and cloned
into the double SapI sites of the AAV-CRISPR GBM vector. The library cloning
was done at over 100× coverage to ensure proper representation. Plasmid library
representation was read out by barcoded Illumina sequencing as described previously55 with primers customized to this vector.

Stereotaxic surgery and virus transduction in the mouse brain. Conditional
LSL-Cas9 knock-in mice were bred in a mixed 129/C57BL/6 background. Mixed
gender (randomized males and females) 6- to 14-week-old mice were used in
experiments. Animals were maintained and bred in standard individualized cages
with maximum of 5 mice per cage, with regular room temperature (65–75°F, or
18–23 °C), 40–60% humidity and a 12-h:12-h light cycle. Mice were anesthetized
by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) or by
inhalation of isoflurane at approximately 2% for 20–30 min. We also administered
buprenorphine HCl (0.1 mg/kg) or carprofen (5.0 mg/kg) intraperitoneally as
a pre-emptive analgesic. Reflexes were tested before surgical procedures. Once
subject mice were in deep anesthesia, they were immobilized in a stereotaxic
apparatus (Kopf or Stoelting) using intra-aural positioning studs and a tooth
bar to immobilize the skull. Heat was provided by a standard heating pad or a
heat lamp. According to the mouse brain stereotaxic coordinates56, we drilled a
1–2 mm hole on the surface of the skull and used a 33-gauge Nanofil syringe
needle (World Precision Instrument) to inject into the lateral ventricle (LV) at
0.6–1.0 mm caudal/posterior to bregma, 0.8–1.5 mm right-side lateral to bregma
and 2.0–3.0 mm deep from the pial surface for injection (coordinates: A/P −0.6
to −1.0, M/L 0.8 to 1.5, D/V −2.0 to −3.0). For a small fraction of animals, injections were made into hippocampus (HPF) at the following coordinates: A/P −1.3,
M/L 0.6, D/V −1.7). We injected PBS, AAV (1 × 1010 to 1 × 1011 viral genome
copies or Cre copy-number equivalent) or lentivirus (8 × 109 to 8 × 1010 viral
particles or p24 equivalent) into the right hemisphere of the brain for each
mouse (8 Ml for LV, 2 Ml for HPF). Injection rates were monitored by an
UltraMicroPump3 (World Precision Instruments). After injection, the incision
site was closed with 6-0 Ethilon sutures (Ethicon by Johnson & Johnson) or
VetBond tissue glue (3M). Animal were postoperatively hydrated with 1 mL lactated
Ringer’s solution (subcutaneous) and housed in warmed cages or in a temperaturecontrolled (37 °C) environment until achieving ambulatory recovery. Meloxicam
(1–2 mg/kg) was also administered subcutaneously directly after surgery.

AAV-mTSG viral library production. The AAV-CRISPR GBM plasmid vector
(AAV-vector) and library (AAV-mTSG) were subjected to AAV9 production and
chemical purification. Briefly, HEK293FT cells (ThermoFisher) were transiently
transfected with transfer (AAV-vector or AAV-mTSG), serotype (AAV9) and
packaging (pDF6) plasmids using polyethyleneimine (PEI). Each replicate consist
of five 80% confluent HEK293FT cells in 15-cm tissue culture dishes or T-175
flasks (Corning). Multiple replicates were pooled to enhance production yield.
Approximately 72 h post-transfection, cells were dislodged and transferred to
a conical tube in sterile PBS. We added 1/10 volume of pure chloroform and
the mixture was incubated at 37 °C and vigorously shaken for 1 h. NaCl was
added to a final concentration of 1 M, and the mixture was shaken until dissolved and then pelleted at 20,000g at 4 °C for 15 min. The chloroform layer was
discarded while the aqueous layer was transferred to another tube. PEG8000 was
added to 10% (w/v) and shaken until dissolved. The mixture was incubated at
4 °C for 1 h and then spun at 20,000g at 4 °C for 15 min. The supernatant was discarded and the pellet was resuspended in DPBS + MgCl2, treated with benzonase
(Sigma) and incubated at 37 °C for 30 min. Chloroform (1:1 volume) was then
added, shaken and spun down at 12,000g at 4C for 15 min. The aqueous layer was
isolated and passed through a 100-kDa MWCO (Millipore). The concentrated
solution was washed with PBS and the filtration process was repeated. Virus was
titered by qPCR using custom Taqman assays (ThermoFisher) targeted to Cre.
Design, cloning of lentiCRISPR GBM vectors and mTSG sgRNA library, and
lentivirus production. Two lentiCRISPR vectors were designed, one for constitutive and the other for astrocyte-specific genome editing. These vectors contain
a cassette specifically expressing Cre recombinase under the control of an EFS
promoter or a GFAP promoter for conditional induction of Cas9 expression in the
brain when delivered to LSL-Cas9 mice. Two sgRNA cassettes were built in this
vector, one encoding an sgRNA targeting Trp53 and the other an empty sgRNA
cassette (double BsmbI sites for sgRNA cloning) enabling flexible targeting of
genes of interest in either individual or pooled manner. These vectors were generated by gBlock gene fragment synthesis (IDT) followed by Gibson assembly (NEB).
The mTSG libraries were generated by oligonucleotide synthesis, pooled and
cloned into the double BsmbI sites of the lentiCRISPR GBM vectors. The library
cloning was done at over 100× coverage to ensure proper representation.
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MRI. MRI imaging was performed using standard imaging protocol with MRI
machines (Varian 7T/310/ASR-whole-mouse MRI system or Bruker 9.4T horizontal small-animal systems). Briefly, animals were anesthetized using isoflurane
and setup in the imaging bed with a nosecone providing constant isoflurane. A
total of 20–30 views were acquired for each mouse brain using a custom setting:
echo time (TE) = 20, repetition time (TR) = 2,000, slicing = 0.5 mm. Raw image
stacks were processed using Osirix or Slicer tools57. Rendering and quantification
were performed using Slicer (https://www.slicer.org/). For all mice with brain
tumors, only one tumor was observed per mouse. Tumors were approximated as
spheres and their sizes were calculated with the following formula:
Volume (mm3 )  0.5 r length (mm) r height (mm) r depth (mm)
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Survival analysis. We observed that mice that developed brain tumors rapidly
deteriorated in their body condition scores. Mice with observed macrocephaly
and body condition score a 1 were euthanized and the euthanasia date was
recorded as the last survival date. Occasionally mice bearing brain tumors died
unexpectedly early, and the date of death was recorded as the last survival date.
Cohorts of mice stereotaxically injected with PBS, AAV-vector or AAV-mTSG
virus were monitored for their survival. Survival analysis was analyzed using a
standard Kaplan-Meier analysis. Of note, several AAV-vector or PBS injected
mice were killed for analysis at time points earlier than 299 d (at times when a
certain AAV-mTSG mice were found dead or euthanized due to poor body conditions) to provide time-matched histology, but those mice were healthy, without
brain tumors or other signs of detectable symptoms. Mice killed for analysis early
in healthy states were excluded from the calculation of survival percentage.

preferred close matches = 3, where initial selection of probes for a given region
will only include probes with three or fewer close matches; and maximum close
matches = 20, where if there are insufficient probes available for a given region at
the preferred close match number, the threshold will be incrementally increased
to 20 until adequate coverage is achieved. After consolidation, 178 regions covering 277 sgRNAs, with a total of 33,638 bp, were covered in the probe set, with
target bases covered = 32,239 (95.8%) and one target sgRNA without coverage
due to a lack of qualified candidate probes in the region.
Targeted-capture sequencing. The mTSG-Amplicon targeted-capture sequencing probes were synthesized using the SeqCap EZ Probe Pool synthesis procedure
(Roche). The capture sequencing was done following standard Illumina-RocheIllumina protocols. Genomic DNA samples from mouse organs were fragmented,
followed by library preparation using a KAPA Library Preparation Kit (Illumina).
The libraries were then amplified using LM-PCR, hybridized to the mTSGAmplicon probe pool, washed and recovered, and amplified with multiplexing
barcodes using LM-PCR. The multiplexed library was then quality-controlled
using qPCR, and subjected to high-throughput sequencing using the HiSeq-2500
or HiSeq-4000 platforms (Illumina) at the Yale Center for Genome Analysis. We
captured 277 of 278 (99.6%) of unique targeted sgRNAs for all samples from this
experiment, missing only Arid1a-sg5 due to unavailability of qualified probes
in this locus.

Mouse brain dissection, fluorescence imaging and histology. Mice were killed
for analysis by carbon dioxide asphyxiation or deep anesthesia with isoflurane
followed by cervical dislocation. Mouse brains were manually dissected under a
fluorescence stereoscope (Zeiss, Olympus or Leica). Brightfield and/or GFP fluorescence images were taken for the dissected brain and overlaid using ImageJ58.
Brains were then fixed in 4% formaldehyde or 10% formalin for 48–96 h, embedded in paraffin, sectioned at 6 Mm and stained with hematoxylin and eosin (H&E)
for pathology. For tumor size quantification, H&E slides were scanned using an
Aperio digital slide scanner (Leica). Tumors were manually outlined as regions
of interest (ROI) and subsequently quantified using ImageScope (Leica). Sections
were dewaxed, rehydrated and stained using standard immunohistochemistry
(IHC) protocols as previously55,59. The following commonly used antibodies
were used for IHC: rabbit anti-Ki67 (Abcam ab16667, 1:500), rabbit anti-GFP
(ThermoFisher Scientific A11122, 1:300), rabbit anti-GFAP (Dako, 1:500) and
mouse anti-Cas9 (Diagenode, 1:300).

mTSG sgRNA cutting efficiency measurement. The mouse mTSG sgRNA cutting efficiency measurement was performed similarly to the screen, with the
exception of early sampling. Briefly, AAV-mTSG library virus was injected in to
the LV of LSL-Cas9 mice, but instead of waiting until mice reached tumor endpoints, they were killed for analysis at an early time point (3.5 weeks postinjection)
and examined under a fluorescence stereoscope to dissect GFP+ regions from the
brain. Genomic DNA was extracted and subjected to capture sequencing.

Mouse tissue collection for molecular biology. Mouse brain (the targeted
organ) and liver (a nontargeted organ) were dissected and collected manually.
For molecular biology, tissues were flash-frozen with liquid nitrogen and ground
in 24-well polyethylene vials with metal beads in a GenoGrinder machine (OPS
diagnostics). Homogenized tissues were used for DNA/RNA/protein extractions
using standard molecular biology protocols.

Mouse whole-exome capture sequencing. The mouse whole-exome capture was
performed using the SeqCap EZ exome kit (Roche). Briefly, capture sequencing
was done following standard Illumina-Roche-Illumina protocols. Genomic DNA
samples from mouse organs were fragmented, followed by library preparation
using KAPA Library Preparation Kit (Illumina). The libraries were then amplified using LM-PCR, hybridized to the exome probe pool, washed and recovered,
and then amplified with multiplexing barcodes using LM-PCR. The multiplexed
library was then quality-controlled using qPCR and subjected to high-throughput
sequencing using the HiSeq-2500 or HiSeq-4000 platforms (Illumina) at the Yale
Center for Genome Analysis.

Genomic DNA extraction from cells and mouse tissues. For genomic DNA
(gDNA) extraction, 50–200 mg of frozen ground tissue was resuspended in
6 mL of Lysis Buffer (50 mM Tris, 50 mM EDTA, 1% SDS, pH 8) in a 15-mL
conical tube, and 30 ML of 20-mg/ml Proteinase K (Qiagen) was added to the
tissue/cell sample and incubated at 55 °C overnight. The next day, 30 ML of
10-mg/ml RNase A (Qiagen) was added to the lysed sample, which was then
inverted 25 times and incubated at 37 °C for 30 min. Samples were cooled on
ice before addition of 2 mL of prechilled 7.5-M ammonium acetate (Sigma) to
precipitate proteins. The samples were vortexed at high speed for 20 s and then
centrifuged at q4,000g for 10 min. At this point a tight pellet was visible in each
tube, and the supernatant was carefully decanted into a new 15-mL conical tube.
We added 6 mL 100% isopropanol to the tube, inverted it 50 times and centrifuged
it at q4,000g for 10 min. Genomic DNA was visible as a small white pellet in each
tube. The supernatant was discarded, 6 mL of freshly prepared 70% ethanol was
added, and the tube was inverted 10 times and then centrifuged at q4,000g for
1 min. The supernatant was poured off and discarded; the tube was briefly spun,
and remaining ethanol was removed using a P200 pipette. After air-drying for
10–30 min, the DNA changed appearance from a milky white pellet to slightly
translucent. We then added 500 ML of ddH2O, and the tube was incubated at
65 °C for 1 h and at room temperature overnight to fully resuspend the DNA. The
next day, the gDNA samples were vortexed briefly. The gDNA concentration was
measured using a Nanodrop (Thermo Scientific).

Illumina sequencing data processing and variant calling. FASTQ reads were
mapped to the mm10 genome using the ‘bwa mem’ function in BWA v0.7.13
(ref. 61). Bam files were merged, sorted and indexed using bamtools62 v2.4.0 and
samtools63 v1.3. For each sample, indel variants were called using samtools and
VarScan64 v2.3.9. Specifically, we used samtools mpileup (-d 1000000000 -B -q 10)
and piped the output to VarScan pileup2indel (--min-coverage 1 --min-reads2 1
--min-var-freq 0.001 --p-value 0.05). To link each indel to the sgRNA that most
likely caused the mutation, we took the center position of each indel and mapped
it to the closest sgRNA cut site.
Calling significantly mutated sgRNAs and significantly mutated genes.
We further filtered all detected indels by requiring that each indel must overlap the
o3 base pairs flanking the closest sgRNA cut site, as Cas9-induced double-strand
breaks are expected to occur within a narrow window of the predicted cut site. We
then used a series of criteria to identify high-confidence mutations. (i) As an initial
pass to exclude possible germline mutations, we removed any sgRNAs with indels
present in more than half of the control samples with greater than 5% variant
frequency. In our data, this filter specifically removed Rps19-sg5 from further consideration. (ii) To determine significantly cutting sgRNAs in each sample, we used
a false-discovery approach based on the PBS and vector control samples. For each
sgRNA, we first took the highest percent of variant-read frequency across all control samples; for a mutation to be called in an mTSG sample, the percent variantread frequency had to exceed the control sample cutoff. However, since the base
vector contained a Trp53 sgRNA (Trp53-sg8) whose cut site was only 1 bp away
from the target site of Trp53-sg4 (from the mTSG library), we only considered PBS

Targeted-capture sequencing probe design. Targeted-capture sequencing probes
were designed as following: the predicted cutting sites (3 bp 5` of PAM) of the 280
gene-targeting sgRNAs in the mTSG library, plus the Trp53-targeting sgRNA in
the vector, were retrieved from the mouse reference genome (mm10). The 140-bp
sequences of the flanking regions of the cutting sites (5`, 70 bp; and 3`, 70 bp) were
retrieved using Bedtools60. The regions were consolidated using NimbleDesign
(Roche/NimbleGen), and probe matches were set with these parameters:
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(ThermoFisher). After packaging, AAV minipools were stereotaxically injected
into the ventricle of LSL-Cas9 mice. Survival and histology analysis followed
injection as described above. Several control mice (uninjected, EYFP and vector)
were killed for analysis as surrogate histology samples although they were in good
body condition and were subsequently found to be devoid of tumors.

samples when calculating the false-discovery cutoff for Trp53-sg4. Nevertheless,
in the current study this exception was unnecessary because of our third filter.
(iii) As we were most interested in identifying the dominant clones in each sample,
we further set a 5% variant frequency cutoff on top of the false-discovery
cutoff. These criteria gave us a binary table (i.e., not significantly mutated versus
significantly mutated) detailing each sgRNA and whether its target site was
significantly mutated in each sample. None of the AAV-vector samples passed
the 5% cutoff at the p53 sg4/8 target site, which is consistent with our observation
that no tumors were found in vector-treated animals. To convert significantly
cutting sgRNAs into significantly mutated genes, we simply collapsed the binary
sgRNA scores by gene, such that if any of the sgRNAs for a gene were found to be
significantly cutting, the gene would be called as significantly mutated.

Generation of Nf1- and Rb1-mutant cell lines from primary GBMs induced
by AAV-CRISPR minipools. Autochthonous mouse GBMs were induced by
stereotaxic injection with the Nf1 or Rb1 AAV minipool (in the AAV9-sgTrp53sgX-GFAP-Cre vector described above). Tumor-containing brains were visually
inspected under a fluorescence dissecting scope, made into single-cell suspension
through physical dissociation plus Collagenase/DNase digestion and cultured in
DMEM supplemented with 10% FBS and Pen/Strep. Growing clones were further
established as autochthonous mouse GBM cell lines.

Exome sequencing data analysis. For exome sequencing analysis, we imposed a
modified set of criteria on each detected variant: (i) q 10 supporting reads for the
reference allele; (ii) q 10 supporting reads for the variant allele; (iii) the variant
must be within o6 bp of a Cas9 PAM or NGG (or CCN on the reverse strand); (iv)
a variant allele frequency < 75%, as this was the maximum detected variant frequency out of the mTSG brain samples; and (v) the variant must not be detected
in any sequenced control samples, which were considered germline variants.

Single-sgRNA knockout lentiviral production. Lenti-pHKO-U6-sgBsmBIEF1a-Puro-P2A-FLuc was generated by subcloning a P2A-Fluc expression cassette
into a lentiviral CRISPR knockout vector by Gibson assembly. To clone sgRNA
targeting individual genes, such as Pten, Arid1b, Mll3 (Kmt2c), B2m and Zc3h13
(Supplementary Table 1), the corresponding oligos were synthesized, annealed
and cloned into BsmBI linearized lentiviral knockout vectors. Lentiviruses were
produced by transfecting lentiviral knockout plasmids, together with pMD2.G
and psPAX2, into 80–90% confluent HEK293FT cells, with viral supernatants
collected 48 and 72 h post-transfection, aliquoted and stored at −80 °C.

Clustering of variant frequencies to infer clonality of tumors. For each
mTSG brain sample, we extracted the individual variants that comprised the
SMS calls in that sample, with a cutoff of 5% variant frequency to eliminate lowabundance variants. Because of these cutoffs, three sequenced mTSG brain
samples were not eligible for variant frequency clustering analysis. To identify
clusters of variant frequencies in an unbiased manner, we modeled the
variant frequency distribution with a Gaussian kernel density estimate, using
the Sheather-Jones method to select the smoothing bandwidth. From the kernel
density estimate, we then identified the number of local maxima (i.e., peaks)
within the density function. The number of peaks thus represented the number
of variant frequency clusters for an individual sample, which is an approximation
for the clonality of the tumors.

Generation of NF1–/– geneX and RB1–/– geneX knockout cell lines.
The Nf1- and Rb1-knockout tumor cells were infected by single-sgRNA knockout lentiviruses at M.O.I a 0.3 to further knockout desired gene X. Twenty-four
hours postinfection, lentiviral transduced cells were selected by the addition of
4–8 Mg/mL puromycin; they were then split after 2–3 d.
TMZ treatment, cell viability assay and RNA preparation. After 7–9 d culture
under puromycin selection, lentivirus-infected Nf1- and Rb1-knockout tumor cells
were plated in triplicates into 96-well plate at a density of 2.5 × 103 cells per well,
and ~5 × 106 cells were collected at the same time and for cutting efficiency analysis. One day after plating, either TMZ or DMSO was added at a concentration of
10 MM, 100 MM, 500 MM, 1 mM or 2 mM. After 3 d of drug/vehicle treatment, cell
viability was measured using CellTiter Glo (Promega) according to the manufactures’ protocol. Briefly, we first equilibrated the CellTiter Glo at room temperature
for 1 h before use. Media from the 96-well plates was aspirated, and 50 ML fresh
DMEM + 10% FBS and 50 ML CellTiter Glo was added. The luminescent signals
were readout using EnVision plate reader (PerkinElmer). For RNA-seq sample
preparation, cell lines harboring specific gene knockouts were cultured for 7–9 d
under the selection pressure of puromycin, and then plated into 6-well plates
at a density of 2 × 105 cells per well in triplicates. Twenty-four hours after plating, 1 mM TMZ or DMSO in fresh DEME + 10% FBS was added and cultured
for another 48 h. Cellular RNA of control or treated cells was then extracted
by adding 350 ML TRIzol Reagent (Invitrogen) directly into the 6-well plates
to lyse the cells, followed by gently shaking the plates and incubating them for
5–10 min to complete and lysis and homogenization. Then, 70 ML chloroform
was added, vigorously mixed and centrifuged at 16,000g for 15 min. The RNA
containing the aqueous phase was transferred to a new tube and further purified using RNeasy mini kit (Qiagen). After eluting RNA from the column using
nuclease-free water, the concentrations of sample RNA were normalized into
150–300 ng/ML for RNA-seq.

Coding frame analysis. For coding frame and exonic/intronic analysis, we only
considered the indels that were associated with a sgRNA which had been considered significantly mutated in that particular sample. This final set of significant indels was converted to .avinput format and subsequently annotated using
ANNOVAR v. 2016Feb01, using default settings65.
Co-occurrence and correlation analysis. Co-occurrence analysis was performed
by first generating a double-mutant count table for each pairwise combination
of genes in the mTSG library. Statistical significance of the co-occurrence was
assessed by hypergeometric test. For correlation analysis, we first collapsed the
percent variant frequency tables on the gene level (in other words, summing
the percent variant frequencies for all five of the targeting sgRNAs for each
gene). Using these summed percent variant frequency values, we calculated the
Spearman correlation between all gene pairs, across each mTSG sample. Statistical
significance of the correlation was determined by converting the correlation coefficient to a t-statistic and using the t-distribution to find the associated probability. A similar approach was used to analyze co-occurring mutations in human
TCGA GBM data.
Testing driver combinations with sgRNA minipools. Mixtures of five sgRNAs
targeting each gene were cloned as sgRNA minipools into the same astrocytespecific AAV-CRISPR vector. For gene pair targeting, the five-sgRNA single gene
minipools from both genes were mixed at 1:1. Plasmid mixes were then packaged into AAV1/2. Briefly, HEK293FT cells were transfected with the minipool
plasmids, pAAV1 plasmid, pAAV2 plasmid, helper plasmid pDF6 and PEI Max
(Polysciences, Inc. 24765-2) in DMEM (ThermoFisher, 10569-010). Seventy-two
hours post-transfection, cell culture media was discarded, and cells were rinsed
and pelleted via low-speed centrifugation. Cells were then lysed, and the supernatant containing viruses was applied to HiTrap heparin columns (GE Biosciences
17-0406-01) and washed with a series of salt solutions with increasing molarities.
During the final stages, the eluates from the heparin columns were concentrated
using Amicon ultra-15 centrifugal filter units (Millipore UFC910024). Viral particles were titered by quantitative PCR using custom Cre-targeted Taqman probes

NATURE NEUROSCIENCE

T7 endonuclease I (T7E1) assays. The genomic DNA of cells collected after 9 d of
puromycin selection was extracted using QuickExtract DNA Extraction Solution
(Epicentre), mixed well and incubated at 65 °C for 30–60 min. Then, 1–2 ML of
genomic DNA from parental or lenti-sgRNA-transduced cells was used as the
template to amplify the gene of interest using surveyor primers (Supplementary
Table 33) with thermocycling conditions set at 98 °C for 1 min; 35 cycles of
98 °C for 1 s, 60 °C for 5 s and 72 °C for 10 s; and 72 °C for 1 min. The PCR products were gel-purified using QIAquick Gel Extraction Kit from 2% E-gel EX and
quantified, followed by PCR product denaturing at 95 °C for 5 min and annealing
under the following conditions: ramp from 95 to 85 °C at a rate of −2 °C per s;
from 85 °C to 25 °C at a rate of −0.1 °C per s and hold at 4 °C. We added 1 ML of T7
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Statistical tests. In addition to the statistical tests detailed above, we used a twotailed Welch’s t test for comparisons in which group variances were unequal.
If the variances were found to be sufficiently equal and the data was normally
distributed, we used a standard two-tailed t test. To evaluate differences in the
incidence of tumors in different groups, we used Fisher’s exact test. See the Life
Sciences Reporting Summary for additional information about the methods
used in this study.

endonuclease I into annealed oligo and incubated it at 37 °C for 60 min to digest
the mismatched sites. The digested PCR products were loaded into 2% E-gel EX,
and the amount of DNA fragments were quantified. The cutting efficiency was
calculated to estimate gene editing using the following formula:
indels (%)  100 r (1 (1 fraction cleaved)1 / 2)
Transcriptome profiling of different driver combinations in the presence
and absence of chemotherapy. Mixtures of five sgRNAs targeting each gene
were cloned as sgRNA minipools into the same astrocyte-specific AAV-CRISPR
vector. After packaging, AAV minipools were stereotaxically injected into the
lateral ventricles of LSL-Cas9 mice. Cell lines were derived from mouse GBMs
by single-cell isolation, plating and culture in DMEM media. Additional driver
mutations were introduced by lentiCRISPR, where applicable. GBM cells with
different drivers were treated with DMSO or TMZ for 48 h and harvested for
mRNA-seq for transcriptome profiling. Briefly, total RNA was extracted from
cancer cells derived from AAV-CRISPR minipool-induced GBM treated with
DMSO or TMZ, using commercially available kits (Qiagen / ThermoFisher). A
poly-A mRNA library was constructed using Illumina TruSeq mRNA library prep
kit and sequenced on an Illumina HiSeq 2500 and/or HiSeq 4000 platform.

Blinding statement. Investigators were blinded with respect to histology scoring,
capture sequencing and RNA-seq collection but not for dissection, MRI, survival
analysis or sequencing analysis.
Determination of sample sizes. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous
publications cited here.
Code availability. Key custom scripts used to process and analyze the data are
included in Supplementary Software. Other accessory scripts are available
on request.
Data availability. Genomic sequencing (targeted capture, exome) and RNA-seq
data have all been deposited in NCBI SRA (PRJNA393202). CRISPR reagents
(AAV-CRISPR and lentiCRISPR backbone plasmids and mTSG libraries) are
available to the academic community through Addgene (https://www.addgene.
org/browse/article/28190058/) or upon request.

RNA-seq differential expression analysis. Strand-specific single-end
RNA-seq read files were analyzed to obtain transcript level counts using
Kallisto66, with the settings --rf-stranded -b 100.The counts were subsequently
passed to the ‘tximport’ R package to collapse to gene-level counts. Pairwise
differential expression analysis between groups was then performed using edgeR
with default settings67.
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Pathway enrichment analysis of differentially expressed transcripts. Using an
adjusted P value cutoff of 0.05 and a log fold-change threshold of o 1, we determined the set of genes that were significantly upregulated or downregulated. We
then used the resultant gene sets for DAVID functional annotation analysis68.
We considered a GO category statistically significant if the Benjamini-Hochberg
adjusted P < 0.05.
GBM comparative cancer genomics analysis using TCGA datasets. Somatic
mutation calls, copy-number variation calls, RNA-seq expression z-scores and
clinical data containing patient survival information were obtained through cBioPortal for GBM on 15 November, 2016. Pearson correlation coefficients were
calculated, comparing mouse and human mutation frequencies; statistical significance was calculated by converting the correlation coefficient to a t-statistic
and then using the t-distribution to calculate significance.
GBM comparative cancer genomics analysis using Yale glioma datasets.
Somatic mutation calls, copy-number variation calls and partial clinical data
containing diagnostic information were obtained from the Yale Brain Tumor
Program. All patient samples were deidentified. The general description, demographics and tumor characteristics are noted in Supplementary Tables 14
and 15. Total events for each patient were calculated as the sum of mutation events
and copy-number variant events. Pearson correlation coefficients were calculated
comparing mouse and human mutation frequencies; statistical significance was
calculated by converting the correlation coefficient to a t-statistic and then using
the t-distribution to calculate significance.
Histology analysis of clinical GBM samples from Yale glioma tissue bank.
Histology sections were obtained from the Yale Brain Tumor Program. All patient
samples were deidentified. The mutations associated with specific samples were
obtained from the Yale glioma databank. Slides stained with H&E or antiGFAP were subsequently scanned using a slide scanner (Leica) and subjected to
pathological analysis.
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2.2: Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using
AAV-CRISPR–mediated direct in vivo screening
Concurrently with our work on glioblastoma, we also adapted the autochthonous CRISPR
screening approach to study genetic regulators of liver tumorigenesis, in fully immunocompetent
mice

93

. This work revealed that many of the strongest tumor suppressors in the liver are not

necessarily the same as those in the brain, in line with observations from large-scale clinical
sequencing studies and genetic mouse models.
This line of investigation was initially conceived by my advisor Dr. Sidi Chen and our
collaborator Dr. Randall Platt. The study was performed in close collaboration with several
colleagues, particularly Guangchuan Wang. As with the glioblastoma CRISPR screen study, my
primary role in this study was the development of integrative analytical approaches to understand
the CRISPR-mediated genetic perturbations leading to liver tumorigenesis. I prepared the
manuscript text and figures, together with Dr. Sidi Chen.
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are represented by thousands of mutant variants; however, the functional
roles of many of these mutants remain to be explicitly tested in controlled
experimental settings.
Genetically engineered mouse models (GEMMs) have been
instrumental for studying the mechanisms of oncogenes and tumor
suppressors in vivo (16). Conditional or germline knockout alleles enable in vivo modeling of diverse diseases, including a wide variety of
cancer types. Because the microenvironment is increasingly recognized
to have a critical influence on cancer progression, GEMMs enable autochthonous modeling of cancer, that is, in the native tissue of origin
(17), which provides a higher degree of precision for cancer modeling
and preclinical testing. However, the production of GEMMs is timeconsuming and requires a complex multistep process, involving embryonic stem cell modifications, the generation of chimeras, germline
transmission, and mouse colony expansion (18). Owing to the technical
difficulties of this process and the complexity of breeding with large
numbers of genetic modifications, GEMMs have largely been limited
to the study of only a handful of genes at a time. Thus, a systematic
characterization of the hundreds of RMGs identified through tumor sequencing studies is impractical using regular GEMMs.
One promising approach for high-throughput assessment of cancer
RMGs is through the use of clustered regularly interspaced short palindromic repeats (CRISPR)–mediated genome engineering in mammalian
species (19–22). Hydrodynamic injection of plasmids encoding singleguide RNAs (sgRNAs) and CRISPR-associated protein 9 (Cas9) (23, 24)
has been used to directly mutate several tumor suppressor genes (TSGs)
in the mouse liver (23, 25). Viruses have also been used to generate lossof-function or gain-of-function mutations in tumor suppressors and
oncogenes in vivo (26–30). In addition, the CRISPR system has been
used to perform genome-scale knockout screens in vitro and in transplant models (31–34). However, current screens rely on the sequencing
of sgRNAs, which is an indirect measurement of the selective forces
acting on specific gene perturbations.
To directly interrogate the comparative selective advantage of mutants in the tumor-initiating organs, it is necessary to first generate and

INTRODUCTION

Large-scale molecular profiling of patient samples has tremendously
improved our understanding of human cancers (1–6). The multidimensional landscapes produced by international consortia such as
The Cancer Genome Atlas (TCGA) and Catalogue of Somatic Mutations
in Cancer (COSMIC), encompassing key data sets such as somatic mutations, copy number variants, epigenetic marks, mRNA and microRNA
transcriptomes, as well as protein levels, have illuminated the molecular
underpinnings of cancer at an unprecedented resolution and scale (7–9).
Consequently, we now have an extensive catalog of genes that are recurrently mutated across different patients, both within and across histological subtypes (1, 2, 10, 11). Whereas some of these recurrently mutated
genes (RMGs) are well-known tumor suppressors or oncogenes, many
other RMGs still have an unclear role in cancer. Although the identification of RMGs is an important first step toward the development of new
therapeutic avenues, functional evidence is required to definitively determine which genomic alterations are essential for the growth of an individual cancer (4, 6, 12, 13). A number of statistical algorithms, which aim
to distinguish RMGs that are “drivers” of cancer growth from those that
are mere “passengers,” have been developed (2, 12, 14, 15). These RMGs
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Cancer genomics consortia have charted the landscapes of numerous human cancers. Whereas some mutations were
found in classical oncogenes and tumor suppressors, others have not yet been functionally studied in vivo. To date, a
comprehensive assessment of how these genes influence oncogenesis is lacking. We performed direct highthroughput in vivo mapping of functional variants in an autochthonous mouse model of cancer. Using adenoassociated viruses (AAVs) carrying a single-guide RNA (sgRNA) library targeting putative tumor suppressor genes
significantly mutated in human cancers, we directly pool-mutagenized the livers of Cre-inducible CRISPR (clustered
regularly interspaced short palindromic repeats)–associated protein 9 (Cas9) mice. All mice that received the AAV-mTSG
library developed liver cancer and died within 4 months. We used molecular inversion probe sequencing of the sgRNA
target sites to chart the mutational landscape of these tumors, revealing the functional consequence of multiple variants in driving liver tumorigenesis in immunocompetent mice. AAV-mediated autochthonous CRISPR screens provide
a powerful means for mapping a provisional functional cancer genome atlas of tumor suppressors in vivo.
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Mice that received the AAV-CRISPR mTSG library (n = 27) did not
survive more than 4 months (median survival, 90 days; 95% confidence
interval, 84 to 90 days), whereas mice that were treated with PBS (n =
10) or vector control (n = 11) all survived the duration of the experiment
(log-rank test, P = 1.8 × 10−11; Fig. 1C and table S4). By gross examination under a fluorescent dissecting scope, detectable GFP+ nodules were
observed in mTSG-treated livers but not in PBS or vector samples (Fig. 1D
and fig. S2). Notably, in mTSG-treated mice, we occasionally observed
tumors that were not primarily located in the liver. Chief among these
were several big abdominal tumors (BATs; n = 6), as well as a few
sarcomas (n = 4) and ear tumors (n = 2), although BATs were later
found to be of liver origin on the basis of histological analysis.
We analyzed endpoint histological sections from PBS-treated (n =
7), vector-treated (n = 5), and mTSG-treated mice (n = 13), sacrificed 3
to 4 months after treatment (Fig. 2A and figs. S3 and S4). No tumors
were found in PBS-treated mice, whereas rare small tumors were found
in vector-treated mice (total tumor area = 5.96 ± 3.27 mm2; Fig. 2B).
Consistent with the MRI results, mice that received the mTSG library
had significantly larger liver tumors, with the pathology of LIHC (total
tumor area = 100.6 ± 47.19 mm2; one-sided Welch’s t test, P = 0.027
compared to PBS and P = 0.034 compared to vector; Fig. 2, A and B, and
table S5). Because these mice were found to have multiple liver tumors,
we also compared the size of each individual tumor across the three
treatment groups (Fig. 2C). The mTSG-treated mice collectively had
tumors that were significantly larger (26.69 ± 6.18 mm2) than those
found in vector-treated animals (3.31 ± 1.55 mm2; P = 0.0003), although
the latter were too small to be detected by gross examination under a
GFP dissecting scope. We assessed the proliferation of liver samples
from PBS-, vector-, and mTSG-treated mice by Ki67 expression and
found that rapid proliferation was restricted to tumor cells (fig. S4B). In
addition, we found that the tumors in mTSG-treated mice, but not in
vector-treated mice, were largely positive for AE1/AE3 (pan-cytokeratin),
which is a marker of LIHC (Fig. 2D and fig. S4C). These data collectively
indicate that the AAV-CRISPR mTSG library directly promotes aggressive
liver tumorigenesis in otherwise wild-type LSL-Cas9 mice.
To understand the molecular alterations driving the development of
tumors in mTSG-treated mice, we designed MIPs to enable capture sequencing of the ±70–base pair (bp) regions surrounding the predicted cut
site of each sgRNA in the mTSG library (namely, the +17 position of each
20-bp spacer sequence; Materials and Methods). As opposed to simply
sequencing the sgRNA cassettes to find the relative enrichment of each
sgRNA within the cell population, MIP capture sequencing enables a direct quantitative analysis of the mutations induced by the Cas9-sgRNA
complex. To generate this pool of MIPs (termed mTSG-MIPs; table S6),
we synthesized a total of 266 extension and ligation probes targeting 266
genomic loci with an average size of 158 ± 8 (SEM) bp, covering 278
unique sgRNA sites. Liver genomic DNA was extracted from PBS-treated
(n = 8 mice), vector-treated (n = 8 mice), and mTSG-treated mice (n = 27
mice; 37 liver lobes in total). To assess the potential for AAV-CRISPR–
mediated mutagenesis of other organs, we also collected DNA from all
observed non-liver tumors (n = 23), as well as a wide variety of tissues
(such as brain, lung, colon, spleen, and kidney) without detectable tumors
under a fluorescent dissecting scope (n = 57 samples) from all three
groups. We performed MIP capture sequencing on all genomic DNA
samples (total n = 133; table S7). Sequencing depth of the sgRNA target
regions was sufficiently powerful to detect variants at <0.01% frequency,
with a mean read depth of 13,286 ± 1033 (SEM) across all MIPs after
mapping to the mouse genome (table S8). Median read depth across
all MIPs approximated a log-normal distribution, indicating relatively

RESULTS

We first sought to compile a list of the top RMGs in the pan-cancer
TCGA data sets. Applying a similar approach, as in previous studies
(1–3), we identified the top 50 RMGs after excluding known oncogenes
(Fig. 1A). Of the top 50 putative TSGs, 49 genes had mouse orthologs
(mouse TSGs, hereafter referred to as mTSG). We also selected seven
housekeeping genes to serve as controls. Then, we designed a library of
sgRNAs targeting these 56 different genes, with 5 sgRNAs for each gene,
totaling 280 sgRNAs (hereafter referred to as the mTSG library; Fig. 1A
and table S1). For Cdkn2a and Rpl22, only four unique sgRNAs were
synthesized, with the fifth sgRNA being a duplicate. The duplicates were
treated as identical in downstream analyses. After oligo synthesis, we
cloned the mTSG library into a base vector containing a U6 promoter
driving the expression of the sgRNA cassette, as well as a Cre expression
cassette (Fig. 1A). Because mutation of a single TSG rarely leads to rapid
tumorigenesis in humans or autochthonous mouse models, we included
an sgRNA targeting Trp53 in the base vector with the initial hypothesis
that concomitant Trp53 loss of function might facilitate tumorigenesis.
Sequencing of the plasmid pool revealed a complete coverage of the
278 unique sgRNAs represented in the mTSG library (table S2). After
generating AAVs (serotype AAV9) containing the base vector or the
mTSG library, we then intravenously injected phosphate-buffered saline (PBS), vector AAVs, or mTSG AAVs into fully immunocompetent
LSL-Cas9 mice (Fig. 1A). Upon AAV infection, Cre is expressed and
excises the stop codon, activating Cas9 and enhanced green fluorescent
protein (EGFP) expression.
Live magnetic resonance imaging (MRI) of mice 3 months after
treatment revealed large nodules in mTSG-treated animals (n = 4),
whereas vector-treated animals (n = 3) only occasionally had small nodules and PBS-treated animals (n = 3) were devoid of detectable nodules
(Fig. 1B; fig. S1, A and B; and table S3). The total tumor volume in each
mouse was significantly larger in mTSG samples compared to PBS and
vector samples (one-sided Mann-Whitney test, P = 0.0286 and P =
0.0286, respectively; fig. S1B). These data suggest that the AAV-CRISPR
mTSG library is sufficient to induce rapid tumorigenesis in the livers of
LSL-Cas9 transgenic mice.
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then subsequently sequence pools of mutant cells within the native tumor environment. Adeno-associated viruses (AAVs) are powerful carriers of transgenes and have been shown to mediate efficient genome
editing in various organs in mice (29, 35). Given that AAVs can efficiently infect the liver after intravenous injection (36), we reasoned that
liver hepatocellular carcinoma (LIHC; also known as HCC), a deadly
cancer with poor 5-year survival (37), would be a suitable and relevant
model.
Here, we directly mapped functional cancer genome variants of tumor suppressors in the autochthonous mouse liver using massively
parallel CRISPR/Cas9 genome editing. We performed a direct in vivo
CRISPR screen by intravenously injecting AAV pools carrying a library
of 278 sgRNAs that target a set of the most frequently mutated, known,
or putative TSGs into Rosa-LSL-Cas9-EGFP knock-in mice (LSL-Cas9
mice) to generate highly complex autochthonous liver tumors, followed
by direct readout of the Cas9-generated variants at predicted sgRNA cut
sites using molecular inversion probe (MIP) sequencing. This combination of direct mutagenesis and pooled variant readout illuminated the
mutational landscape of the tumors. Mutagenesis of individual or combinations of the top genes represented by high-frequency variants led to
liver tumorigenesis in fully immunocompetent mice.
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even capture of the target loci (fig. S5A). Insertions and deletions (indels) were then called across all samples to reveal detectable indel variants at each sgRNA cut site (Materials and Methods; table S9). We
excluded single-nucleotide variants from the analysis because indels
are the dominant variants generated by nonhomologous end-joining
(NHEJ) following Cas9-mediated double-strand breaks (DSBs) in vivo
(38, 39). For downstream analysis, we only considered indels that overlapped the ±3-bp flanks around each of the predicted sgRNA cut sites
because Cas9 tends to create DSBs within a tight window near the predicted sgRNA cut site in mammalian cells (39). A representative exam-

ple of the genotypes observed by MIP capture sequencing is shown at
the Setd2 sgRNA 1 cut site for PBS-, vector-, or mTSG-treated samples
(Fig. 3A), illustrating the diversity of Cas9-induced indels in mTSGtreated mice.
After collapsing each of the filtered indel calls to the closest sgRNA
by summing their constituent variant frequencies (table S10), we plotted
the overall spectrum of variant frequencies across all sequenced samples
(Fig. 3C). We then calculated the mean variant frequency for each
sgRNA and each sample (Fig. 3C, right and bottom panels, respectively). The mTSG-treated organs without visible tumors (0.148 ± 0.037
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Fig. 1. AAV-CRISPR mTSG library rapidly induces robust liver tumorigenesis in LSL-Cas9 mice. (A) Schematics of the overall design and experimental outline. First, the top
MGs were identified from pan-cancer TCGA data sets. After removing known oncogenes and genes without mouse orthologs, a set of 49 most recurrently mutated putative TSGs
were chosen (mTSG). Seven additional genes with housekeeping functions were spiked-in, leading to a final set of 56 genes. sgRNAs targeting these genes were then identified
computationally, and five were chosen for each gene. Two hundred eighty sgRNAs plus 8 NTC sgRNAs were synthesized, and the sgRNA library (mTSG; 288 sgRNAs) was cloned
into an expression vector that also contained Cre recombinase and a Trp53 sgRNA. AAVs carrying the mTSG library were produced and injected into the tail veins of LSL-Cas9 mice.
After a specified time period, the mice were subjected to MRI, histology, and MIP capture sequencing for readout and deep variant analysis of molecular landscape of all targeted
genes and mutations. (B) MRI of abdomens of mice treated with PBS, vector, or mTSG library. Detectable tumors are circled with green dashed lines. PBS-treated mice (n = 3) did
not have any detectable tumors, whereas vector-treated mice (n = 3) occasionally had small nodules. In contrast, mTSG-treated mice (n = 4) often had multiple detectable tumors.
(C) Kaplan-Meier survival curves for PBS-treated (purple, n = 10), vector-treated (teal, n = 11), and mTSG-treated (orange, n = 27) mice. No mTSG-treated mice survived longer than
4 months after treatment, whereas all PBS- and vector-treated animals survived the duration of the experiment. Statistical significance was assessed by the log-rank test (P = 1.8 ×
10−11). (D) Bright-field images with GFP fluorescence overlay (green) of livers from representative PBS-, vector-, and mTSG-treated mice 4 months after treatment. Large GFP+
tumors are marked with yellow arrowheads. In contrast to PBS- or vector-treated mice, mTSG-treated mice had numerous detectable GFP+ nodules.
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samples presented with highly heterogeneous mutational signatures, indicating that a diverse array of mutations had undergone positive selection in different samples (Fig. 3B and fig. S6).
We then collapsed MSs in each sample to the gene level to find MGs
within individual tumors (table S12). Analysis of all mTSG liver samples
revealed a full mutational landscape of the entire cohort, unfolded as a
binary mutation spectrum (Fig. 4) and a quantitative spectrum with
sum allele frequencies of each gene in a tumor (fig. S7). Of the 37
mTSG-treated liver samples, 33 (89%) were found to have major indels
(≥5% sum variant frequency and FDR < 0.0625; Materials and Methods)
in one or more of the 56 genes in the mTSG library (average number of
MGs per sample, 11.7 ± 1.53). Trp53, Setd2, Cic, and Pik3r1 were the top
MGs in the cohort (mutated in 24 of 37, 18 of 37, 17 of 37, and 17 of 37
samples, respectively). Trp53 is a well-known tumor suppressor that has
been found to directly induce liver tumors upon loss of function in hepatocytes (40); Setd2 is an epigenetic modifier that has been implicated
in clear cell renal carcinoma (41) but is not yet functionally characterized in liver cancer; Cic is a transcriptional repressor that has been
shown to be a negative regulator of epidermal growth factor receptor
(EGFR) signaling (42); Pik3r1 is a modulator of phosphatidylinositol
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Fig. 2. Histology analysis of autochthonous tumors generated by AAV-CRISPR mTSG library. (A) Hematoxylin and eosin (H&E) staining of liver sections from mice treated
with PBS (n = 7), vector (n = 5), or mTSG library (n = 13). Tumor-normal boundaries are demarcated with yellow dashed lines. No tumors were found in PBS samples, whereas small
nodules were found, although rare, in vector samples. On the other hand, mTSG-treated livers were replete with tumors [statistics in (B) and (C)]. (B) Dot plot of the total tumor area
per mouse (mm2) in liver sections from mice treated with PBS (black, n = 7), vector (gray, n = 5), or mTSG library (purple, n = 13). mTSG-treated mice had a significantly higher total
tumor burden than PBS-treated (one-sided Welch’s t test, P = 0.027) or vector-treated mice (P = 0.034). (C) Dot plot of the individual tumor area (mm2) in liver sections from mice
treated with PBS (black, n = 7), vector (gray, n = 9), or mTSG library (purple, n = 49). mTSG-treated mice had significantly larger tumors than PBS-treated (one-sided Welch’s t test, P <
0.0001) or vector-treated mice (P = 0.0003). (D) Representative immunohistochemical staining of an LIHC marker, pan-cytokeratin (AE1/AE3), from mice treated with PBS, vector, or
mTSG library. The tumors from mTSG-treated samples shown revealed positive staining for AE1/AE3, consistent with LIHC pathology. Certain mTSG tumors were partially positive
for cytokeratin, revealing tumor heterogeneity. The tumors from vector-treated samples were relatively small and almost always negative or slightly positive for cytokeratin. Scale
bar, 0.5 mm.
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SEM) had significantly lower mean variant frequencies compared to
mTSG-treated tumors and livers (BATs, 3.098 ± 0.600; unpaired t test,
P < 0.0001), non-liver tumors (1.919 ± 0.338; P < 0.0001), and livers
(1.451 ± 0.203; P < 0.0001). Livers and other organs from vector-treated
animals (0.398 ± 0.179 and 0.054 ± 0.004, respectively) and PBS-treated
animals (0.140 ± 0.067 and 0.063 ± 0.021, respectively) all had significantly lower variant frequencies than mTSG-treated livers (P < 0.0001
for all comparisons). The low background variant frequencies observed
in vector- and PBS-treated samples may be due to noise that was generated during sequencing, as well as stochastic or germline mutations.
Notably, the vector contains a Trp53 sgRNA that potentially contributes
to higher variant frequencies in vector-treated livers due to genome instability of Trp53-deficient cells.
We identified MSs in the mTSG-treated liver samples using the false
discovery rate (FDR) method as compared to PBS- and vector-treated
liver samples such that no control sample would have any called MSs
(Materials and Methods). Because we were most interested in analyzing
dominant clones that had undergone strong positive selection in the tumor, we further required that at least 5% of the reads must have an indel
in that region to call an MS (table S11). Different mTSG-treated liver
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Fig. 3. Mutational variant-level mutational landscape of mouse AAV-mTSG–induced LIHC. (A) Unique variants observed at the genomic region targeted by Setd2 sg1 in
representative PBS-, vector-, and mTSG-treated liver samples. The percentage of total reads that correspond to each genotype is indicated on the right in the blue boxes. No indels
were found in the PBS- or vector-treated samples, whereas several unique variants were identified in the mTSG-treated sample (mTSG 042). (B) Waterfall plots of two mTSG-treated
samples (042 and 066) detailing sum variant frequencies in mutated sgRNA sites (MSs). Individual mice presented with distinct mutational signatures, suggesting that a wide
variety of mutations induced by the mTSG library had undergone positive selection. (C) Global heat map detailing the square root of sum variant frequency across all sequenced
samples (n = 133) from mTSG-treated (n = 98 samples), vector-treated (n = 21 samples), or PBS-treated mice (n = 14 samples) in terms of sgRNAs. Square root transformation was
used to even out the distribution of variant frequencies for visualization. Each row represents one sgRNA, whereas each column represents one sample. Treatment conditions and
tissue type are annotated at the top of the heat map: BAT (dark purple), detectable tumor outside liver (light purple), liver (teal), brain (light pink), gastrointestinal (GI; dark pink),
lung (brown), and other organs (gray). Bar plots of the mean square root variant frequencies for each sgRNA (right, green bars) and each sample (bottom, purple bars) are also
shown. mTSG-treated organs without visible tumors (0.148 ± 0.037 SEM) had significantly lower mean variant frequencies compared to mTSG-treated tumors and livers (BATs,
3.098 ± 0.600; two-sided unpaired t test, P < 0.0001), non-liver tumors (1.919 ± 0.338; P < 0.0001), and livers (1.451 ± 0.203; P < 0.0001). Livers and other organs from vector-treated
animals (0.398 ± 0.179 and 0.054 ± 0.004, respectively) and PBS-treated animals (0.140 ± 0.067 and 0.063 ± 0.021, respectively) all had significantly lower variant frequencies than
mTSG-treated livers (P < 0.0001 for all comparisons).
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Fig. 4. Mouse gene-level mutational landscape of LIHC. Each row in the figure corresponds to one gene in the mTSG library, whereas each column corresponds to one mTSGtreated liver sample. (Top) Bar plots of the total number of MGs identified in each mTSG-treated liver sample (n = 37). Samples originating from the same mouse are grouped
together and denoted with a gray bar underneath. (Middle) Tile chart depicting the mutational landscape of primary liver samples infected with the mTSG library. Genes are
grouped and colored according to their functional classifications (DNA repair/replication, epigenetic modifier, cell death/cycle, repressor, immune regulator, ubiquitination,
transcription factor, cadherin, ribosome-related, and RNA synthesis/splicing), as noted in the legend in the top-right corner. Colored boxes indicate that the gene was mutated
in a given sample, whereas a gray box indicates no significant mutation. Asterisks denote several preselected genes that were generally considered housekeeping genes. (Right)
Bar plots of the percentage of liver samples that had a mutation in each of the genes in the mTSG library. Trp53, Setd2, Pik3r1, Cic, B2m, Vhl, Notch1, Cdh1, Rpl22, and Polr2a were the
top MGs in each of the 10 functional classifications, respectively. (Bottom) Stacked bar plots describing the type of indels observed in each sample, color-coded according to the
legend in the bottom-right corner. Frameshift insertions or deletions comprised the majority of variant reads (median, 59.2% across all samples). (Left) Heat map of the number of
mutated sgRNA sites (0 to 5 MSs) for each gene. Multiple mutated sgRNA sites for a given gene are indicative of a strong selective force for loss-of-function mutations in that gene.
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and correlation analyses (Fig. 5G). One of the top gene pairs was Arid2 +
Cdkn1b, representing a previously unreported synergistic interaction
between an epigenetic regulator and a cell cycle regulator.
To examine the mutational landscape of the liver tumors induced by
the AAV-CRISPR mTSG library at a finer resolution, we reframed our
analysis to the level of specific indel variants. Across all 37 mTSG-treated
liver samples, we identified 593 unique variants that had a variant
frequency of ≥1% in at least one sample (table S15). The majority of
these variants (80.94%) were deletions rather than insertions (table S15).
Hierarchical clustering of the variant-level data across all mTSG-treated
liver samples revealed the existence of sample-specific variants: 70.15%
(416 of 593) of the variants were sample-specific (private variants),
whereas 29.85% (177 of 593) of the variants were found across multiple
samples (shared variants; fig. S9). Shared variants could originate from
convergent processes of NHEJ following Cas9/sgRNA-mediated DSBs,
leading to the same indel pattern. Alternatively, shared variants in different liver lobes from the same mouse could also arise from clonal expansion or metastasis.
To deepen our understanding of the clonal architecture in this genetically complex, highly heterogeneous yet fully gene-targeted autochthonous tumor model, we focused on a single mTSG-treated mouse
that had presented with multiple visible tumors in several liver lobes,
five of which had been harvested for MIP capture sequencing (Fig. 6A).
Analysis of the sgRNA-level variant frequencies in the five lobes revealed strong pairwise correlations between multiple lobes (Fig. 6B
and table S16). For instance, lobes 3 and 5 were significantly correlated
[Spearman rank correlation (R) = 0.700, P < 2.2 × 10−16]. Lobes 2 and 4
were also significantly correlated, though to a lesser extent (R = 0.207, P =
5.08 × 10−4). Furthermore, lobes 1, 2, and 4 were also significantly
correlated with lobe 5 (R = 0.248, P = 2.99 × 10−5; R = 0.146, P =
0.0146; and R = 0.243, P = 4.31 × 10−5, respectively). The interlobe
correlations are suggestive of similar variant compositions within
these liver lobes.
To delineate any potential clonal mixtures among the five lobes, we
next examined the unique variant patterns across these samples. We
identified 178 unique variants (≥1% variant frequency threshold) represented within the five liver lobes (table S17). Using binary variant
calls (that is, whether a given variant is present or absent in a sample),
we clustered these 178 variants into eight groups (Fig. 6C and table S17).
Variants in clusters 1, 2, 3, 5, and 6 were specific to a single lobe (private
variant clusters), whereas variants in clusters 4, 7, and 8 were present
across multiple lobes (shared variant clusters). By averaging the variant
frequencies within each cluster for a given sample, we then analyzed the
relative contribution of each cluster to the overall composition of the
five lobes (Fig. 6, D and E). The degree of correlation between lobes
(Fig. 6B) is echoed by their degree of variant cluster sharing (lobe
1 shares cluster 4 with lobe 5, lobes 2 and 4 share variant cluster 8 with
lobe 5, and lobe 3 shares clusters 7 and 8 with lobe 5; Fig. 6, D and E).
The presence of cluster 8 in four of five lobes is especially notable, because it comprised a large percentage of the mutational burden in these
four lobes (Fig. 6, D and E). Cluster 8 was defined by mutations in Mll3
(also known as Kmt2c), Setd2, and Trp53 (Fig. 6E). Variant-level analyses therefore recaptured the pairwise correlations identified on the
sgRNA level, suggesting clonal mixture between individual liver lobes
within a single mouse.
We individually tested the functional roles of mutations in several of
the top genes in a Trp53-sensitized background. We chose gene pairs
based on their ranking in the screen, potential biological function, and
literature. We generated an AAV vector for liver-specific CRISPR
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3-kinase (PI3K) signaling, and loss-of-function mutations of this gene
have been found to induce liver tumorigenesis in mice (43). In terms of
cellular pathways, epigenetic modifiers and cell death/cell cycle regulators were frequently mutated, with multiple genes that were mutated in
more than 20% of samples (Fig. 4). Although the importance of epigenetic modifiers in cancer is now accepted (44), direct functional testing
of groups of epigenetic regulators in an autochthonous model of tumorigenesis has not yet been shown in a systems manner.
Of the genes that were mutated in at least one sample, the vast majority (91%, or 50 of 55) had multiple MSs (median, 3 MSs of 5 total
sgRNAs per gene), suggesting that these genes are functional tumor
suppressors (Fig. 4). ANNOVAR analysis of the indels present in the
mTSG liver cohort revealed that frameshift insertions and frameshift
deletions comprised the majority of total variant reads (median,
59.2% across all samples; Fig. 4 and fig. S5B), consistent with the notion
that frameshift mutations are expected to cause loss of function in genes.
Intronic, splice site, and non-frameshift mutations nevertheless comprised a sizeable proportion of total variant reads (Fig. 4).
To explore synergistic effects between different genes in the mTSG
library, we performed co-mutation analysis. For each pair of genes, by
tabulating the number of samples that were double mutant, single mutant, or double wild-type, we determined the strength of mutational
co-occurrence (Materials and Methods; Fig. 5A). Of all 1540 possible
gene pairs, we found that a total of 226 pairs were significantly
enriched beyond what would be expected by chance (hypergeometric
test, Benjamini-Hochberg–adjusted, P < 0.05), with highly significant
pairs such as Cdkn2a + Pten (co-occurrence rate = 7/10 = 70%; hypergeometric test, P = 2.63 × 10−5), Cdkn2a + Rasa1 (co-occurrence rate =
6/9 = 67%; P = 7.96 × 10−5), Arid2 + Cdkn1b (co-occurrence rate = 11/17 =
65%; P = 9.13 × 10−5), and B2m + Kansl1 (co-occurrence rate = 11/18 = 61%;
P = 3.6 × 10−4; Fig. 5, B and C, and table S13). Loss-of-function mutations in both genes of these combinations might synergistically enhance
tumor progression.
We then investigated whether genes correlated with each other in
terms of mutation frequencies within individual tumors. Because the
variant frequency is a metric for the positive selection that acts on a given mutation, genes whose variant frequencies are highly correlated
across samples could also be synergistic in driving tumorigenesis. A caveat is that some passenger mutations could be hitchhiking on strong
drivers within a given tumor; however, the probability of finding a cooccurring passenger-driver mutation pair is vanishingly small across
increasing numbers of mice. We calculated the total variant frequency
for each gene by summing all the values from all five sgRNAs, used these
summed gene-level variant frequencies across each sample to calculate
the Spearman correlation between all 1540 possible gene pairs, and assessed whether the correlations were statistically significant (Materials
and Methods; Fig. 5D and table S14). A total of 128 gene pairs were
significantly correlated (Spearman correlation, Benjamini-Hochberg–
adjusted, P < 0.05). The top four correlated pairs were Cdkn2a + Pten
(Spearman R = 0.817, P = 6.97 × 10−10), Nf1 + Rasa1 (R = 0.791, P = 5.86 ×
10−9), Arid2 + Cdkn1b (R = 0.788, P = 7.16 × 10−9), and Cdkn2a + Rasa1
(R = 0.761, P = 4.45 × 10−8; Fig. 5, E and F). We performed the same
analysis using Pearson correlation, finding extensive similarities in the
identified pairs (fig. S8, A and B, and table S14). Because the base vector
contained a Trp53 sgRNA, we also performed the co-mutation analyses
excluding all pairs involving Trp53 (fig. S8, C and D). The correlation
analysis thus revealed a number of highly significant associations in
specific pairs of genes. Four gene pairs were statistically significant
at Benjamini-Hochberg–adjusted P < 0.05 in both the co-occurrence
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Fig. 5. Co-mutation analysis of liver samples from mTSG-treated mice reveals potential synergistic combinations of driver mutations. (A) Upper-left triangle: Heat map
of the co-occurrence rates for each gene pair. To calculate co-occurrence rates, the intersection is defined as the number of double-mutant samples, and the union is defined as the
number of samples with a mutation in either of the two genes. The co-occurrence rate was then calculated as the intersection divided by the union. Lower-right triangle: Heat map
of −log10 P values by hypergeometric test to evaluate whether specific pairs of genes are statistically significantly co-mutated. (B) Scatterplot of the co-occurrence rates for each
gene pair, plotted against −log10 P values by hypergeometric test. Highly co-occurring pairs include Cdkn2a + Pten (co-occurrence rate = 7/10 = 70%; hypergeometric test, P =
2.63 × 10−5), Cdkn2a + Rasa1 (co-occurrence rate = 6/9 = 67%; P = 7.96 × 10−5), Arid2 + Cdkn1b (co-occurrence rate = 11/17 = 65%; P = 9.13 × 10−5), and Kansl1 + B2m (cooccurrence rate = 11/18 = 61%; P = 3.6 × 10−4). (C) Venn diagrams showing the strong co-occurrence of mutations in B2m + Kansl1 (top left), Cdkn2a + Pten (top right), Cdkn2a +
Rasa1 (bottom left), and Arid2 + Cdkn1b (bottom right). Numbers shown correspond to the number of mTSG-treated liver samples with a given mutation profile. (D) Upper-left
triangle: Heat map of the pairwise Spearman correlation of sum % variant frequency for each gene, summed across sgRNAs. Lower-right triangle: Heat map of −log10 P values by t
distribution to evaluate the statistical significance of the pairwise correlations. (E) Scatterplot of pairwise Spearman correlations plotted against −log10 P values. The top four
correlated pairs were Cdkn2a + Pten (R = 0.817, P = 6.97 × 10−10), Nf1 + Rasa1 (R = 0.791, P = 5.86 × 10−9), Arid2 + Cdkn1b (R = 0.788, P = 7.16 × 10−9), and Cdkn2a + Rasa1 (R = 0.761, P =
4.45 × 10−8). (F) Scatterplot comparing sum level % variant frequency for Arid2 versus Cdkn1b across all mTSG-treated liver samples. Spearman and Pearson correlation coefficients
are noted on the plot (Spearman R = 0.788; Pearson R = 0.746). (G) Heat map of the P values associated with the top mutation pairs that were found to be statistically significant
(Benjamini-Hochberg–adjusted, P < 0.05) in both co-occurrence (left) and correlation (right) analyses.
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E

Fig. 6. Systematic dissection of variant compositions across individual liver lobes within a single mTSG-treated mouse reveals substantial clonal mixture between
lobes. (A) Schematic of the experimental workflow for analysis of multiple liver lobes (n = 5) from a single mTSG-treated mouse. (B) Heat map of Spearman rank correlation
coefficients among five liver samples from a single mTSG-treated mouse, calculated on the basis of variant frequency for all unique variants present within the five samples.
Notably, lobes 1 to 4 are all significantly correlated with lobe 5, with lobe 3 having the strongest correlation to lobe 5. (C) Heat map of variant frequencies for each unique variant
identified across the five individual liver lobes after square root transformation. Rows correspond to different liver lobes, whereas columns denote unique variants. Eight clusters
were identified based on binary mutation calls and are indicated on the bottom of the heat map. (D) Pie charts depicting the proportional contribution of each cluster to the five
liver lobes. In order for a cluster to be considered, at least half of the variants within the cluster must be present in that particular sample. For each lobe, variant frequencies within a
cluster were averaged and converted to relative proportions, as shown in the pie charts. The pie charts accurately recapture the correlation analysis in (B) while additionally
providing quantitative insight into the shared variants between the five liver lobes. (E) Each box corresponds to one cluster, color-coded as in (C) and (D), showing the top four
variants in each cluster. On the basis of whether a variant cluster was present in multiple liver lobes, each box is also classified as either a private or a shared variant cluster. Clusters
1, 2, 3, 5, and 6 are largely unique to individual lobes (private variant clusters), whereas clusters 4, 7, and 8 are present in multiple lobes (shared variant clusters). Cluster 8 was found
in four of five lobes and is characterized by mutations in Mll3, Setd2, and Trp53.
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by Cas9 mutagenesis. By refocusing our analysis to the variant level,
we systematically dissected the variant compositions across multiple liver lobes from a single mouse, uncovering evidence of clonal mixture
between lobes. We thus demonstrate that massively parallel autochthonous in vivo CRISPR screens can be achieved through the use of pooled
AAVs in conjunction with MIP capture sequencing in the mouse liver.
To date, library-scale CRISPR screens have largely been demonstrated
in in vitro or cellular transplant studies; however, it has remained a challenge to perform such screens in a direct in vivo manner. Because AAVs
do not typically integrate into the genome, direct sgRNA cassette readout
is rendered infeasible. Instead, we read out a high-throughput in vivo
CRISPR experiment by targeted capture sequencing, demonstrating a
new approach for in vivo CRISPR screens. Whereas traditional sgRNA
sequencing can only provide information about the relative abundances
of each sgRNA, capture sequencing enables high-resolution analysis of
individual indel variants for clonal analysis of tumor heterogeneity.
Co-mutation analysis identified several pairs of significantly cooccurring mutations. A binary metric, such as mutation occurrence
(that is, number of mice or patient with a gene mutated), tends to reflect
the prevalence of a driver. On the other hand, a quantitative metric such
as allele frequency of a mutant or a gene in a complex tumor tends to
reflect the strength of in vivo selection, where dominant mutants with
strong effects may outcompete other mutant cells in the same mouse.
To gain a more comprehensive picture of both processes, we had leveraged both binary metrics and allele frequency as surrogate statistics
(tables S10 and S11), each of which has distinct advantages and limitations. We picked a top co-occurring pair (B2m + Kansl1), two moderate
co-occurring pairs (Pik3r1 + Pten and Pik3r1 + Stk11), and a nonsignificantly co-occurring pair (Arid2 + Kdm5c). We then knocked
out these genes, individually and combinatorially, to study their
independent and synergistic roles in liver tumorigenesis along with
Trp53 loss in immunocompetent mice. According to the IVIS data
(fig. S10), combinatorial knockout of the top co-occurring pair B2m +
Kansl1 led to significantly faster liver tumorigenesis than knocking
out either B2m or Kansl1 individually, whereas the combinatorial
knockout of the gene pair Arid2 + Kdm5c that was not found to significantly co-occur did not show any synergistic effect. The validation
results were consistent with our analysis of the screening data, indicating that the in vivo AAV-CRISPR screen is an effective approach to
identify potent TSGs and potential synergistic drivers of liver tumorigenesis in immunocompetent mice.
In the pooled AAV-CRISPR tumorigenesis system, some passenger
mutations could be hitchhiking on advantageous mutated clones, thus
showing relatively high mutation frequencies. Nevertheless, because
neutral mutations hitchhike by chance, the probability for a passenger
mutation to be recurrently co-mutated with a strong driver across
multiple samples is low compared to co-mutation of two true drivers.
Here, we adopted both binary mutant calls and allele frequency analysis
in exploring potentially synergistic interactions to minimize the possibility of identifying selectively neutral passenger-driver pairs.
As an approximation to the clonality of these tumors, we also
calculated the number of major clusters (fig. S11), in which each major
cluster has one or more mutations at similar frequencies as compared to
other mutants. From this analysis, we found that 6 of 30 mTSG livers
had single-cluster tumors, with the majority (24 of 30) being composed
of multiple clusters (fig. S11). Given the nature of pooled mutagenesis,
the detected mutations comprising co-occurring gene pairs can be either in the same clone or in different clones within the same tumor. On
the basis of allele frequency analysis, we would expect that most of the

DISCUSSION

We developed an approach for direct in vivo CRISPR screens to directly
map functional variants of tumor suppressors in mice in an autochthonous cancer model. Using an AAV library carrying 278 different
CRISPR sgRNAs, we generated hundreds of variants in the top 49
known or putative TSGs and assayed their ability to promote tumorigenesis in the mouse liver upon loss of function by Cas9 mutagenesis.
Capture sequencing of the resultant liver tumors revealed a heterogeneous mutational landscape, indicating that several of the genes in
the mTSG library function as tumor suppressors. Notably, our
experiments were conducted in immunocompetent mice; considering
the critical role of the tumor microenvironment and associated immune
context in human disease progression, the use of autochthonous tumor
models in immunocompetent animals is especially important to enhance clinical relevance (17).
Compared to conventional sgRNA sequencing, MIP capture sequencing enabled direct, multiplexed analysis of the indels induced
Wang et al., Sci. Adv. 2018; 4 : eaao5508
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knockout that expressed Cre recombinase under a TBG promoter,
together with a Trp53-targeting sgRNA cassette and an open (GeneXtargeting) sgRNA cassette (fig. S10A). The vector also contained a firefly
luciferase gene (FLuc) co-cistronic with Cre under the TBG promoter
for live imaging of tumorigenesis in mice. We cloned either a nontargeting control (NTC) sgRNA (thus only mutating Trp53) or a top candidate GeneX-targeting sgRNA (GTS; thus mutating both GeneX and
Trp53) into the second sgRNA expression cassette. After AAV packaging,
we injected NTC + Trp53 or GTS + Trp53 AAVs into LSL-Cas9 mice
(fig. S10A). We assessed the growth of potential liver tumors by
monitoring their luciferase activities using a bioluminescent in vivo imaging system (IVIS; fig. S10B). Compared to mice treated with NTC
AAVs (n = 8), sgRNAs targeting multiple candidates identified in the
screen, including Cic (n = 4), Pik3r1 (n = 7), Pten (n = 4), Stk11 (n = 8),
Arid2 (n = 3), and Kdm5c (n = 3), had significantly stronger luciferase
activity (two-sided unpaired t test, P < 0.05 for all groups; fig. S10, B to
D), suggesting that knocking out these genes accelerated liver tumorigenesis at high penetrance in a Trp53-sensitized background. Double
knockouts such as Pik3r1 + Pten (n = 3) and Arid2 + Kdm5c (n = 4)
also had significantly stronger luciferase activity compared to NTC
(two-sided unpaired t test, P < 0.001) but not significant compared to
respective single knockouts (fig. S10, C and D), suggesting that these
genes are strong drivers alone but do not have synergistic effect with
each other. B2m + Kansl1 is one of the top co-occurring gene pairs identified in the screen (co-occurrence rate = 11/18 = 61%, P = 3.6 × 10−4).
Whereas LSL-Cas9 mice injected with AAVs for individual knockout of
B2m or Kansl1 alone did not show significantly stronger luminescence intensities compared to the NTC group, AAVs targeting the B2m + Kansl1
combination showed significantly higher luminescence intensities as compared to NTC (two-sided unpaired t test, P < 0.01), B2m alone (P < 0.01),
and Kansl1 alone (P < 0.05; fig. S10, C and D). These results suggested that
combinatorial knockout of B2m and Kansl1 had a synergistic effect in accelerating liver tumor development, whereas the single knockouts of B2m
or Kansl1 were not sufficient to induce liver tumorigenesis in a Trp53sensitized background. In summary, the single and combinatorial AAVCRISPR knockout experiments further confirmed the phenotypes of
several top-ranked genes and co-occurring gene pairs in liver tumorigenesis. Our study demonstrates a powerful strategy for quantitatively
mapping functional suppressors in the cancer genome and their synergistic relationships directly in vivo in a fully immunocompetent setting.
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significantly correlated gene pairs had coevolved in the same clone. To
definitively distinguish the monoclonal or multiclonal synergistic effects
of gene pairs in vitro and in vivo, double knockouts must be introduced
simultaneously into the same cell using a dual-sgRNA expression system and compare them to single knockout cells.
The AAV-CRISPR screen approach can potentially be extended to
identify genetic factors with a significant impact on various cancer types
and other human diseases. Our strategy for selecting genes to target in
the mTSG library was based on pan-cancer TCGA data sets, with an
initial aim of identifying genes that are more likely to function as tumor
suppressors in a wide variety of tissues such that the same AAVCRISPR mTSG library could potentially be used in other organs. We
recently applied this approach to map functional tumor suppressors
in glioblastoma (45), finding that the strongest single and co-occurring
driver mutations differ between mouse liver and brain. A technical distinction is that the present study used MIPs for reading out variants,
whereas the glioblastoma study used Roche probes. MIPs provide more
flexibility and are more cost-efficient as compared to Roche probes,
making it simple for utilization of the AAV-CRISPR–MIP screening
approach. In light of the previous success of in vivo transposon-based,
short hairpin RNA (shRNA), or lentiviral screens in other cancers (46–49),
we anticipate that our approach (AAV-CRISPR mutagenesis followed
by MIP capture sequencing) can be readily expanded to other organ
systems, potentially enabling the construction of a multiorgan functional variant mapping of tumor suppressors.
One limitation of this study is the exclusion of oncogenes. Because
advantageous alterations in proto-oncogenes are generally thought to
occur through several different mechanisms, such as mutations to specific
amino acid residues, increased expression by transcriptional amplification,
or copy number amplification (3), modeling proto-oncogenes in a massively parallel manner requires more sophisticated methods. Several in
vitro gene activation screens using CRISPR have been described,
opening the possibility for overexpression screens of proto-oncogenes
(50, 51). CRISPR has also recently been engineered to mutate specific
DNA nucleotides (52, 53). Adapting these new tools for use in vivo
would allow high-throughput oncogene screens, thereby enabling functional variant mapping of oncogenes. Although we focused on a set of
highly mutated pan-cancer tumor suppressors in mouse liver in this
study, given the immense programmability of CRISPR-mediated genome editing, it is feasible to apply this AAV-CRISPR screen approach
to target different sets of genes or noncoding elements, potentially at
genome scale, to functionally assess phenotypes in an unbiased fashion.
The versatility of this new platform provides a powerful means for mapping a provisional functional cancer genome atlas of tumor suppressors,
oncogenes, and other types of genetic events of tumor evolution, in isolation or as combinations and larger pools, in virtually any cancer type.
Application of this approach in conjunction with therapeutic agents will
enable precision preclinical testing for rapid identification of effective
compounds against specific mutant genotypes, paving new ways for
cancer target discovery.

mouse homologs (mTSG) were retrieved from mouse genome informatics (www.informatics.jax.org). A total of 49 mTSGs were found.
A total of seven known housekeeping genes were chosen as internal
controls. sgRNAs against these 56 genes were designed using a previously described method (31, 32) with our custom scripts. Five sgRNAs
were chosen for each gene, plus eight NTCs, making a total of 288
sgRNAs in the mTSG library. NTCs do not target any predicted sites
in the genome; thus, they were not included in subsequent MIPs analysis. Notably, two sgRNA pairs happened to be identical by design,
namely, Rpl22_sg4/sg5 and Cdkn2a_sg2/sg5. These sgRNAs were treated as the same in subsequent analyses.

AAV-mTSG viral library production
The AAV-CRISPR plasmid vector (AAV-vector) and library (AAVmTSG) were subjected to AAV9 production and chemical purification.
Briefly, human embryonic kidney (HEK) 293FT cells (Thermo Fisher
Scientific) were transiently transfected with AAV-vector or AAVmTSG, AAV9 serotype plasmid, and pDF6 using polyethyleneimine.
Each replicate consisted of five 80% confluent HEK 293FT cells in
15-cm tissue culture dishes or T-175 flasks (Corning). Multiple replicates were pooled to enhance production yield. Approximately 72 hours
after transfection, cells were dislodged and transferred to a conical tube
in sterile PBS. Pure chloroform (1/10 volume) was added, and the mixture was incubated at 37°C and vigorously shaken for 1 hour. NaCl was
added to a final concentration of 1 M, and the mixture was shaken until
dissolved and then pelleted at 20,000g at 4°C for 15 min. The aqueous
layer was discarded, whereas the chloroform layer was transferred to
another tube. PEG8000 was added to 10% (w/v) and shaken until dissolved. The mixture was incubated at 4°C for 1 hour and then spun at
20,000g at 4°C for 15 min. The supernatant was discarded, and the pellet
was resuspended in Dulbecco’s PBS plus MgCl2 and treated with
Benzonase (Sigma) and incubated at 37°C for 30 min. Chloroform
(1:1 volume) was then added, shaken, and spun down at 12,000g at
4°C for 15 min. The aqueous layer was isolated and passed through a
100-kDa molecular weight cutoff (Millipore). The concentrated solution was washed with PBS, and the filtration process was repeated.
Genomic copy number (GC) of AAV was titrated by real-time quantitative polymerase chain reaction (qPCR) using custom TaqMan assays
(Thermo Fisher Scientific) targeted to Cre.

MATERIALS AND METHODS

Design, synthesis, and cloning of the mTSG library
Pan-cancer mutation data from 15 cancer types were retrieved from the
TCGA portal via cBioPortal (54) and Synapse (www.synapse.org).
RMGs were calculated similarly to previously described methods
(1–3, 15). Known oncogenes were excluded, and only known or predicted TSGs were included. The top 50 TSGs were chosen, and their
Wang et al., Sci. Adv. 2018; 4 : eaao5508
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Design, cloning of AAV-CRISPR vectors, and mTSG sgRNA
library cloning
AAV-CRISPR vectors were designed to express Cre recombinase for
the induction of Cas9 expression using constitutive or conditional promoters when delivered to LSL-Cas9 mice (29). Two sgRNA cassettes
were built in these vectors, one encoding an sgRNA targeting Trp53,
with the other being an open sgRNA cassette (double Sap I sites for
sgRNA cloning). The vector was generated by gBlocks Gene Fragment
synthesis [Integrated DNA Technologies (IDT)] followed by Gibson
assembly [New England Biolabs (NEB)]. The mTSG library was generated by oligo synthesis, pooled, and cloned into the double Sap I sites of
the AAV-CRISPR vectors. Library cloning was done at over 100× coverage to ensure proper representation. Representation of plasmid libraries was read out by barcoded Illumina sequencing as described
previously (33) with customized primers.
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Institute of Technology Committee for Animal Care, with approved
protocols (Chen-2015-20068 and Sharp-0914-091-17), and were
consistent with the Guide for the Care and Use of Laboratory Animals
(National Research Council, 1996) (institutional animal welfare assurance no. A-3125-01).

organs were manually dissected and examined under a fluorescent
stereoscope (Zeiss, Olympus, or Leica). Bright-field and/or GFP fluorescent images were taken for the dissected organs and overlaid using ImageJ. Organs were then fixed in 4% formaldehyde or 10% formalin for
48 to 96 hours, embedded in paraffin, sectioned at 6 mm, and stained
with H&E for pathology. For tumor size quantification, H&E slides
were scanned using an Aperio digital slide scanner (Leica). Tumors
were manually outlined as region of interest (ROI) and subsequently
quantified using ImageScope (Leica). Statistical significance was assessed by Welch’s t test, given the unequal sample numbers and variances for each treatment condition.
Mouse tissue collection for molecular biology
Mouse livers and various other organs (Supplementary Materials) were
dissected and collected manually. For molecular biology, tissues were
flash-frozen with liquid nitrogen and ground in 24-well polyethylene
vials with metal beads in a GenoGrinder machine (OPS Diagnostics).
Homogenized tissues were used for DNA/RNA/protein extractions
using standard molecular biology protocols.
Genomic DNA extraction from cells and mouse tissues
For genomic DNA extraction, 50 to 200 mg of frozen ground tissue
were resuspended in 6 ml of lysis buffer [50 mM tris, 50 mM EDTA,
1% SDS (pH 8)] in a 15-ml conical tube, and 30 ml of proteinase K
(20 mg/ml; Qiagen) was added to the tissue/cell sample and incubated at
55°C overnight. The next day, 30 ml of ribonuclease A (10 mg/ml;
Qiagen) was added to the lysed sample, which was then inverted
25 times and incubated at 37°C for 30 min. Samples were cooled on
ice before the addition of 2 ml of prechilled 7.5 M ammonium acetate
(Sigma) to precipitate proteins. The samples were vortexed at high
speed for >20 s and then centrifuged at ≥4000g for 10 min. A tight pellet
was visible in each tube, and the supernatant was carefully decanted into
a new 15-ml conical tube. Then, 6 ml of 99% isopropanol was added to
the tube, inverted 50 times, and centrifuged at ≥4000g for 10 min. Genomic DNA was visible as a small white pellet in each tube. The supernatant was discarded, 6 ml of freshly prepared 70% ethanol was added,
and the tube was inverted 10 times and then centrifuged at ≥4000g for
5 min. The supernatant was discarded, and the remaining ethanol was
removed using a P200 pipette. After air drying for 10 to 30 min, the
DNA changed appearance from a milky white pellet to slightly translucent. Then, ~500 ml of double-distilled water was added, and the tube was
incubated at 65°C for 1 hour and at room temperature overnight to fully
resuspend the DNA. The next day, the genomic DNA samples were vortexed briefly. The concentration of genomic DNA was measured using a
NanoDrop spectrophotometer (Thermo Fisher Scientific).

Magnetic resonance imaging
MRI was performed using standard imaging protocol with MRI machines (Varian 7T/310/ASR-whole mouse MRI system or Bruker
9.4T horizontal small animal systems). Briefly, animals were anesthetized using isoflurane and positioned in the imaging bed with a nose
cone providing constant isoflurane. A total of 20 to 30 frontal views were
acquired for each mouse using a custom setting: echo time (TE) = 20,
repetition time (TR) = 2000, slicing = 1.0 mm. Raw image stacks were
processed using OsiriX or Slicer tools. Rendering and quantification were
performed using Slicer (www.slicer.org). Tumor size was calculated with
the following formula: volume (mm3) = 1/6 × 3.14 × length (mm) ×
height (mm) × depth (mm). Statistical significance was assessed by nonparametric Mann-Whitney test, as sample numbers and sample distributions varied across treatment conditions.
Survival analysis
We observed that LSL-Cas9 mice receiving AAV-mTSG intravenous
injections rapidly deteriorated in their body condition scores (BSCs)
(due to tumor development in most cases). Mice with BSC < 2 were
euthanized, and the euthanasia date was recorded as the last survival
date. Occasionally, mice bearing tumors died unexpectedly early, and
the date of death was recorded as the last survival date. Cohorts of mice
intravenously injected with PBS, AAV-vector, or AAV-mTSG virus
were monitored for their survival. Survival analysis was analyzed by
standard Kaplan-Meier method, using the survival and survminer R
packages. Differences among the three treatment groups were assessed
by the log-rank test. Notably, several AAV-vector– or PBS-injected
mice were sacrificed at time points earlier than the last day of survival
analysis (at times when certain AAV-mTSG mice were found dead or
euthanized due to poor body conditions) to provide time-matched histology, although those mice presented with good body condition (BSC ≥ 4).
Mice euthanized early in a healthy state were excluded from calculation
of survival percentages.

MIP design and synthesis
MIPs were designed according to previously published protocols (55, 56).
Briefly, the 70 bp flanking the predicted cut site of each sgRNA of all 278
unique sgRNA were chosen as targeting regions, and the bed file with
these coordinates was used as an input. Because Trp53 sg4 targets a similar region as the Trp53 sgRNA within the base vector, the same MIP
was used to sequence both of these loci.
These coordinates contained overlapping regions, which were subsequently merged into 173 unique regions. Each probe contains an
extension probe sequence, a ligation probe sequence, and a 7-bp
degenerate barcode (NNNNNNN) for PCR duplicate removal. A total
of 266 MIP probes were designed, covering a total amplicon of 42,478 bp.
The statistics for the MIP target size were as follows: minimum, 155 bp;

Mouse organ dissection, fluorescent imaging, and histology
Mice were sacrificed by carbon dioxide asphyxiation or deep anesthesia
with isoflurane followed by cervical dislocation. Mouse livers and other
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Intravenous virus injection for liver transduction
Conditional LSL-Cas9 knock-in mice were bred in a mixed 129/C57BL/6
background. Mixed-gender (randomized males and females) 8- to
14-week-old mice were used in experiments. Mice were maintained
and bred in standard individualized cages with a maximum of five mice
per cage, with regular room temperature (65° to 75°F, or 18° to 23°C),
40 to 60% humidity, and a 12-hour–12-hour light-dark cycle. To intravenously inject AAVs, mice were restrained in a rodent restrainer
(Braintree Scientific), their tails were dilated using a heat lamp or warm
water and sterilized by 70% ethanol, and 200 ml of concentrated AAV
(~1 × 1010 GC/ml, 2 × 1012 GC per mouse) was injected into the tail vein
of each mouse. One hundred percent of the mice survived the
procedure. Animals that failed injections (<70% of total volume injected
into the tail vein after multiple attempts) were excluded from the study.
No specific methods were implemented to choose sample sizes.
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maximum, 190 bp; mean, 159.7 bp; median, 156.0 bp (Supplementary
Materials). Each of the mTSG-MIPs was synthesized using standard
oligo synthesis (IDT), normalized, and pooled.

was converted to .avinput format and subsequently annotated using
ANNOVAR v. 2016Feb01, using default settings (60).

Illumina sequencing data preprocessing
FASTQ reads were mapped to the mm10 genome using the bwa mem
function in BWA v0.7.13 (57). Bam files were sorted and indexed using
SAMtools v1.3 (58).
Variant calling
For each sample, indel variants were called using SAMtools and VarScan
v2.3.9 (59). Specifically, we used SAMtools mpileup (−d 1000000000 –B
–q 10) and piped the output to VarScan pileup2indel (−−min-coverage
1 –min-reads2 1 –min-var-freq 0.001 –p-value 0.05). To link each indel
to the sgRNA that most likely caused the mutation, we took the center
position of each indel and mapped it to the closest sgRNA cut site.

Unique variant analysis
Instead of first collapsing variant calls to the sgRNA level as above,
unique variants and their associated mutant frequencies were compiled
across all sequenced samples. To be considered present in a given sample, a particular variant must have a mutant frequency of ≥1%. Heat
maps of the unique variant landscape were created in R using the
NMF package, with average linkage and Euclidean distance. We also
performed a focused analysis on the unique variant landscape within
a single mouse, as presented in Fig. 5. For the correlation heat map in
Fig. 5B, we used Spearman rank correlation to assess the pairwise correlation between different liver lobes. In Fig. 5C, clusters of variants were
defined on the basis of binary mutation calls (that is, whether a given
variant is present or not within each sample). To determine the proportional contribution of each cluster, for each sample, we only included
the clusters in which at least half of the variants in the cluster are present
in that sample. We then took the average mutant frequency across the
variants within each cluster and used these values to determine the relative contribution of each cluster to the overall sample. To identify the
top four variants in each cluster, we ranked all the variants by the average variant frequency across all lobes in which the variant cluster was
considered present.

Calling MSs and MGs
We further filtered all detected indels by requiring that each indel must
overlap the ±3-bp flank of the closest sgRNA cut site, because Cas9induced DSBs are expected to occur within a narrow window of the
predicted cut site. To exclude any possible germline mutations, we also
removed any sgRNAs with indels present in more than half of the control samples with greater than 5% variant frequency. In particular, high
variant frequencies were observed across all samples at the Rps19 sg5 cut
site, suggesting that these were germline variants; thus, we excluded
Rps19 sg5 from all analyses.
To determine MSs in each liver sample, we used a false discovery
approach based on the PBS and vector control samples. For each
sgRNA, we first took the highest % variant read frequency across all
control liver samples; for a mutation to be called in an mTSG sample,
the % variant read frequency had to exceed the control sample cutoff.
However, because the base vector contained a Trp53 sgRNA (p53 sg8)
whose cut site was only 1 bp away from the target site of Trp53 sg4 (from
the mTSG library), we only considered PBS samples when calculating
the false discovery cutoff for Trp53 sg4. Finally, because we were most
interested in identifying the dominant clones in each sample, we further
set a 5% variant frequency cutoff on top of the false discovery cutoff.
These criteria gave us a binary table (that is, not mutated versus mutated) detailing each sgRNA and whether its target site was mutated
in each sample. To convert mutated sgRNA sites into MGs, we simply
collapsed the binary sgRNA scores by gene such that, if any of the five
sgRNAs for a gene were found to be strongly cutting, the entire gene
would be called as mutated.

Clustering of variant frequencies to infer clonality of tumors
For each mTSG liver sample, we extracted the individual variants that
comprised the MS calls in that sample, with a cutoff of 5% variant frequency to eliminate low-abundance variants. To identify clusters of variant frequencies in an unbiased manner, we modeled the variant
frequency distribution with a Gaussian kernel density estimate, using
the Sheather-Jones method to select the smoothing bandwidth. From
the kernel density estimate, we then identified the number of local maxima (that is, “peaks”) within the density function. The number of peaks
thus represents the number of variant frequency clusters for an individual sample, which is an approximation for the clonality of the tumors.

Coding frame analysis
For coding frame and exonic/intronic analysis, we only considered the
indels that were associated with an sgRNA, which had been considered
mutated in that particular sample. This final set of significant indels
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Direct in vivo validation of drivers or combinations
Liver-specific AAV-CRISPR vectors were designed to co-cistronically
express FLuc and Cre recombinase for induction of Cas9 expression
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Co-occurrence and correlation analysis
Co-occurrence analysis was performed by first generating a doublemutant count table for each pairwise combination of genes in the mTSG
library. Statistical significance of the co-occurrence was assessed by twosided hypergeometric test. To calculate co-occurrence rates, we defined
the “intersection” as the number of double-mutant samples, and the
“union” as the number of samples with a mutation in either (or both)
of the two genes, and then divided the intersection by the union. For
correlation analysis, we first collapsed the table of variant frequencies
to the gene level (that is, summing the variant frequencies for all five
of the targeting sgRNAs for each gene). Using these summed variant
frequency values, we calculated the Spearman or Pearson correlation
between all gene pairs across each mTSG sample. Statistical significance
of the correlation was determined by converting the correlation coefficient to a t statistic and then using the t distribution to find the associated probability. For both co-occurrence and correlation analyses,
P values were adjusted for multiple hypothesis testing by the BenjaminiHochberg method to obtain q values.

MIP capture sequencing
Genomic DNA sample (150 ng) from each mouse organ was used as
input. MIP capture sequencing was done according to previously published protocols (55, 56) with some slight modifications. The multiplexed library was then quality controlled using qPCR and subjected
to high-throughput sequencing using the HiSeq 2500 or HiSeq 4000
platforms (Illumina) at the Yale Center for Genome Analysis. Targeted
sgRNAs (280 of 281, 99.6%) were captured for all samples from this
experiment, with the missing one being Arid1a sg5.
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under a TBG promoter when delivered to LSL-Cas9 mice (plasmids
available at Addgene). Two sgRNA expression cassettes were built in
these vectors, one encoding an sgRNA targeting Trp53, with the other
being an open sgRNA cassette (double Sap I sites for GTS cloning). The
vector was generated by gBlocks Gene Fragment synthesis (IDT)
followed by Gibson assembly (NEB). Each specific sgRNA targeting a
driver gene was cloned separately into this vector. AAV9 virus was
produced and qPCR-titrated, as described above. Total viral particles
(1 × 1011) were introduced by intravenous injection into LSL-Cas9 mice.
For combinations of two AAVs, 5 × 1010 viral particles were used from
each AAV to generate equal titer mixtures and injected. Four to six mice
were injected per group. Starting 1 month after injection, mice were imaged by IVIS each month. Briefly, mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg)
and imaged for in vivo tumor growth using an IVIS machine (PerkinElmer)
with firefly D-luciferin potassium salt (150 mg/kg body weight) injected
intraperitoneally. Relative luciferase activity was quantified using Living
Image software (PerkinElmer).
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2.3: CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator
of immune checkpoint blockade
Extending on our work using autochthonous CRISPR screens to identify suppressors of
liver tumorigenesis, we then sought to capitalize on a key advantage of this experimental system:
that tumorigenesis occurs in the native microenvironment of fully immunocompetent hosts. In
particular, we compared the relative enrichment or depletion of different mutations when the
mice were treated with checkpoint blockade immunotherapy 94.
This line of investigation was conceived together with my advisor Dr. Sidi Chen and
Guangchuan Wang. The study was performed in close collaboration with several colleagues,
including Guangchuan Wang, Lvyun Zhu, and Zhigang Bai. My primary contributions to this
study were to interrogate the genetic changes that promoted resistance or sensitivity to
checkpoint immunotherapy, to validate our findings through integrative analysis of several largescale patient cohorts, and to characterize the chromatin accessibility changes following depletion
of our lead hit Kmt2d. I prepared the manuscript text and figures, together with Guangchuan
Wang and Dr. Sidi Chen.
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CRISPR-GEMM Pooled Mutagenic Screening
Identiﬁes KMT2D as a Major Modulator of
Immune Checkpoint Blockade
Guangchuan Wang1,2,3, Ryan D. Chow1,2,3,4, Lvyun Zhu1,2,3, Zhigang Bai1,2,3, Lupeng Ye1,2,3, Feifei Zhang1,2,3,
Paul A. Renauer1,2,3,5,6, Matthew B. Dong1,2,3,4,5,7,8, Xiaoyun Dai1,2,3, Xiaoya Zhang1,2,3, Yaying Du1,2,3,
Yujing Cheng1,2,3, Leilei Niu1,2,3, Zhiyuan Chu1,2,3, Kristin Kim1,2,3, Cun Liao1,2,3, Paul Clark1,2,3,
Youssef Errami1,2,3, and Sidi Chen1,2,3,4,5,6,7,9,10,11,12,13,14

Immune checkpoint blockade (ICB) has shown remarkable clinical efﬁcacy in several
cancer types. However, only a fraction of patients will respond to ICB. Here, we
performed pooled mutagenic screening with CRISPR-mediated genetically engineered mouse models
(CRISPR-GEMM) in ICB settings, and identiﬁed KMT2D as a major modulator of ICB response across
multiple cancer types. KMT2D encodes a histone H3K4 methyltransferase and is among the most frequently mutated genes in patients with cancer. Kmt2d loss led to increased DNA damage and mutation
burden, chromatin remodeling, intron retention, and activation of transposable elements. In addition,
Kmt2d-mutant cells exhibited increased protein turnover and IFNγ-stimulated antigen presentation. In
turn, Kmt2d-mutant tumors in both mouse and human were characterized by increased immune inﬁltration. These data demonstrate that Kmt2d deﬁciency sensitizes tumors to ICB by augmenting tumor
immunogenicity, and also highlight the power of CRISPR-GEMMs for interrogating complex molecular
landscapes in immunotherapeutic contexts that preserve the native tumor microenvironment.
SIGNIFICANCE: ICB is ineffective in the majority of patients. Through direct in vivo CRISPR mutagenesis screening in GEMMs of cancer, we ﬁnd Kmt2d deﬁciency sensitizes tumors to ICB. Considering the
prevalence of KMT2D mutations, this ﬁnding potentially has broad implications for patient stratiﬁcation and clinical decision-making.
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INTRODUCTION
Checkpoint immunotherapy has achieved substantial success, showing clinical beneﬁts across multiple tumor types
with durable responses even in chemoresistant and metastatic cancers (1–4). However, the majority of patients do not
respond to checkpoint immunotherapy (5, 6), indicating the
importance of precision immunotherapy, where patients are
stratiﬁed on the basis of functional and clinical evidence,
subsequently receiving the treatments or combinations most
likely to beneﬁt them.
A multitude of approaches have been applied to understand the features associated with immunotherapy response
(7, 8). These include whole-genome sequencing (7, 9, 10), proteomic analysis (11), single-cell transcriptomic analysis (12),
in vitro cancer–immune cell cocultures (13, 14), and ex vivo/in
vivo screens using cell lines in tumor transplant models (15).
Several factors, including PD-L1 expression, tumor mutation
burden (16), neoantigen burden (17), and immune inﬁltration status (18, 19), as well as certain oncogenic pathways

(20), have been demonstrated to be correlated with immunotherapy response. In addition, many mechanisms have been
described in primary or acquired resistance to immunotherapy (21, 22). For instance, tumors can foster the development
of an immunosuppressive tumor microenvironment (23), or
acquire new mutations that reduce immune recognition and
apoptosis (24).
Despite these advances, our understanding of the genetic
factors that dictate response to checkpoint immunotherapy
remains incomplete. Analysis of patient cohorts can reveal associations with immune checkpoint blockade (ICB) response,
but such studies cannot ﬁrmly establish causality. Current
genetic screening approaches using in vitro or ex vivo cultured
cell lines are conﬁned by the mutation background and may
miss subtle factors that inﬂuence ICB response in the complex immunologic setting of the tumor microenvironment.
Genetically engineered mouse models (GEMM; ref. 25) can
more precisely mimic the features of human cancers, because
such tumors develop from cells within the native organs
of fully immunocompetent animals, thereby preserving the
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immune microenvironment. Because of these features,
GEMMs offer certain distinct advantages for the studies of
tumor immunology. Although traditional GEMMs can target
only a handful of genes at a time, CRISPR enables pooled
targeting of multiple genes through somatic genome editing.
We have previously developed CRISPR-GEMMs that enabled
large-scale direct in vivo screening of functional tumor suppressors (26, 27). Using CRISPR-GEMMs, genetically complex
tumors can be readily generated in individual mice that each
reﬂect the genetic and cellular heterogeneity of human tumors, with the ﬂexibility to target any desired sets of genes.
Here, we performed a CRISPR-GEMM screen of signiﬁcantly mutated genes (SMG) in human cancers (28, 29),
examining the effect of these mutations on ICB response. We
speciﬁcally pinpoint Kmt2d deﬁciency as a major mediator of
sensitivity to ICB therapy in diverse cancer types, suggesting
its potential as a biomarker for patient stratiﬁcation.

RESULTS
A CRISPR-GEMM Screen Identiﬁes Genetic
Modulators of Immunotherapy Response In Vivo
To perform a screen for genetic modulators of immunotherapy response in conditions that closely mimic human cancers,
we developed a CRISPR-GEMM model of liver cancer in which
AAV-CRISPR–mediated pooled mutagenesis drives autochthonous liver tumorigenesis in fully immunocompetent mice. We
designed an AAV-CRISPR vector that expresses Cre recombinase
under a liver-speciﬁc thyroxine-binding globulin (TBG) promoter, together with two single guide RNA (sgRNA) expression
cassettes: one for a Trp53-targeting sgRNA, and the other as a
backbone sgRNA designed for cloning and expression of additional speciﬁc sgRNA(s). We utilized the mouse tumor suppressor gene (mTSG) library, which targets the top 49 most frequently
mutated tumor suppressor genes in the pan-cancer datasets of
The Cancer Genome Atlas (TCGA) with 7 housekeeping genes
as internal controls (26, 27). We cloned the mTSG library into
the AAV-TBG-CRISPR vector, and generated AAVs carrying the
pooled sgRNA library (Fig. 1A). To monitor liver tumorigenesis
in vivo, we crossed LSL-Cas9–2A-EGFP (LSL-Cas9) mice with LSLﬁreﬂy luciferase (LSL-Fluc) mice to generate LSL-Cas9; LSL-Fluc
mice. We then introduced the base vector AAVs (AAV-Vector),
sgTrp53-delivering AAVs (AAV-sgTrp53) or mTSG library AAVs
(AAV-mTSG) into the mice by intravenous injection.
We monitored the bioluminescence signals in the injected
mice using the intravital imaging system (IVIS). We observed

a steady increase of luciferase signal from day 40 to day
60, indicative of ongoing tumorigenesis (Supplementary
Fig. S1A). On the basis of the IVIS data, we assigned the AAVmTSG injected mice into 3 size-matched cohorts to receive
PBS, anti–PD-1, or anti-CTLA4 treatment (Fig. 1A). All of the
AAV-mTSG–injected mice treated with PBS died within 100
days (Fig. 1B), having developed large liver tumors with 100%
penetrance. In sharp contrast, no mice died from tumors in
the AAV-Vector– or AAV-sgTrp53–injected groups. Although
the IVIS data suggested no signiﬁcant change between ICB
therapy and PBS treatment groups, anti–PD-1 (n = 11) or
anti-CTLA4 (n = 11) treatment prolonged overall survival in
comparison with mice receiving PBS treatment (n = 15; Fig. 1B;
Supplementary Fig. S1B). We then harvested all liver lobes for
genomic sequencing and histologic characterization. Endpoint
histologic sections from vector-treated mice (n = 3) revealed no
tumor lesions, whereas all mTSG-treated mice (n = 37) developed large and heterogenous liver tumors (Fig. 1C).
We processed the tumors for targeted analysis of the predicted sgRNA cut sites using molecular inversion probe (MIP)
sequencing (27). Representative variants of insertions and
deletions (indels) detected by MIP capture sequencing are
shown at the cut sites of B2m sg3 (Fig. 1D), Arid1a sg4
(Fig. 1E), and Kmt2d sg3 (Fig. 1F). We summed the constituent variant frequencies of each sgRNA and charted the mutation landscape associated with each treatment (Fig. 1G). We
then calculated the mean variant frequencies for each gene,
grouping samples by treatment condition. By comparing the
gene mutation frequencies in the different treatment groups,
we uncovered genetic perturbations that were comparatively
enriched or depleted with anti–PD-1 or anti-CTLA4 treatment (Fig. 1G and A). Comparing the anti-CTLA4–treated
mice with PBS-treated mice, the mutation frequencies of
B2m, Grlf1, Bcor, and Kdm5c were signiﬁcantly increased,
whereas the mutation frequencies of Arid1a were signiﬁcantly
decreased (Fig. 2B). Comparing anti–PD-1-treated mice with
PBS-treated mice, knockout of B2m, Grif1, Vhl, Cdkn1b, or Bcor
was correlated with anti–PD-1 resistance, whereas knockout
of Kmt2d, Arid1a, Rnf43, or Atrx was associated with anti–PD-1
responsiveness (Fig. 2C).

Loss-of-Function Mutations of KMT2D Potentiate
Anti–PD-1 Checkpoint Immunotherapy
From our screen data, Arid1a loss sensitized tumors to both
anti-CTLA4 and anti–PD-1 treatment, whereas Kmt2d mutations
showed the largest magnitude of sensitization to anti–PD-1.

Figure 1. AAV-CRISPR direct in vivo screening to pinpoint genetic modulators of immunotherapy response. A, Schematic of the experimental design.
An sgRNA library targeting the murine homologs of the 49 most frequently mutated tumor suppressor genes, along with 7 housekeeping genes (mTSG; 288
sgRNAs) was cloned into an AAV-CRISPR vector containing a liver-speciﬁc Cre expression cassette and a Trp53-targeting sgRNA. AAVs were produced
and injected intravenously into LSL-Cas9 LSL-Fluc mice. The mice were assigned into three groups based on luciferase imaging, then received anti–PD-1
(aPD-1), anti-CTLA4 (aCTLA4), or PBS treatment. Tumors were processed for histology and MIP capture sequencing to proﬁle the mutational landscape of
all targeted genes. B, Kaplan–Meier survival curves of AAV-mTSG–injected mice, treated with PBS (black, n = 15), aPD-1 (blue, n = 11), or aCTLA4 (orange,
n = 11) mice. All PBS-treated mice died within 3 months, while aPD-1–treated mice (P = 0.0389) and aCTLA4-treated mice (P = 0.0185) had longer survival
(log-rank test). Starting from day 50, the mice were randomly assigned and treated with PBS, 8 mg/kg anti–PD-1, or 4 mg/kg anti-CTLA4, twice a week for
6 doses at the indicated times (arrowheads). C, Representative images of hematoxylin and eosin (H&E), CD3, and AE1/AE3 staining of liver sections from
AAV-Vector or AAV-mTSG injected mice, treated with PBS, aPD-1, or aCTLA4. Scale bar, 200 μm. D–F, Representative insertions and deletions (indels)
observed at the genomic region targeted by B2m sgRNA3 (D), Arid1a sgRNA4 (E), and Kmt2d sgRNA 3 (F) in mTSG-treated samples from PBS, aPD-1, or
aCTLA4 treatment groups. The percentage of each variant is indicated on the right. G, Mutational landscape of AAV-mTSG liver tumors (PBS, n = 53; aPD-1,
n = 66; aCTLA4, n = 74). Top, bar plot of the number of mutated genes in each sample. Center, heat map of mutation enrichment scores for each of the 56
targeted genes across all samples. Right, dot plot of the average mutation enrichment score for each gene, grouped by treatment condition (PBS, gray line;
aPD-1, blue; aCTLA4, orange). *, P < 0.05; **, P < 0.01; ***, P < 0.001. See also Supplementary Fig. S1
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To individually validate these ﬁndings, we developed and
utilized several genetic liver cancer models. We ﬁrst crossed
CAG-LSL-Myc transgenic mice with LSL-Cas9 mice, and then
injected these mice with AAVs carrying TBG-Cre and sgTrp53
to drive ectopic Myc expression and Trp53 knockout in the
liver (Fig. 2D). To interrogate the effects of concurrent Kmt2d
or Arid1a mutations in the setting of Myc overexpression and
Trp53 loss, we injected AAVs carrying sgTrp53+sgKmt2d or
sgTrp53+sgArid1a into LSL-Myc;LSL-Cas9 mice. As a control,
we injected sgTrp53+sgNTC AAVs. Mice bearing Myc+sgTrp53
tumors had a median survival of 155 days, with 50% (3/6) of
mice dying within 4 months, and anti–PD-1 treatment did not
show a signiﬁcant survival beneﬁt (median survival of 199 days;
Fig. 2E). Additional Arid1a mutations on top of Myc+sgTrp53
resulted in more aggressive tumors, with 100% (9/9) of mice
dying within 4 months (median survival of 83 days). Treatment with anti–PD-1 marginally prolonged survival (median
survival 105 days), with 12.5% (1/8) of mice alive 400 days
post-injection (Fig. 2F). Similar results were found using a
liver cancer model with Trp53 and Apc knockout as the genetic
background, with Arid1a-mutant tumors showing a signiﬁcant
response to anti–PD-1 (Supplementary Fig. S1C–S1E)
For mice bearing Myc+sgTrp53+sgKmt2d tumors, 8 of 9
(88.9%) mice died within 4 months (median survival of 73
days), indicating that KMT2D functions as a tumor suppressor in this context. Strikingly, anti–PD-1 therapy prolonged
survival of mice bearing Myc+sgTrp53+sgKmt2d tumors,
with >50% mice alive at 400 dpi (Fig. 2G). We collected
endpoint liver tumors for histologic and IHC characterization of these tumors (Fig. 2H–K), observing that Arid1a- or
Kmt2d-mutant liver tumors were more inﬁltrated with CD45+
immune cells (Fig. 2I) and CD3+ T cells (Fig. 2J), particularly
after anti–PD-1 therapy. Upon anti–PD-1 treatment, F4/80+
macrophages were more abundant in Arid1a-mutant liver
tumors, with similar trends in Kmt2d-mutant liver tumors
(Fig. 2K). Collectively, these data demonstrate that Arid1a
and Kmt2d encode functional tumor suppressors in the liver,
and autochthonous liver tumors with mutations in Kmt2d are

more likely to respond to anti–PD-1 treatment, validating the
results from the initial screen.

Kmt2d Deﬁciency Sensitizes Multiple Cancer
Types to Anti–PD-1 Therapy
To further assess the role of Kmt2d loss on the cancer–
immune interactions in liver cancer, we ﬁrst established a
primary tumor cell line from autochthonous Myc+sgTrp53
liver tumors generated in C57BL/6J (B6) mice (MA1L cells).
We then transduced these cells with either vector control or
sgKmt2d (Supplementary Fig. S2A). As Kmt2d deﬁciency has
previously been implicated in genome instability (30), we
cultured MA1L-Vector and MA1L-sgKmt2d cells in vitro for
approximately 100 days and then transplanted the cells into
mice to investigate the impact of Kmt2d deﬁciency. MA1LsgKmt2d cells formed larger tumors in immunocompromised
Rag1−/− mice compared with vector control, again indicating
the role of KMT2D as a tumor suppressor (Supplementary
Fig. S2B). In contrast, in immunocompetent C57BL/6J mice,
the tumors formed by Kmt2d-mutant cells were eliminated
more rapidly compared with the control (Supplementary
Fig. S2C). Notably, the MA1L cell line was established from
an endpoint liver tumor and therefore had likely accumulated
genetic/epigenetic alterations that increased the immunogenicity of the MA1L cells. In addition, the immunogenicity
of Cas9 in the CRISPR system may contribute to the rejection of the MA1L cells by C57BL/6J mice. Nevertheless, these
data reafﬁrm that Kmt2d mutation sensitizes liver tumors to
immune rejection.
KMT2D is highly mutated in multiple human cancer types,
with an average mutation frequency of 4% to 8% across all
patients with cancer, and more than 20% of patients with skin
cancer and bladder cancer (Fig. 3A; Supplementary Fig. S2D).
These mutations are often truncating mutations or putative
driver missense mutations (Fig 3B; Supplementary Fig. S2D),
supporting the general role of KMT2D as a tumor suppressor gene in humans. Given the prevalence of KMT2D mutations across diverse human cancers, we sought to investigate

Figure 2. Identiﬁcation and validation of genetic factors that modulate response to checkpoint immunotherapy. A, Scatter plot of average mutation
enrichment scores across aCTLA4-treated or aPD-1–treated samples, subtracted by the average score in PBS samples. Negative values indicate relative
depletion, whereas positive values indicate relative enrichment. B, Volcano plot comparing the mutation enrichment scores in aCTLA4-treated versus
PBS-treated samples. Negative mutation enrichment scores indicate gene mutations that confer sensitivity to aCTLA4 treatment upon CRISPR mutagenesis, whereas positive scores indicate gene mutations that confer resistance. C, Volcano plot comparing the mutation enrichment scores in aPD-1–treated
versus PBS-treated samples. Negative mutation enrichment scores indicate gene mutations that confer sensitivity to aPD-1 treatment upon CRISPR
mutagenesis, whereas positive scores indicate gene mutations that confer resistance. D, Schematic of experimental design for single-gene validation
experiments. AAV-CRISPR vectors with a liver-speciﬁc Cre expression cassette were intravenously injected into LSL-Cas9 LSL-Myc mice to induce Myc
overexpression and Cas9 expression for sgRNA-mediated mutagenesis. E and F, Mice were randomly assigned into 2 groups and treated with either PBS
or 8 mg/kg anti–PD-1 starting from day 60, twice a week, for 5 doses. E, Kaplan–Meier survival curves of mice bearing liver tumors with Myc overexpression and Trp53 knockout. PBS-treated (n = 6) and aPD-1-treated (n = 5) mice showed no signiﬁcant survival difference (P = 0.581). F, Kaplan–Meier survival
curves of mice bearing liver tumors with Myc overexpression, Trp53 knockout, and Arid1a knockout. PBS-treated (n = 9) and aPD-1–treated (n = 8)
mice showed no signiﬁcant survival difference (P = 0.072). G, Kaplan–Meier survival curves of mice bearing liver tumors with Myc overexpression, Trp53
knockout, and Kmt2d knockout. PBS-treated (n = 9) and aPD-1–treated (n = 11) mice showed a signiﬁcant survival difference (P = 0.0231). H, Representative images of H&E, CD45, CD3, and F4/80 staining of liver sections from Myc+sgTrp53, Myc+sgTrp53+sgArid1a, Myc+sgTrp53+sgKmt2d tumors with or
without anti–PD-1 treatment. Scale bar, 200 μm. I–K, Quantiﬁcation of CD45+ immune cells (I), CD3+ T cells (J), or F4/80+ macrophages (K) in liver sections
from control, Kmt2d-mutant, or Arid1a-mutant tumors, with or without anti–PD-1 treatment. I, CD45+ cells in different groups. Two-tailed unpaired t test,
CD45+ cells in PBS group: sgKmt2d (n = 57) versus control (n = 14), P = 0.8672; sgArid1a (n = 16) versus control (n = 57), P = 0.0012. CD45+ cells in anti–
PD-1 group: sgKmt2d (n = 31) versus control (n = 17), P = 0.0008; sgArid1a (n = 18) versus control (n = 17), P = 0.0005. J, CD3+ cells in different groups
t test, CD3+ T cells in PBS group: sgKmt2d (n = 9) versus control (n = 10), P = 0.1988; sgArid1a (n = 11) versus control (n = 10), P = 0.1373. CD3+ T cells in
anti–PD-1 group: sgKmt2d (n = 8) versus control (n = 9), P = 0.0026; sgArid1a (n = 6) versus control (n = 9), P = 0.050. K, F4/80+ cells in different groups.
t test, F4/80+ cells in PBS group: sgKmt2d (n = 25) versus control (n = 12), P = 0.708; sgArid1a (n = 14) versus control (n = 12), P = 0.0454. CD3+ T cells in
anti–PD-1 group: sgKmt2d (n = 16) versus control (n = 14), P = 0.4038; sgArid1a (n = 12) versus control (n = 14), P = 0.0104. N represents different IHC
staining regions of the slides collected from ≥ 2 mice per treatment group. Error bars, all data points in this ﬁgure are presented as mean ± SEM. *, P < 0.05;
**, P < 0.01; ***, P < 0.001. See also Supplementary Fig. S1.
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Figure 3. KMT2D loss-of-function mutations are prevalent and associated with improved responses to aPD-1 therapy across diverse cancer types. A, Bar
plot of the percentage of patients with loss-of-function (LOF) or putative driver mutations in KMT2D across multiple cancer types. B, Landscape of truncating and
putative driver missense mutations in KMT2D across multiple cancer types. C, Growth curves of MB49 bladder cancer cells transduced with Vector or sgKmt2d,
transplanted into syngeneic C57BL/6J mice. Starting from day 7, tumor-bearing mice were treated with either PBS (solid line) or 8 mg/kg aPD-1 (dotted line),
twice a week for 2 doses at the indicated times (arrowheads). Two-way ANOVA: MB49-Vector, PBS (n = 12) versus aPD-1 (n = 12), P < 0.0001; MB49-sgKmt2d,
PBS (n = 12) versus aPD-1 (n = 12), P < 0.0001; PBS group, MB49-sgKmt2d (n = 12) versus MB49-Vector (n = 12), P = 0.5988; aPD-1 group, MB-sgKmt2d (n = 12)
versus MB49-Vector (n = 12), P = 0.0081. D, Kaplan–Meier survival curves of mice bearing MB49 bladder cancer cells transduced with Vector or sgKmt2d that
were treated by PBS and aPD-1, respectively. Log-rank test: MB49-Vector, aPD-1 (n = 12) versus PBS (n = 12), P = 0.0046; MB49-sgKmt2d, aPD-1 (n = 12) versus
PBS (n = 12), P < 0.0001. E and F, Growth curves of E0771 triple-negative breast cancer cells transduced with Vector (E) or sgKmt2d (F) in syngeneic C57BL/6J
mice. Starting from day 13, tumor-bearing mice were treated with either PBS (solid line) or 8 mg/kg aPD-1 (dotted line), twice a week for 3 doses at the indicated
times (arrowheads). Two-way ANOVA: E0771-Vector, PBS (n = 12) versus aPD-1 (n = 11), P = 0.3677; E0771-sgKmt2d, PBS (n = 11) versus aPD-1 (n = 12), P = 0.005.
G and H, Growth curves of B16F10 melanoma cells transduced with Vector (G) or sgKmt2d (H), transplanted into syngeneic C57BL/6J mice. Starting from day
10, tumor-bearing mice were treated with either PBS (solid line) or 8 mg/kg aPD-1 (dotted line), twice a week for 5 doses at the indicated times (arrowheads).
Two-way ANOVA: B16F10-Vector, PBS (n = 10) versus aPD-1 (n = 9), P = 0.012; B16F10-sgKmt2d, PBS (n = 9) versus aPD-1 (n = 10), P < 0.0001. I and J, Growth
curves of Lewis lung cancer (LLC) cells transduced with Vector (I) or sgKmt2d (J), transplanted into syngeneic C57BL/6J mice. Starting from day 7, tumor-bearing
mice were treated with either PBS (solid line) or 8 mg/kg aPD-1 (dotted line), twice a week for 5 doses at the indicated times (arrowheads). Two-way ANOVA: LLCVector, PBS (n = 10) versus aPD-1 (n = 11), P = 0.1867; LLC-sgKmt2d, PBS (n = 11) versus aPD-1 (n = 11), P < 0.0001. Data were collected from two independent
experiments. Error bars, all data points in this ﬁgure are presented as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. See also Supplementary Figs. S2 and S3.
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whether Kmt2d deﬁciency promotes anti–PD-1 responsiveness in other tumor types.
As KMT2D is highly mutated in human bladder cancers,
we mutated Kmt2d in MB49 bladder cancer cells (MB49sgKmt2d; Supplementary Fig. S2E) and transplanted the cells
into C57BL/6J mice, with vector-transduced cells (MB49Vector) as a control. When treated at an early stage, both
MB49-sgKmt2d and MB49-Vector tumors responded to anti–
PD-1 treatment (Fig. 3C). However, MB49-sgKmt2d tumors
were comparatively more responsive to anti–PD-1 therapy
(Fig. 3C). Accordingly, anti–PD-1 treatment signiﬁcantly
improved overall survival, with MB49-sgKmt2d tumor-bearing
mice surviving slightly longer than mice with MB49-Vector
tumors (Fig. 3D). Examining the tumor growth kinetics, we
noted an early stage of immune elimination of the MB49
tumors around 10 days post-injection. We therefore investigated the responses of late-stage MB49 tumors to anti–PD-1
therapy. When treated at a later time point after the initial
immune response, MB49-Vector tumors did not respond to
anti–PD-1 treatment (Supplementary Fig. S2F), but Kmt2dmutant tumors were still responsive to anti–PD-1 treatment
(Supplementary Fig. S2G). Anti–PD-1 therapy showed a
signiﬁcant survival beneﬁt in mice bearing MB49-sgKmt2d
tumors, but not in mice with MB49-Vector tumors (Supplementary Fig. S2H).
Similarly, we mutated Kmt2d in E0771 triple-negative
breast cancer cells, B16F10 melanoma cells, and Lewis lung
cancer (LLC) cells (Supplementary Fig. S2I), and then transplanted them into C57BL/6J mice. For the orthotopic E0771
model, only the mice bearing Kmt2d-mutant tumors signiﬁcantly beneﬁted from the anti–PD-1 treatment (Fig. 3E and
F; Supplementary Fig. S2J and S2K). Orthotopic tumors
formed by vector-transduced B16F10 cells (B16F10-Vector)
were resistant to anti–PD-1 treatment (Fig. 3G), but the
addition of Kmt2d loss sensitized the tumors to anti–PD-1
treatment (Fig. 3H). Similarly, subcutaneous Vector-transduced LLC tumors were resistant to anti–PD-1 treatment, but
Kmt2d-mutant LLC tumors partially responded to anti–PD-1
treatment (Fig. 3I and J).
To examine whether Kmt2d loss induces anti–PD-1 sensitivity by speciﬁcally reshaping the local microenvironment,
we utilized a dual-tumor model in which we transplanted
LLC-Vector cells in the left ﬂanks and LLC-sgKmt2d cells in
the right ﬂanks of individual mice. We found that only the
Kmt2d-mutant tumors responded to anti–PD-1, anti–PD-L1,
or anti-CTLA4 treatment (Supplementary Fig. S3A–S3D), suggesting that Kmt2d loss sensitizes tumors to checkpoint therapy by altering the tumor microenvironment. Together, these
results demonstrate that Kmt2d mutation promotes anti–PD-1
response in 4 additional tumor types (bladder cancer, triplenegative breast cancer, melanoma, and lung cancer), generalizing the ﬁndings from the CRISPR-GEMM liver cancer system
(Fig. 2G).

Kmt2d-Mutant Tumors Exhibit
Enhanced Immune Inﬁltration in the
Tumor Microenvironment
To investigate the mechanisms underlying the enhanced
antitumor response against Kmt2d-mutant MA1L liver
tumors, we analyzed the tumor immune microenviron-

ment by flow cytometry (Supplementary Fig. S4) at day
11 when tumor regression begins. We found that Kmt2dmutant MA1L tumors had more CD45+ immune cells,
CD4+ T cells, and macrophages compared with controls
(Supplementary Fig. S5A). CD8+ T-cell infiltration also
trended toward an increase in Kmt2d-mutant tumors,
although this was not statistically significant. To examine
whether Kmt2d knockout consistently promotes immune
inﬁltration, we further analyzed the tumor microenvironment of control or Kmt2d-mutant MB49 bladder cancers.
We similarly found increased inﬁltration of CD45+ immune
cells, especially CD8+ T cells, in MB49-sgKmt2d tumors
(Supplementary Fig. S5B).
Because the MA1L liver tumors and MB49 bladder tumors
were often rejected after anti–PD-1 therapy, we used the
anti–PD-1–resistant LLC model to further investigate the
effect of anti–PD-1 therapy on Kmt2d-mutant tumors. At 19
days post-induction of the dual-tumor LLC model (Fig. 4A),
we analyzed the immune context of tumors formed by LLCsgKmt2d and LLC-Vector cells, with or without anti–PD-1
therapy (Fig. 4B; Supplementary Fig. S6A). We observed
that Lewis-sgKmt2d tumors had increased inﬁltration of
CD45+ immune cells compared with Lewis-Vector tumors,
particularly after anti–PD-1 treatment (Fig. 4B; Supplementary Fig. S6B). In Kmt2d-mutant tumors, we found signiﬁcantly increased inﬁltration of T cells, including CD4+ T
cells, CD8+ T cells, and IFNγ+ CD8+ T cells (Fig. 4B), as well
as increased antigen-presenting cells, such as dendritic cells
and macrophages (Fig. 4C). These changes became apparent after anti–PD-1 treatment. No difference was observed
in the abundance of neutrophils and regulatory T cells
(Fig. 4C; Supplementary Fig. S6A). By further analyzing the
polarizations of tumor-inﬁltrating macrophages, we found
the macrophages were dominated by tumor-associated macrophage 1 (TAM1), although the abundances of TAM1 and
TAM2 were both increased in Kmt2d-mutant tumors after
anti–PD-1 treatment (Fig. 4C). Notably, tumor-inﬁltrating
T cells and innate immune populations (i.e., monocytes,
neutrophils, and macrophages) expressed PD-1 on their
surface (Fig. 4D; Supplementary Fig. S6A). Similar results
were obtained using the single-tumor LLC model (Supplementary Fig. S6B). These data suggest that the enhanced
efﬁcacy of anti–PD-1 therapy in Kmt2d-mutant tumors may
be due to its effects on T cells as well as myeloid cells, in
concordance with a recent observation in these cell types
(31).
To assess the relevance of these ﬁndings in clinical cohorts,
we evaluated the correlation of KMT2D expression and
immune inﬁltration status across multiple human cancers.
In the TCGA, KMT2D expression levels are negatively correlated with intratumoral macrophage abundance in 21 of
33 (63.6%) human cancer types (Fig. 4E and F). Similarly, we
observed that, across multiple cancer types, KMT2D expression is negatively correlated with expression of the monocytemacrophage marker CD14 and the cytotoxic T-cell markers
GZMB and GZMA (Supplementary Fig. S7A–S7C). Collectively, these analyses indicate intratumoral macrophage and
cytotoxic CD8+ T-cell abundance is increased in tumors with
low KMT2D levels, substantiating the results from the FACS
data.
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Figure 4. Kmt2d-mutant tumors are associated with increased innate and adaptive immune inﬁltration. A, Schematic of experimental design for
generating the syngeneic LLC dual-tumor model. LLC-Vector and LLC-sgKmt2d cells were transplanted into the left and right ﬂanks of C57BL/6J mice,
respectively, followed by treatment with PBS or anti-PD-1. Tumor-inﬁltrating immune cells were analyzed by FACS analysis. B, Abundance of intratumoral
CD45+ pan-immune cells, CD4+ T cells, CD8+ T cells, and IFNγ+ CD8+ T cells in LLC-Vector or LLC-sgKmt2d tumors, treated with PBS (n ≥ 5) or aPD-1 (n ≥ 5).
Mann–Whitney test: sgKmt2d + aPD-1 versus Vector + aPD-1: CD45+ cells, P = 0.052; CD4+ T cells, P = 0.0029; CD8+ T cells, P = 0.0003; IFNγ+ CD8+ T cells,
P = 0.0079. C, The intratumoral abundance of monocytes, neutrophils, dendritic cells, macrophages, TAM1, and TAM2 in LLC-Vector or LLC-sgKmt2d
tumors, treated with PBS (n = 5) or aPD-1 (n = 5). Mann–Whitney test, sgKmt2d + aPD-1 versus Vector + aPD-1: monocytes, P = 0.4206; neutrophils, P =
0.3095; dendritic cells, P = 0.0159; macrophages, P = 0.0079; TAM1, P = 0.0317; TAM2, P = 0.0159. D, PD-1 expression in different immune populations
present within LLC-Vector or LLC-sgKmt2d tumors, treated with PBS (n = 5) or aPD-1 (n = 5). Mann–Whitney test, sgKmt2d + aPD-1 versus Vector + aPD-1:
PD -1+CD4+ T cells, P = 0.2222; PD-1+CD8+ T cells, P = 0.2222; PD-1+ macrophages, P = 0.4206; PD-1+ monocytes, P = 0.6905. E, Volcano plot of the
Spearman correlation between KMT2D mRNA expression and macrophage abundance in 33 cancer types. Red dots indicate cancer types in which KMT2D
is signiﬁcantly negatively correlated with macrophage abundance (adjusted P < 0.05). F, Scatter plots comparing KMT2D expression and macrophage
abundance in TCGA BLCA, BRCA, LUSC, and LIHC cohorts. Error bars, all data points in this ﬁgure are presented as mean ± SEM. *, P < 0.05; **, P < 0.01;
***, P < 0.001. See also Supplementary Figs. S4–S6.
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Figure 5. Loss of Kmt2d leads to DNA damage and increased mutation burden. A, Western blot analysis of KMT2D and GAPDH expression in MA1L

cells isolated from the liver tumors of Myc+ Trp53−/− mice, transduced ex vivo with either Vector or sgKmt2d. B, Quantiﬁcation of KMT2D protein, normalized to GAPDH internal control. Mann–Whitney test, Vector (n = 4) versus sgKmt2d (n = 4), P = 0.0286. C, Western blot analysis of H3K4 mono-methylation level (H3K4me1) and total H3 in MA1L cells transduced with Vector, sgKmt2d, or sgArid1a. D, Quantiﬁcation of H3K4me1 levels, normalized to
total H3. Mann–Whitney test, Vector (n = 7) versus sgKmt2d (n = 7), P = 0.0006; Vector (n = 7) versus sgArid1a (n = 6), P = 0.3065. E, DAVID gene ontology
analysis of genes positively correlated with KMT2D expression in ≥ 30 cancer types. F, DAVID gene ontology analysis of genes negatively correlated with
KMT2D expression in ≥ 21 cancer types. G, Representative images of γH2AX immunoﬂuorescence staining in MA1L cells transduced with Vector, sgKmt2d,
or sgArid1a. H, Quantiﬁcation of γH2AX nuclear foci in MA1L cells transduced with Vector, sgKmt2d, or sgArid1a. Mann–Whitney test, Vector (n = 18)
versus sgKmt2d (n = 23), P = 0.0022; Vector (n = 18) versus sgArid1a (n = 10), P < 0.0001. I, Exome-sequencing analysis of MA1L cells transduced with
Vector or sgKmt2d, 10 days (D10), or 71 days (D71) post-transduction. The percentage change in mutation burden was calculated for each condition,
comparing D71 (n = 3) to D10 (n = 3). Two-tailed unpaired t test, P = 0.0003. (continued on next page)

Kmt2d Deﬁciency Leads to Elevated DNA Damage
and Mutation Burden
We sought to unravel the mechanisms by which Kmt2d mutation leads to elevated immune inﬁltration. We ﬁrst validated
that CRISPR targeting of Kmt2d led to a loss of KMT2D protein (Fig. 5A and B), with decreased levels of H3K4me1 but not
H3K4me3 (Fig. 5C and D; Supplementary Fig. S7D). To explore
the consequences of KMT2D loss, we further analyzed the
TCGA data and identiﬁed all genes that are signiﬁcantly correlated with KMT2D expression. To pinpoint associations that
are generalizable across multiple cancer types, we selected genes
that were concordantly correlated with KMT2D in several independent cohorts (Supplementary Fig. S7E). Genes positively
correlated with KMT2D are enriched for transcription, poly(A)

RNA binding, UBL conjugation pathway, mRNA processing,
DNA damage and repair, and ubiquitin-protein transferase
activity (Fig. 5E). Genes negatively correlated with KMT2D
expression are enriched in ribosomal protein, mitochondrion,
oxidative phosphorylation, antigen processing and presentation
by major histocompatibility complex class I (MHC-I), proteasome, and cellular oxidant detoxiﬁcation (Fig. 5F). These results
indicate that KMT2D has an important role in transcriptional
regulation and DNA repair. Indeed, recent studies showed that
KMT2D could prevent collisions between transcription and
replication machineries (32), and Kmt2d mutation resulted in
transcription stress and DNA breaks in replicating regions (30).
To assess DNA damage in Kmt2d-mutant and control
cells, we used immunofluorescence assays to quantify
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Figure 5. (Continued) J, Box plots of log2 mutation count in TCGA LIHC, SKCM, LUAD, and BRCA cohorts, grouped by KMT2D mutation status. KMT2D

mutant versus wild-type (WT), two-tailed Mann–Whitney test: LIHC, P = 0.00046; SKCM, P = 1.24 × 10−6; LUAD, P = 0.0192; BRCA, P = 5.90 × 10−6. K, Bar plots
detailing the association between KMT2D mutation and tumor mutation burden (TMB) across cancer types (ﬁltered by cancer types with at least 5 KMT2Dmutant tumors). L, Comparison of tumor mutation burden between patients with wild-type or mutant KMT2D in a cohort of patients with bladder cancer
receiving anti–PD-L1 ICB (Snyder and colleagues; ref. 34). KMT2D LOF mutant versus wild-type, Mann–Whitney test: P = 0.0110. M, Comparison of tumor
mutation burden between patients with KMT2D LOF mutations and wild-type KMT2D in the Mariathasan cohort of patients with bladder cancer receiving anti–PD-L1 ICB (35). KMT2D LOF mutant versus wild-type, Mann–Whitney test: P = 0.0466. N, Relationship between KMT2D status and anti–PD-L1
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ﬁgure are presented as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. See also Supplementary Figs. S7–S9.

nuclear γH2AX foci, a marker of unrepaired DNA lesions
(Fig. 5G). As a control, we found Arid1a-mutant cells had
significantly higher numbers of γH2AX foci compared
with the control (Fig. 5H), consistent with the role of
ARID1A in mismatch repair (MMR; ref. 33). Notably, we
found Kmt2d-mutant cells also had significantly higher
levels of γH2AX foci in MA1L liver cancer cells (Fig. 5G
and H) and MB49 bladder cancer cells (Supplementary
Fig. S8A and S8B). These differences were not solely due to
Cas9-induced double-stranded breaks, because cells transduced with sgKmt2d similarly showed increased γH2AX
foci compared with cells transduced with Aavs1 locus
(Ppp1r12c)–targeting sgRNA (Supplementary Fig. S8C and
S8D). To confirm that Kmt2d mutation leads to elevated
DNA damage, we cultured the Kmt2d-mutant cells and vector control cells in vitro for 71 days and performed wholeexome sequencing. We found that the mutation burden of
vector cells decreased over time, whereas the mutation burden of Kmt2d-mutant cells increased (Fig. 5I). This increase
was not due to differences in cell proliferation, because
cells transduced with sgKmt2d or sgArid1a proliferated at

similar rates as Vector-transduced cells (Supplementary
Fig. S8E and S8F).
To examine whether these ﬁndings are recapitulated in
human cancer, we knocked out KMT2D in H1299 human
lung cancer cells (Supplementary Fig. S8G), ﬁnding that
KMT2D loss led to signiﬁcantly higher levels of γH2AX and
53BP1 foci (Supplementary Fig. S8H and S8I). We then analyzed the TCGA datasets and found that the tumor mutation burden (TMB) of KMT2D-mutant tumors was indeed
signiﬁcantly higher than the TMB of KMT2D–wild-type
tumors across multiple cancer types (Fig. 5J and K). Because
KMT2D is highly mutated in human bladder cancers
(Fig. 3A), we further analyzed the correlations of KMT2D
mutation with TMB and anti–PD-1 responses using two
cohorts of patients with bladder cancer (34, 35). In both
cohorts, we found that KMT2D-mutant bladder cancers
had signiﬁcantly higher TMB (Fig. 5L and M), and were
more likely to respond to ICB with anti–PD-L1 (Fig. 5N and
O), especially in the TMB-high patients (Supplementary
Fig. S9A and S9B). Thus, KMT2D mutation leads to elevated
DNA damage and is correlated with higher TMB in multiple
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types of human cancers, as well as better responses to checkpoint immunotherapy (10).

Kmt2d Deﬁciency Reshapes the Chromatin
Accessibility of IFNg-Regulated Regions
As KMT2D is an epigenetic modiﬁer associated with chromatin regulation and enhancer activation, we performed
assay for transposase-accessible chromatin using sequencing
(ATAC-seq) to examine the chromatin landscape of Kmt2dmutant or control MA1L liver tumor cells (Fig. 6A), with
or without IFNγ treatment. Correlation analysis revealed a
robust clustering of sgKmt2d cells separately from control
cells (Fig. 6B). Comparing Kmt2d-mutant to control cells
(without IFNγ treatment), 10,791 sites were more accessible
and 9,553 sites were less accessible (Fig. 6C). Motif analysis
of the more accessible sites revealed enrichment for AP1 family factors, CTCF, and TCF3/TCF4 (Fig. 6D), whereas the
less acessible sites were also enriched for AP1 family factors
(Fig. 6E). The common enrichment for AP1-binding motifs
suggests a global rewiring of AP1-driven programs upon perturbation of Kmt2d.
Upon IFNγ treatment, we observed large changes in chromatin accessibility. Interestingly, signiﬁcantly fewer sites
became less accessible in sgKmt2d cells compared with Vector
cells after IFNγ treatment, whereas a similar number of sites
became more accessible (Fig. 6F). These differentially accessible sites could be broadly classiﬁed into 6 clusters (Fig. 6G).
Sites in Cluster 3 (989 sites) were less accessible in sgKmt2d
cells compared with control cells at baseline prior to IFNγ,
but became more accessible after IFNγ treatment to match
the levels in control cells (Fig. 6G-I). Conversely, sites in
Cluster 5 were more acessible in control cells compared with
sgKmt2d cells prior to IFNγ treatment, but became less accessible after IFNγ treatment to a level similar to sgKmt2d cells.
These ﬁndings indicate that IFNγ stimulation converges
the chromatin landscapes of wild-type and Kmt2d-mutant
cells (Supplementary Fig. S9C). Thus, Kmt2d deﬁciency systematically reshapes the chromatin accessibility of IFNγinduced genes at baseline, and IFNγ stimulation partially
normalizes these differences. Motif analysis reafﬁrmed the
systematic rewiring of AP1 family factors in Kmt2d-mutant
cells (Fig. 6J–M), further demonstrating that these alterations also inﬂuence chromatin changes in response to IFNγ
treatment.

Kmt2d Deﬁciency Remodels the Transcriptome,
Leading to Altered Chemokine Proﬁles In Vitro
and In Vivo
The association of KMT2D with transcription regulation and DNA damage (Fig. 5; Supplementary Fig. S8),
along with the broad alterations in chromatin accessibility
(Fig. 6), suggest that Kmt2d loss would lead to systematic
transcriptional remodeling. To study the transcriptomic
changes caused by Kmt2d mutation, we performed RNA
sequencing (RNA-seq) on the MA1L liver tumor cells.
Comparing with vector controls, we found that 753 genes
were upregulated and 1,540 genes were downregulated
in Kmt2d-mutant cells (Fig. 7A). As the ATAC-seq analyses had pointed to a rewiring of AP1 family factors, we
investigated the expression of genes encoding different

transcription factors that constitute AP1 dimers. In MA1LsgKmt2d cells, we observed upregulation of Fosl2, Mafb, and
Maf (Supplementary Fig. S9D), and downregulation of
Fosl1, Maff, and Atf3 (Supplementary Fig. S9E). To explore
the potential downstream consequences of increasing the
relative abundance of FOSL2 within AP1 dimers, we examined FOSL2 chromatin immunoprecipitation sequencing
(ChIP-seq) data from HepG2 human liver cancer cells.
We found that FOSL2 binds near important regulators of
tumor–immune interactions, including IFNGR1, IFNGR2,
JAK1, and JAK2 (Supplementary Fig. S9F).
Analysis of the upregulated genes in Kmt2d-mutant cells
revealed multiple enriched categories, including extracellular
matrix, transcription regulation, focal adhesion, zinc-ﬁnger,
ECM–receptor interaction, and WNT signaling (Fig. 7B). Conversely, Kmt2d-mutant cells showed downregulation of oxidoreductase genes and multiple metabolic pathways, including
cholesterol metabolism, tricarboxylic acid (TCA) cycle, and
lipid metabolism, as well as mitochondrion, lysosome, and
innate immunity (Fig. 7C).
Genes encoding chemokines (Cxcl1, Cxcl5, Cxcl15) related
to neutrophil recruitment were upregulated in Kmt2d-mutant
cells compared with the vector control (Supplementary
Fig. S10A and S10B). qPCR validation experiments conﬁrmed
the upregulation of Cxcl1 and Cxcl15 mRNA upon Kmt2d loss
in both MA1L liver cancer cells and MB49 bladder cancer
cells (Supplementary Fig. S10B and S10C). We then investigated whether these in vitro transcriptional changes were
reﬂected in vivo. When proﬁling the chemokines in MA1Lderived tumors, we detected signiﬁcantly higher levels of
CCL2, CCL5, CCL22, and CXCL9 protein in MA1L-sgKmt2d
tumors, but similar levels of CXCL1 and CXCL5 protein
(Fig. 7D). These chemokine changes were notably distinct
from the chemokine proﬁles of in vitro cultured MA1L cells
(Supplementary Fig. S10D), suggesting that the upregulation of CCL5, CCL22, and CXCL9 in MA1L-sgKmt2d tumors
in vivo was likely contributed by other immune cells that
were recruited to the tumors. Thus, the increase of these
chemokines may explain the increased recruitment of antigen-presenting cells and T cells in Kmt2d-mutant liver tumors
(Supplementary Fig. S5). However, we did not detect signiﬁcant changes of these chemokines in MB49 tumors (Supplementary Fig. S10E and S10F) or LLC tumors (Supplementary
Fig. S10G–S10I). These differences could be caused by a
multitude of complex factors, including differences in tumor
stage, the cell types involved, and their genetic backgrounds.

Kmt2d Deﬁciency Causes Intron
Retention and Activation of
Transposable Elements
We next used the RNA-seq data to predict the neoantigens in Kmt2d-mutant and control cells. We found that
Kmt2d-mutant and control cells shared 96 predicted neoantigens. Notably, Kmt2d-mutant cells have an additional
56 predicted neoantigens that were not predicted in the
control cells, whereas the control cells have 10 additional
predicted neoantigens (Fig. 7E). In addition to neoantigens
encoded within the canonical proteome, aberrant ribosomal products and alleged noncoding regions can serve
as a major source of tumor antigens (36–39). A previous
DECEMBER 2020CANCER DISCOVERY | OF12

69
Downloaded from cancerdiscovery.aacrjournals.org on November 20, 2020. © 2020 American Association for

Published OnlineFirst September 4, 2020; DOI: 10.1158/2159-8290.CD-19-1448

Wang et al.

RESEARCH ARTICLE
A

B

MA1L primary
liver cancer cells

Spearman correlation
0.85

0.90

0.95

C

D

ATAC-seq
sgKmt2d vs. vector (−IFNγ)

1.00

More accessible sites (sgKmt2d vs. vector)
AP1 family
P = 1*10−261

150
Vector

–Log10 (Padj)

sgKmt2d

CTCF

n = 10791 sites
n = 9553 sites

P = 1*10−237
TCF3/TCF4
P = 1*10−132

100

E
Less accessible sites (sgKmt2d vs. vector)

50

−IFNγ +IFNγ −IFNγ +IFNγ

AP1 family
P = 1*10−2245
RUNX1/RUNX2

sgKmt2d

ATAC-seq profiling

−IFNγ

Vector

P = 1*10−177

–2.5

+IFNγ +IFNγ −IFNγ

F

0.0
2.5
Log2 fold change

5.0

KLF5
P = 1*10−62

H

I
Vector (−IFNγ)

# of differential sites (×103)

P = 0.0787

G

0

3

sgKmt2d (−IFNγ)

sgKmt2d (+IFNγ)

P = 2.00 *10−115

2511

2

Vector (+IFNγ)

1.0

2389
⏐LFC⏐ ≥ 0.5; q < 0.05

1711

C1

617

1.0

1.2

0

+IFNγ: more
accessible
Vector

+IFNγ: less
accessible

C1

C2

0.5

C2

Vector
sgKmt2d
+IFNγ vs. −IFNγ

sgKmt2d (−IFNγ)
sgKmt2d (+IFNγ)

0.5

More accessible
Less accessible

1

Vector (−IFNγ)
Vector (+IFNγ)

C3

0.6

C4

1.2

C3

C4
0.6

Vector
C2
1111

C5
1527

C5

0.3

C1
1400
C3
989

0.9

C5

C4
184
sgKmt2d

C6
433

0.9
sgKmt2d

C6

C6

0.3
−2 kb

J

K

L

Common IFNγ-induced sites (C1)

Common IFNγ-inhibited sites (C4)

IRF1/IRF2/IRF8

RUNX1/RUNX2
P = 1*10−384

ISRE/IRF3

P = 1*10−11

P = 1*10−321
AP1 family

P = 1*10−10
AP1 family

Vector-specific IFNγ-inhibited sites (C5)
AP1 family

P = 1*10−143

P = 1*10−141
RUNX1/RUNX2

TCF3/TCF4

P = 1*10−93

+2 kb

M
sgKmt2d-specific IFNγ-induced sites (C3)
AP1 family

TEAD family

Start

P = 1*10−52
IRF1/IRF2/IRF8

P = 1*10−6

P = 1*10−48
TEAD family

P = 1*10−34

P = 1*10−31

Figure 6. Kmt2d deﬁciency remodels the chromatin accessibility of IFNγ-regulated regions. A, Schematic of the experimental design. MA1L primary
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I, Average signal proﬁles across the six clusters shown in H. J and K, Motif analysis of the genomic regions that are more (J) or less (K) accessible with
IFNγ stimulation in both Vector and sgKmt2d cells. L, Motif analysis of genomic regions that were more accessible with IFNγ stimulation only in sgKmt2d
cells. M, Motif analysis of genomic regions that were less accessible with IFNγ stimulation only in Vector cells. See also Supplementary Fig. S9.
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Figure 7. Pleiotropic effects of Kmt2d deﬁciency on transcriptional regulation, protein turnover, and antigen presentation. A, Volcano plot of RNA-seq
data, comparing MA1L cells transduced with sgKmt2d (n = 3) versus Vector (n = 3). 753 genes were signiﬁcantly upregulated, whereas 1,540 genes were
downregulated (Padj < 0.05). B and C, DAVID gene ontology analysis of genes signiﬁcantly upregulated (B) or downregulated (C) with Kmt2d deﬁciency. D,
Chemokines in the tumors formed by MA1L-Vector and MA1L-sgKmt2d were proﬁled using the LEGENDplex Mouse Proinﬂammatory Chemokine Panel
(13-plex). t test between MA1L-sgKmt2d (n = 7) versus MA1L-Vector (n = 7): CCL2, P = 0.0072; CCL5, P = 0.0003; CCL11, P = 0.1961; CCL22, P = 0.0202;
CXCL1, P = 0.0948; CXCL5, P = 0.1322; CXCL9, P = 0.0105. E, Venn diagram of predicted neoantigens in Vector versus sgKmt2d-transduced cells. F, Relative proportion of RNA-seq reads mapping to intronic regions, comparing Vector (n = 3) versus sgKmt2d (n = 3) transduced cells. Two-tailed unpaired t test,
P = 0.0033. G, Volcano plot of transposable element (TE) expression proﬁles by RNA-seq, comparing MA1L cells transduced with sgKmt2d (n = 3) versus
Vector (n = 3). 66 TEs were signiﬁcantly upregulated, whereas 8 TEs were downregulated (Padj < 0.05). H, Heat map of top differentially expressed genes
involved in protein turnover, shown as z-scores. I, Western blot analysis of ubiquitin (conjugated or free form) and GAPDH in Vector or sgKmt2d-transduced
MA1L liver cancer cells, with (+MG132, right) or without (−MG132, left) proteasome inhibitor treatment. J, Quantiﬁcation of ubiquitin conjugates in the
absence of proteasome inhibition, normalized to Vector. K, Quantiﬁcation of ubiquitin conjugates in the presence of proteasome inhibition, normalized to
Vector. Paired t test, sgKmt2d (n = 4) versus Vector (n = 4), P = 0.0403. L, Western blot analysis of ubiquitin conjugates and GAPDH in Vector or sgKmt2dtransduced MB49 bladder cancer cells, with or without the addition of proteasome inhibitor MG132. M, Quantiﬁcation of ubiquitin conjugates in Kmt2dmutant MB49 bladder cancer cells with or without MG132, normalized to the vector control. Two-tailed paired t test, without MG132: sgKmt2d (n = 24)
versus Vector (n = 24), P < 0.0001; with MG132: sgKmt2d (n = 24) versus Vector (n = 24), P = 0.0054. (continued on next page)

DECEMBER 2020CANCER DISCOVERY | OF14

71
Downloaded from cancerdiscovery.aacrjournals.org on November 20, 2020. © 2020 American Association for

Published OnlineFirst September 4, 2020; DOI: 10.1158/2159-8290.CD-19-1448

Wang et al.

RESEARCH ARTICLE

MA1L: Total H-2Kb
Geometric MFI (×103)

150

Vector
sgKmt2d

100

*

50
n.s.
2

O

SIINFEKL-H2Kb pMHC-l
600

P
KMT2D LOF
DNA damage
Mutation burden
Chromatin remodeling
Transcription rewiring
Intron retention
TE activation

Vector
sgKmt2d

Geometric MFI

N

400

***

IFNγ-stimulated
antigen presentation

0

αPD-1
PD-1

PD-1

n.s.

1

Neoantigen burden
Protein turnover

αPD-1

200
T cell

Tumor cell

DC

M

0
10
0
IFNγ (ng/mL)

0
10
IFNγ (ng/mL)

Immunogenicity & chemokines
Innate immune infiltration

Adaptive immune infiltration
Response to aPD-1 therapy

Figure 7. (Continued) N, Flow cytometry analysis of total H-2Kb expression levels in Vector versus sgKmt2d-transduced cells, cultured in 0 ng/mL

or 10 ng/mL IFNγ. Two-tailed unpaired t test, Vector (n = 36) versus sgKmt2d (n = 36): 0 ng/mL IFNγ, P = 0.9931; 10 ng/mL IFNγ, P = 0.0250. O, Flow
cytometry analysis of SIINFEKL-H-2Kb peptide–MHC-I complexes in Vector versus sgKmt2d-transduced cells, cultured in 0 ng/mL or 10 ng/mL IFNγ.
Two-tailed unpaired t test, Vector (n = 30) versus sgKmt2d (n = 30): 0 ng/mL IFNγ, P = 0.9109; 10 ng/mL IFNγ, P < 0.0001. Data of N and O were collected
from four independent experiments. P, Schematic summarizing the pleiotropic consequences of Kmt2d deﬁciency on tumor cell-intrinsic properties, leading to increased immune inﬁltration and potentiating response to aPD-1 immunotherapy. DC, dendritic cell. Error bars, all data points in this ﬁgure are
presented as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. See also Supplementary Fig. S10 and S11.

study suggested that Kmt2d mutation leads to transcriptional stress (30), and our analysis of the TCGA implicated
KMT2D in transcription regulation and mRNA processing
(Fig. 5E). We therefore assessed whether Kmt2d mutation
affects RNA splicing and transcript quality by examining
intronic retention rates in mRNA. Kmt2d-mutant cells had
signiﬁcantly increased intronic retention in the mRNA,
with approximately 12% more intronic reads than vector
control cells (Fig. 7F). This is consistent with a role for
KMT2D in transcription regulation and mRNA processing.
As many transposable elements (TE) such as endogenous
retroviruses are often contained within introns, we then
assessed the expression of TEs in Kmt2d-mutant versus control cells. We observed that 66 TEs were signiﬁcantly upregulated in Kmt2d-mutant cells, whereas only 8 TEs were
downregulated (Fig. 7G). These data suggested that Kmt2d
mutation leads to transcriptional stress and dysregulated
RNA splicing, leading to intron retention and heightened
expression of TEs. In conjunction with the increased DNA
damage and mutation burden upon KMT2D loss, these
ﬁndings illuminate several sources of potential neoantigens
in Kmt2d-mutant cells.

Kmt2d-Mutant Cells Exhibit Increased
Proteasomal Degradation and
IFNg-Stimulated Antigen Presentation
To generate antigenic peptides, coding transcripts must
ﬁrst be translated and the resultant proteins ubiquitinated
for proteasome-mediated degradation. A number of genes
involved in ubiquitination were transcriptionally upregulated in Kmt2d-mutant cells compared with vector control
cells (Fig. 7H). To examine whether the levels of ubiquitinated proteins destined for proteasomal degradation are
higher in Kmt2d-mutant cells, we performed immunoblot
assays of ubiquitinated proteins with or without MG132, an
inhibitor of proteasome degradation (Fig. 7I–M). Without
MG132, Kmt2d-mutant cells had either higher or comparable levels of ubiquitinated proteins compared with control

(Fig. 7I, J, L, and M; Supplementary Fig. S11A and S11B).
When proteasome degradation was inhibited by MG132, we
detected signiﬁcantly higher levels of ubiquitinated proteins
in Kmt2d-mutant MA1L and Kmt2d-mutant MB49 cancer
cells compared with the corresponding controls (Fig. 7K
and M), although we did not see the same trend in LLC
cells (Supplementary Fig. S11A and S11B). Interestingly,
when treated by IFNγ, both Kmt2d-mutant and control
MB49 cells showed higher levels of ubiquitinated proteins
(Supplementary Fig. S11C and S11D). These results indicated that Kmt2d-mutant cells generated more proteins,
which were ubiquitinated and subjected to proteasomal
degradation. This ﬁnding is further supported in patient
cohorts, as proteasome-related genes were enriched among
the genes negatively correlated with KMT2D expression in
the TCGA (Fig. 5F).
Following protein ubiquitination and proteasomal degradation, the resultant peptides must be loaded onto MHC-I
to be presented. However, the RNA-seq data revealed that
several genes in the MHC-I family were downregulated in
Kmt2d-mutant MA1L cells compared with vector control
cells (Supplementary Fig. S11E), potentially dampening
the presentation of potential antigens. Analyzing the levels
of cell-surface MHC-I by ﬂow cytometry, we found that
the baseline levels of surface H2-Kb on Kmt2d-mutant cells
were comparable to that of vector control (Fig. 7N; Supplementary Fig. S11F). When stimulated by IFNγ, the surface
levels of total H2-Kb were signiﬁcantly increased and Kmt2dmutant cells exhibited even higher levels of H2-Kb than the
control cells (Fig. 7N; Supplementary Fig. S11F). To explicitly test whether tumor antigens would be more efﬁciently
presented in Kmt2d-mutant cells, we transduced the MA1L
tumor cells with a phosphoglycerate kinase (PGK) promoter
driving ovalbumin (OVA) to examine the presentation levels
of H2-Kb-SIINFEKL. We did not observe any difference in
the levels of surface H2-Kb-SIINFEKL in Kmt2d-mutant
and vector control cells without IFNγ treatment (Fig. 7O).
However, Kmt2d-mutant cells had signiﬁcantly higher levels
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of H2-Kb-SIINFEKL than vector control cells when stimulated by IFNγ (Fig. 7O), indicating that Kmt2d-mutant cells
respond strongly to IFNγ treatment by upregulating antigen
presentation.
Taken together, these results demonstrate that Kmt2d
mutation in tumor cells may lead to higher levels of neoantigens by causing DNA damage, increasing mutation burden,
inducing intronic retention, and activating expression of
TEs. Furthermore, Kmt2d-mutant cells are characterized by
increased proteasomal degradation as well as increased IFNγstimulated antigen presentation. As a consequence, Kmt2dmutant tumors exhibit elevated inﬁltration of PD-1+ T cells
and macrophages, the latter of which may further amplify
the antitumor effect of anti–PD-1 therapy by activating the
adaptive immune system. As a histone methyltransferase,
KMT2D likely has pleiotropic effects on tumors; at least
in the context of the experiments shown here, a plausible
mechanistic explanation is that multiple pathways perturbed
by Kmt2d deﬁciency converge to potentiate response to anti–
PD-1 immunotherapy (Fig. 7P).

DISCUSSION
In this study, we performed a mutagenesis screen in a
CRISPR-GEMM liver tumor model to pinpoint genetic modulators of immunotherapy response. Distinct from previous
studies using in vitro coculture and tumor transplantation
models, our screening system utilizes an autochthonous
tumor model that preserves the native microenvironmental context. Here, we systematically mapped the ﬁtness
of diverse mutations under immunotherapy treatments,
demonstrating the power of this platform for interrogating causal relationships of speciﬁc mutations and response
to ICB.
Identifying the molecular features that dictate response
to immunotherapy has the potential to provide valuable guidance to clinicians. We found that mutations in
the H3K4 methyltransferase Kmt2d potentiate response
to anti–PD-1 therapy in diverse cancer types. Of note, the
heightened anti–PD-1 response and elevated DNA damage
caused by Kmt2d loss does not appear to be dependent on
mutant p53. Among the tumor cell lines used in this study,
E0771, B16F10, and MA1L cells are p53-deﬁcient, whereas
LLC and MB49 cells are p53-competent. In addition, a
prior study that demonstrated that Kmt2d deﬁciency leads
to DNA damage and genomic instability was performed
using Trp53–wild-type mouse MEF cells (30). As KMT2D is
a tumor suppressor gene that is recurrently mutated across
multiple human cancers, the identiﬁcation of KMT2D deﬁciency as a predictor of anti–PD-1 therapy response may
have important implications for patient stratiﬁcation and
clinical decision-making.
Our study revealed that Kmt2d-mutant cancer cells exhibited an elevated level of DNA damage and higher mutation burden, and we further corroborated these ﬁndings
in patient tumor datasets. These ﬁndings are consistent
with the reported role of KMT2D in genome stability, as
KMT2C- and KMT2D-dependent H3K4 methylation at replication forks was found to be involved in replication stress
(40). We also found that Kmt2d deﬁciency led to compro-

mised RNA splicing and activation of TEs. Intron retention
and activation of TEs can potentially result in the presentation of immunogenic antigens, and we observed that
Kmt2d-mutant cells exhibit increased protein ubiquitination, indicating increased proteasomal degradation. Given
the increased mutation burden and aberrant transcription
of Kmt2d-mutant cells, we speculate that upregulation of
proteasome activity may be a compensatory response to
the production of abnormal proteins in these cells. Importantly, the resultant increase in proteasomal degradation is
further associated with increased IFNγ-stimulated antigen
presentation in these cells, thus providing an explanation
for the enhanced sensitivity to anti–PD-1 therapy in Kmt2dmutant tumors.
Interestingly, when we rechallenged mice that had successfully rejected Kmt2d-mutant tumors with either Kmt2dmutant or wild-type tumor cells, both types of tumors were
rejected within 2 weeks (Supplementary Fig. S11G). Although
the Kmt2d-mutant cells had accumulated more mutations,
it is worth emphasizing that the Kmt2d-mutant and wildtype cells nevertheless share most of their mutations by
virtue of their common background, and tumor rejection is
often mediated by multifaceted immune responses against
multiple antigens. In addition, Kmt2d-mutant tumors display higher levels of both unique and shared antigens after
anti–PD-1 treatment, thereby promoting the development
of immune memory against both unique and shared tumor
antigens. We also note that the CRISPR components may
have some degree of immunogenicity, thus contributing to
the rejection of these cells by B6 mice; nevertheless, all experiments were conducted in parallel with mutant (gene-targeting
sgRNAs) groups directly compared with controls (vector or
nontargeting guide RNA).
We further found that Kmt2d-mutant cells had increased
levels of the myeloid-recruiting cytokines Cxcl1 and Cxcl5
at both the RNA and protein level. However, when proﬁling the chemokines in primary tumors derived from these
cells, we instead detected increased CCL2, CCL5, CCL22,
and CXCL9 levels in Kmt2d-mutant tumors (Supplementary Fig. S11C), suggesting that the upregulation of these
chemokines was due to host immune cells recruited to the
tumors. These chemokines would promote the inﬁltration
of antigen-presenting cells and T cells into the tumors.
Indeed, Kmt2d-mutant tumors had signiﬁcantly increased
inﬁltration by antigen-presenting cells, CD4+ T cells, and
CD8+ T cells, which all expressed high levels of PD-1. Recent
work has demonstrated that PD-1 blockade promotes antitumor immunity not only through its action on T cells,
but also by leveraging myeloid-derived innate immune
cells toward antitumor function (31, 41). The elevated
immune inﬁltration in Kmt2d-mutant tumors can therefore
be explained by the elevated antigenicity of Kmt2d-mutant
cells as well as elevated myeloid cell recruitment. However,
a limitation of these data is that certain validation experiments were performed using subcutaneous transplantation
models that may not accurately reﬂect the tumor microenvironment of the cancer’s origin.
In summary, these data collectively demonstrate that
Kmt2d loss sensitizes diverse tumor types to checkpoint
blockade immunotherapy. This study showcases the
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power of CRISPR-GEMM models for interrogating complex molecular landscapes in native tumor microenvironments, enabling the dissection of immunotherapeutic
responses. Given the prevalence of KMT2D mutations in
diverse cancer types, our study could help identify a sizeable patient subpopulation that may have higher chances
of being sensitive to ICB therapies such as PD-1 checkpoint blockade.

METHODS
Institutional Approval
This study has received institutional regulatory approval. All recombinant DNA and biosafety work was performed under the guidelines
of the Yale Environment, Health and Safety (EHS) Committee with
an approved protocol (Chen-rDNA-15–45; Chen-rDNA-18–45). All
animal work was performed under the guidelines of Yale University
Institutional Animal Care and Use Committee with approved protocols (Chen-2015–20068; Chen-2018–20068). All human sample work
was performed under the guidelines of Yale University Institutional
Review Board with an approved protocol (HIC#2000020784).

AAV-CRISPR Vector and mTSG Library Cloning
The AAV-CRISPR vector was designed to express Cre recombinase
under a liver-speciﬁc TBG promoter. Each vector has two sgRNA
expression cassettes, with one of them encoding an sgRNA targeting
Trp53, and the other as an open sgRNA expression cassette (double
SapI sites for sgRNA cloning). We also designed a liver-speciﬁc AAVCRISPR vector with only one sgRNA expression cassette as a control
to study the impact of Trp53 knockout. The mTSG library was generated as described previously (26, 27), with more than 100× coverage
to ensure proper representation of the library.

Production and Puriﬁcation of AAVs Carrying mTSG
Library or Individual sgRNA
8.7 μg of AAV9 serotype plasmid, 10.4 μg of pDF6 helper plasmid,
and 5.2 μg of AAV expression plasmid were added into 450 μL OptiMEM and mixed well, then complexed with PEI, incubating at room
temperature for 10 to 15 minutes before adding them drop-wise into
HEK293FT cells at 80% to 90% conﬂuency. Forty-eight to 72 hours
post-transfection, the transfected cells were collected. AAVs were
puriﬁed using chloroform extraction and titrated by qPCR assay (see
Supplementary Methods).

Intravenous Administration of AAVs for
Liver Transduction
Rosa26-LSL-Cas9–2A-EGFP (LSL-Cas9) mice were bred with
C57BL/6J mice, FVB.129S6(B6)-Gt(ROSA)26Sortm1(Luc)Kael/J mice
(LSL-Luc), or C57BL/6N-Gt(ROSA)26Sortm13(CAG-MYC,-CD2*)Rsky/
J mice (LSL-Myc for short). Mixed-gender (randomized males and
females) 8- to 12-week-old mice were used for experiments. For intravenous injection of AAVs, the mice were restrained in a rodent
restrainer (Braintree Scientiﬁc). Tails were sterilized by 70% ethanol,
and 100 to 200 μL of concentrated AAVs (∼1–2 × 1011 GCs in total)
were injected per mouse. All the mice survived the procedure. When
tumor initiation was observed, the mice were randomly assigned into
3 groups to receive treatment of PBS, 8 mg/kg anti–PD-1, or 4 mg/kg
anti-CTLA4 twice a week, for 5–6 doses at the indicated times.

Bioluminescence Imaging Using IVIS
After AAV injection, mice were imaged by IVIS each month.
Briefly, mice were anesthetized by isofluorane, and then 100
to 150 μL of 30 mg/mL firefly D-luciferin potassium salt was

intraperitoneally injected with approximately 150 mg/kg body
weight. Ten to 15 minutes after injection, the mice were imaged
for in vivo tumor growth using an IVIS machine (PerkinElmer).
Relative tumor burden was quantified using LivingImage software
(PerkinElmer).

Survival Analysis
We observed that the LSL-Cas9 mice receiving AAV-mTSG intravenous injections rapidly deteriorated in their body condition
scores (due to tumor development in most cases). Mice with body
condition score < 2 were euthanized, and the euthanasia date was
recorded as the last survival date. Survival data was analyzed by
standard Kaplan–Meier method, using GraphPad Prism. Statistical signiﬁcance was assessed by log-rank test. Mice euthanized
early in a healthy state were excluded from calculation of survival
percentages.

Genomic DNA Extraction from Cells and Mouse Tissues
The genomic DNA from frozen ground tissue was puriﬁed using
DNeasy Blood & Tissue Kits (Qiagen) or standard DNA extraction protocol (see Supplementary Methods). The concentration was measured
using a NanoDrop (Thermo Fisher Scientiﬁc).

Validation Using CAG-LSL-MYC Transgenic Mice plus Trp53
Knockout as a Tumorigenic Background
Rosa26-LSL-Cas9–2A-EGFP knock-in mice were bred with C57BL/
6N-Gt(ROSA)26Sortm13(CAG-MYC,-CD2*)Rsky/J mice (LSL-Myc
for short) to obtain LSL-Myc; LSL-Cas9 mice. Mixed-gender mice
of 7–12 weeks old were used for experiments. Autochthonous liver
tumors with Myc overexpression and mutant Trp53 were induced by
injecting 1–2*1011 GCs of TBG-Cre AAVs carrying sgTrp53+sgNTC
into immunocompetent LSL-Myc;LSL-Cas9 mice. Autochthonous
liver tumors with additional Arid1a or Kmt2d mutations were induced
by injecting 1–2 × 1011 GCs of AAVs carrying sgTrp53 + sgArid1a or
sgTrp53 + sgKmt2d into LSL-MYC; LSL-Cas9 mice. Liver tumorigenesis was detectable 60 days after AAV injection, at which point the
mice were randomly assigned into 2 groups to receive treatment of
PBS or 8 mg/kg anti–PD-1, twice a week for 5 doses.

Histology and IHC
Liver tumors were collected and ﬁxed in 10% neutral formalin for
2 to 5 days, then transferred into 70% ethanol. Hematoxylin and
eosin staining or IHC staining of CD45, CD3, F4/80, or cytokeratin
pan-cytokeratin were performed on 3- to 5-μm tissue sections using
standard procedures at Yale Pathology Core Facility. To quantify
CD45-, CD3-, and F4/80-positive cells, the slides of different regions
of tumor samples were quantitatively scored using the IHC proﬁler
in ImageJ software (42), and only the percentage distribution of high
positive was regarded as positive staining.

Cell Lines
HEK293FT cells were purchased from Thermo Fisher Scientiﬁc
(catalog no. R70007). E0771 mouse triple-negative breast cancer
cells were purchased from CH3 (catalog no. 940001). B16F10 mouse
melanoma cells (catalog no. CRL-6475), mouse Lewis lung cancer
carcinoma cells (catalog no. CRL-1642), and H1299 human lung
carcinoma (non–small cell lung cancer) cells (catalog no. CRL-5803)
were purchased from ATCC. MB49 mouse bladder cancer carcinoma
cells were purchased from Sigma-Aldrich (catalog no. SCC148).
MA1L and MA1NC cells were established from autochthonous liver
tumors with Myc overexpression and Trp53 knockout mutation
generated by the intravenous injection of sgTrp53-targeted AAVs
into B6 background LSL-Myc;LSL-Cas9 mice. The cells tested negative for Mycoplasma contamination. All the purchased cell lines have
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been authenticated by the original vendors. All cells were cultured in
DMEM supplemented with 10% FBS and 1% penicillin/streptomycin,
in a CO2 cell incubator 37°C.

Establishing Tumor Cell Lines from Autochthonous
Liver Tumors
Autochthonous liver tumors with Myc overexpression and Trp53
knockout mutation were generated by the intravenous injection of
Trp53-targeted AAVs into LSL-Myc;LSL-Cas9 mice. At the survival
endpoint, the liver tumors were isolated and made into single-cell
suspensions by digestion with collagenase IV after mincing into
small pieces and passing through 40-μm cell restrainer. The cells
were then cultured in DMEM supplemented with 10% FBS and 1%
penicillin/streptomycin. To knock out Kmt2d or Arid1a, the tumor
cells were transduced with lentiviruses carrying sgRNAs targeting
Kmt2d or Arid1a. The transduced cells were selected with 3 to 5 μg/mL
puromycin, and the knockout of Kmt2d and Arid1a was conﬁrmed
by T7E1 assay.

Validating the Role of Kmt2d in Multiple Cancer Models
Cas9-expressing MB49 cells, E0771 cells, B16F10 cells, and LLC
cells were generated by transduction with lentiviruses carrying
EFS-Cas9–2A-BlastR-WPRE and selected under 10 μg/mL blasticidin S. To knock out Kmt2d, these Cas9-expressing cells were
transduced with lentiviruses carrying an Kmt2d sgRNA, and cells
transduced with lentiviral vector or nontargeting sgRNA were
used as a control. The transduced cells were selected with 3 to 5
μg/mL puromycin at 24 hours post-infection. To generate syngeneic mouse bladder tumors, 5 × 106 of vector- or Kmt2d sgRNAtransduced MB49 cells were transplanted subcutaneously into
the right flank of C57BL/6J mice. To generate orthotopic breast
tumors, 2 × 106 of vector- or Kmt2d sgRNA–transduced E0771
cells were transplanted into the fat pad of C57BL/6J mice. To
generate melanoma or Lewis lung tumors in C57BL/6J mice,
2 × 106 vector- or Kmt2d sgRNA–transduced B16F10 cells or LLC
cells were subcutaneously transplanted into the right flank of
C57BL/6J mice. Tumor growth was monitored and assigned into
two groups to receive the treatment of 8 mg/kg anti–PD-1 or PBS
twice a week at the indicated time.

Dual-Tumor Model of LLC-Vector and LLC-sgKmt2d Cells
To generate a dual-tumor model of LLC, 2 × 106 of LLC-Vector
and LLC-sgKmt2d cells were transplanted into the left ﬂank and
right ﬂank of C57BL/6J mice, respectively. Tumor growth was monitored, and mice were assigned into two groups to receive 8 mg/kg
anti–PD-1 or PBS twice a week at indicated times.

CTATGTCGGGCCTGT; sgRNA3: GTGTGTGAGACATGTGACAA.
For Arid1a, sgRNA4: GACGCATGAGCCATTCTCCC. Lentiviruses
were produced by cotransfecting the lentiviral CRISPR knockout
plasmids, together with packing plasmids pMD2.G and psPAX2, into
80% to 90% conﬂuent HEK293FT cells. The lentivirus-containing
supernatants were collected at 48 and 72 hours post-transfection,
aliquoted, and stored at −80°C before use. To knock out KMT2D
in human lung cancer H1299 cells, the corresponding oligos of
sgRNA1: GGTGGAAATTCCCGCCAACG; sgRNA2: AAATGGC
TGTTGATCCCATG were synthesized, annealed, and cloned into
BsmBI linearized lentiviral knockout vectors. After lentiviral production, the Cas9-transduced tumor cells were infected and selected
with 3–5 μg/mL puromycin to obtain individual gene knockout cells.
CRISPR mutagenesis was conﬁrmed by extracting genomic DNA for
T7E1 assays.

Immunoblot to Quantify the Levels of
Ubiquitinated Proteins
Vector, sgKmt2d, or sgArid1a transduced primary liver tumor
cells (MA1L), MB49-Vector, MB49-sgKmt2d, LLC-Vector, and LLCsgKmt2d cells were seeded into 6-well plates or 10-cm dishes and
cultured for 24 hours. Then, 15 μmol/L MG132, 10 ng/mL IFNγ, or
DMSO was added and incubated for 2 to 3 hours before harvesting
the treated cells. The harvested cells were washed twice with ice-cold
PBS, and then lysed with 1× RIPA buffer on ice for 15 minutes. Cell
lysates were centrifuged at 12,000 × g for 15 minutes at 4°C and
protein-containing supernatant was collected. Protein concentration
was measured using a BCA assay (Abcam) and approximately 20 μg
of protein from each sample were loaded into SDS-PAGE gels. After
electrophoresis and transmembrane, immunoblot assays were performed with antibody against ubiquitin (clone Ubi-1, Sigma), with
GAPDH being used as internal control. The relative levels of ubiquitinated protein were quantiﬁed by grayscale analysis.

Flow Cytometry to Quantify Cell Surface
MHC-I and Peptide–MHC-I Complex
2 × 105 vector-, sgKmt2d-, or sgArid1a-transduced MA1L primary
liver tumor cells (MA1L-Vector, MA1L-sgKmt2d, MA1L-sgArid1a),
MB49-Vector, and MB49-sgKmt2d cells were seeded into 12-well
plates. To test the effect of IFNγ on surface MHC-I or peptide–MHC-I
presentation, 0, 5 ng/mL, or 10 ng/mL IFNγ were added and treated
for 24 to 48 hours. The treated cells were collected and washed twice
with 2% FBS in PBS. Then, the cells were stained with 1:100 diluted
PE-H-2Kb/H-2Db, and APC-SIINFEKL-H-2Kb for 30 minutes on ice
and washed twice with 2% FBS in PBS before ﬂow cytometry analysis. Samples were run on Attune NxT Flow Cytometer and the mean
ﬂuorescence intensities were quantiﬁed.

Flow Cytometry Analysis and Sorting
All antibodies for ﬂow were purchased from BioLegend or eBioscience. Single-cell suspensions of tumors or spleens were prepared
using a gentleMACS tissue dissociation system. All ﬂow antibodies
were used at 1:100 dilutions for staining unless otherwise noted.
After staining, cells were centrifuged at 300–600 × g for 5 minutes,
and washed twice with staining buffer before being analyzed or
sorted on a BD FACSAria. The data was analyzed using the FlowJo
software (v9.9.4 or v10.3). A previously reported strategy was used to
deﬁne the immune populations in tumors (43).

RNA Extraction, Reverse Transcription,
and Quantitative PCR
RNA from control and Kmt2d-mutant cells was extracted using
TRIzol Reagent (Invitrogen) by following standard RNA extraction
protocols. The ﬁrst-strand cDNA of RNA was synthesized using
SuperScript IV Reverse Transcriptase (Invitrogen). After normalizing
the concentrations of cDNA with nuclease-free water, quantitative
PCR (qPCR) was performed by adding designated TaqMan probe
of genes of interest, and GAPDH was used as an internal positive
control.

Mutagenesis with Lentiviral CRISPR
The CRISPR knockout construct Lenti-U6-sgBsmBI-EFS-PuroWPRE was generated. To clone sgRNA targeting individual genes,
such as Kmt2d and Arid1a, the corresponding oligos were synthesized,
annealed, and cloned into BsmBI linearized lentiviral knockout vectors. The following sgRNAs were used for Kmt2d. sgRNA1: GCCGG

Western Blot Analysis
Cells in a 6-well plate or 10-cm dish were washed twice with
ice-cold PBS. The cells were then lysed with 1× RIPA buffer on
ice for 15 minutes, or nuclear protein puriﬁcation using Nuclear
Extraction Kit (Abcam). Cell lysates were centrifuged at 12,000 × g
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for 15 minutes at 4°C, and protein-containing supernatant was
collected. Protein concentration was measured using a BCA Assay
(Abcam) and 20 μg of protein in each sample was loaded into
SDS-PAGE gel. After electrophoresis, proteins separated in gel
were transferred into nitrocellulose membranes. Membranes were
blocked at room temperature for 1 hour using 5% skim milk
in TBST, followed by incubation with primary antibody in 4°C
overnight. After washing three times with TBST, horseradish
peroxidase–conjugated secondary antibody was added and incubated at room temperature for 30 to 60 minutes. The chemiluminescent substrate (Clarity Western ECL Substrate, Bio-Rad) was
added on top of blot membrane according to the manufacturer’s
instructions. The signals were captured using a CCD camera-based
imager (GE Healthcare).

correlated with KMT2D across multiple cancer types. On the basis of
the empirical cumulative density function of the number of cancer
types for which each gene was signiﬁcantly correlated with KMT2D,
we selected a cutoff that would select approximately the top 5% of
genes (30+ cancer types among positively correlated genes, 21+ cancer types among negatively correlated genes). DAVID gene ontology
analysis was performed on the resultant gene sets.

MIP Sequencing Data Analysis

ATAC-seq Analysis

Raw FASTQ reads were mapped to the mm10 genome using bwa
mem v.0.7.17 (44). BAM ﬁles were sorted and indexed using SAMtools
v1.3 (45). Indel variants were then called using SAMtools and VarScan v2.3.9 (46). All detected indels were ﬁltered by requiring that
each indel must overlap the ±3 bp window surrounding the predicted
cut site of the closest sgRNA. We excluded variants at Rps19 sg5
because vector control samples were also found to have heterozygous
mutations at this site.
The remaining indel variants were summed for each sgRNA site
to obtain a mutation frequency table. To further ﬁlter detected variants, we employed a false discovery approach based on vector control
samples. For each sgRNA in the library, we took the highest variant
frequency across all the vector control samples and set this value as
the minimum cutoff when ﬁltering the mTSG samples. In addition,
we further set a 5% variant frequency cutoff to ensure stringent detection of indels. The ﬁltered sgRNA variant frequency table was then
averaged by gene to obtain the gene-level frequency table. We then
used the gene-level variant frequencies to determine enrichment or
depletion of speciﬁc mutations in ICB-treated versus PBS-treated
samples by two-tailed unpaired t test.

Raw FASTQ reads were mapped to the mm10 genome using Bowtie v2 (48). ATAC-seq accessible regions were called using MACS2
(49). Accessible regions across all samples were combined and the
read counts in each region were tabulated. Pairwise Spearman
correlations were calculated using the read counts in each region.
Differential accessibility analysis was performed using DESeq2 (50).
Intersection of accessible regions and motif analysis was performed
using HOMER (51).

Analysis of KMT2D Mutation Status in Patient Cohorts
KMT2D mutation status was queried using cBioPortal using
the OQL speciﬁers “MUT HOMDEL” for all mutations and deletions (47), or “DRIVER NONSENSE NONSTART NONSTOP
FRAMESHIFT SPLICE TRUNC HOMDEL” for anticipated lossof-function mutations and deletions. The different cancer types in
the curated nonredundant set were consolidated on the basis of the
tissue of origin.
To determine the association between KMT2D and tumor mutation burden, the cBioPortal was queried across the PanCancer TCGA
cohorts. Tumor types with at least 5 KMT2D-mutant samples were
considered for analysis. Statistical signiﬁcance was assessed by twotailed Mann–Whitney test.

Analysis of Genes and Cell Types Correlated with
KMT2D Expression in Tumors
RNA-seq count data from TCGA were downloaded from the GDC
Data Portal and normalized to transcripts per million. The Spearman correlation between each gene and KMT2D was calculated, and
P values were adjusted for multiple comparisons by the Benjamini–
Hochberg method. We then tabulated the number of individual
cancer types for which a given gene was concordantly correlated with
KMT2D. Inferred cell type abundances in TCGA tumors were downloaded from the xCell website (http://xcell.ucsf.edu/). Correlations
between KMT2D and cell type abundances were calculated in the
same manner as with individual genes.
To obtain the pan-cancer gene sets that are positively or negatively
correlated with KMT2D, we selected for genes that are concordantly

Exome-Sequencing Analysis
Raw FASTQ reads were mapped to the mm10 genome using the
bwa mem function in BWA v.0.7.17. Mutations in MA1L cells were
called using Strelka v2.9.2 by comparing with wild-type liver exomes
from C57BL/6J mice.

RNA-seq Analysis
Raw FASTQ reads were quantiﬁed to the mm10 transcriptome
using Kallisto (52). Differential expression analysis was performed
using Sleuth (53). DAVID gene ontology analysis was performed on
genes with an adjusted P < 0.05. For neoantigen prediction, RNA-seq
reads were aligned to the mm10 genome using STAR, then mutations
were called using the RNA-seq mode of Strelka v2 (54). The resultant mutations were annotated using VEP, then neoantigens were
predicted using pVACtools with H-2Kb and H-2Db as the candidate
MHC-I alleles (55).
To analyze expression of transposable elements, the raw FASTQ
reads were ﬁrst realigned using STAR (56) with modiﬁed settings
(outFilterMultimapNmax 100, winAnchorMultimapNmax 100).
Transposable elements were quantiﬁed by TEcount from TEToolkit.
Differential expression was assessed using the raw counts of all genes
and transposable elements with DEseq2.

Analysis of FOSL2 Binding in Human Liver Cancer Cells
FOSL2 ChIP-seq data in HepG2 cells were downloaded from the
ENCODE database and visualized in the Integrative Genomics Viewer.

Sample Size Determination
Sample size was determined according to the lab’s prior work or
similar studies in the literature.

Randomization and Blinding Statements
In animal experiments, mice were randomized by sex, cage, and
littermates. In vitro experiments were not randomized or blinded.
Investigators were blinded in mouse experiments by labeling cages
with generic identiﬁers. In next-generation sequencing data analysis,
investigators were blinded for initial processing of the original data
using key-coded metadata.

Standard Statistical Analysis
Data between two groups were analyzed using a two-tailed unpaired
t test. Different levels of statistical signiﬁcance were accessed on the
basis of speciﬁc P values and type I error cutoffs (0.05, 0.01, 0.001,
0.0001). GraphPad Prism and R were used for analyses.

OF19 | CANCER DISCOVERYDECEMBER 2020

AACRJournals.org

76
Downloaded from cancerdiscovery.aacrjournals.org on November 20, 2020. © 2020 American Association for

Published OnlineFirst September 4, 2020; DOI: 10.1158/2159-8290.CD-19-1448

Kmt2d Deﬁciency Sensitizes Tumors to Checkpoint Blockade

RESEARCH ARTICLE

Code Availability
Codes used for data analysis or generation of the ﬁgures related
to this study are available on GitHub (https://github.com/rdchow/
immunoMIPS/).

Data and Resource Availability
All data generated or analyzed during this study are included in
this article and its supplementary information ﬁles. Speciﬁcally,
source data and statistics for non–high-throughput experiments such
as ﬂow cytometry, qPCR, protein experiments, and other molecular
or cellular assays are provided in Supplementary Tables. Processed
data for genomic sequencing (e.g., RNA-seq, exome sequencing,
ATAC-seq) and other forms of high-throughput experiments are provided as processed quantiﬁcations in Supplementary Datasets. Raw
sequencing data have been deposited to NIH Sequence Read Archive
(SRA) or Gene Expression Omnibus: MIPS sequencing of mouse tissue and exome sequencing of MA1L cells (PRJNA634679); ATAC-seq
and RNA-seq (GSE151227). Original cell lines are available at commercial sources listed in Supplementary Data. Genetically modiﬁed
cell lines are available via the Chen lab. Most data, reagents, methods,
computational codes, and materials that support the ﬁndings of this
research are available from the corresponding author upon reasonable request. Some material used in the reported research may require
requests to collaborators and agreements with other entities. Requests
are reviewed by Yale University to verify whether the request is subject
to any intellectual property or conﬁdentiality obligations. Any material
that can be shared will be released via a Material Transfer Agreement.
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§ CHAPTER 3: GENOME-WIDE INVESTIGATION OF FACTORS REGULATING
ANTI-TUMOR IMMUNITY

3.1: Sno-derived RNAs are prevalent molecular markers of cancer immunity
After reading a review about small noncoding RNAs, I became interested to explore
whether these RNA species might be associated with different cancer-associated processes 95. I
grew particularly interested in snoRNAs, as it had been recently demonstrated that they could be
further processed into sno-derived RNAs, some of which could exhibit microRNA-like gene
regulatory properties 96,97. I also found that snoRNAs were comparatively understudied in cancer,
so I set out to define a pan-cancer atlas of snoRNA expression and their relation to several
different immune parameters 98.
This line of investigation was conceived together with my advisor Dr. Sidi Chen. I
designed the study and carried out the analyses. I also prepared the manuscript text and figures
together with Dr. Sidi Chen.
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Abstract
Small nucleolar RNAs (snoRNAs) constitute a family of noncoding RNAs that are classically known as guide RNAs for
processing and modiﬁcation of ribosomal RNAs. Recently, it was discovered that snoRNAs can be further processed into
sno-derived RNAs (sdRNAs), some of which are known to exhibit microRNA-like properties. SdRNAs have been
implicated in human cancer; however, a systems-level sdRNA landscape in human cancers is lacking. Through integrative
analysis of ~22 nt size-selected smRNA-seq datasets from 10,262 patient samples across 32 cancer types, we mapped a pancancer sdRNAome and interrogated its signatures in multiple clinically relevant features, particularly cancer immunity and
clinical outcome. Aggregating sdRNA abundances by parental snoRNAs, these expression signatures alone are sufﬁcient to
distinguish patients with distinct cancer types. Interestingly, a large panel of sdRNAs are signiﬁcantly correlated with
features of the tumor-immune microenvironment, such as immunosuppressive markers, CD8+ T cell inﬁltration, cytolytic T
cell activity, and tumor vasculature. A set of individual sdRNAs with tumor-immune signatures can also stratify patient
survival. These ﬁndings implicate snoRNAs and their derivative sdRNAs as a class of prevalent noncoding molecular
markers of human cancer immunity.

Introduction
Over the past decade, tumor immunity has realized its
central importance in oncology [1]. Checkpoint blockade
immunotherapies targeting the program cell death protein 1
(PD-1) and cytotoxic T lymphocyte associated protein 4
pathways have revolutionized cancer therapeutics with
unprecedented durable responses across multiple cancer
types [2–4]. However, not all patients respond to checkpoint
inhibitors [5]. Identifying the molecular correspondents
underlying these differential responses is essential to
expanding the patient population that can beneﬁt from
cancer immunotherapy. Emerging biomarkers for anti-PD-1
response include the expression level of its ligand PD-L1
[2], mutation burden or mismatch-repair deﬁciency [6], and
tumor-inﬁltrating lymphocytes [7]. However, currently
available markers are insufﬁcient for accurate prediction of
immunotherapy responses. Thus, development and investigation of further molecular markers for tumor immunity,
especially in large cohorts of human patients, might provide
novel insights for precision diagnostics and treatments in
immunooncology.
Somatic mutations in oncogenes and tumor suppressors
represent the most classic biomarkers as they are the main
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direct drivers of cancer progression [8, 9]. Small noncoding
RNAs have great potential as molecular markers due to their
important biological roles and bioavailability in circulation,
facilitating implementation in liquid biopsy settings [10].
Since the last decade, microRNAs have been documented as
biomarkers for classifying human cancers. For example,
analysis of the miRnome using Fluidigm expression proﬁling has revealed its functional and prognostic importance
in classifying clinical populations [11]. More recently,
molecular proﬁling of >3000 tumors from 11 human cancer
types in TCGA has enabled systematic analysis of microRNAs and their targets [12]. Several other types of noncoding RNAs, such as long-noncoding RNAs [13, 14],
enhancer RNAs [15, 16], and circular RNAs [17] have also
been implicated in various cancer types [18]. While these
markers have enhanced our knowledge of cancer diagnostics and prognosis, the immense heterogeneity observed
within and across cancer patients far exceeds our current
understanding. Molecular markers that can further inform
distinct signatures of tumor initiation, progression, and
anticancer immunity will continue to be of high clinical
importance.
Small nucleolar RNAs (snoRNAs) comprise a class of
highly conserved small noncoding RNAs that are primarily
localized in the nucleolus [19]. SnoRNAs have essential
roles as guide RNAs for ribosomal RNA processing and
several types of RNA modiﬁcations such as methylation
and pseudouridylation [20]. In addition to their essential
role in ribosome biogenesis, snoRNAs have also been
implicated in chromatin structure regulation [21], RNA
splicing [22, 23], and protein signaling [24]. A number of
biologically and clinically important snoRNAs have
recently been reported in several cancer types [25, 26],
implying that snoRNAs might have more pervasive roles in
human cancer than previously appreciated.
Recent studies have revealed that snoRNAs can be further processed into smaller RNAs, termed sno-derived
RNAs (sdRNAs) [27–30]. Whereas snoRNAs range widely
in size from 60 to 300 nt, sdRNAs generally vary from 20 to
30 nt [27–33], and are similar in size to microRNAs
(19–25 nt) [34]. Interestingly, sdRNAs preferentially arise
from the 5′ or 3′ ends of snoRNAs [31, 32, 35, 36], and the
classical RNAi processing proteins Argonaute and Dicer are
important for catalyzing sdRNA biogenesis [30, 37]. Crucially, a handful of sdRNAs have also been demonstrated to
have microRNA-like gene regulatory activity [27]. Given
the remarkable similarities between microRNAs and
sdRNAs, it has been hypothesized that sdRNAs might also
contribute to the pathogenesis of diverse diseases—for
instance, cancer.
Here, we performed a pan-cancer analysis of ~22 nt sizeselected small RNA-seq (smRNA-seq) datasets from
TCGA, exploring the expression of small RNAs mapping to

annotated human snoRNAs in 10,262 patient samples
across 32 cancer types. Due to the size selection strategy
used for generating the sequencing libraries, it was anticipated that the resultant mapped reads were from sdRNAs
rather than full-length snoRNAs. This hypothesis was borne
out by subsequent analysis of the read lengths mapping to
snoRNAs and the read distributions along individual
snoRNAs, which demonstrated heavily skewed read densities that are characteristic of sdRNA biogenesis. We
therefore generated a landscape of the sdRNAome, subsequently linking sdRNAs to clinically signiﬁcant features
including tumor immunity and overall survival (OS). Since
few sdRNAs have been characterized and ofﬁcially named,
in the interest of clarity, we refer to sdRNAs using the name
of the parental snoRNA (i.e., SNORD116 refers to the
sdRNA derived from SNORD116), and aggregate sdRNA
abundances to the level of snoRNAs. Nevertheless, we
emphasize that the data and analyses presented here pertain
to sdRNAs, rather than full-length snoRNAs.
Aggregated by parental snoRNA, we found that sdRNA
expression signatures alone can classify patients from distinct cancer types at high resolution. Over 40 single
sdRNAs can stratify patient survival in 2 or more cancer
types, alongside with numerous single-cancer-type-speciﬁc
ones. Furthermore, many sdRNAs signiﬁcantly correlate
with tumor-immune microenvironment features such as PDL1 levels, T cell inﬁltration, functional anticancer cytotoxic
scores, and tumor vascularization. A panel of sdRNAs are
signiﬁcant markers for both immune and survival features,
with a total of 25 sdRNAs scored in 4 or more cancer types,
in addition to their angiogenesis, copy number, and
metastasis signals. Our analyses demonstrate that sdRNAs
are signiﬁcant and prevalent molecular markers across
multiple types of human cancer.

Results
A comprehensive map of the sdRNA transcriptome
across multiple human cancer types
We retrieved all available small RNA-seq (smRNA-seq)
reads from TCGA via NCI GDC, which consist of a total of
10,262 patient tumor samples and 675 adjacent normal
samples, encompassing 32 cancer types (Methods). The
smRNA-seq library construction protocols used by TCGA
investigators were designed to enrich for ~22 nt sized
transcripts, with the primary goal of capturing microRNAs
[38]. Whereas full-length snoRNAs range in size from 60 to
300 nt, and thus would not be expected to be captured,
sdRNAs are anticipated to be found within this size range
[27–30, 30–33, 39]. We consequently quantiﬁed the reads
mapping to all annotated snoRNAs (snoRNAome) [40] to
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construct the sdRNA transcriptome (Figure S1a, b, Fig. 1a).
This pan-cancer sdRNA transcriptome is derived from
several subtypes of snoRNAs with distinct structures and
motifs, such as canonical C/D box snoRNAs, H/ACA box
snoRNAs, C/D box small Cajal body RNAs (scaRNAs), H/

TES 3'

5' TSS

TES 3'

5' TSS

TES 3'

ACA box scaRNAs, hybrid snoRNAs, and several other
subtypes (Fig. 1b, Tables S1 and S2).
To conﬁrm that the TCGA smRNA-seq datasets are
indeed suitable for analysis of sdRNAs, we randomly
selected ﬁve tumors from each cancer type and tabulated the
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Fig. 1 A pan-cancer landscape of the sdRNA transcriptome. a Schematic of datasets and analytic ﬂowchart for integrative analysis of the
pan-cancer sdRNAome. b Schematic depicting the structural features
of different snoRNAs. Five select snoRNA types are illustrated here. c
Schematic describing the three types of C/D snoRNA read distributions identiﬁed in the smRNA-seq datasets. These read distributions
correspond to three different types of sdRNAs produced from the
parental snoRNAs. d Average proﬁle and heat map of SNORD30 read
distributions in 32 cancer types. The smRNA-seq reads that mapped to
SNORD30 were consistently concentrated on the 5′ end, suggesting
that SNORD30 is processed into 5′ sdRNAs. e Average proﬁle and
heat map of SNORD104 read distributions in 32 cancer types. The
smRNA-seq reads that mapped to SNORD104 were consistently
concentrated on the 3′ end, suggesting that SNORD30 is processed into
3′ sdRNAs. f Average proﬁle and heat map of SNORD27 read distributions in 32 cancer types. The smRNA-seq reads that mapped to
SNORD27 were concentrated on either the 5′ or 3′ end, suggesting that
SNORD30 is processed into 5′ or 3′ sdRNAs. g Average proﬁles and
heat maps of the mapped read distributions from all expressed C/D
snoRNAs in kidney chromophobe cancers (KICH, left), low-grade
glioma (LGG, center), and ovarian adenocarcinoma (OV, right). The
read distributions clustered into three groups by k-means clustering
(k1–k3) corresponding to the types depicted in (c). Values shown are
normalized to maximum read depth for each snoRNA. h Average
proﬁles and heat maps of the mapped read distributions from all
expressed H/ACA snoRNAs in adrenocortical carcinoma (ACC, left),
breast adenocarcinoma (BRCA, center), and uterine carcinosarcoma
(UCS, right). The read distributions clustered into three groups by kmeans clustering (k1–k3). Values shown are normalized to maximum
read depth for each snoRNA. TSS transcription start site; TES transcription end site

performed these analyses with H/ACA snoRNAs and found
three types of read distributions, corresponding to 5′
sdRNAs, 3′ sdRNAs, and centrally located sdRNAs (Fig.
1h, Figure S4). Collectively, these analyses indicate that the
TCGA smRNA-seq datasets can be utilized for the study of
sdRNAs, and not necessarily for full-length snoRNAs.
Though we, hereafter, refer to the data aggregated by parental snoRNA, we reiterate that the analyses presented here
are based on the sdRNA transcriptome, rather than fulllength snoRNAs.
To explore the landscape of sdRNA expression across
cancers, we calculated the median abundance of each
snoRNA (speciﬁcally, using aggregated sdRNA levels)
within each cancer type (n = 942 snoRNAs) (Figure S1c,
Table S3). The sdRNA transcriptome exhibited a wide
dynamic range of expression across all cancers (Figure
S5a), such that 300.13 ± 4.21 (mean ± s.e.m.) sdRNAs were
identiﬁed in each cancer type with abundances of median
log2 transcripts per million (tpm) ≥ 1. To test whether certain sdRNAs were more highly expressed in speciﬁc cancer
types, we assessed the relative expression patterns for each
sdRNA across all cancer types (Fig. 2a). This revealed that
different cancer types are associated with unique sdRNA
signatures. Based on median expression within each cancer
type, there are three categories of sdRNAs: (1) highly prevalent sdRNAs (expressed in ≥10 cancer types, n = 320);
(2) subgroup-associated sdRNAs (expressed in 3–9 cancer
types, n = 45); and (3) tissue-speciﬁc sdRNAs (expressed in
only 1 or 2 cancer types, n = 34). For instance, 15 different
sdRNAs appeared highly speciﬁc for testicular germ cell
tumors (TGCT) in terms of median expression (z-score > 5).
We next looked to characterize the sdRNA expression
landscape in individual tumors, and identiﬁed 300 expressed sdRNAs as “high variance” (variance > 0.1, median >
0). By examining coexpression modules, we found that a
subset of these 300 high variance sdRNAs clustered into
discrete groups (Figure S5b, Table S4). Note that the constituent sdRNAs within a cluster did not necessarily have
equivalent median expression levels over the dataset (Figure
S5b). This analysis indicates that speciﬁc sets of sdRNAs
are coordinately expressed across cancers from different
tissues of origin, further suggesting that the process of
sdRNA biogenesis from snoRNAs is coordinately regulated
in cancer.
Of note, previous studies of snoRNAs have occasionally
utilized transcription levels of host genes (i.e., the proteincoding genes within which snoRNAs are encoded) as a
proxy for snoRNA expression [24]. To evaluate this
assumption in the context of sdRNAs in cancer, we
extracted matching mRNA-seq data from the TCGA database (n = 8954 cancer samples with corresponding
smRNA-seq and mRNA-seq data). Using snoRNA-host
gene annotations [40], we calculated the Spearman

read lengths mapping to the snoRNAome (Figure S2). As
anticipated, these analyses revealed that snoRNA-mapping
reads mostly ranged in size from 20 to 30 nt, which is
consistent with the size ranges of known sdRNAs. Prior
studies have also established that sdRNAs tend to be
asymmetrically produced from either the 5′ or 3′ ends of
snoRNA transcripts [30]. We computed the distribution of
the reads mapping to each snoRNA to see if the ~22 nt size
selected transcripts could be consistent with sdRNAs. In the
case of C/D snoRNAs, these analyses revealed three classes
of read distributions, corresponding to 5′ sdRNAs, 3′
sdRNAs, or mixed sdRNAs (Fig. 1c). For instance, reads
that mapped to SNORD30 were consistently concentrated
on the 5′ end, indicating that SNORD30 is processed into 5′
sdRNAs in a highly conserved manner between different
cancer types (Fig. 1d). In contrast, reads that mapped to
SNORD104 were heavily concentrated on the 3′ end in all
cancer types, suggesting that SNORD104 is processed into
3′ sdRNAs (Fig. 1e). Unlike with SNORD30 and
SNORD104, reads mapping to SNORD27 were instead
distributed along both 5′ and 3′ ends (Fig. 1f). Of note,
different cancer types exhibited distinct balances between
the abundance of 5′ and 3′ sdRNAs, suggesting alternate
modes of sdRNA biogenesis from SNORD27. Across all
expressed C/D snoRNAs, read distributions for each
snoRNA were consistently clustered into these three groups
regardless of cancer type (Fig. 1g, Figure S3). We similarly
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We further investigated this correlation in a cancer typespeciﬁc manner (Fig. 2d), again ﬁnding that the majority of
sdRNA–host gene pairs are not signiﬁcantly correlated in
any single-cancer type (Fig. 2e, f, Table S6). There were a
few notable exceptions, most strikingly SNORD123 and
SNHG18, as well as ZL79 and GRIP2. SNORD123 was
found to be signiﬁcantly correlated with SNHG18 in 30
different cancer types, as was ZL79 with GRIP2 (Fig. 2f).
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Fig. 2 sdRNA expression patterns differ among cancer types and are
not adequately explained by host–gene transcription. a Heat map of
relative sdRNA expression aggregated by parental snoRNA across
cancer types, ﬁltered for sdRNAs exhibiting nonzero variance in
median values. Values shown are z-score transformations of the
median log2 tpm, normalized by individual sdRNAs. These data
demonstrate that while some sdRNAs are relatively evenly expressed
among all cancer types, there are clusters of sdRNAs with highly
tissue-speciﬁc expression patterns. b Violin plot comparing the
aggregated abundance of sdRNAs from each snoRNA with its host
gene (n = 736 snoRNA–host gene pairs) across all cancers. The top
schematic illustrates an intronic snoRNA and the associated sdRNA.
The Spearman correlation across all pairs was 0.089 ± 0.004 (mean ± s.
e.m.), indicating that sdRNA abundance cannot be adequately
explained by host–gene transcription. c Empirical cumulative density
function of the Spearman correlation distribution in (b). The dotted
lines indicate what cumulative proportion of total snoRNA–host gene
pairs (y-axis) have a correlation coefﬁcient up to the indicated point (xaxis). d Violin plot comparing the aggregated sdRNA abundance of
each snoRNA with its host gene (n = 736 sdRNA–host gene pairs) in
each individual cancer type. e Bar plot detailing the number of signiﬁcantly correlated sdRNA–host gene pairs in each cancer type
(adjusted p < 0.05). f Bar plot detailing the percentage of cancer types
in which each sdRNA–host gene pair was found to be signiﬁcantly
correlated (adjusted p < 0.05). Inset, top sdRNA–host gene pairs and
the number of cancer types that the pair was found to be signiﬁcantly
correlated

types such as thyroid carcinoma (THCA), lower grade
gliomas (LGG), pheochromocytomas and paragangliomas
(PCPG), skin cutaneous melanoma (SKCM), kidney
papillary cell carcinoma (KIRP), uterine corpus endometrial
carcinoma (UCEC), and ovarian adenocarcinoma (OV)
(Fig. 3a, Figure S6). An especially striking example was
observed for prostate adenocarcinoma (PRAD), where three
subclusters are readily apparent on t-SNE visualization (Fig.
3a, Figure S6). In general, samples from the same cancer
type can either cluster tightly as primarily one cluster (e.g.,
adrenocortical carcinoma (ACC), OV, pancreatic adenocarcinoma (PAAD), PCPG, SKCM, THCA, and uveal
melanoma (UVM)), fragment into several discrete subclusters (e.g., breast adenocarcinoma (BRCA), cervical
squamous cell carcinoma and endocervical adenocarcinoma
(CESC), colon adenocarcinoma (COAD), kidney clear cell
carcinoma (KIRC), and PRAD), or have a relatively diffuse
distribution across the multidimensional space (e.g., bladder
urothelial carcinoma (BLCA), LIHC, lung adenocarcinoma
(LUAD), lung squamous cell carcinoma (LUSC), SARC,
stomach adenocarcinoma (STAD), and UCEC) (Figure S6).
Accordingly, several clusters were comprised of patient
populations from multiple cancer types, as sub-populations
of patients from different types occupied the same multidimensional space (Fig. 3a). Collectively, these results
demonstrate that sdRNA expression signatures alone are
sufﬁcient to distinguish certain cancer types, while also
uncovering substantial patient heterogeneity within individual cancer types.
We wondered if the divergent sdRNA expression signatures were due to cancer-speciﬁc molecular changes, or
rather simply due to sdRNA expression differences in the
normal tissues from which the cancers had risen. Analysis
of 675 adjacent normal samples revealed that sdRNA
expression patterns were quite distinct across the various
normal tissues (Figure S7a), suggesting that the differences
in sdRNA expression across different cancer types are at
least partly attributable to the tissue of origin. To further
investigate this possibility, we selected tissues with multiple
cognate cancer types represented: gastrointestinal (COAD,
rectal adenocarcinoma (READ), and STAD), kidney (kidney chromophobe (KICH), KIRC, and KIRP), lung (LUAD
and LUSC), and melanocytes (SKCM and UVM). We
found that whereas kidney-derived and melanocyte-derived
cancers could be readily distinguished, the gastrointestinalderived and lung-derived cancers were much more heterogeneous (Fig. 3b). Even still, the three types of kidney
cancers and two types of melanomas were nevertheless
clearly distinguishable from each other (Figure S7b). This
ﬁnding indicates that despite having arisen from a similar
tissue of origin, different cancer types exhibit divergent
sdRNA expression patterns. To further investigate this
relationship, we next directly compared all normal kidney

However, these particular examples were clearly not
representative of all sdRNA–host gene pairs. Thus, these
analyses suggest that in the TCGA smRNA-seq data, the
bulk of sdRNA expression patterns are incompletely captured by the transcription levels of host genes alone,
potentially reﬂecting the importance of regulating sdRNA
biogenesis from snoRNAs, which in turn may derive from
host gene transcription. Together, this initial analysis generated a pan-cancer dataset of the sdRNA transcriptome
(PANCAN32), where the dynamic range and tissue-speciﬁc
or cancer type-speciﬁc patterns enables subsequent analysis
of associated quantitative phenotypes and clinical features.

SdRNA transcriptome stratiﬁes distinct groups of
patients from various cancer types
To test whether sdRNA expression can mark molecular
signatures or classify distinct cancer types, we ﬁrst utilized a
dimensional reduction approach. We performed tdistributed stochastic neighbor embedding (t-SNE) [41] on
the PANCAN32 dataset and visualized the resulting transformations both in individual cancer types (Figure S6) and
all cancers as a whole (Fig. 3a). The t-SNE visualization
revealed a high-level clustering map of all 32 cancer types
according to the expression of the sdRNA transcriptome in
each patient sample. This map showed that while several
cancer types clustered together, there are multiple clusters
that were primarily comprised of patient populations from
only one cancer type (Fig. 3a). These type-speciﬁc segregations were particularly apparent for individual cancer
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Fig. 3 High dimensional pan-cancer patient clustering based on
sdRNA expression signatures. a t-SNE plot of sdRNA expression in
tumors from 32 different cancer types (n = 10,262), aggregated by
parental snoRNA. Samples are colored by cancer type. b t-SNE plot of

gastrointestinal, kidney, lung, and melanocyte-derived cancers,
colored by tissue of origin. c t-SNE plot of all normal kidney and
kidney tumor samples. d t-SNE plot of all normal lung and lung tumor
samples

and kidney tumor samples. These analyses revealed that
while the normal kidney samples were grouped together in
the center of the multidimensional space, the different
kidney cancer subtypes radiated outwards from the center,
indicating progressive changes in sdRNA expression

signatures from the normal tissue in a cancer type-speciﬁc
manner (Fig. 3c). This ﬁnding was similarly corroborated
by analysis of all normal lung and lung tumor samples, with
normal lung samples grouped together and the different
lung cancer types splayed out across the multidimensional
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space (Fig. 3d). Of note, LUSC tumors were more distant
from normal samples compared to LUAD samples. This is
consistent with our understanding of the different cell types

SNORA31 sdRNA

R = -0.307
p = 7.66*10
15

10

5
0

1

2
PD-L1

3

4

present in LUAD vs. LUSC; whereas LUAD is characterized by alveolar-like cells that are present in the normal
lung, LUSC is characterized by basal cells that instead
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sdRNAs for each cancer type, and found that sdRNAs are
most predictive (in terms of the number of signiﬁcant
sdRNAs) in cancer types such as ACC, BLCA, COAD,
LGG, PCPG, TGCT, THCA, and thymoma (THYM) (Fig.
4a). In contrast, several cancer types have few predictive
sdRNAs for PD-L1, such as CESC, diffuse large B-cell
lymphoma, esophageal carcinoma (ESCA), KICH, acute
myeloid leukemia, mesothelioma, READ, SKCM, UCEC,
and UVM (Fig. 4a). Among all 32 cancer types, LGG has
the most sdRNAs positively correlated with PD-L1,
whereas COAD has the most sdRNAs negatively correlated
with PD-L1 (Fig. 4a). Of the signiﬁcant sdRNAs, 36 were
found to be positively correlated in 3 or more cancer types
(adjusted p < 0.05) (Fig. 4b, Table S8). For instance,
sdRNAs derived from SNORA44, an H/ACA-type snoRNA,
were signiﬁcantly correlated with PD-L1 expression in
LGG (Fig. 4c), PRAD, THCA, and THYM (Fig. 4d). We
further identiﬁed sdRNAs that were signiﬁcantly negatively
correlated with PD-L1 expression (adjusted p < 0.05) (Fig.
4e, Table S8). A total of 51 sdRNAs were negatively correlated with PD-L1 expression in at least 3 cancer types. For
instance, sdRNAs produced from SNORA31, another H/
ACA box snoRNA, were inversely correlated with PD-L1
levels in BRCA, COAD, PAAD, PCPG (Fig. 4f), and
PRAD (Fig. 4g). Collectively, these ﬁndings link sdRNAs
to PD-L1 expression in cancers of diverse origins, suggesting that sdRNAs have predictive power in the expression of this immunosuppressive molecule across diverse
patient tumors.
The number of TILs, especially cytotoxic CD8+ T cells,
is a strong positive predictive biomarker of checkpoint
blockade immunotherapy efﬁcacy and patient outcome for
certain types of solid tumors [2, 5]. We interrogated the
sdRNAome (aggregated by parental snoRNA) in relation to
intratumoral CD8+ T cell abundance. We found that a total
of 366 sdRNAs were signiﬁcantly correlated with CD8+
inﬁltration level in at least one cancer type (adjusted p <
0.05) (Table S9). The number of predictive sdRNAs also
varied between cancer types, among which the most predictive ones are BRCA, head and neck squamous cell carcinoma (HNSC), LGG, LUAD, LUSC, PAAD, PRAD,
STAD, TGCT, and THYM (Fig. 5a). In contrast, cancer
types such as CESC, COAD, KIRP, READ, SKCM,
UCEC, UCS, and UVM have few or no predictive sdRNAs
for CD8+ T cell abundance (Fig. 5a). Thymoma has the
most sdRNAs positively correlated with CD8+ T cell
inﬁltration, whereas testicular germ cell tumor has the most
sdRNAs negatively correlated with CD8+ TILs (Fig. 5a).
Forty-eight sdRNAs were positively correlated with CD8+
T cell abundance in at least two cancer types (adjusted p <
0.05) (Fig. 5b, Table S9). As an example, sdRNAs from the
C/D box snoRNA SNORD95 were signiﬁcant in LUAD
(Fig. 5c), LUSC, SARC, STAD, and TGCT (Fig. 5d). On

Fig. 4 sdRNAs are correlated with PD-L1 expression in human cancers.
a Bar plot depicting the number of signiﬁcant sdRNAs in each cancer
type, aggregated by parental snoRNA, in relation to PD-L1 expression.
Red, positive correlation; blue, negative correlation. b Heat map of
sdRNAs positively correlated with PD-L1 (CD274) expression (adjusted
p < 0.05, adjusted within each cancer type). For visibility, only sdRNAs
that were positively correlated in three or more cancer types are shown.
Boxes are colored according to the Spearman correlation with PD-L1.
Parental snoRNAs without annotated names are instead labeled by their
host gene in parentheses. SnoRNA classiﬁcations are annotated on top
based on a color legend on the right panel. c Scatter plot depicting the
correlation between PD-L1 and SNORA44 sdRNA expression in lower
grade gliomas (LGG, n = 453). Spearman correlation R = 0.399, p <
2.20 × 10−16. d Scatter plot depicting the correlation between PD-L1 and
SNORA44 sdRNA expression in thymomas (THYM, n = 111). R =
0.530, p = 3.60 × 10−9. e Heat map of snoRNAs negatively correlated
with PD-L1 (CD274) expression (adjusted p < 0.05, adjusted within each
cancer type). For visibility, only sdRNAs that were positively correlated
in three or more cancer types are shown. Boxes are colored according to
the Spearman correlation with PD-L1. Parental snoRNAs without
annotated names are instead labeled by their host gene in parentheses.
SnoRNA classiﬁcations are annotated on top based on a color legend on
the right panel. f Scatter plot depicting the correlation between PD-L1
and SNORA31 sdRNA expression in pheochromoytomas and paragangliomas (PCPG, n = 157). R = −0.437, p = 1.46 × 10−8. g Scatter
plot depicting the correlation between PD-L1 and SNORA7B sdRNA
expression in prostate adenocarcinoma (PRAD, n = 435). R = −0.307,
p = 7.66 × 10−11. c, d, f, g Data are shown as tpm, normalized separately
for mRNA-seq and smRNA-seq datasets

mimic the esophageal squamous epithelium [42]. In
aggregate, these analyses demonstrate that while tissue of
origin certainly inﬂuences sdRNA expression in cancer,
different cancers arising from the same organ can nevertheless be distinguished by their sdRNA signatures.
The PANCAN32 t-SNE visualization coded by tumorimmune signature or patient survival presented overviews
of the sdRNA transcriptome across all these patients as
related to various relevant clinical features (Figure S7c–f),
suggesting that sdRNA expression might demarcate these
clinical features, which are analyzed in further depth (later
in text).

SdRNA transcriptome informs molecular and cellular
features of tumor immunity
To investigate the potential utility of sdRNAs in understanding tumor immunity, we ﬁrst systematically assessed
the correlation between all individual snoRNAs (through
sdRNA abundance levels) and PD-L1 (encoded by the
CD274 gene) expression as determined by mRNA-seq. We
reiterate that all analyses pertain to sdRNA abundances, but
are described in reference to the parental snoRNAs.
Remarkably, a total of 350 sdRNAs were found to be signiﬁcantly correlated with PD-L1 in at least one cancer type
(Benjamini–Hochberg adjusted p < 0.05) (Table S8). We
analyzed the distribution of the number of predictive
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the other hand, 23 sdRNAs were signiﬁcantly negatively
correlated with CD8+ T cell abundance in 4 or more cancer
types (adjusted p < 0.05) (Fig. 5e, Table S9). These include
sdRNAs from SNORD83A, a C/D box snoRNA which was
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found to be signiﬁcant in HNSC (Fig. 5f), PCPG (Fig. 5g),
LUSC, and PAAD.
While inﬁltration of CD8+ T cells is a critical prerequisite for anticancer immune responses, intratumoral
T cells may be anergic, exhausted, or nonfunctional. To
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Fig. 5 sdRNAs are correlated with CD8+ T cell inﬁltration in diverse
cancers. a Bar plot depicting the number of signiﬁcant sdRNAs in each
cancer type, aggregated by parental snoRNA, in relation to CD8+ T
cell abundance. Red, positive correlation; blue, negative correlation. b
Heat map of sdRNAs positively correlated with CD8+ T cell abundance (adjusted p < 0.05, adjusted within each cancer type). For visibility, only sdRNAs that were positively correlated in two or more
cancer types are shown. Boxes are colored according to the Spearman
correlation with CD8+ T cell abundance. Parental snoRNAs without
annotated names are instead labeled by their host gene in parentheses.
SnoRNA classiﬁcations are annotated on top based on a color legend
on the right panel. c Scatter plot depicting the correlation between CD8
+
T cell abundance and SNORD95 sdRNA expression in lung adenocarcinoma (LUAD, n = 454). R = 0.264, p = 1.11 × 10−8. d Scatter
plot depicting the correlation between CD8+ T cell abundance and
SNORD95 sdRNA expression in testicular germ cell tumors (TGCT, n
= 135). R = 0.339, p = 5.88 × 10−5. e Heat map of sdRNAs negatively
correlated with CD8+ T cell abundance (adjusted p < 0.05, adjusted
within each cancer type). For visibility, only sdRNAs that were
positively correlated in four or more cancer types are shown. Boxes are
colored according to the Spearman correlation with CD8+ T cell
abundance. Parental snoRNAs without annotated names are instead
labeled by their host gene in parentheses. SnoRNA classiﬁcations are
annotated on top based on a color legend on the right panel. f Scatter
plot depicting the correlation between CD8+ T cell abundance and
SNORD83A sdRNA expression in head and neck squamous cell carcinoma (HNSC, n = 435). R = −0.218, p = 4.36 × 10−6. g Scatter plot
depicting the correlation between CD8+ T cell abundance and
SNORD83A sdRNA expression in pheochromocytomas and paragangliomas (PCPG, n = 157). R = −0.286, p = 2.86 × 10−4. c, d, f, g
Data are shown as tpm for smRNA-seq datasets

at least 3 cancer types (Fig. 6e, Table S10). SdRNAs
derived from an H/ACA scaRNA SCARNA4 were negatively correlated with GZMA in BLCA (Fig. 6f), BRCA
(Fig. 6g), CESC, HNSC, LUSC, PAAD, and TGCT. These
analyses revealed a set of sdRNAs that signiﬁcantly correlate with intratumoral cytotoxic T cell activity across multiple cancer types.

SdRNA expression associates with angiogenesis in
the tumor microenvironment
To further investigate the contribution of sdRNAs to the
tumor microenvironment, we explored the connection
between sdRNA expression signatures and tumor vascularization. Surprisingly, 449 sdRNAs were signiﬁcantly
correlated with endothelial cell abundance in at least one
cancer type (EndothelialScore), among which 61 sdRNAs
were positively correlated in 4 or more cancer types (Figure
S8a, b, Table S11). TGCT again have the most sdRNAs
positively correlated with endothelial cell abundance,
whereas LUSC again has the most sdRNAs negatively
correlated with endothelial cell abundance (Figure S8a).
Strikingly, sdRNAs produced from the C/D snoRNA
SNORD114-1 were positively correlated with endothelial
cell abundance in 16 different cancer types, including
BRCA, COAD, HNSC, SARC, SKCM, STAD, THYM,
and UCEC (Figure S8c). These data suggest that sdRNAs
derived from snoRNAs such as SNORD114-1 play highly
conserved roles in tumor vascularization across different
tissues.

assess T cell cytolytic activity, we next investigated the
relationship between expression of sdRNAs and GZMA, a
gene that encodes the serine protease granzyme A, a key
component of cytotoxic T cell granules that has previously
been used as a marker of cytolytic activity in human cancer
[43]. Of note, mRNA levels of Perforin1 (PRF1) across the
PANCAN32 dataset strongly correlates with GZMA (correlation = 0.9), and thus the cytotoxic scores using either
GZMA, PRF1, or GZMA + PRF1 are highly similar. We
pinpointed that a total of 346 sdRNAs were found to be
signiﬁcantly correlated with GZMA level in one or more
cancer types (adjusted p < 0.05) (Supplementary Table
S10), where the most predictive cancer types include
BLCA, BRCA, LGG, LUAD, LUSC, PAAD, PRAD,
TGCT, and THCA (Fig. 6a). In contrast, cancer types such
as ESCA, KICH, PCPG, READ, UCEC, and UCS have few
predictive sdRNAs for GZMA expression (Fig. 6a). THCA
has the most sdRNAs positively correlated with GZMA
expression, whereas LUSC has most sdRNAs negatively
correlated with GZMA (Fig. 6a). Among the signiﬁcant
sdRNAs, 42 were positively correlated with GZMA levels in
3 or more cancer types (Fig. 6b, Table S10). Of note,
sdRNAs from the hybrid snoRNA SCARNA5 were positively correlated in BLCA, SKCM (Fig. 6c), TGCT (Fig.
6d), and THCA. On the other hand, 40 sdRNAs were
negatively correlated with intratumoral cytolytic activity in

SdRNA expression predicts patient survival across
diverse human cancers
Collectively, our analyses above pointed to a wide-ranging
set of sdRNAs as statistically signiﬁcant molecular markers
of important features of cancer immunity. We, therefore,
hypothesized that the expression of sdRNAs might be
associated with patient survival, akin to previous studies
with snoRNAs [44, 45]. For each cancer type, we classiﬁed
patients into either “high” or “low” expression of an sdRNA
based on the median expression value (aggregated by parental snoRNA) within the cohort. Using these groups, we
performed Kaplan–Meier survival analysis to identify
sdRNAs with prognostic signiﬁcance to OS (adjusted p <
0.05 by log-rank test) (Table S12). In terms of cancer types,
KIRC, KIRP, LGG, and LIHC have the largest number of
OS-predictive sdRNAs (Table S12, Fig. 7a). Remarkably,
247 sdRNAs had signiﬁcant survival associations in one or
more cancer type(s), out of which 45 sdRNAs can stratify
OS in 2 or more cancer types (Fig. 7a). For instance, high
expression of sdRNAs derived from SNORA116, an H/ACA
snoRNA, was connected to poorer survival in three
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independent cohorts: LGG, liver hepatocellular carcinoma
(LIHC), and UCEC (Fig. 7b). As another example, high
levels of sdRNAs from SNORD145, a CD snoRNA, were
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associated with shorter survival times in KIRC, SARC, and
UCEC (Fig. 7c). SdRNAs from SNORA116 and
SNORD145 thus appear to be indicators of cancers with a
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Strikingly, 25 sdRNAs met the ImmuneSurv ≥2 cutoff in 4
or more cancer types (Fig. 8b), suggesting potentially more
conserved roles for these short noncoding RNAs. The top
sdRNA was that derived from SCARNA4, an H/ACA
scaRNA, which had ImmuneSurv scores ≥2 in a total of 9
cancer types, including BLCA, BRCA, COAD, HNSC,
KIRC, LGG, LUSC, PAAD, and STAD (Fig. 8c). This
surprising ﬁnding implicates sdRNAs derived from
SCARNA4 as a potential uncharacterized small RNA marker
for cancer immunity and clinical outcome across tumors
from diverse tissues of origin.
Focusing on individual cancer types, we found that each
cancer type has a set of sdRNAs that were associated with
more than one ImmuneSurv features (Table S13). For
example, 10 sdRNAs were signiﬁcantly associated with
PD-L1 expression, intratumoral CD8+ T cell abundance,
and GZMA levels in pancreatic adenocarcinoma (Fig. 8d,
Table S14). These ten sdRNAs included those derived from
C/D snoRNAs (SNORD76, SNORD79, SNORD24,
SNORD12B, SNORD68, SNORD11B, and ZL11) and H/
ACA snoRNAs (SNORA3, SNORA8, SNORA69, and
SNORA31). Of note, no individual sdRNAs were signiﬁcantly associated with survival in the TCGA pancreatic
adenocarcinoma cohort, perhaps due to the relatively
smaller patient cohort and the highly aggressive course of
this disease. Remarkably, among the LGG patients, eight
sdRNAs had ImmuneSurv scores of 4, meaning that they
were signiﬁcantly associated with all four dimensions: PDL1, CD8+ T cell abundance, GZMA, and patient survival
(Fig. 8e, Table S14). These eight parental snoRNAs were
SNORD31, SNORD26, SNORD13, SNORD69, SNORD11510, SNORD123, ZL23, and snoID_0379, an as-of-yet
unnamed snoRNA encoded within the host gene FLNC.
Because the ImmuneSurv score analyses were conducted in
a cancer type-speciﬁc manner, we then sought a global
assessment of sdRNAs and their relationships to cancer
immunity regardless of cancer type (PANCAN32), by
compiling all sdRNAs that were found to be signiﬁcant in
any of the ﬁve categories: PD-L1, CD8+ T cell abundance,
GZMA, survival, or copy number variation (CNV) (Supplemental results, Figure S9) in any cancer type. Intersecting these lists, we identiﬁed 133 sdRNAs that were found to
be signiﬁcant in all 5 categories (Fig. 8f). Together with the
metastatic signature (Supplemental results, Figure S10),
these data collectively suggest a prevalent role of sdRNAs
in tumor immunity, thereby inﬂuencing signiﬁcant clinical
features of human cancer.

Fig. 6 sdRNAs are correlated with cytolytic T cell activity across
multiple cancer types. a Bar plot depicting the number of signiﬁcant
sdRNAs in each cancer type, aggregated by parental snoRNA, in
relation to GZMA expression. Red, positive correlation; blue, negative
correlation. b Heat map of sdRNAs positively correlated with GZMA
expression (adjusted p < 0.05, adjusted within each cancer type), a
marker of cytolytic T cell activity. For visibility, only sdRNAs that
were positively correlated in three or more cancer types are shown.
Boxes are colored according to the Spearman correlation with GZMA.
Parental snoRNAs without annotated names are instead labeled by
their host gene in parentheses. SnoRNA classiﬁcations are annotated
on top based on a color legend on the right panel. c Scatter plot
depicting the correlation between GZMA and SCARNA5 sdRNA
expression in skin cutaneous melanoma (SKCM, n = 89). Spearman
correlation R = 0.401, p = 1.11 × 10−4. d Scatter plot depicting the
correlation between GZMA and SCARNA5 sdRNA expression in testicular germ cell tumors (TGCT, n = 135). R = 0.403, p = 1.56 × 10−6.
e Heat map of sdRNAs negatively correlated with GZMA expression
(adjusted p < 0.05, adjusted within each cancer type). For visibility,
only sdRNAs that were positively correlated in three or more cancer
types are shown. Boxes are colored according to the Spearman correlation with GZMA. Parental snoRNAs without annotated names are
instead labeled by their host gene in parentheses. SnoRNA classiﬁcations are annotated on top based on a color legend on the right panel.
f Scatter plot depicting the correlation between GZMA and SCARNA4
sdRNA expression in bladder carcinomas (BLCA, n = 362). R =
−0.267, p = 2.60 × 10−7. g Scatter plot depicting the correlation
between GZMA and SCARNA4 sdRNA expression in cervical squamous cell carcinoma (CESC, n = 265). R = −0.315, p = 1.98 × 10−7.
c, d, f, g Data are shown as tpm, normalized separately for mRNA-seq
and smRNA-seq datasets

more aggressive course. Interestingly, several sdRNAs are
associated with opposite outcomes in different cancer types
(Fig. 7a). For example, sdRNAs produced from the H/ACA
snoRNA SNORA77 were divergently associated with survival. In KIRC, patients with high SNORA77 had poor
survival, whereas the opposite was true in KIRP and LIHC
(Fig. 7d). Thus, the same sdRNA can be differentially
associated with survival in different cancers, even when
these cancers arise from the same organ.

Integrative analysis of sdRNAome and pan-cancer
tumor immunity
In light of these data, we wondered whether any individual
sdRNAs were signiﬁcantly associated with multiple clinically relevant features. Toward this end, we conceived an
ImmuneSurv score to rank sdRNAs (aggregated by
snoRNA) based on several dimensions. We calculate the
ImmuneSurv score for each sdRNA based on its statistical
signiﬁcance of correlations with PD-L1 expression, CD8+ T
cell abundance, GZMA expression, and/or patient survival
(when available) in a cancer type-speciﬁc manner (Fig. 8a,
Table S13). As we were particularly interested in sdRNAs
with signiﬁcant associations in multiple aspects of cancer
immunity, we focused on sdRNAs with ImmuneSurv scores
≥2 (Table S14). A total of 267 sdRNAs were found to meet
this criteria in at least one cancer type (Fig. 8b, Table S15).

Discussion
SnoRNAs are a class of short RNAs that mainly reside in
the nucleolus, though some have also been found in the
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cytoplasm [46]. The known primary functions of snoRNAs
are to guide chemical modiﬁcations of other types of RNAs,
predominantly rRNAs, and small nuclear RNAs (snRNAs).

C/D box snoRNAs, together with their protein partners,
form small nucleolar ribonucleoprotein (snoRNP) complexes that have catalytic function for RNA methylation
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It has been discovered that snoRNAs can be processed
into smaller RNAs called sdRNAs, some of which possess
microRNA-like functionality [27, 57, 58]. Certain sdRNAs
could therefore inﬂuence carcinogenesis through gene regulation. As the TCGA smRNA-seq libraries were sizeselected for ~22 nt species, these datasets offer the opportunity to investigate the role of sdRNAs in cancer. A recent
study of TCGA smRNA-seq datasets looked to explore the
associations between snoRNAs and other genomic features,
but we note this study did not address the issue of ~22 nt
size selection during library preparation nor comprehensively investigate the relationships to tumor immunity, as
we have done here [59]. For the majority of the several
hundred sdRNAs, their roles in cancer have been unexplored until this point. Moreover, the roles of sdRNAs in the
tumor microenvironment—for example, whether they are
linked to angiogenesis or immunological features—are
largely unknown. Here, we successfully generated the
expression proﬁles of the sdRNAome across more than
10,000 patient samples. With this quantitative map of
sdRNA abundance across several cancer types, we uncovered a large set of constitutive, cancer type-speciﬁc and
cancer group-speciﬁc sdRNAs. Interestingly, the expression
signatures of these sdRNAs alone are sufﬁcient to distinguish samples from differing cancer types, while also
revealing subclusters within individual cancer types.
Though these differences in sdRNA expression are partly
driven by the tissue of origin, different cancer types arising
from the same organ can nevertheless be distinguished. We
found that many sdRNAs (aggregated by parental snoRNA)
are signiﬁcantly correlated with the immunosuppressive
biomarker PD-L1, such as sdRNAs derived from
SNORA36B in thymoma and SNORA44 in LGG. Various
sdRNAs, such as those derived from SCARNA5, SNORD6
and SNORD114-22, are strongly positively correlated with
intratumoral T cell-mediated cytotoxicity by granzyme A.
PD-L1 is an indicative biomarker for checkpoint blockade
immunotherapy and has been successfully used to guide
major clinical trials of immunotherapy. GZMA levels have
also been proposed as a predictor of the overall response
rate of checkpoint blockade agents. Thus, with further
development by the ﬁeld, the immunological signatures of
sdRNAs could potentially be implemented into new paradigms to better identify patients who may potentially beneﬁt
from checkpoint blockade. The ImmuneSurv scores presented here, which incorporate both immune and survival
signatures, could guide the selection of top candidate
sdRNAs for further mechanistic investigation and translational efforts. Though the library design of the TCGA
datasets precludes a direct comparison between parental
snoRNAs and sdRNAs, it is possible that the differential
regulation of sdRNA biogenesis from the parental snoRNAs
is a key mechanism through which snoRNAs can affect

Fig. 7 sdRNAs are associated with patient survival across multiple
cancer types. a Heat map of sdRNAs associated with patient survival,
aggregated by parental snoRNA (adjusted p < 0.05 by log-rank test,
adjusted within each cancer type). For visibility, only sdRNAs that
were signiﬁcantly associated with survival in two or more cancer types
are shown. Boxes are colored according to log2 hazard ratios, where
positive values indicate increased mortality risk and negative values
denote decreased mortality risk. Parental snoRNAs without annotated
names are labeled by their host gene in parentheses. SnoRNA classiﬁcations are annotated on top based on a color legend on the right
panel. b Kaplan–Meier survival curves in lower grade glioma (LGG, n
= 498; left), liver hepatocellular carcinoma (LIHC, n = 369; middle),
and uterine corpus endometrial carcinoma (UCEC, n = 528; right),
stratiﬁed by SNORA116 sdRNA expression. High SNORA116 sdRNA
expression was concordantly associated with poorer survival in all
three cohorts (p = 0.0036, p = 0.0048, p = 0.0003). c Kaplan–Meier
survival curves in clear cell kidney carcinoma (KIRC, n = 511; left),
sarcoma (SARC, n = 257; middle), and uterine corpus endometrial
carcinoma (UCEC, n = 528; right), stratiﬁed by SNORD145 sdRNA
expression. High SNORD145 sdRNA expression was consistently
associated with poorer survival in all three cohorts (p < 0.0001, p <
0.0001, p = 0.00018). d Kaplan–Meier survival curves in clear cell
kidney carcinoma (KIRC, n = 511; left), papillary renal cell carcinoma
(KIRP, n = 288; middle), and hepatocellular carcinoma (LIHC, n =
369; right), stratiﬁed by SNORA77 sdRNA expression. High
SNORA77 sdRNA expression was associated with poorer survival in
KIRC, but with better survival in KIRP and LIHC (p = 0.013, p =
0.00031, p = 0.00036)

[47]. Similarly the H/ACA box snoRNPs can catalyze RNA
pseudouridylation [48]. As mounting evidence points to
ribosome biogenesis as a key contributing factor to cancer
[49], it is likely that the canonical functions of C/D and H/
ACA snoRNAs to guide rRNA processing may play a role
in carcinogenesis. ScaRNAs, a subgroup of snoRNAs speciﬁcally localized to the Cajal body, a nuclear organelle
involved in the biogenesis of (snRNPs), guide the methylation and pseudouridylation of RNA polymerase II (pol II)
transcribed spliceosomal RNAs U1, U2, U4, U5, and U12
[50]. Additionally, scaRNAs have been demonstrated to
control the nuclear localization of Cajal bodies, indicating a
role in genome organization, and thus gene expression [51].
Various cases of snoRNAs have been associated with
cancer progression, behaving as oncogenic or tumor suppressive small RNAs. For example, SNORA50A/B have
been reported to act as tumor suppressors by opposing the
KRAS oncogene [24]. On the other hand, SNORD14D and
SNORD35A have recently been demonstrated to potentiate
the oncogenic effects of the AML1-ETO fusion in leukemia
through rRNA methylation [52]. A number of other studies
have reported prognostically relevant snoRNAs, such as
SNORD93 in breast cancer [33], SNORA42 in lung cancer
[53], SNORA21 in colon cancer [54], and SNORD47 in
glioblastoma [55]. Of note, SNORD115 has been demonstrated to act as a regulator of alternative splicing [22, 23,
56], and its deletion is sufﬁcient to cause Prader–Willi
syndrome.
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Intratumoral heterogeneity is increasingly recognized as
a critical feature of cancers, inﬂuencing tumor progression
and therapeutic responses [60–62]. Given that the TCGA
smRNA-seq libraries were prepared from bulk RNA preparations, these datasets cannot be used to explore intratumoral heterogeneity in sdRNA expression. Additional
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wise normalized sdRNA read counts to tpm. mRNA-seq
gene-level counts were also downloaded from the NIH NCI
GDC Data Portal in June 2017, and sample-wise normalized
to tpm. SdRNA and RNA tpm values were subsequently
log2 transformed. To compare sdRNAs across cancer types,
the log2 transformed median expression values were further
converted to z-scores normalized within each parental
snoRNA. GISTIC 2.0 CNV calls were obtained from the
GDAC Firehose (http://gdac.broadinstitute.org/) on September 2017. Patient clinical data were obtained through
cBioPortal [66, 67].
Raw fastq ﬁles for independent smRNA-seq datasets
(GSE33858, GSE46622, E-MTAB-3494) were accessed by
NCBI GEO (https://www.ncbi.nlm.nih.gov/geo/) or EBI
(https://www.ebi.ac.uk/). Data were uniformly processed as
for the TCGA smRNA-seq datasets, using BWA to ﬁrst
map the reads to the hg38 reference genome prior to
quantiﬁcation with featureCounts. Principal component
analysis was performed in R.

Fig. 8 Multidimensional analysis of sdRNAs at the interface of tumor
immunity and survival. a Schematic of the ImmuneSurv score. In a
cancer type-speciﬁc manner, each sdRNA is assessed for whether it is
signiﬁcantly associated with PD-L1 expression, CD8+ T cell abundance, GZMA expression, and patient survival. Each signiﬁcant
association adds one point to the ImmuneSurv score. b Left: bar plot of
sdRNAs aggregated by parental snoRNA with ImmuneSurv scores ≥2
in at least one cancer type. Right: bar plot of the 25 parental snoRNAs
with ImmuneSurv scores ≥2 in at least 4 cancer types. Strikingly,
SCARNA4 was found to have ImmuneSurv scores ≥2 in nine independent cancer types. c Heat map of ImmuneSurv scores for the 25
parental snoRNAs in (b). Individual cells are colored based on
ImmuneSurv score for the indicated snoRNA in each cancer type. d
Venn diagram of sdRNAs signiﬁcantly associated with PD-L1, CD8+
T cells, and/or GZMA in pancreatic adenocarcinoma (PAAD). e Venn
diagram of sdRNAs signiﬁcantly associated with PD-L1, CD8+
T cells, GZMA, and/or survival in lower grade glioma (LGG). f Venn
diagram of sdRNAs signiﬁcant for PD-L1 correlation, CD8+ T cell
abundance, GZMA correlation, patient survival, and/or copy number
variation in any cancer type (PANCAN32)

studies using microdissection or single-cell smRNA-seq
will be necessary to investigate the potential contribution of
intratumoral sdRNA expression heterogeneity toward cancer biology, such as tumor immunity.
In summary, our comprehensive pan-cancer analysis of
sdRNAs generated a global view of these transcripts in
characterizing different cancer types, leading to the identiﬁcation of multiple sdRNAs strongly associated with fundamentally important clinical features such as angiogenesis,
tumor immunity and OS, while simultaneously identifying
large sets of novel candidates for further functional studies.
Because of their high abundance, short length, tissuespeciﬁcity and availability in circulation [63], many novel
sdRNAs could be developed as next-generation diagnostic
or prognostic biomarkers.

Characterization of snoRNA expression proﬁles
To characterize the sdRNA reads mapping to snoRNAs, we
employed a normalized binning approach. We randomly
selected 5 samples from each cancer type, and used these to
quantify the read density along the length of each snoRNA,
with each snoRNA divided into 50 equally sized bins. For
visualization, these values were subsequently normalized by
maximum intensity, such that the read depths along a given
snoRNA were multiplied by a constant scaling factor.
Average proﬁles and hierarchically clustered heat maps
were then produced using deepTools v2.5 [68]. We also
tabulated the lengths of reads mapping to snoRNA loci
using Samtools [69] and expressed these data as a percentage of total snoRNA-mapped reads.
To explore the overall expression of sdRNAs, we calculated the median expression of each snoRNA within each
cancer type. To characterize differences in snoRNA expression across different cancers, we then calculated z-scores for
the median snoRNA expression values and visualized them as
a heat map using the NMF R library. For unbiased visualization of individual tumors in terms of snoRNA expression,
we utilized t-SNE [41]. Additional t-SNE plots were generated using alternate coloring schema—CD274 expression,
GZMA expression, EndothelialScore (see below), and OS. For
survival t-SNE visualization, only patients that had died were
included to circumvent issues with censored data.

Materials and methods
Data acquisition and preprocessing
TCGA smRNA-seq sequencing bam ﬁles were downloaded
through the NIH NCI GDC Data Portal (https://portal.gdc.
cancer.gov/) in June 2017. Of note, only normal control
smRNA-seq data were available for GBM, leaving a total of
32 cancer types for further analysis. To obtain reads speciﬁc
to sdRNAs, we used featureCounts [64] with settings—Q
20 largestOverlap–minOverlap 3-s1, using the human
snoRNAome as the reference region set [40]. By this
approach, all reads corresponding to sdRNAs were totaled
by the parental snoRNA. Since an earlier database was used
to map the smRNA-seq ﬁles, we removed any snoRNAs
that had ≤1 read across all the samples. For conﬁrming
concordance between the mapped data and our annotations,
we visually inspected the bams using IGV [65]. We sample-

Correlation analysis between sdRNAs and host
genes
For correlation analysis between different sdRNAs, we ﬁrst
extracted sdRNAs (aggregated by parental snoRNA) with a
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variance >0.1 and median log2 tpm > 0. These high-variance
sdRNAs were analyzed by Pearson correlation. For correlation analysis between snoRNAs/sdRNAs and host gene
expression, we utilized previously published snoRNA annotations [40] and calculated the Spearman correlation between
all deﬁned snoRNA–host gene pairs (n = 736). The empirical
cumulative density function of the Spearman correlation distribution was further calculated to illustrate the relative proportion of snoRNA–host gene pairs with Spearman
correlations above a speciﬁed threshold. Cancer-speciﬁc
analyses were performed in the same manner. Statistical signiﬁcance was determined by conversion to a t-statistic, and
multiple hypothesis correction was performed by the
Benjamini–Hochberg method. The Benjamini–Hochberg
procedure is based on controlling the false discovery rate. We
set a signiﬁcance level of adjusted p < 0.05.

abundance of constituent sdRNAs per parental snoRNA)
was used as the threshold to deﬁne “low” or “high”
expression. Any sdRNAs for which either group had less
than four samples were subsequently excluded. To assess
survival differences between patient groups stratiﬁed by
sdRNA expression, we used the log-rank test. Associated p
values were adjusted for multiple comparisons by the
Benjamini–Hochberg approach, adjusting within each cancer type. An adjusted p < 0.05 was considered signiﬁcant.
For the heat map visualization, sdRNAs with signiﬁcant
survival associations were colored by their associated log2
hazard ratio, as determined by a Cox hazards model. Positive log2 hazard ratios indicate increased mortality, while
negative log2 hazard ratios indicate decreased mortality.

Correlation analysis between sdRNAs and other
transcriptomic variables

For identiﬁcation of snoRNAs subject to signiﬁcant CNV,
we utilized the GISTIC 2.0 output ﬁles (speciﬁcally
*amp_genes.conf_99.txt and *del_genes.conf_99.txt). As
these tables report the precise genomic coordinates in which
the ampliﬁcation or deletion was identiﬁed, we utilized a q
< 0.05 threshold and subsequently intersected the coordinates with the snoRNA annotations [40]. Ampliﬁcation and
deletion calls for individual snoRNAs were then compiled
into separate tables. For heat map visualization, the associated GISTIC q values for a given snoRNA in each cancer
type were −log10 transformed.

CNV in snoRNAs

For correlation analysis between sdRNAs and PD-L1 or
GZMA expression, we extracted the corresponding mRNAseq data and computed the Spearman correlation between
each sdRNA (aggregated by parental snoRNA) and the gene
of interest. Using the correlation coefﬁcient and sample
sizes, the correlation coefﬁcients were converted to a tstatistic, from which the associated p values was calculated.
The p values were then adjusted for multiple comparisons
within each cancer type by the Benjamini–Hochberg
approach, using an adjusted p value of 0.05 as the signiﬁcance threshold. For visualization in the ﬁgures, we
divided the resulting correlation tables into positive and
negative correlations. To improve readability in the ﬁgures,
we selected sdRNAs that were signiﬁcantly correlated in
multiple cancer types (precise number indicated on ﬁgures).
SdRNAs that were not signiﬁcantly correlated in a given
cancer type were ﬁltered for visualization purposes (i.e., set
to “0”). The complete correlation tables are available in the
supplementary tables. To identify sdRNAs associated with
CD8+ T cell abundance or tumor vascularization, we utilized the xCell algorithm [70] (http://xcell.ucsf.edu/) and the
computed abundances of multiple cell types within TCGA
samples. Each sdRNA was then compared to the “CD8+
T cells” or “Endothelial cells” entry (“EndothelialScore”) in
the xCell output matrix. The same statistical procedures
were used as above for PD-L1 and GZMA expression.

Differential expression analysis
For differential expression analysis comparing metastases to
primary tumors, we utilized limma [71]. For multiple
hypothesis correction, we used the Benjamini–Hochberg
method. An adjusted p < 0.05 was used a threshold for
signiﬁcance.

Intersection of signiﬁcant snoRNA lists
For pan-cancer analysis, we considered all sdRNAs that
were found to be signiﬁcant in at least one cancer type
across the following ﬁve analyses: CD274 correlation,
GMZA correlation, CD8+ T cell abundance, CNV, and
survival. For intersection of these ﬁve analyses, the directionality of the association was not considered (i.e., an
sdRNA would be included regardless of whether it was
positively or negatively correlated with CD274). The pancancer ﬁve-way intersection was visualized using the web
tool available at http://bioinformatics.psb.ugent.be/w
ebtools/Venn/.
For cancer type-speciﬁc analysis, we iterated through
each parental snoRNA and tabulated whether it was signiﬁcant in the ﬁve aforementioned categories, in addition to

Survival analysis
For survival analysis, only primary tumor samples were
considered such that each patient had exactly one sample
for consideration. Within each cancer type, the median
expression value for each sdRNA (taking the aggregate
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Compliance with ethical standards

tumor vascularization. This information was recorded
through a six character custom coding scheme (i.e.,
NNSNSN for snoRNA “X” in cancer type “Y”). “N”
denotes “not signiﬁcant”, “S” denotes “signiﬁcant”, and “o”
signiﬁes that data was not available. Each position corresponds to a speciﬁc signiﬁcant list. Position1: CD274;
Position2: GZMA; Position3: Survival; Position4: CD8+
T cells; Position5: CNV; Position 6: EndothelialScore.
Thus, for the example above (NNSNSN), sdRNAs from
snoRNA X were found to be signiﬁcantly associated with
survival and signiﬁcant for CNV in cancer type Y. The
complete table of codes is available in Table S12. For
focused analysis of immune signatures and patient survival,
we developed an ImmuneSurv score based on the above
coding schema. In this score, the ﬁrst four letters are considered (corresponding to CD274 correlation, GZMA correlation, survival association, and CD8+ T cell correlation).
For a given snoRNA in a speciﬁc cancer type, each “S”
adds 1 to the ImmuneSurv score, up to a total of four.

Conﬂict of interest The authors declare no conﬂict of interest.
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3.2: Systematic immunotherapy target discovery using genome-scale in vivo CRISPR
screens in CD8 T cells
CD8 T cells are a major player in anti-tumor immune responses 99. By virtue of their T
cell receptors, CD8 T cells can recognize cancer cells expressing foreign peptides on the cell
surface and target these mutant cells for destruction

24

. However, CD8 T cells rapidly become

exhausted in the tumor microenvironment, leading to reduced effector activity and longevity
100,101

. Antibodies that block proteins such as PD-1, which acts as a brake on immune responses,

have demonstrated clinical success in various cancer types by reinvigorating anti-tumor
immunity 102,103. Reasoning that other endogenous brakes on anti-tumor responses likely exist in
CD8 T cells, we sought to perform a genome-scale CRISPR screen in CD8 T cells to identify
new genes that control CD8 T cell survival and infiltration into tumor, as well as their effector
activity 104.
This line of investigation was conceived by my advisor Dr. Sidi Chen and my colleague
Matthew Dong. My primary role in this study was to analyze the CRISPR screening data,
mRNA-seq profiling, scRNA-seq datasets, and patient cohort data. I also prepared the
manuscript text and figures together with Matthew Dong and Dr. Sidi Chen.
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SUMMARY

CD8 T cells play essential roles in anti-tumor immune responses. Here, we performed genomescale CRISPR screens in CD8 T cells directly under
cancer immunotherapy settings and identiﬁed
regulators of tumor inﬁltration and degranulation.
The in vivo screen robustly re-identiﬁed canonical
immunotherapy targets such as PD-1 and Tim-3,
along with genes that have not been characterized in T cells. The inﬁltration and degranulation
screens converged on an RNA helicase Dhx37.
Dhx37 knockout enhanced the efﬁcacy of antigen-speciﬁc CD8 T cells against triple-negative
breast cancer in vivo. Immunological characterization in mouse and human CD8 T cells revealed that
DHX37 suppresses effector functions, cytokine
production, and T cell activation. Transcriptomic
proﬁling and biochemical interrogation revealed
a role for DHX37 in modulating NF-kB. These
data demonstrate high-throughput in vivo genetic
screens for immunotherapy target discovery and

establishes DHX37 as a functional regulator of
CD8 T cells.
INTRODUCTION
T cells play a central role in maintaining the cellular integrity of
the body against intracellular pathogens and tumors (Kaech
et al., 2002; Tscharke et al., 2015; Zhang and Bevan, 2011).
Activation of antigen-speciﬁc CD8 T cells is mediated by
T cell receptor (TCR) recognition of cognate antigen on surface major histocompatibility complex (MHC) class I (MHC-I)
(Blum et al., 2013; Cox et al., 2011; Tscharke et al., 2015), resulting in T cell proliferation, cytokine production, and killing of
target cells (Wong and Pamer, 2003). Defects in T cells can
lead to recurrent infections (Dumontet et al., 2015; Hersperger
et al., 2011; Kurktschiev et al., 2014; Zhang et al., 2009) or
cancer (Chia et al., 2009; Clementi et al., 2005; Mortaz
et al., 2016), while dysregulated activation of CD8+ T cells
can result in immunopathology and autoimmunity (Gravano
and Hoyer, 2013; Holzelova et al., 2004; Valori et al., 2017;
Walter and Santamaria, 2005). CD8 T cells have become the
central focus of new cancer therapeutics (Blankenstein
et al., 2012; Chen and Mellman, 2013; Fridman et al., 2012;
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Figure 1. Genome-Scale In Vivo CD8 T Cell Screen Identiﬁed Genes Regulating Tumor Inﬁltration
(A) Schematics of the design of a T cell CRISPR vector, MKO library cloning, and lentiviral library production.
(B) Schematics of experiment design.
(C) Measurement of antigen presentation in E0771-mCh-OVA clonal cell lines with a SIINFEKL:H-2kb antibody.
(D) Growth curve of intramammary fat pad tumors from transplanted E0771-mCh-OVA cells in Rag1 / mice following different treatments. PBS control
(n = 3), adoptive transfer of OT-I;Cas9 CD8 T cells infected with vector (n = 3) or MKO (n = 8). Red arrow indicates the time of adoptive transfer.
Data are shown as mean ± SEM. Note that some error bars are not visible because the values are small. *p < 0.05, **p < 0.01, ***p < 0.001 by twoway ANOVA.
(E) Venn diagram of the three enrichment criteria to identify the top gene hits (R2% read abundance in one sample [n = 36], signiﬁcant in R20% of samples
[n = 220], and R2 independent enriched sgRNAs [n = 26]).
(F) Meta-analysis of inﬁltration screen using RIGER with the second-best sgRNA method.

(legend continued on next page)
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Spranger et al., 2013). Approved immune checkpoint inhibitors enhance anti-tumor response of CD8 T cells by neutralizing CTLA-4 or PD-1/PD-L1 (Brahmer et al., 2010; Kvistborg
et al., 2014; Pardoll, 2012; Ribas, 2012; Swart et al., 2016; Tumeh et al., 2014). These drugs have been effective in multiple
oncology indications (Mellman et al., 2011; Sharon et al.,
2014), either as monotherapies or in combination with other
therapies (Larkin et al., 2015; Postow et al., 2015). Newer
checkpoint inhibitors are now under active investigation,
such as TIM-3, LAG3, 4-1BB, CD28, ICOS, OX-40, and VISTA
(Johnson and June, 2017; Mahoney et al., 2015). Meanwhile,
cellular therapeutics utilizing CD8 T cells with chimeric antigen
receptors (CARs) (Fesnak et al., 2016; Srivastava and Riddell,
2015) have demonstrated clinical success against hematopoietic malignancies (Esensten et al., 2016; Jackson et al., 2016;
Johnson and June, 2017) and have been recently approved.
Discovery of previously unknown genes that modulate T cell
function is of urgent need to open different avenues for immunotherapies (Mellman et al., 2011), as a large fraction of patients still do not respond to, or have undesired side effects
to currently approved therapies (Kelderman et al., 2014; Restifo et al., 2016). Systematic approaches to identify new regulators of T cell functions in vivo can provide potentially orthogonal or complementary opportunities (Ghoneim et al., 2016).
Studies using RNAi or shRNA (short hairpin RNA) libraries
have been used to identify CD8 T cell regulators (Chen et al.,
2014; Zhou et al., 2014). RNAi operate by degrading mRNA or
suppressing their translation but have substantial off-target effects (Nijman, 2015). CRISPR technologies have dramatically
enhanced our ability in genome editing (Cong et al., 2013;
Hsu et al., 2014; Jinek et al., 2012; Komor et al., 2017; Mali
et al., 2013; Wright et al., 2016). High-throughput CRISPR
screens have been developed for discovery of novel genes
(Shalem et al., 2014; Wang et al., 2014; Shalem et al., 2015).
Application of CRISPR technologies has enabled the manipulation of the T cell genome (Beil-Wagner et al., 2016; Singer et al.,
2016; Su et al., 2016). Genetic screens have been performed
in vitro for discovery of regulators for T cell proliferation and differentiation (Henriksson et al., 2019; Shifrut et al., 2018). Given
the complexity of physiological cues, it is critical to perform
in vivo screens to better identify clinically relevant targets.
High-throughput in vivo CRISPR screens in primary CD8
T cells would enable rapid identiﬁcation of negative regulators
of T cell anti-tumor function, thereby providing potential targets
for immunotherapy.
In this study, we performed in vivo genome-scale CRISPR
screens in CD8 T cells for tumor inﬁltration in mouse models of
triple-negative breast cancer (TNBC). Our screen re-discovered
prime immunotherapy targets such as PD-1 and Tim-3, as well
as previously undocumented targets. We also performed an
orthogonal screen to identify factors that modulate CD8 T cell
degranulation ability. The screens converged on a small number
of hits that included Dhx37, a previously uncharacterized target

in T cells. We subsequently interrogated the function of Dhx37/
DHX37 in both mouse and human CD8 T cells. Our data revealed
that Dhx37 suppresses CD8 T cell activity in response to antigenic stimulation. Biochemical experiments along with transcriptome proﬁling revealed that DHX37 interacts with both
nuclear factor kB (NF-kB) p65 and PDCD11 and modulates
NF-kB pathway activity in CD8 T cells.
RESULTS
Development of Genetic Screens of In Vivo Tumor
Inﬁltration and Cytotoxic Function in Primary CD8 T Cells
We designed and generated a lentiviral CRISPR vector that contains an sgRNA expression cassette and Thy1.1 (STAR Methods)
(Figure 1A). Next, we cloned into this vector a mouse genomescale single guide RNA (sgRNA) library (MKO) containing
128,209 gene-speciﬁc sgRNAs and 1,000 non-targeting controls
(NTCs) (Table S1). We generated lentivirus from this library (Figures 1A and 1B) (STAR Methods), which enabled T cell CRISPR
screens.
To set up a model system for T cell immunotherapy screens,
we utilized E0771 cells, a murine TNBC line, as a transplant tumor model (Figure 1B). To enable T cell recognition of cognate
antigen in cancer cells, we generated clonal E0771 cell lines
that constitutively express chicken ovalbumin (OVA) (STAR
Methods) (Figure 1C). Using an antibody that recognizes the
SIINFEKL: H-2Kb complex (Porgador et al., 1997), we conﬁrmed
that the SIINFEKL epitope of OVA was presented on surface
H-2Kb (Figure 1C). Clone 3 of E0771-mCherry-OVA (E0771mCh-OVA) cell lines was chosen for further studies because it
presented a low-level, single-peak SIINFEKL: H-2Kb (Figure 1C).
We then isolated naive CD8+ T cells from OT-I;Cas9 mice,
cultured for 3 days, and then adoptively transferred these cells
into Rag1-deﬁcient mice (Figure S1A). Prior to adoptive transfer,
these cells were analyzed by ﬂow cytometry and found to have
upregulated the T cell activation markers, CD44 and CD69 (Figures S1B and S1C). 7 days post-transfer, spleens were isolated
and CD8+ T cells were puriﬁed and co-cultured with either E0771
or E0771-mCh-OVA cells in the presence of CD107a antibody, a
granule-speciﬁc marker that is transiently deposited on the surface of T cells in response to antigenic stimulation (Betts et al.,
2003), to quantitatively measure the degree of T cell degranulation (degranulation assay) (STAR Methods) (Figure S1D). We
found that the transferred OT-I;Cas9 CD8 T cells degranulated
in the presence of OVA, demonstrating that the transferred
T cells retained antigenic speciﬁcity (Figure S1E). To determine
whether the observed anti-tumor responses were OVA speciﬁc,
we performed an in vivo experiment using E0771 cells or E0771mCh-OVA cells transplanted into the mammary fat pad of
Rag1 / female mice. After 10 days, these mice were treated
with either PBS or OT-I;Cas9 CD8 T cells (Figure S1F). We found
that tumor regression occurred only in mice bearing E0771mCh-OVA tumors treated with OT-I;Cas9 CD8+ T cells but not

(G) Meta-analysis of inﬁltration screen using MAGeCK analysis of survival screen.
(H) Single gene-level analysis of individual for their sgRNA distributions across each sample, showing representative genes depleted (His1h4d) or enriched
(Pdcd1, Stradb, and Havcr2) in tumors as compared to cells.
See also Figures S1, S3, and S3 and Table S1.
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in the groups treated with either PBS or in mice carrying E0771
tumors (Figure S1G). Together, these data conﬁrmed the antigenic speciﬁcity of this model system, providing a normalized
baseline for in vivo genetic screens in primary CD8 T cells.
We then performed the in vivo T cell tumor inﬁltration screen
(Figure 1B), using a mammary fat pad orthotopic tumor
model (Figure 1D), as well as a subcutaneous model in parallel
(Figures S2A and S2B) (STAR Methods). We transduced CD8+
T cells from OT-I;Cas9 mice with the MKO sgRNA library and
adoptively transferred them into E0771-OVA tumor-bearing
mice bearing tumors (STAR Methods). In both orthotopic and
subcutaneous models, we observed that T cell injections (either
vector or MKO transduced) mitigated tumor growth and that the
MKO transduced population had a stronger therapeutic effect
compared to vector control (Figure 1D). Histological and pathological analysis revealed the presence of tumor-inﬁltrating lymphocytes (TILs) from mice receiving adoptive transfer but not in
PBS-treated mice (Figure S2B). Flow cytometric analysis of
single-cell suspensions of spleens, lymph nodes, and tumors
also detected adoptively transferred CD8+ T cells (Figure S2C).
Tumors from a cohort of mice were subjected to high-throughput
sgRNA library sequencing (STAR Methods), which revealed the
sgRNA representations of MKO transduced OT-I;Cas9 CD8
T cells before injection and in all tumor samples (Table S1;
Figures S2D and S2E). While the library representation of preinjected T cells follows a log-normal distribution for both genetargeting sgRNAs and NTCs, the sgRNA representation in
organs is characterized by the dominance of a small fraction of
sgRNAs (Figure S2D). At the individual mouse level, we found
that the sgRNA representation between different mice are correlated with each other (Figure S2E).
Convergent T Cell Screens Identiﬁed Known and
Undocumented Immunotherapy Targets
Using stringent criteria (false discovery rate [FDR] <0.5%), we
identiﬁed signiﬁcantly enriched sgRNAs in each tumor (STAR
Methods). A composite of multiple ranking approaches, including
sgRNA abundance, multiple independent sgRNAs and multiple
mouse replicates (STAR Methods), revealed rank lists of top
scoring sgRNAs and genes (Figure 1E; Figures S3A ad S3B).
The inﬁltration screen revealed high-rank genes representing
three classes of genes: immune regulators, growth controlling
genes, and largely uncharacterized genes (Figures 1E–1G; Figures S3A and S3B). A total of 6 genes were signiﬁcantly enriched
with all three criteria fulﬁlled (Cd247, Fam103a1, Hacvr2/Tim-3,
Pdcd1/PD-1, Prkar1a, and Stradb) (Figure 1E). To further assess
the robustness of screen performance, we ﬁrst applied RIGER
(STAR Methods), an analysis method considering the performance of multiple sgRNAs for the same gene. RIGER analysis
with the 2nd-best sgRNA method revealed 13 genes at toplevel statistical signiﬁcance (p % 1e-4) (Figure 1F), while the
weighted-sum method scored 7 genes at top signiﬁcance (Figure S3C), where 6 of them were shared with the 2nd-best sgRNA
method. In fact, these six genes (Cd247, Fam103a1, Hacvr2,
Pdcd1, Prkar1a, and Stradb) are exactly identical to the 3-way
shared hits identiﬁed by our custom FDR method. We also performed a parallel analysis with MAGeCK, a model-based algorithm for genome-scale CRISPR screens (Li et al., 2014), which
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again revealed Stradb, Pdcd1, Prkar1a, and Fam103a1 on top
of the list (Figure 1G; Figure S3D). Examination of individual genes
revealed strongly depleted sgRNAs targeting essential genes
(e.g., Hist1h4d) and enriched sgRNAs targeting known or potentially new T cell phenotype modulators (Figure 1H). PD-1 and
Tim-3 are well-known immunotherapy targets, thereby benchmarking the success and technical rigor of the screen. Collectively, these analyses demonstrate the rigor of in vivo CRISPR
screen for CD8 T cell tumor inﬁltration and revealed targets for
cancer immunotherapy.
We set out to independently identify genes that could modulate
the ability of CD8 T cells to kill cancer cells. We performed a
screen using degranulation assay (Figure 2A). We pulsed E0771
cells with varying concentrations of SIINFEKL peptide and found
that they presented SIINFEKL peptide on surface MHC-I in a
dose-dependent manner (Figure 2B). We isolated naive OTI;Cas9 CD8 T cells and transduced them with MKO library, stimulated them for 6 days, rested them for 12 h, and then co-cultured
them with SIINFEKL-pulsed E0771 cells at 1:1 of T cell: cancer
cell (Effector: Target, or E: T) ratio in the presence of CD107a antibody (STAR Methods) (Betts et al., 2003). With three biological
replicates, we sorted the top 5% CD107a+ cells (Figure 2C) and
then subjected them to screen readout and data analysis
(STAR Methods). Using the FDR <0.5% signiﬁcance cutoff, we
identiﬁed signiﬁcantly enriched sgRNAs and their corresponding
genes (Figure 2D), which represented potential negative regulators of T cell degranulation. Three genes emerged as common
hits between the degranulation screen and the tumor inﬁltration
screen (Dhx37, Lyn, and Odc1) (Figure 2E).
Immunotherapeutic Potential of Dhx37 Gene-Edited
CD8 T Cells
To examine the function of these genes in a model of immunotherapy, we cloned sgRNAs targeting Dhx37 and Odc1 that
scored in both screens, along with Pdcd1 (which only scored
in the inﬁltration screen) into the T cell lentiviral CRISPR vector.
We did not pursue Lyn because it is not normally expressed in
T cells (Tsantikos et al., 2009; Yamanashi et al., 1989). We then
prepared lentivirus, transduced T cells, and adoptively transferred them into mice bearing E0771-mCh-OVA tumors (STAR
Methods). Despite initially growing for 3 days post-adoptive
transfer, the tumors treated by adoptive T cells regressed over
the following 2.5 weeks (Figures 2F and 2G). All OT-I;Cas9
CD8 T cell-treatment groups demonstrated strong anti-tumor effects beginning 7 days after adoptive transfer (Figure 2G).
Notably, sgDhx37 infected OT-I;Cas9 CD8 T cells signiﬁcantly
suppressed relapse when compared to mice treated with vector-infected T cells (Figure 2G). We observed that (5/5, 100%)
of the mice in the sgDhx37 group had smaller tumors as
compared to the vector group, compared to 2/5 in sgPdcd1
and 3/5 in sgOdc1 groups (Figure 2H). These data suggest that
CRISPR targeting of Dhx37 enhanced the anti-tumor effects of
OT-I;Cas9 CD8 T cells against E0771-mCh-OVA tumors.
Analysis of Gene Expression Signatures in Dhx37
Tumor-Inﬁltrating Lymphocytes by Single-Cell RNA-Seq
Dhx37 is a highly conserved DEAH box RNA helicase that has
been reported to be involved with biogenesis of the small
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Figure 2. High-Throughput CRISPR Screen of CD8 T Cell Degranulation Identiﬁed Dhx37 and Odc1 as Top Hits Convergent with Inﬁltration
(A) Schematics of experiment.
(B) Titration of SIINFEKL peptide on MHC-I in E0771 cells.
(C) Representative histogram of CD107a+ T cells analyzed from the co-culture of OT-I;Cas9 CD8 T cells and E0771 cancer cells.
(D) Waterfall plot of the top-ranked sgRNAs across all sorted cell samples.
(E) Venn diagram comparing the hits from the degranulation screen and from the tumor inﬁltration screen.
(F) Schematics of efﬁcacy testing experiments with adoptive transfer of single-gene knockout CD8 T cells
(G) Growth curves of mammary fat pad E0771-mCh-OVA tumors in Rag1 / mice following different treatments: PBS control, adoptive transfer of OT-I;Cas9 CD8
T cells infected with lentiviral vector, lenti-sgDhx37, lenti-sgOdc1, and lenti-sgPdcd1. Note: arrow indicates the time of adoptive transfer of MKO or vector
transduced OT-I; Cas9 CD8 T cells. Data are shown as mean ± SEM. Statistical comparisons were made with two-way ANOVA for each group against vector, with
p values indicated.
(H) Spider plots of (G) separated by treatment group for visibility.
See also Figures S4 and S5.
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Figure 3. Single-Cell Transcriptomics of Dhx37 Knockout CD8 Tumor-Inﬁltrating Lymphocytes
(A) Schematics of experiment.
(B) Volcano plot of differentially expressed genes in tumor-inﬁltrating CD8 cells treated with sgDhx37 compared to vector control.
(C) Gene Ontology (GO) analysis of signiﬁcantly upregulated genes in sgDhx37-treated tumor-inﬁltrating CD8 cells.
(D) GO analysis of signiﬁcantly downregulated genes in sgDhx37-treated tumor-inﬁltrating CD8 cells.
Note: for (C) and (D), signiﬁcantly enriched (Bonferroni adjusted p < 0.05) GO categories were shown. See also Table S2.

ribosomal subunit through its release of U3 small nucleolar RNA
(snoRNA) (Roychowdhury et al., 2019). Its homologs have also
been found to regulate escape behavior via glycine receptor
expression in zebraﬁsh (Hirata et al., 2013) and cause microcephaly in rare gene variants (Karaca et al., 2015). However,
this gene has not been previously associated with T cell function.
The putative ATP-dependent RNA helicase domain and conservation implies that it might affect gene expression (Abdelhaleem,
2005). Because the heterogeneous tumor microenvironment
might inﬂuence the functional state of individual TILs, we performed single-cell RNA sequencing (scRNA-seq) to investigate
the transcriptomes of adoptively transferred sgDhx37-transduced OT-I;Cas9 CD8 TILs (sgDhx37 TILs) (Figure 3A) (STAR
Methods).
After processing, stringent ﬁltering and normalizing the raw
scRNA-seq data (STAR Methods), the TIL scRNA-seq dataset
was composed of 552 cells (sgDhx37, n = 191 cells; vector,
n = 361 cells), collectively measuring 8,244 expressed genes in
TILs (Table S2). We performed differential expression analysis
between sgDhx37- and vector-treated TILs, identifying sets of
signiﬁcantly upregulated and downregulated genes (Table S2).
215 genes were signiﬁcantly downregulated in sgDhx37 TILs,
while 137 genes were signiﬁcantly upregulated (BenjaminiHochberg adjusted p < 0.05), with the mostly highly upregulated
genes being Rgs16, Tox, and Nr4a2 (Figure 3B). Tox has been
recently implicated as a critical regulator of CD8 T cell and
TILs (Alfei et al., 2019; Khan et al., 2019; Scott et al., 2019).
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NR4A family members were found to regulate CAR-T potency
against solid tumors (Chen et al., 2019). Other signiﬁcantly upregulated genes included known immune-related genes such as
Eomes, Nr4a3, Ccl4, Ifnar1, and Ikzf2 (Figure 3B; Table S2).
The sgDhx37-upregulated genes also include genes involved
in negative regulation of leukocyte activation such as Ctla4,
Lag3, and Pdcd1, albeit to a lesser extent, which mirrors the positive correlation of T cell cytotoxic scores with these markers in
TILs from human melanoma patients (Tirosh et al., 2016). As a
gene set, gene ontology (GO) analysis revealed multiple immune-related pathways that were signiﬁcantly upregulated in
sgDhx37 TILs (adjusted p < 0.05), including lymphocyte activation, positive regulation of cytokine production, regulation of
cell-cell adhesion, regulation of immune effector process, and
positive regulation of interferon-gamma (IFN-g) production (Figure 3C). Downregulated genes in sgDhx37 TILs are enriched in
ribosomal small subunit assembly and ribosomal large subunit
biogenesis (Figure 3D), consistent with its known role in rRNA
modiﬁcation and processing. Taken together, the scRNA-seq
data revealed signiﬁcant changes in the transcriptomes of
sgDhx37 TILs in the heterogeneous tumor microenvironment at
the single-cell level.
Validation and Immunologic Characterization of Dhx37
as a Regulator of Primary CD8 T Cells
We generated an adeno-associated virus (AAV) vector (AAVsgRNA-Thy1.1) capable of producing bona ﬁde gene editing in
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Figure 4. AAV-Mediated Gene Editing in Primary Murine CD8 T Cells and Effect of Dhx37 Perturbation
(A) Schematics of the AAV-CRISPR T cell knockout vector.
(B) Schematics of experiment.
(C) Dhx37 gene editing in mouse CD8 T cells with AAV-CRISPR measured by T7E1 assay.
(D) Representative Illumina targeted amplicon sequencing of the sgRNA target site 5 days after infection with AAV-sgDhx37. Top most frequent variants were
shown, with the associated variant frequencies in the box to the right. PAM and sgRNA spacers were indicated above. Red arrows indicate predicted cleavage
sites. Red dashed lines indicate deletions.
(E) qPCR of Dhx37 mRNA level in murine CD8 T cells with AAV-sgDhx37 transduction.
(F) Western blot of Dhx37 protein level in murine CD8 T cells with AAV-sgDhx37 transduction.
(G) Representative ﬂow histograms of CD107a degranulation assay for Dhx37 knockout CD8 T cells.
(H) Quantiﬁcation of data from (G) with independent experimental replicates.
(I) Anti-tumor activity of adoptive transfer of AAV-CRISPR mediated Dhx37 knockout CD8 T cells. Growth curves of mammary fat pad E0771-mCh-OVA tumors in
Rag1 / mice following different treatments.
Note: in all bar plots, data are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, by unpaired two-sided t test. In tumor growth curves, arrow indicates the
time of adoptive transfer. ****p < 0.0001 by two-way ANOVA.
See also Figures S4 and S5 and Table S3.

primary murine CD8 T cells (Figure 4A) (STAR Methods). By
isolating OT-I;Cas9 CD8 T cells and infecting them with respective AAV vectors, we performed molecular, functional, and
immunological analysis of Dhx37 loss, in addition to anti-tumor
efﬁcacy testing (Figure 4B). Amplicon sequencing showed that
AAV-sgDhx37 potently mutagenized the targeted loci 5 days
post-infection (Figures 4C and 4D; Table S3). This observation
is corroborated with a reduction of Dhx37 mRNA and Dhx37 protein levels in T cells (Figures 4E and 4F). The partial knockdown is
likely due to incomplete gene editing efﬁciency, mRNA and
Dhx37 protein stability at this time point, and the fact that not
all indels lead to effective loss of protein, which together might
under-estimate the effect of Dhx37 mutagenesis by CRISPR.

Despite the incomplete knockout, we observed that compared
to vector control, AAV-sgDhx37-treated OT-I;Cas9 CD8 T cells
had signiﬁcantly increased degranulation (surface CD107a)
when co-cultured with cognate SIINFEKL-pulsed E0771 cells,
at baseline (0 ng/mL), physiological (1 ng/mL), and saturation
(10 ng/mL) conditions of anti-CD3 stimulation (Figures 4G and
4H). Moreover, we found no differences in cell growth between
sgDhx37 and control T cells in culture (Figure S4A), ruling out
the possibility that the degranulation result was simply due to a
growth advantage.
Using the same E0771-mCh-OVA tumor model, we again validated that Dhx37 perturbation by AAV-sgDhx37 showed
enhanced efﬁcacy of adoptive T cell therapy (Figure 4I). During

110

Cell 178, 1189–1204, August 22, 2019 1195

A

B

C

D

E

F

G
H

I

J

Figure 5. Immunological Characterization of Dhx37 Knockout Mouse CD8 T Cells
(A–F) Flow cytometry analysis of key immune markers of T cell function, including CD69 (A), CD27 (B), Granzyme B (C), PD-1 (D), Lag3 (E), and Tim-3 (F). Left panel
in each plot is a representative histogram of sgDhx37 (red) and vector (black) CD8+ T cells. Right panel is a bar plot of quantiﬁcation for each marker. Data are
shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, by unpaired two-sided Mann-Whitney test.
(G) Flow cytometry analysis plot of IFN-g production of sgDhx37 and Vector CD8 T cells with or without anti-CD3 stimulation.
(H) Quantiﬁcation bar plot of (G). Data are shown as mean ± SEM. **p < 0.01, by unpaired two-sided Mann-Whitney test.

(legend continued on next page)
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the long-term in vivo tumor growth (6.5 week time course), we
observed antigen decrease (Figures S4B–S4D), decrease of effective TILs (Figures S4F–S4H), and loss of T cell stimulation ability in
cancer cells (Figures S5A–S5D), which is consistent with the current model of cancer immunoediting that might partly explain the
ultimate rebound of tumors after adoptive transfer (Figure 2G
and Figure 4I). These data validated that acute genetic perturbation of Dhx37 led to enhanced killing by CD8 T cells, both in vitro
and in vivo, together further validating the screen results.
We then characterized the immunological features of Dhx37
mutant CD8 T cells. We found that Dhx37 mutant CD8
T cells have higher levels of an activation marker CD69, as well
as a co-stimulatory receptor CD27 (Figures 5A and 5B). Concordantly, Dhx37 mutant cells produced higher level of granzyme B
(Figure 5C). In line with the TIL scRNA-seq result, Dhx37 mutant
have higher levels of surface PD-1, Lag3, and Tim-3 (Figures 5D–
5F), which are known immune checkpoints and also linked to
intrinsic T cell activation (Lee et al., 2011). We then measured
the ability of Dhx37 mutant T cell’s ability to produce IFN-g, a major effector cytokine, and found that Dhx37 mutant produced
higher level of IFN-g both at baseline and upon 1 mg/mL antiCD3 stimulation (Figures 5G and 5H). In a co-culture assay, we
found that Dhx37 mutant (AAV-sgDhx37 treated) CD8 T cells
are more potent in killing E0771-mCh-OVA cancer cell as
compared to wild-type (vector treated) T cells (Figure 5I). The
enhanced killing does not occur in parental E0771 cells without
OVA, indicating that the effect is antigen speciﬁc (Figure 5I). By
examining the epigenetic status of the Dhx37 locus, we also
found that memory precursor and terminal effector CD8 T cells
have high levels of chromatin accessibility (assay for transposase-accessible chromatin using sequencing [ATAC-seq]
peaks), promoter activity (H3K4me3) and enhancer activity
(H3K27ac), while naive CD8 T cells have low levels of these
markers (Figure 5J). These data together link Dhx37 to T cell activation and effector function.
Of note, we also performed AAV-mediated gene editing and
immunological assays for Odc1 (Figures S6A and S6B; Table
S3). We found that Odc1 mutant T cells were able to degranulate
in higher abundance in response to 1 ng/mL of SIINFEKL-pulsed
E0771 cells compared to vector controls (Figures S6C and S6D).
However, this increased responsiveness was not observed
at a saturating dose of SIINFEKL peptide (10 ng/mL) (Figures
S6C and S6D). Moreover, we revealed that Odc1 mutant T cells
also as showed increased effector functions in terms of granzyme
and IFN-g production (Figures S6E–S6G) as well as higher levels
of CD69, CD27, PD-1, Lag3, and Tim-3 (Figure S6G).
Bulk Transcriptome Proﬁling of Dhx37 Mutant CD8 T
Cells Revealed Immunologic Signatures of T Cell
Activation and Effector Function along an NF-kB Axis
To identify genes downstream of Dhx37, we performed transcriptome proﬁling of Dhx37 mutant CD8 T cells as compared

to control T cells, using bulk mRNA-seq with 4 experimental
replicates each (STAR Methods) (Table S4). We found a total of
97 signiﬁcantly upregulated genes in Dhx37 mutant CD8
T cells (sgDhx37 high genes) and 69 downregulated genes
(sgDhx37 low genes) (Figure 6A) (Table S5). Consistent with
the immune phenotyping results, among the Dhx37 mutant upregulated genes are genes encoding effector cytokines such as
various granzymes and IFN-g, Cd69, Tim-3 (Havcr2), and other
immune genes Serpinb6b and Serpinb9b (Figure 6B). Examples
of genes downregulated upon Dhx37 loss include Foxp3, Il6ra,
Lyz2, and Ly6c2 (Figure 6B). We validated 5 individual genes
by single-gene qPCR, and conﬁrmed that all 5, i.e., Gzmc,
Gzmd, Sepinb9b, Tim-3, and Il6ra, are differentially expressed
(Figure 6C).
Because there are no existing studies of Dhx37 perturbation in
T cells, we compared the differential expression signatures to the
expression proﬁles of naive, memory, and effector T cells, as well
as effector cells under induced activation. We found that the upregulated gene set in Dhx37 mutant is enriched in genes associated with T cell activation (Figure 6D; Table S6). We also found
that the downregulated gene set is depleted in effector genes
as compared to naive or memory T cells (Figure 6E; Table S6).
Furthermore, DAVID pathway analysis (STAR Methods) revealed
that the top two enriched pathways are immune response and
cytolysis for Dhx37 mutant upregulated gene set (Figure 6F),
with the next tier of signiﬁcant terms being inﬂammatory
response, cell-surface protein, and extracellular exosome (Table
S6). These analyses further linked Dhx37 to T cell activation and
effector function. Interestingly, when we examined the regulatory
sequences in the promoters of genes upregulated upon Dhx37
loss, the strongest sequence motif corresponded to the NF-kB
motif (p = 1.053e-5) (Figure 6G), suggesting that Dhx37 may
act, at least in part, through NF-kB components.
Characterization of DHX37 in Human T Cells
Human DHX37 encodes a 1,150 amino acid protein with several
conserved domains, including the DEAH box (DEXDc), HrpA,
NTPase, H2A, and the helicase (HELICc) domains (Figure S7A).
Sequence alignment of DHX37 homologs from 32 species
showed that this protein is highly conserved, especially in the
DEXDc and helicase domains (Figure S7A). We made N- and
C-terminal reporter fusion constructs and used them together
with endogenous anti-DHX37 antibody to perform staining and
imaging (STAR Methods). We found that both exogenous GFPDHX37 and DHX37-GFP fusions overlap with those of the
endogenous DHX37 protein, and they localize in nucleoli (Figures
S7B and S7C). By western blot, we found that DHX37 protein is
expressed in primary human CD4+ and CD8+ T cells, as well as
patient TILs (Figure 7A). Based on the transcriptomic signature,
pathway analysis, and motif analysis, we hypothesized that
DHX37 interacts with NF-kB components. We performed immunoprecipitation (IP) on endogenous DHX37 protein with lysate

(I) Co-culture luciferase assay that measures the ability of sgDhx37 and Vector-treated CD8 T cells to kill antigen-expressing (E0771-OVA) and parental control
(E0771-Ctrl) cells. Data are shown as mean ± SEM. ****p < 0.0001, by unpaired two-sided t test.
(J) Normalized signal tracks of ATAC-seq, H3K27ac, H3K4me3, and H3K27me3 chromatin immunoprecipitation sequencing (ChIP-seq) at the Dhx37 locus in
naive, memory precursor, and terminal effector CD8+ T cells.
See also Figure S6.
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Figure 6. Transcriptome Analysis of Dhx37 Knockout Mouse CD8 T Cells by mRNA-Seq
(A) Volcano plot of differentially expressed genes between Dhx37 knockout and Vector control CD8 T cells, as quantiﬁed by bulk mRNA-seq (n = 4 biological
replicates each).
(B) Heatmap of differentially mRNA-seq expressed genes in between Dhx37 knockout and Vector control CD8 T cells.
(C) qPCR single-gene validation of representative highly upregulated or downregulated genes, including Gzmc, Gzmd, Serpinb9b, Tim-3, and Il6ra. Data are
shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, by unpaired two-sided t test.
(D and E) GSEA analysis of differentially expressed (DE) genes in Dhx37 knockout CD8 T cells in known T effector signatures. (D) Analysis of Dhx37-DE
upregulated gene set in (left) gene signature of IL-12 treatment versus control T effector cell and in (right) D6 versus D12 T effector cell in culture. (E) Analysis of
Dhx37-DE downregulated gene set in (left) gene signature of effector versus naive CD8 T cell and in (right) effector versus memory CD8 T cell.
(F) DAVID GO analysis of Dhx37-DE upregulated gene set.
(G) Motif analysis of the regulatory DNA elements of the Dhx37-DE upregulated gene set, identifying the consensus NF-kB binding site as the top enriched motif.
See also Tables S4, S5, S6.
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Figure 7. Characterization of DHX37 in Human T Cells
(A) Western blot analysis of DHX37 protein in human cells. From left to right, HEK293FT cells with DHX37 cDNA overexpression as a positive control; peripheral
blood CD4+ T cells from a healthy donor; peripheral blood CD8+ T cells from a healthy donor; TILs from a tumor biopsy freshly isolated from an non-small-cell lung
carcinoma (NSCLC) patient.
(B) CoIP western experiment of DHX37 and NF-kB pathway components (PDCD11 and p65) in human primary CD8 T cells. Anti-DHX37 and Anti-PDCD11
reciprocal IPs were blotted with endogenous antibody against PDCD11, DHX37, and also along with p65.
(C) DHX37 mRNA expression in normal human CD8+ and CD4+ T cells in activated and naive states. Statistical comparisons were made with two-sided unpaired
Mann-Whitney test.
(D) TIDE analyses of DHX37 expression in T cell dysfunction signatures linked to survival beneﬁts in patients, with luminal-A or TNBC.
(E–G) Gene editing of the DHX37 locus in primary human CD8 T cells, with Cas9 RNP (E), Cas9 mRNA (F), or Cpf1 mRNA (G) systems. Representative Illumina
targeted amplicon sequencing of the sgRNA target site. Top most frequent variants were shown, with the associated variant frequencies in the box to the right.
PAM and sgRNA spacers were indicated above. Red arrows indicate predicted cleavage sites. Red dashed lines indicate deletions. Red A/C/G/T where
applicable indicate insertions.
(H) Schematics summarizing DHX37 targeting.
See also Figure S7 and Table S3.
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from primary human CD8 T cells. We found that the NF-kB binding protein (PDCD11) and the NF-kB transcription factor p65
were detected in the DHX37-IP from CD8 T cell lysate (Figure 7B).
We then performed a reciprocal IP with anti-PDCD11 antibody
and detected both p65 and DHX37 in the PDCD11-IP fraction
(Figure 7B).
Human DHX37 is expressed in most organs, with highest
expression in lymphoid tissues such as the bone marrow, lymph
nodes, spleen, and appendix (Fagerberg et al., 2014). By
analyzing DHX37 expression in normal human T cells according
to activation state, we found that activated T cells, both CD8+
and CD4+, have higher levels of DHX37 (Figure 7C). By analyzing
scRNA-seq data of human CD8+ TILs from cancer patients, we
found that DHX37 is expressed at higher level in exhausted
TILs compared to non-exhausted (Figure S7D). To examine the
relevant roles of DHX37 in human T cells, we further analyzed a
recent single-cell transcriptomics dataset of human TILs (Zheng
et al., 2017a). DHX37 mRNA expression was detected in a fraction of peripheral blood T cells, tissue-resident T cells, and tumor-inﬁltrating T cells (Figure S7E). DHX37 was expressed in
CD3+/CD8+ (cytotoxic T cell), CD3+/CD4+/CD25– (T helper
cell), and CD3+/CD4+/CD25+ (Treg) populations (Figure S7E), in
those T cells from peripheral blood, resident tissue, tumornormal junction, or inﬁltrated in the tumor (Figure S7E). To assess
the clinical relevance of DHX37 in cancer, we used Tumor Immune Dysfunction and Exclusion (TIDE) analysis to examine
whether DHX37 expression in T cells is linked to breast cancer
outcomes (STAR Methods). While high cytotoxic T lymphocyte
(CTL) score is associated with an overall survival beneﬁt, highlevel of DHX37 expression abolishes or negates this beneﬁt, in
both luminal-A and TNBC subtypes (Figure 7D). Together, these
data showed that DHX37 is expressed in normal and tumorassociated human T cells, interacts with NF-kB core components, and is associated with T cell dysfunction related clinical
outcomes in breast cancer patients.

types directly in immunotherapy-relevant settings, and identiﬁed enriched targets of various functional categories including
known and undocumented.
A particularly exciting aspect of the inﬁltration screen is that,
unlike other screens to date, PD-1 and Tim-3 emerged as top
hits in an unbiased manner. These markers highlight the sensitivity of the in vivo screen in physiologically relevant conditions.
This study can also serve as a reference for high-throughput genetic interrogation of T cells in vivo for immunotherapy target
discovery. Possible alternative applications include a variety of
cancer models such as genetically engineered mouse models
as well as genome-editing based cancer models for diverse
oncology indications, with or without other treatments in
conjunction. Other CRISPR technologies such as CRISPR
activation or repression, other vector or screening systems,
and orthogonal genetic manipulation strategies may further
empower the study of cancer immunotherapy with available
and evolving toolkits (Dominguez et al., 2016; Esvelt et al.,
2013; Gilbert et al., 2013; Thakore et al., 2016).
Validation and characterization of a top convergent hit, Dhx37,
showed that modulation of this gene in CD8 T cells can lead to
enhanced anti-tumor activity in vitro and in vivo by adoptive
transfer. Due to the current lack of available compounds targeting DHX37, we reasoned that genetically editing DHX37 in
human CD8 T cells presented an approach for attenuating its
activity. We performed ribonucleoprotein (RNP)-mediated and
mRNA-mediated editing of DHX37 in human CD8 T cells, using
both Cas9 (Figures 7E and 7F; Table S3), and Cas12a-Cpf1 (Figure 7G; Table S3) systems. Multiple modes of delivery can be
applied, including lentivirus, AAV, RNP, or mRNA (Figure 7H).
Future studies may develop compounds targeting DHX37 by
screening small molecule libraries or may use structure-based
drug design.

DISCUSSION

Detailed methods are provided in the online version of this paper
and include the following:

Tumor-derived TILs possess the ability to recognize and kill
cancer cells in autologous transplantation studies (Rosenberg
et al., 1985). The discovery of CTLA-4 and PD-1 pathways revealed how inhibitory signals of CD8 T cells can be exploited
by tumors to evade immune recognition (Ishida et al., 1992;
Leach et al., 1996). Targeting T cell inhibitory factors has led
to the paradigm of checkpoint blockade immunotherapy (Fesnak et al., 2016; Maude et al., 2014; Maus and June, 2016;
Mellman et al., 2011; Ribas, 2012), suggesting that better understanding of the genetic landscape governing T cell function
will facilitate the development of better immunotherapies.
CRISPR technology has provided a set of tools to open unique
opportunities for direct manipulation of the T cell genome (Eyquem et al., 2017), and its scalability enabled genetic screens
in T cells, which to date have been performed in vitro (Henriksson et al., 2019; Shifrut et al., 2018). Here, we performed
convergent in vivo tumor inﬁltration and in vitro degranulation
screens to systematically study the anti-tumor potential of
CD8 T cells. Our screens generated genome-scale quantitative
measurements of genetic factors modulating CD8 T cell pheno-
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3.3: Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor
immunity
As discussed above, cancer is a disease of acquired genetic mutations. By virtue of these
genetic alterations, tumors are able to grow indefinitely and spread throughout the body

19

. In

theory, at least some of these “neoantigens” should be presented on the surface of tumor cells for
recognition by the immune system

105,106

. However, tumors can evolve strategies to evade

immune recognition, such as downregulating their antigen presentation machinery 107–109.
The initial premise of this study was to perform a genome-scale CRISPR activation
(CRISPRa) screen to identify genes that, when ectopically overexpressed, would promote
tumorigenesis (e.g. oncogenes). However, we were surprised to find that tumor cells carrying the
CRISPRa library overwhelmingly failed to generate tumors, in stark contrast to vector controls.
This led us to hypothesize that ectopic activation of various mutant genes in the tumor cells was
in fact promoting anti-tumor immunity by increasing the density and diversity of neoantigens
presented on the surface of the tumor cells. We thus refocused the study to leverage CRISPRa
machinery as a new strategy for cancer immunotherapy, termed MAEGI 110.
This line of investigation was conceived together with my advisor Dr. Sidi Chen and my
colleague Guangchuan Wang. My primary role in this study was to analyze the CRISPR
screening data, TCR-seq profiling, scRNA-seq datasets, and patient cohort data, as well as
design the personalized sgRNA libraries. I also prepared the manuscript text and figures together
with Guangchuan Wang and Dr. Sidi Chen.
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Multiplexed activation of endogenous genes by
CRISPRa elicits potent antitumor immunity
Guangchuan Wang 1,2,3,16, Ryan D. Chow 1,2,3,4,16, Zhigang Bai 1,2,3,15, Lvyun Zhu1,2,3, Youssef Errami1,2,3,
Xiaoyun Dai1,2,3, Matthew B. Dong1,2,3,4,5,6, Lupeng Ye 1,2,3, Xiaoya Zhang1,2,3, Paul A. Renauer1,2,3,7,
Jonathan J. Park 1,2,3,4, Li Shen1,2,3, Hanghui Ye1,2,3, Charles S. Fuchs8,9,10 and Sidi Chen 1,2,3,4,6,7,10,11,12,13,14*
Immunotherapy has transformed cancer treatment. However, current immunotherapy modalities face various limitations. In
the present study, we developed multiplexed activation of endogenous genes as an immunotherapy (MAEGI), a new form of
immunotherapy that elicits antitumor immunity through multiplexed activation of endogenous genes in tumors. We leveraged
CRISPR activation (CRISPRa) to directly augment the in situ expression of endogenous genes, and thereby the presentation of
tumor antigens, leading to dramatic antitumor immune responses. Deploying this as a cell-based vaccination strategy showed
efficacy in both prophylactic and therapeutic settings. Intratumoral adeno-associated virus delivery of CRISPRa libraries elicited
strong antitumor immunity across multiple cancer types. Precision targeting of mutated gene sets eradicated a large fraction
of established tumors at both local and distant sites. This treatment modality led to alterations in the tumor microenvironment,
marked by enhanced T cell infiltration and antitumor immune signatures. Multiplexed endogenous gene activation is a versatile
and highly scalable strategy to elicit potent immune responses against cancer, distinct from all existing cancer therapies.

I

mmunotherapy leverages the patient’s immune system against
cancer, turning certain previously lethal cancer types into manageable diseases1–5. Major types of immunotherapy include
checkpoint blockade6, adoptive cell transfer7, human recombinant
cytokines and cancer vaccines8. These regimens have transformed
cancer treatment9–11. In particular, checkpoint blockade immunotherapies targeting cytotoxic T lymphocyte-associated protein 4
(CTLA-4) and programmed cell death protein 1 (PD-1) pathways
have yielded clinical benefits across a broad spectrum of cancer
types, with durable responses even in late-stage, metastatic and chemoresistant tumors12–15. However, only a fraction of patients show
sustained clinical responses to the currently available regimens5,
urging for new types of immunotherapies.
As a consequence of cumulative genetic and epigenetic aberrations, cancers can be recognized and eliminated by the immune
system if mutant or abnormally expressed antigens are adequately
presented16,17. Recognition of tumor-associated antigens (TAAs)
formed by mutations and dysregulated gene expression programs
is an essential step for cancer immunotherapy17,18. However,
the spontaneous immune recognition of tumor antigens is
often insufficient to elicit effective immune responses, because
the abnormal products may not be adequately presented19.
Moreover, neoantigen loss often occurs during malignancy18.
We reasoned that augmenting the expression and thus the presentation of endogenous antigens in tumors could amplify the
‘nonself ’ identity of cancer cells, thereby flagging them for
immune destruction20.

Neoantigen-targeting approaches based on the delivery of
synthetic mutant peptides or transcripts have demonstrated the
concept of leveraging personalized neoantigens as cancer treatments21–24. However, the efficacy and scalability of these approaches
is limited. The CRISPRa system uses a catalytically inactive Cas9
(dCas9)25, enabling simple and flexible gene expression regulation
through dCas9-transcriptional activators paired with single guide
RNAs (sgRNAs)26–29. Using CRISPRa, multiplexed augmentation of
desired gene sets can be readily achieved by utilizing pools of guide
RNAs27. In the present study, we developed CRISPRa-mediated
MAEGI, which acts by directly augmenting the expression and
presentation of endogenous genes that encode potentially immunogenic antigens. MAEGI showed therapeutic efficacy across three
tumor types. Mechanistically, MAEGI treatment elicits antitumor
immune responses by recruiting effector T cells and remodeling the
tumor microenvironment.

Results
CRISPRa enhances in situ antigen presentation and promotes
T cell effector function. To investigate whether CRISPRa can
elicit immune responses by enhancing the presentation of TAAs
(Fig. 1a), we examined the effect of CRISPRa on the surface presentation of a target antigenic peptide. Triple-negative breast
cancer (TNBC) E0771 cells were transduced with CRISPRa
lentiviral vectors expressing dCas9-VP64 and MS2-p65-HSF1
(MPH) (E0771-dCas9-VP64-MPH; see Supplementary Fig. 1a).
By introducing a model antigen transgene (chicken ovalbumin,
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Fig. 1 | CRISPRa augments tumor antigen presentation to promote T cell effector function. a, Schematic of the experimental design for using CRISPRa to
enhance the immune recognition of TAAs, eliciting systemic immune responses. b,c, E0771-dCas9-VP64 cells were transduced with lentivirus to express
OVA under a PGK promoter (E0771-OVA), and further transduced with either vector or CRISPRa sgRNAs targeting the PGK promoter. b, Representative
flow cytometry analysis of surface staining for OVA-derived SIINFEKL–H-2Kb complex on cells transduced with vector or sgRNAs. c, Mean fluorescence
intensity of APC–SIINFEKL–H-2Kb on E0771-OVA cells transduced with vector or sgRNAs (n=15 cell replicates (SIINFEKL–H-2Kb staining in vector); n=13
(isotype in vector); n=19 (SIINFEKL–H-2Kb staining in CRISPRa sgRNAs); or n=15 (isotype in CRISPRa sgRNAs) from four independent experiments;
two-sided Mann–Whitney test: SIINFEKL–H-2Kb staining versus isotype in vector, P=0.0356; SIINFEKL-H-2Kb staining versus isotype in CRISPRa sgRNAs,
P<0.0001; SIINFEKL-H-2Kb staining in CRISPRa sgRNAs versus vector, P<0.0001). d, The percentage of IFN-γ-producing OT-I CD8+ T effector cells after
co-culture with the indicated E0771-OVA cancer cells for 3h (n=11 co-culture samples from three independent experiments with Welch’s two-tailed,
unpaired t-test: CRISPRa sgRNAs versus vector in E:T=1:1, P=0.0218; CRISPRa sgRNAs versus vector in E:T=0.5:1, P=0.002). e, The percentage of viable
cancer cells (excluding dead cells and apoptotic cells) when co-cultured with OT-I CD8+ T effector cells for 24h (n=11 co-culture samples from three
independent experiments; Welch’s two-tailed, unpaired t-test: CRISPRa sgRNAs versus vector in E:T=1:1, P<0.0001; CRISPRa sgRNAs versus vector in
E:T=0.5:1, P<0.0001). Error bars: all data points in this figure are presented as mean±s.e.m. *P<0.05, **P<0.01, ***P<0.001. Additional supporting
data: see Supplementary Fig. 1.

OVA) driven by a phosphoglycerate kinase (PGK) promoter into
E0771-dCas9-VP64-MPH cells (E0771-OVA cells), we found
that PGK-targeting CRISPRa sgRNAs enhanced the presentation
of the target antigenic peptide (SIINFEKL) on the H-2Kb class
I major histocompatibility complex (MHC-I) (Fig. 1b,c and see
Supplementary Table 1).
We then used a co-culture assay to investigate the effect of
CRISPRa-enhanced antigen presentation on cancer-immune cell
interactions. To assess the effector function of T cells, SIINFEKL–
H-2Kb-specific CD8+ T cells were isolated from ovalbumin peptidespecific (OVA) OT-I mice and were co-cultured with E0771-OVA
cells for 3 h. E0771-OVA cells expressing PGK-targeting sgRNAs
elicited a higher percentage of interferon-γ (IFN-γ)-producing
T cells (Fig. 1d and see Supplementary Fig. 1b). To assess T cell–
mediated killing of cancer cells, OT-I T cells were co-cultured with
E0771-OVA cells for 24 h and the viability and apoptosis of the cancer cells analyzed. Consistent with the increase in IFN-γ production,
CRISPRa treatment led to a lower percentage of viable cancer cells,
with most of the cancer cells either killed or undergoing apoptosis
(Fig. 1e and see Supplementary Fig. 1c and Supplementary Table 1).
These data demonstrate that CRISPRa enhanced the presentation
of a target antigen in cancer cells, thereby eliciting a stronger T cell
effector response.

CRISPRa-mediated gene activation leads to immune-mediated
tumor clearance. To test the effect of endogenous gene activation
on the immunogenicity of cancer cells in vivo, we examined the
tumorigenic ability of CRISPRa-transduced cancer cells in immunocompetent C57BL/6J mice (Fig. 2a and see Methods). A mouse,
genome-scale lentiviral, CRISPRa sgRNA library (mSAM)27 was
transduced into E0771-dCas9-VP64-MPH cells (E0771–SAM) (see
Supplementary Fig. 1d,e and Supplementary Table 2). After confirming the efficient activation of endogenous genes using this system (Fig. 2b), we transplanted the library-transduced E0771 cells
into C57BL/6J mice. In sharp contrast to E0771-vector cells (0/8
rejection, that is 8/8 engrafted, all with large tumors), the E0771–
SAM cell pool was rejected in most (42/50, 84%) of the mice, with
the remaining mice (8/50, 16%) developing small tumors (Fig. 2c).
To examine the contribution of the immune system toward rejection of E0771–SAM cells, E0771–SAM cells were transplanted into
immunodeficient Nude (Foxn1nu) and Rag1–/– mice. Unlike immunocompetent C57BL/6J hosts (5/5 either completely rejected or
with small modules), all immunodeficient Nude (Foxn1nu) (4/4)
and Rag1–/– (5/5) mice rapidly grew large tumors from E0771–SAM
cells (Fig. 2d). When both CD4+ and CD8+ T cells were depleted
in C57BL/6J mice using anti-CD4 and anti-CD8 monoclonal antibodies, all mice receiving E0771–SAM cells formed large tumors
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c-MAEGI@–d14 (n=5), c-MAEGI@–d7 (n=6) and c-MAEGI@–d3 (n=6) (two-way ANOVA: cell–vector@–d7 versus PBS, P=0.2077; c-MAEGI@–d3
versus PBS or vector@–d7, P<0.0001; c-MAEGI@–d7 versus PBS or vector@–d7, P<0.0001; c-MAEGI@–d14 versus PBS or vector@–d7, P<0.0001).
h, E0771 tumor-bearing mice were treated with PBS (n=16 mice), cell–vector (n=5) or c-MAEGI (n=8) at indicated times (blue arrows) (two-way
ANOVA: PBS versus vector, P=0.2955; c-MAEGI versus PBS, P<0.0001; c-MAEGI versus vector, P=0.0005). i, Tumor growth curves in E0771 tumorbearing mice that were treated by PBS (n=8 mice), c-MAEGI (n=8), α-CTLA-4 (n=6) or c-MAEGI+α-CTLA-4 (n=4) (blue arrows, c-MAEGI treatment;
yellow arrows, α-CTLA-4 treatment; two-way ANOVA: c-MAEGI versus PBS, P=0.0105; α-CTLA-4 versus PBS, P<0.0001; c-MAEGI+α-CTLA-4 versus
α-CTLA-4 alone, P=0.0005; c-MAEGI+α-CTLA-4 versus c-MAEGI, P<0.0001). Error bars: all data points in this figure are presented as mean±s.e.m.
*P<0.05, **P<0.01, ***P<0.001. NS, not significant. dpi, days post injection. Additional supporting data: see Supplementary Fig. 1.

(4/4), in contrast to untreated mice (0/11 with tumors) (Fig. 2e).
Together, these results indicate that pooled activation of endogenous genes induced potent tumor rejection in vivo only in immunocompetent hosts.
NATURE IMMUNOLOGY | www.nature.com/natureimmunology

C-MAEGI has prophylactic and therapeutic efficacy in syngeneic tumor models. Intrigued by the immune rejection of E0771–
SAM cells, we considered whether CRISPRa-mediated activation
of endogenous genes within tumor cells could be harnessed as a
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new approach for immunotherapy (MAEGI). The lentiviral SAM
sgRNA library was transduced into E0771-dCas9-VP64-MPH cells
to generate E0771–SAM cells, followed by mitomycin treatment
to induce senescence, while maintaining the integrity of peptide–
MHC-I complexes (Fig. 2f), generating c-MAEGI. E0771–vector
cells that were treated with mitomycin were generated in parallel as
the cell–vector control. Then, c-MAEGI or cell–vector was inoculated into C57BL/6J mice before E0771 tumor induction (Fig. 2g
and see Methods). In sharp contrast to untreated mice or cell–vector control-treated mice (both 0% tumor free), c-MAEGI-treated
mice had complete protection (100% tumor free) against subsequent tumor challenges with the unmodified parental E0771 cells
(Fig. 2g). This held true across two vaccination regiments, that is
7 or 14 d before tumor challenge, whereas vaccination 3 d before
tumor challenge granted near-complete protection (1/6 mice with a
small nodule, 5/6 tumor free) (Fig. 2g and see Supplementary Table
1). The results demonstrate that genome-scale activation of endogenous genes using CRISPRa is an effective approach for prophylaxis
against tumors with an otherwise identical genetic background.
Given its efficacy as a prophylactic agent, we postulated that
c-MAEGI could also potentially be used as a therapeutic intervention against established tumors. Orthotopic E0771 tumors were
implanted before treating the mice with c-MAEGI. Using a threedose treatment scheme, tumors in c-MAEGI-treated mice were
notably smaller than those in mice treated with cell–vector control
or phosphate-buffered saline (PBS) (Fig. 2h and see Supplementary
Table 1). To examine the contribution of T cell–mediated immunity
in the antitumor response, CD8+ T cells were depleted in C57BL/6J
mice with anti-CD8 antibodies. CD8+ T cell depletion abolished the
therapeutic efficacy of c-MAEGI (see Supplementary Fig. 1e–h),
indicating that CD8+ T cells are essential for c-MAEGI-mediated
antitumor responses. We then investigated whether c-MAEGI
could be used together with other immunotherapies or immunomodulatory agents. The combination of c-MAEGI + anti-CTLA-4
was more effective than c-MAEGI alone or anti-CTLA-4 alone,
leading to complete regression of established tumors (Fig. 2i and
see Supplementary Table 1). Collectively, the data demonstrate that
c-MAEGI has efficacy in both prophylactic and therapeutic settings.
AAV-mediated, in situ gene activation as an immunotherapeutic modality (AAV-MAEGI). As enhanced antigen presentation by
CRISPRa elicited strong immune responses, we reasoned that direct
in vivo delivery of CRISPRa components into target tumors could
boost the presentation level of TAAs, thereby serving as a therapeutic modality. Adeno-associated viruses (AAVs) are viral vectors capable of mediating efficient transgene delivery30,31. To enable
direct delivery of MAEGI to tumors, an AAV version of MAEGI
was devised by generating an AAV-CRISPRa vector containing the
CRISPRa modules (EF1α-MPH and U6-sgRNABackbone-MS2).
The effectiveness of AAV-CRISPRa in activating endogenous genes
was confirmed by infecting E0771-dCas9-VP64 cells with CRISPRa
AAVs carrying a small pool of sgRNAs (see Supplementary Fig. 2a).
In the E0771-OVA model, AAV-delivered sgRNAs targeting the
PGK promoter increased the presentation of antigenic peptide (see
Supplementary Fig. 2b).
The genome-scale SAM sgRNA library was then cloned into the
AAV-CRISPRa vector to produce AAV-g-MAEGI (see Methods).
C57BL/6J mice bearing orthotopic E0771-dCas9-VP64 tumors
were treated with AAV-g-MAEGI by intratumoral administration (Fig. 3a). AAV-g-MAEGI treatment led to reduced tumor
burden compared with either AAV-vector or PBS (Fig. 3b). AAVvector (EF1α-MPH and U6-sgRNABackbone-MS2) treatment
also showed an antitumor effect, consistent with the baseline
immunogenicity of viral vectors carrying the MPH transgenes,
but was nevertheless weaker than AAV-g-MAEGI treatment containing the sgRNA library (Fig. 3b). Using ELISpot, it was found

that AAV-g-MAEGI elicited higher frequencies of tumor-reactive
immune cells (in terms of the frequencies of IFN-γ-producing
splenocytes stimulated by tumor antigens) compared with AAVvector or PBS (Fig. 3c,d). No difference was observed in the frequencies of tumor-specific, IFN-γ-secreting splenocytes between
PBS and AAV-vector (Fig. 3d). These data demonstrate that multiplexed in situ activation of endogenous genes by AAV-g-MAEGI
elicits robust and specific antitumor immune responses in vivo.
To evaluate the broader utility of MAEGI, the same treatment
modality was tested on other tumor types. On a syngeneic melanoma mouse model (B16F10, expressing dCas9-VP64), AAV-gMAEGI again demonstrated notable efficacy (Fig. 3e). The efficacy
of AAV-g-MAEGI was tested further in a syngeneic pancreatic
cancer model using the Pan02 cell line. Against established Pan02dCas9-VP64 tumors, it was observed that, although AAV-vector
had an antitumor effect compared with PBS, AAV-g-MAEGI has
stronger efficacy compared with both AAV-vector and PBS (Fig. 3f
and see Supplementary Table 1). Thus, AAV-mediated delivery of
genome-scale MAEGI elicits host immune responses against established tumors across multiple aggressive cancer types.
Multiplexed in situ activation of mutated gene sets as proof-ofconcept precision immunotherapy. As individual tumors have
unique mutation profiles distinguishing them from normal tissues,
we investigated whether MAEGI could be customized to tumorspecific mutated gene sets. This approach was termed precision
MAEGI (p-MAEGI) (Fig. 4a). We hypothesized that the precision
version could more specifically enhance the presentation of mutant
peptides. To this end, whole-exome sequencing of E0771 cells was
performed and all genic SNPs, insertions and deletions (indels)
called by comparison to healthy mammary fat-pad cells from wildtype C57BL/6J mice sequenced in parallel (Fig. 4a and see Methods),
revealing the E0771-specific mutation profile (see Supplementary
Fig. 3a,b). The differential mutation data were then harnessed
for CRISPRa sgRNA library design, generating a library of 3,839
sgRNAs targeting 1,116 E0771-mutated genes (see Supplementary
Table 2). The library was synthesized and pool cloned, successful
cloning verified by sequencing and the AAV pool produced (AAVp-MAEGI) (see Supplementary Fig. 3c).
C57BL/6J mice bearing orthotopic E0771 TNBC were treated
with AAV-p-MAEGI, along with AAV-vector and PBS controls.
Although the AAV-vector itself showed antitumor effects compared
with PBS, AAV-p-MAEGI exhibited dramatic efficacy compared
with both AAV-vector and PBS (Fig. 4b and see Supplementary
Fig. 3d). The CR and nCR rates were determined for each treatment
(see Methods), which revealed a combined nCR and CR rate of 4%
for PBS, 0% for AAV-vector and 44% for AAV-p-MAEGI (Fig. 4c).
Three months after the initial tumor transplantation, nine AAV-pMAEGI-treated mice that had undergone CR were re-challenged.
All (9/9) mice completely rejected the E0771 tumor re-challenges
(Fig. 4d) and retained a long-term complete remission for over
180 d (Fig. 4d), indicating that AAV-p-MAEGI had induced potent
and durable antitumor responses.
The efficacy of AAV-p-MAEGI was abolished in immunodeficient Rag1–/– mice (see Supplementary Fig. 3e), indicating that
the adaptive immune system is essential for the antitumor effect
of AAV-p-MAEGI. Consistent with this, CD8+ T cell infiltration
into tumors was observed by histology and immunohistochemistry
(see Supplementary Fig. 4a,b). AAV-p-MAEGI-treated tumors also
showed reduced proliferation (see Supplementary Fig. 4c,d). Given
the importance of adaptive immunity in driving these antitumor
responses, we wondered whether intratumoral delivery of AAV-pMAEGI could elicit systemic antitumor immunity and affect distant sites (Fig. 4e). A syngeneic model of E0771 TNBC was used
in which mice bear both ‘local’ and ‘distant’ breast tumors. After
administration of AAV-p-MAEGI only to local tumors, antitumor
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Fig. 3 | Antitumor efficacy of MAEGI in an AAV-based formulation. a, Schematics of the experimental design for intratumoral delivery of MAEGI in an
AAV formulation. AAV-g-MAEGI was generated by cloning the genome-scale, activation sgRNA SAM library into an AAV-CRISPRa vector, followed by
pooled viral packaging into AAV9. b, TNBC model. Growth curves of orthotopic E0771-dCas9-VP64 tumor transplants in C57BL/6J mice treated with PBS,
AAV-vector or AAV-g-MAEGI by intratumoral administration at indicated times (blue arrows) (PBS, n=8 mice; AAV-vector, n=6; AAV-g-MAEGI, n=6;
two-way ANOVA: PBS versus AAV-vector, P=0.0013; AAV-g-MAEGI versus PBS, P<0.0001; AAV-g-MAEGI versus AAV-vector, P=0.0303).
c,d, Tumor-specific immune responses in tumor-bearing C57BL/6J mice, assessed by measuring the proportion of IFN-γ-producing splenocytes with
ELISpot assays after stimulation with mitomycin-treated tumor cells. c, Representative images of spots obtained from four mice for each treatment group
(PBS, AAV-vector and AAV-g-MAEGI). d, Quantification of ELISpot assays from mice treated with PBS (n=4 mice), AAV-vector (n=7) or AAV-g-MAEGI
(n=9) (two-sided, unpaired, Student’s t-test: AAV-vector versus PBS, P=0.326; AAV-g-MAEGI versus PBS, P=0.0009; AAV-g-MAEGI versus AAVvector, P=0.0004; results shown are from the aggregation of two independent experiments). e, Melanoma model. Growth curves of orthotopic B16F10dCas9-VP64 tumor transplants in C57BL/6J mice treated with PBS, AAV-vector or AAV-g-MAEGI at indicated times (blue arrows) (PBS, n=6 mice; AAVvector, n=5; AAV-g-MAEGI, n=6; two-way ANOVA: AAV-vector versus PBS, P<0.0001; AAV-g-MAEGI versus PBS, P<0.0001; AAV-g-MAEGI versus
AAV-vector, P<0.0001). f, Pancreatic cancer model. Growth curves of Pan02-dCas9-VP64 tumors in C57BL/6J mice treated with PBS (n=4 mice),
AAV-vector (n=5) or AAV-g-MAEGI (n=5) at indicated times (blue arrows) (two-way ANOVA: AAV-vector versus PBS, P<0.0001; AAV-g-MAEGI
versus PBS, P<0.0001; AAV-g-MAEGI versus AAV-vector, P<0.0001). Error bars: all data points in this figure are presented as mean±s.e.m. *P<0.05,
**P<0.01, ***P<0.001. Additional supporting data: see Supplementary Fig. 2.

effects were observed against both local tumors and distant tumors
that had not been directly infected by AAV-p-MAEGI (Fig. 4f,g and
see Supplementary Table 1). A 67% CR rate was observed at distant
tumors after AAV-p-MAEGI treatment (Fig. 4g). The observation
NATURE IMMUNOLOGY | www.nature.com/natureimmunology

of an abscopal effect indicates that AAV-p-MAEGI had galvanized
systemic antitumor immunity.
A critical step in demonstrating the potential of MAEGI as a
therapeutic modality is to deliver all of the CRISPRa components
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***P<0.001. Additional supporting data: see Supplementary Figs. 3–5.
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in vivo. To assess the infection rate of intratumoral AAV delivery,
the experiments were repeated using titer-matched AAVs expressing
green fluorescent protein (GFP). Four days after intratumoral AAV
injection, cancer cells were successfully transduced in all tumors
injected, with an infection rate of 4.2 ± 0.51% (mean ± s.e.m.) (see
Supplementary Fig. 4e). In contrast, pan-immune (CD45+) cells
exhibited a lower infection rate of 0.74 ± 0.25% (see Supplementary
Fig. 4e). At day 12 after two AAV injections, the infection rate
increased to 30.4 ± 5.1% for tumor cells (see Supplementary Fig. 4f).
The off-target infection rate for the spleen, liver, lung and heart in
the same cohort of mice was 0 ± 0%, 0.04 ± 0.04%, 0.18 ± 0.06% and
0.11 ± 0.08%, respectively (see Supplementary Fig. 4g). In addition,
no severe adverse effects were observed with MAEGI treatment (see
Supplementary Table 1).
To enable delivery of all MAEGI components into tumors, a dual
AAV system was developed in which one vector expresses dCas9
(AAV-dCas9) and a second vector expresses the sgRNA, as well
as MS2-p65-HSF1 (AAV-CRISPRa). To evaluate whether the dual
AAV system can effectively activate target transcripts, E0771 cells
were co-infected in vitro with both AAV-dCas9 and AAV-CRISPRa,
and increased expression of target transcripts was observed 5–7 d
post-infection (see Supplementary Fig. 5a). Then the therapeutic
efficacy of dual AAV-p-MAEGI was examined by co-injection of
AAV-dCas9 and AAV-p-MAEGI into unmodified E0771 tumors
(Fig. 4h). Similar to the results obtained using tumor cells with lentivirally transduced dCas9-VP64, the co-injection of AAV-dCas9 and
AAV-p-MAEGI showed potent antitumor efficacy compared with
both AAV-dCas9+AAV-vector and PBS, whereas the co-injection
of AAV-dCas9 + AAV-vector showed moderate antitumor effects
compared with PBS (Fig. 4i and see Supplementary Table 1). Taken
together, these data demonstrate that, by using a dual AAV system,
all components of MAEGI can be efficiently delivered into tumors
in vivo, resulting in antitumor responses.
AAV-p-MAEGI remodels the tumor-immune microenvironment. To examine the adaptive immune responses over a time
course, flow cytometry analysis was performed of tumor-infiltrating T cell populations (see Supplementary Fig. 5b). AAV-p-MAEGI
treatment augmented CD4+ and CD8+ T cell infiltration in tumors
from day 29 onwards, compared with AAV-vector or PBS treatment (Fig. 5a,b). Other immune cell populations were also examined at day 19, because this is the time point with initial observation
of tumor regression (see Supplementary Fig. 5c). AAV-p-MAEGI
treatment increased the fraction of MHC-II+ antigen-presenting
cells (APCs) over AAV-vector treatment (Fig. 5c), with a trend of
increased dendritic cells (see Supplementary Fig. 5d), but no significant changes in macrophages, monocytes or neutrophils (see
Supplementary Fig. 5e–g and Supplementary Table 1). These results
indicate that AAV-p-MAEGI treatment increased T cell infiltration into tumors and altered the composition of tumor-infiltrating
immune cells (TIICs), ultimately resulting in tumor regression.
Given these findings, we considered whether the adaptive
immune responses induced by AAV-p-MAEGI were tumor specific. To test this, ELISpot assays were performed on both splenocytes and FACS-isolated TIICs, using either E0771 cancer cells
or matched normal tissues (primary C57BL/6J wild-type cells
isolated from mammary fat pads) as the antigen source (Fig. 5d).
In both AAV-vector and AAV-p-MAEGI conditions, the ELISpot
assays showed more IFN-γ-producing splenocytes and TIICs after
stimulation by E0771 tumor cells, compared with stimulation with
normal primary cells (Fig. 5e–h). Importantly, when stimulated
with E0771 cancer cells, AAV-p-MAEGI-treated mice had higher
frequencies of IFN-γ-secreting immune cells than AAV-vector
treated mice. This effect was particularly pronounced in TIICs,
where AAV-p-MAEGI augmented the frequencies of IFN-γsecreting immune cells in response to E0771 stimulation, but not
NATURE IMMUNOLOGY | www.nature.com/natureimmunology

to matched normal cells (Fig. 5g,h). The antitumor specificity of
AAV-p-MAEGI was similarly observed in splenocytes (Fig. 5e,f
and see Supplementary Table 1). The ELISpot data therefore suggest that tumor-antigen specific immune responses were elicited
by AAV-p-MAEGI.
To understand the repertoire of T cells recruited by MAEGI,
T cell antigen receptor sequencing (TCR-seq) was performed in
mice treated with AAV-p-MAEGI, AAV-g-MAEGI, AAV-vector
or PBS (Fig. 6a and see Methods). TCR clonal proportions were
assessed and various metrics calculated (Fig. 6b–d). In comparison
to PBS or AAV-vector treatment, AAV-p-MAEGI increased TCR
diversity in both spleens and tumor-infiltrating lymphocytes (TILs)
as measured by the Chao1 index32 (Fig. 6c and see Supplementary
Table 2). In comparison to AAV-g-MAEGI-treated mice (genomewide AAV-MAEGI), splenocytes from AAV-p-MAEGI-treated
mice (precision AAV-MAEGI) had higher Chao1 indices, with no
notable difference among TILs (Fig. 6c). Next, the Gini–Simpson
indices were calculated, quantifying the evenness of TCR clonal
abundances32. TILs from AAV-p-MAEGI-treated mice had higher
Gini–Simpson indices compared with PBS- or AAV-vectortreated mice, but not compared with AAV-g-MAEGI-treated mice
(Fig. 6d), indicating that MAEGI is associated with the recruitment
of diverse T cell populations. Intrigued by the increased TCR diversity and clonal evenness among TILs from AAV-p-MAEGI-treated
mice, we considered whether these changes were due to differences
in T cell infiltration, in accordance with the FACS data. We examined the number of unique CDR3 clonotypes identified in each
sample (that is TCR richness) (Supplementary Fig. 6)32, finding
that AAV-p-MAEGI mice had more unique clonotypes than PBS
or AAV-vector samples in both spleen and TIL samples (Fig. 6e,f).
Collectively, the TCR-seq data affirmed the conclusion from the
FACS analysis that AAV-p-MAEGI enhanced T cell infiltration into
tumors, while additionally revealing the richness and diversity of
these tumor-infiltrating T cells.
To further investigate the effect of AAV-p-MAEGI on the tumor
microenvironment, single cell RNA sequencing (scRNA-seq) was
performed to simultaneously profile the composition and transcriptome of TIICs (Fig. 7a and see Methods). Total TIICs were isolated
by FACS of CD45+ cells and scRNA-seq was performed, recovering a total of 4,381 cells from AAV-p-MAEGI- and 3,482 cells from
AAV-vector-treated mice (n = 3 mice pooled for each condition; see
Supplementary Table 2). Imputation and k-means clustering were
performed to identify a total of nine clusters. Analysis of differentially expressed genes in each cluster revealed the cellular identities of each cluster (Fig. 7b and see Supplementary Fig. 7a–f). After
excluding a population of cells (k-means cluster 7, or k7) negative
for CD45 gene expression (encoded by Ptprc) (see Supplementary
Fig. 7b), the final dataset comprised the transcriptomes of 4,065
TIICs from AAV-p-MAEGI- and 2,799 TIICs from AAV-vectortreated mice (Fig. 7c).
Given that the FACS and TCR-seq analyses had revealed
increased T cell tumor infiltration with AAV-p-MAEGI compared
with AAV-vector, we sought to investigate whether these findings
were recapitulated by scRNA-seq. To perform in silico analysis on
T cell populations, messenger RNA transcript expression levels
were used to filter cells (‘mRNA gate’) in k6 or k9, because these
clusters comprise the cells that robustly express Cd3e, Cd4 and
Cd8a mRNA (Fig. 7d). On examination of the Cd3e+ cells within
k6 and k9, these cells were then mRNA gated into Cd8a+Cd4– and
Cd4+Cd8a– populations. Visualization of these cell groups revealed
clear separation of putative CD8+ T cells (defined by Cd8a+Cd3e
+
Cd4– mRNA gating) from CD4+ T cells (defined by Cd4+Cd3e+C
d8a– mRNA gating) (Fig. 7d). The relative abundance of these different T cell populations in k6 and k9 was quantified, which showed
that AAV-p-MAEGI mice had notably more Cd3e+ T cells, putative CD8+ T cells and putative CD4+ T cells (Fig. 7e). Furthermore,
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results shown are aggregated from two independent experiments). h, Quantification of IFN-γ ELISpots for TIICs from AAV-vector- (n=6) or AAV-pMAEGI (n=6)-treated mice bearing E0771-dCas9-VP64 tumors that were stimulated with primary C57BL/6J normal cells or cancer cells (two-sided,
unpaired, Student’s t-test: AAV-p-MAEGI versus AAV-vector stimulated by normal cells, P=0.0577; AAV-p-MAEGI versus AAV-vector stimulated by
cancer cells, P<0.0001; cancer versus normal cell stimulation for the AAV-vector group, P=0.0175; cancer versus normal cell stimulation for the AAV-pMAEGI group, P<0.0001). Error bars: all data points in this figure are presented as mean±s.e.m. *P<0.05, **P<0.01, ***P<0.001. Additional supporting
data: see Supplementary Fig. 5.
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supporting data: see Supplementary Fig. 6.
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exact test with Benjamini–Hochberg multiple hypothesis correction. Error bars: all data points in this figure are presented as mean±s.e.m. *P<0.05,
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among these putative CD4+ T cells, AAV-p-MAEGI-treated mice
had increased abundance of Tbx21+, Ifng+ and Tbx21+Ifng+ cells,
indicative of T helper type 1 cells (Fig. 7f and see Supplementary

Table 2). Thus, the single-cell transcriptomic analyses on CD45+
TIICs reaffirmed prior observations by FACS and TCR-seq that
AAV-p-MAEGI promotes T cell infiltration into tumors.
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To investigate the transcriptomic changes in tumor-infiltrating
T cells after AAV-p-MAEGI, differential expression analyses were
performed to compare T cells from AAV-p-MAEGI- and AAVvector-treated mice. Among the putative CD8+ T cells in k6 (characterized by higher Gzmb expression compared with k9) (Fig. 7g),
267 upregulated and 753 downregulated genes were found with
AAV-p-MAEGI treatment compared with AAV-vector (Fig. 7g
and see Supplementary Table 2). Gene ontology analysis revealed
enrichment of several T cell signatures within the upregulated
gene set, including adaptive immunity, T cell activation and the
TCR complex. The strongest enriched gene set was the AIG1 family of GTPases, particularly Gimap genes (GTPases of immunityassociated protein), the associated proteins of which are involved in
T cell activation and survival33. As for the putative CD8+ T cells in
k9, 665 genes were upregulated and 80 genes downregulated with
AAV-p-MAEGI treatment (Fig. 7h). Enriched gene ontologies in
the upregulated gene set included mitochondrion, exosome, proteasome, RNA binding, adaptive immunity, ribonucleoprotein, AIG1/
Gimaps and ribosomal RNA processing. The same analysis was
performed on putative CD4+ T cells, revealing 335 upregulated and
65 downregulated genes with AAV-p-MAEGI treatment (Fig. 7i).
Collectively, the scRNA-seq data reaffirmed that AAV-p-MAEGI
treatment increases T cell infiltration into tumors, and further
revealed transcriptomic changes in TILs after MAEGI treatment.

contains sgRNAs targeting those genes. With a sufficiently diverse
sgRNA library, AAV-g-MAEGI or AAV-p-MAEGI can potentially
remain efficacious even in the face of continual tumor evolution
and immunoediting. It is likely that neutralizing antibodies will be
developed against AAV, dCas9 or other components of MAEGI.
However, we infer that not all the viruses are neutralized, given
our observation that it is important to have consecutive treatments
to maintain efficacy. Local high-dose administration may overcome this issue as long as a fraction of cells is transduced, thereby
becoming hyper-presenters. Other AAV subtypes and other types
of catalytically dead, RNA-guided nucleases can also be used to
reduce neutralization.
In summary, in the present study we demonstrated that direct
activation of endogenous mutant genes through CRISPRa amplifies the ‘nonself ’ signals of tumor cells, inducing potent antitumor
adaptive immunity. The various forms of MAEGI, including AAVg-MAEGI and AAV-p-MAEGI, as well as any future derivatives of
endogenous gene activation-based therapies, offer an orthogonal
modality of cancer immunotherapy that may serve either as single
agents or in concert with other therapeutic modalities. Future clinical translation of MAEGI will require the exclusion of potentially
harmful genes when overexpressed, optimization of composition
and design, toxicity evaluation in animal models, and investigational new drug-enabling studies, before proceeding to a phase I
clinical trial.

Discussion
Tumor cells harbor a multitude of mutated, partially truncated or
amplified genes that are potentially immunogenic17,34,35. However,
these mutant products might not be expressed at levels sufficient to
elicit an effective T cell–mediated response, and cancer cells often
downregulate antigen presentation to escape immune recognition19.
Several approaches have been described to increase the immunogenicity of tumor cells by in situ manipulation of the tumor microenvironment36–43. A key advantage of MAEGI is its versatility, because
CRISPR sgRNA libraries can be easily customized to augment the
expression of any tumor antigens in a multiplexed manner27,44,45, as
well as alleged noncoding transcripts, immunomodulatory molecules, cytokines, chemokines or transcription factors, either individually or in combinations.
With high-throughput exome sequencing, personalized immunotherapy targeting patient-specific mutations is now feasible46.
Synthesis of mutant peptides or transcripts has been used for personal neoantigen vaccine development21–24, but the scalability of
these approaches is limited. We reasoned that recently developed
CRISPRa technologies could radically increase the scale of cancer
antigen targeting. By targeting mutant genes for overexpression,
MAEGI utilizes host cellular machinery to process and present
these abnormal antigens in higher abundance. The data of the present study demonstrate that MAEGI increases target gene expression,
increases antigen presentation, increases T cell effector function,
recruits CD4+ and CD8+ T cells to the tumor microenvironment,
and promotes both local and systemic antitumor T cell responses,
thereby eliciting potent antitumor immunity. Distinct from current neoantigen vaccines, AAV-MAEGI represents an orthogonal
immunotherapy that directly targets the interplay between tumor
cells and the immune microenvironment, inducing longer-term
immune memory.
Of note, AAV is now a US Food and Drug Administration–
approved therapeutic transgene vector (see voretigene neparvovec)47,48. As a potential viral gene therapy in oncology,
administration of AAV-p-MAEGI could be performed to primary
tumors, metastatic sites or residual disease as a surgery adjuvant. Importantly, as AAV-MAEGI activates endogenous genes,
the acquisition of additional mutations by the tumor, which may
have driven relapse by nullifying existing antitumor immunological memory, can still be targeted by MAEGI, as long as the library
NATURE IMMUNOLOGY | www.nature.com/natureimmunology

Online content
Any methods, additional references, Nature Research reporting
summaries, source data, statements of code and data availability and
associated accession codes are available at https://doi.org/10.1038/
s41590-019-0500-4.
Received: 1 July 2019; Accepted: 20 August 2019;
Published: xx xx xxxx

References
1. Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and
acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
2. Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management
of non-small cell lung cancer. Nature 553, 446–454 (2018).
3. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized
immunotherapy for human cancer. Science 348, 62–68 (2015).
4. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma.
N. Engl. J. Med. 372, 2521–2532 (2015).
5. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science
348, 56–61 (2015).
6. Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint
blockade. Science 359, 1350–1355 (2018).
7. June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C.
CAR T cell immunotherapy for human cancer. Science 359,
1361–1365 (2018).
8. Sahin, U. & Tureci, O. Personalized vaccines for cancer immunotherapy.
Science. 359, 1355–1360 (2018).
9. Chen, D. S. & Mellman, I. Oncology meets immunology: the cancerimmunity cycle. Immunity 39, 1–10 (2013).
10. Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancerimmune set point. Nature 541, 321–330 (2017).
11. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age.
Nature 480, 480–489 (2011).
12. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1)
in melanoma. N. Engl. J. Med. 369, 134–144 (2013).
13. Hodi, F. S. et al. Improved survival with ipilimumab in patients with
metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
14. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma.
N. Engl. J. Med. 369, 122–133 (2013).
15. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1
antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
16. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer
immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3,
991–998 (2002).
17. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy.
Science 348, 69–74 (2015).

131

ARTICLES

NATURE IMMUNOLOGY

18. Verdegaal, E. M. et al. Neoantigen landscape dynamics during human
melanoma–T cell interactions. Nature 536, 91–95 (2016).
19. Khong, H. T. & Restifo, N. P. Natural selection of tumor variants in the
generation of ‘tumor escape’ phenotypes. Nat. Immunol. 3, 999–1005 (2002).
20. Spiotto, M. T. et al. Increasing tumor antigen expression overcomes
‘ignorance’ to solid tumors via crosspresentation by bone marrow-derived
stromal cells. Immunity 17, 737–747 (2002).
21. Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients
with melanoma. Nature 547, 217–221 (2017).
22. Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific
therapeutic immunity against cancer. Nature 547, 222–226 (2017).
23. Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed
glioblastoma. Nature 565, 240–245 (2019).
24. Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell
responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019).
25. Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for
sequence-specific control of gene expression. Cell 152, 1173–1183 (2013).
26. Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of
transcription in eukaryotes. Cell 154, 442–451 (2013).
27. Konermann, S. et al. Genome-scale transcriptional activation by an
engineered CRISPR–Cas9 complex. Nature 517, 583–588 (2015).
28. Chavez, A. et al. Highly efficient Cas9-mediated transcriptional programming.
Nat. Methods 12, 326–328 (2015).
29. Tanenbaum, M. E., Gilbert, L. A., Qi, L. S., Weissman, J. S. & Vale, R. D. A
protein-tagging system for signal amplification in gene expression and
fluorescence imaging. Cell 159, 635–646 (2014).
30. Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J. E. Analysis of AAV
serotypes 1–9 mediated gene expression and tropism in mice after systemic
injection. Mol. Ther. 16, 1073–1080 (2008).
31. Mingozzi, F. & High, K. A. Therapeutic in vivo gene transfer for genetic
disease using AAV: progress and challenges. Nat. Rev. Genet. 12,
341–355 (2011).
32. Kirsch, I., Vignali, M. & Robins, H. T-cell receptor profiling in cancer.
Mol. Oncol. 9, 2063–2070 (2015).
33. Ciucci, T. & Bosselut, R. Gimap and T cells: a matter of life or death.
Eur. J. Immunol. 44, 348–351 (2014).
34. Martincorena, I. & Campbell, P. J. Somatic mutation in cancer and normal
cells. Science 349, 1483–1489 (2015).
35. Liu, X. S. & Mardis, E. R. Applications of Immunogenomics to Cancer. Cell
168, 600–612 (2017).
36. van den Boorn, J. G. & Hartmann, G. Turning tumors into vaccines:
co-opting the innate immune system. Immunity 39, 27–37 (2013).
37. Marabelle, A., Tselikas, L., de Baere, T. & Houot, R. Intratumoral
immunotherapy: using the tumor as the remedy. Ann. Oncol. 28,
33–43 (2017).
38. Townsend, S. E. & Allison, J. P. Tumor rejection after direct costimulation of
CD8+ T cells by B7-transfected melanoma cells. Science 259, 368–370 (1993).
39. Chen, L. et al. Costimulation of antitumor immunity by the B7
counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71,
1093–1102 (1992).
40. Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration
and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119 (2017).
41. Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor
resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med.
6, 226ra232 (2014).
42. Suva, M. L. et al. Reconstructing and reprogramming the tumor-propagating
potential of glioblastoma stem-like cells. Cell 157, 580–594 (2014).
43. Roulois, D. et al. DNA-Demethylating agents target colorectal cancer
cells by inducing viral mimicry by endogenous transcripts. Cell 162,
961–973 (2015).
44. Shalem, O. et al. Genome-scale CRISPR–Cas9 knockout screening in human
cells. Science 343, 84–87 (2014).
45. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human
cells using the CRISPR–Cas9 system. Science 343, 80–84 (2014).

46. Robbins, P. F. et al. Mining exomic sequencing data to identify mutated
antigens recognized by adoptively transferred tumor-reactive T cells.
Nat. Med. 19, 747–752 (2013).
47. Russell, S. et al. Efficacy and safety of voretigene neparvovec (AAV2hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a
randomised, controlled, open-label, phase 3 trial. Lancet 390, 849–860 (2017).
48. Bainbridge, J. W. et al. Long-term effect of gene therapy on Leber’s congenital
amaurosis. N. Engl. J. Med. 372, 1887–1897 (2015).

Acknowledgements
We thank all members of the Chen laboratory, as well as various colleagues in the
Department of Genetics, Systems Biology Institute, Immunobiology Program, BBS
Program, Comprehensive Cancer Center, Stem Cell Center and the School of Medicine
at Yale, for their assistance and/or scientific discussion. We thank the Center for
Genome Analysis, Center for Molecular Discovery, Pathology Tissue Services, Histology
Services, High Performance Computing Center, West Campus Analytical Chemistry
Core, and West Campus Imaging Core and Keck Biotechnology Resource Laboratory at
Yale for technical support. We thank P. Cresswell for assistance with ELISpot. S.C. was
supported by Yale SBI/Genetics Startup Fund, National Institutes of Health/National
Cancer Institute (NIH/NCI) (grant nos DP2CA238295, R01CA231112, R33CA225498,
U54CA209992-8697, RF1DA048811, P50CA196530-A10805, P50CA121974-A08306),
Damon Runyon Dale Frey Award (grant no. DFS-13-15), Melanoma Research Alliance
(grant nos 412806, 16-003524), St Baldrick’s Foundation (grant no. 426685), Breast
Cancer Alliance, Cancer Research Institute, American Association for Cancer Research
(grant nos 499395, 17−20-01-CHEN), the Mary Kay Foundation (grant no. 017−81),
the V Foundation (grant no. V2017-022), Ludwig Family Foundation, DoD (grant no.
W81XWH-17-1-0235), Sontag Foundation and Chenevert Family Foundation. C.S.F.
was supported by NIH/NCI Cancer Center Support Grant (no. 3P30CA016359). G.W.
was supported by CRI Irvington and RJ Anderson Postdoctoral Fellowships. R.D.C., J.P.
and M.B.D. were supported by the Yale MSTP training grant from the NIH (grant no.
T32GM007205). P.R. was supported by a Yale PhD training grant from NIH (grant no.
T32GM007499). X.D. was supported by a C Revson Postdoctoral Fellowship.

Author contributions
G.W., R.D.C. and S.C. designed the study. G.W. performed most of the experiments
in the present study. R.D.C. designed the libraries and analyzed most of the highthroughput data. Z.B., L.Z., Y.E., X.D., M.B.D., L.Y., X.Z., L.S. and H.Y. assisted with
the experiments. P.A.R. and J.J.P. assisted with the data analysis. C.S.F. provided clinical
insights. S.C. conceived the study, secured funding and supervised the work. G.W.,
R.D.C. and S.C. prepared the manuscript with input from all authors.

Competing interests
A patent application has been filed by Yale University related to data in the present study.
C.S.F. serves a consulting role for Agios, Bain Capital, Bayer, Celgene, Dicerna, Five
Prime Therapeutics, Gilead Sciences, Eli Lilly, Entrinsic Health, Genentech, KEW, Merck,
Merrimack Pharmaceuticals, Pfizer, Roche, Sanofi, Taiho and Unum Therapeutics, and
also serves as a director for CytomX Therapeutics and owns unexercised stock options
for CytomX and Entrinsic Health.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/
s41590-019-0500-4.
Correspondence and requests for materials should be addressed to S.C.
Peer review information Zoltan Fehervari was the primary editor on this article and
managed its editorial process and peer review in collaboration with the rest of the
editorial team.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
© The Author(s), under exclusive licence to Springer Nature America, Inc. 2019

132

NATURE IMMUNOLOGY | www.nature.com/natureimmunology

ARTICLES

NATURE IMMUNOLOGY
Methods
Institutional approval. This study has received institutional regulatory approval.
All recombinant DNA and biosafety work was performed under the guidelines
of Yale Environment, Health and Safety Committee with an approved protocol
(Chen-rDNA-15-45). All animal work was performed under the guidelines of Yale
University’s Institutional Animal Care and Use Committee with approved protocols
(Chen-2015-20068, Chen-2018-20068), and was consistent with the Guide for Care
and Use of Laboratory Animals, National Research Council, 1996 (Institutional
Animal Welfare Assurance no. A-3125-01).
Cell lines. E0771 was from CH3. Pan02 and B16F10 were from ATCC. HEK293FT was from Thermo Fisher Scientific. Various derivative lines were
made in the present study as described below. All cell lines tested negative for
Mycoplasma spp.
Lentivirus production. Mouse CRISPRa plasmid libraries (lenti-U6-mSAM-EFSPuro) were expanded by electroporation27. An estimated library coverage of more
than ×100 (>100 colonies per sgRNA) was achieved in electroporation, and the
coverage of sgRNAs was subsequently sequence verified by Illumina sequencing.
For lentivirus production, 20 μg of plasmids of lenti-EF1a-NLS-dCas9-VP64-P2ABlast, lenti-EF1a-MS2-p65-HSF1-P2A-Hygro, lenti-U6-sgRNA(ms2)-EFS-Puro
vector or library, together with 10 μg of pMD2.G and 15 μg of psPAX2, were cotransfected into HEK-293FT cells in a 150-mm dish at 80–90% confluency using
130 μg of polyethyleneimine (PEI) as the transfection reagent. Then 6–12 h later,
the medium was replaced by fresh Dulbecco’s minimal essential medium + 10%
fetal bovine serum (FBS). Virus supernatant was collected 48 h and 72 h posttransfection, centrifuged at 1500g for 10 min, passed through a 0.45-μm filter to
remove the cell debris, aliquoted and stored at −80 °C. Library virus was titrated by
infecting E0771 cells, followed by the selection under 5 μg ml–1 of puromycin.
Antigen presentation assay using an OVA-expressing cell line. A lentiviral
mChOva-expressing vector (Lenti-pGK-mCherry-2A-Ova-WPRE; Addgene, no.
129600) was generated via Gibson Assembly. E0771 cells were then transduced
using mChOva-expressing lentiviruses. Then 2–3 d post-transduction, mChOvaexpressing cells (E0771-mChOva) were FACS sorted on a BD FACSAria. OVA
expression was further confirmed by staining these cells with antibody specific
to the complex of SIINFEKL peptide bound to MHC-I (APC anti-mouse H-2Kb
bound to SIINFEKL antibody). Then, E0771-mChOva cells were transduced
with lentiviral lenti-EF1a-NLS-dCas9-VP64-2A-Blast and lenti-EF1a-MS2–p65–
HSF1-2A-Hygro, followed by 7 d of selection under the pressure of 10 μg ml–1 of
blasticidin and 500 μg ml–1 of hygromycin to generate cells stably expressing dCas9VP64 and MS2-P65-HSF1 (E0771-mChOva-dCa9-MPH).
To activate the expression and thus the presentation of mChOva, PGKpromoter-targeting sgRNAs were designed and cloned into Lenti:U6-sgRNA(ms2)EFS-Puro and AAV:U6p-sgSapI-EF1a-MS2-p65-HSF1-WPRE; Addgene, no.
129599) vector. After lentivirus or AAV production, E0771-mChOva-dCa9MPH cells were infected with these lentiviruses or AAVs to activate mChOva
transcription. Then 3–7 d after viral transduction, the cell surface of SIINFEKLH-2Kb was stained with PE anti-mouse H-2Kb bound to SIINFEKL antibody
(AAV experiments) or APC anti-mouse H-2Kb bound to SIINFEKL antibody
(lentiviral experiments). The genomic mean intensity of APC-SIINFEKL-H-2Kb/
PE-SIINFEKL-H-2Kb was used to determine cell surface presentation
of SIINFEKL.
Co-culture of MAEGI-treated cells and effector T cells. SIINFEKL-H-2Kbspecific naive CD8 T cells were isolated from OT-I mice using a naive mouse
CD8 T cell kit (Miltenyi). Before use, the plate was coated with anti-CD3
(5 μg ml–1 in PBS) at 37 °C for 1 h and then washed twice with PBS. After this,
naive T cells were cultured in the anti-CD3-coated plate using cRPMI (RPMI1640 + 10% FBS + 2 mM l-glutamine + 49 nM 2-mercaptoethanol + 100 U
penicillin–streptomycin) supplemented with 1 μg ml–1 of anti-CD28, 2 ng ml–1 of
recombinant mouse interleukin (IL)-2 and 2 ng ml–1 of recombinant mouse IL-12;
3 d later, the effector T cells were cultured in cRPMI supplemented with 2 ng ml–1
of recombinant mouse IL-2 and 5 ng ml–1 of recombinant mouse IL-7 for another
2 d. E0771-mChOva-dCa9-MPH cells transduced with vector or PGK-targeted
sgRNAs were seeded in 24-well plates at a concentration of 2 × 105 cells per well;
2–4 h later, OT-1 T cells were counted, resuspended in cRPMI supplemented with
IL-2, and added to tumor cell-seeded plates at ratios of effector:tumor (E:T) = 0.5
or 1. For killing and apoptosis analysis, the effector T cells and E0771 cells were
co-cultured for 24 h. All the samples were collected and stained with anti-CD8a
Apc/Cy7 to exclude the T cells. The dead and apoptotic cancer cells were analyzed
using PE Annexin V Apoptosis Detection Kit with 7-AAD. For interferon
detection, 5 μg ml–1 Brefeldin A was added and co-cultured for 3 h. Then, samples
were collected and stained with anti-CD45 PerCP/Cy5.5 and anti-CD8a Apc/Cy7
for 30 min. After washing twice, the cells were fixed with BD Cytofix buffer for
10 min on ice and washed with Cytoperm/Wash Buffer. Cells were then subjected
to intracellular staining with anti-IFN-γ APC for 30 min on ice. After washing once
with Cytoperm/Wash Buffer, the samples were resuspended in MACS Buffer and
analyzed via flow cytometry.
NATURE IMMUNOLOGY | www.nature.com/natureimmunology

Generation of mSAM library- and vector- transduced cells. E0771 cells stably
expressing dCas9-VP64 and MS2-P65-HSF1 (E0771-dCas9-VP64-MPH) were
generated by transducing lentiviral lenti-EF1a-NLS-dCas9-VP64-2A-Blast
and lenti-EF1a-MS2–p65–HSF1-2A-Hygro into E0771 cells, followed by 7 d
of selection under the pressure of 10 μg ml–1 of blasticidin and 500 μg ml–1 of
hygromycin. E0771-dCas9-VP64-MPH cells were then infected with lentiviral
mSAM library or vector to obtain mSAM-transduced E0771 (E0771-SAM) or
vector-transduced E0771 (E0771-vector). Some 1 × 108 cells were initially infected
by the lentiviral mSAM sgRNA library at a calculated multiplicity of infection
of 0.2, with a minimal representation of ×200 transduced cells per sgRNA, as
described previously27. Lentivirus-infected cells were cultured at 37 °C for more
than 1 d before replacing with 5 μg ml–1 of puromycin-containing medium, and the
transduced cells were drug selected for 7 d before use.
Sequencing confirmation of SAM sgRNA library representation. Librarytransduced cells were subjected to genomic DNA (gDNA) extraction using
standard molecular biology protocols. The sgRNA library readout was performed
using a two-step PCR strategy, in which the first PCR included enough gDNA to
preserve full library complexity and the second PCR added appropriate sequencing
adapters to the products from the first PCR.
PCR1 primers. Forward:
AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG
Reverse:
CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTCTTTCCC
PCR was performed using Phusion Flash High Fidelity Master Mix (PF)
(Thermo Fisher Scientific). For reactions using PF, in PCR1, the thermocycling
parameters were: 98 °C for 1 min, 16–20 cycles (of 98 °C for 1 s, 62 °C for 5 s, 72 °C
for 30 s) and 72 °C for 2 min. In each PCR1 reaction, 3 μg of total gDNA was used.
A total of 8–12 PCR1 reactions was used to capture the full representation of the
library in the cells. PCR1 products for each biological sample were pooled and used
for amplification with barcoded second PCR primers.
Barcoding second PCR1 primers used. SF5: AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTCGATCGTTACCATCTTGTGGAAAGGACGAAACACCG
SF6: AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTATCGATTCCTTGGTTCTTGTGGAAAGGACGAAACACCG
SR1: CAAGCAGAAGACGGCATACGAGATAAGTAGAGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTTCTACTATTCTTTCCCCTGCACTGT
SR2: CAAGCAGAAGACGGCATACGAGATACACGATCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTATTCTACTATTCTTTCCCCTGCACTGT
SR3: CAAGCAGAAGACGGCATACGAGATCGCGCGGTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGATTCTACTATTCTTTCCCCTGCACTGT
SR4: CAAGCAGAAGACGGCATACGAGATCATGATCGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCGATTCTACTATTCTTTCCCCTGCACTGT
SR5: CAAGCAGAAGACGGCATACGAGATCGTTACCAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCGATCTCTACTATTCTTTCCCCTGCACTGT
SR6: CAAGCAGAAGACGGCATACGAGATTCCTTGGTGTGACTGGAGTT
CAGACGTGTGCTCTTCCGATCTTTCTACTATTCTTTCCCCTGCACTGT
For reactions using Phusion Flash, in PCR2, the thermocycling parameters
were: 98 °C for 1 min, 18–24 cycles (of 98 °C for 1 s, 60 °C for 5 s, 72 °C for 30 s)
and 72 °C for 2 min. PCR2 products were pooled and then normalized for each
biological sample before combining uniquely barcoded, separate biological samples.
The pooled product was then gel purified from a 2% E-gel EX (Life Technologies)
using the QIAquick Gel Extraction Kit (Qiagen). The purified pooled library was
then quantified using a gel-based method with the Low-Range Quantitative Ladder
Life Technologies, dsDNA High-Sensitivity Qubit (Life Technologies), BioAnalyzer
(Agilent) and/or quantitative (q)PCR. Diluted libraries with 5–20% PhiX were
sequenced with MiSeq, HiSeq 2500 or HiSeq 4000 systems (Illumina).
Raw, single-end, fastq-read files were filtered and demultiplexed using
Cutadapt49. To remove sgRNA scaffold sequences downstream (that is 3′-end)
of the sgRNA spacer sequences, the following command was used: cutadapt
--discard-untrimmed -a GTTTTAGAGCTAGGCCAAC. As the forward PCR
primers used to read out sgRNA representation were designed to have a variety
of barcodes to facilitate multiplexed sequencing, these filtered reads were then
demultiplexed with the following settings: cutadapt -g file:fbc.fasta --no-trim,
where fbc.fasta contained the possible barcode sequences within the forward
primers. Finally, to remove non-sgRNA sequences upstream (that is 5′-end) of the
sgRNA spacers, the following command was used: cutadapt --discard-untrimmed
-g GTGGAAAGGACGAAACACCG. Through this procedure, the raw fastq read
files were trimmed to the 20-basepair (bp) sgRNA spacer sequences. The 20-bp
sgRNA spacer sequences from each demulitplexed sample were mapped for the
sgRNA spacers to the mSAM library using Bowtie v.1.1.2 (ref. 50): bowtie -v 2
--suppress 4,5,6,7 --chunkmbs 2000 -best. Using the resultant mapping output, the
number of reads that had mapped to each sgRNA within the library was quantified.
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Mice. Mice of both sexes, between the ages of 5 and 12 weeks, were used for the study.
Various animals were used in this study; 5- to 10-week-old C57BL/6J mice were
used for experiments unless otherwise specified. Female mice were used for breast
cancer (E0771) models. Male mice were used for pancreatic adenocarcinoma (Pan02)
models. A mix of both male and female mice was used for melanoma (B16F10)
models. All animals were housed in standard, individually ventilated, pathogen-free
conditions, with a 12 h:12 h or a 13 h:11 h light cycle, at room temperature (21–23 °C)
and 40–60% relative humidity. Sample size determination (that is, number of mice
per treatment group) was based on similar tumor models in the field. When a cohort
of animals was to receive different treatments, animals were randomized by: (1)
randomly assigning littermates to different groups before treatment, maximizing
the evenness or representation of mice from different cages in each group; (2) group
animals before treatment so that each group has even distribution of initial tumor
sizes; and/or (3) random assignment of mice to minimize the effect of litter, and small
differences in age, cage or housing position, where applicable.

Therapeutic testing of AAV-g-MAEGI in syngeneic tumor models. Syngeneic
orthotopic breast tumors were established by transplanting 2 × 106 E0771-dCas9VP64 cells into the mammary fat pad of 5- to 8-week-old female C57BL/6J mice.
Then, 4, 10, 14 and 21 d after transplantation, 5–10 × 1010 GCs of AAV-g-MAEGI,
AAV-vector or PBS were injected intratumorally into tumor-bearing mice. For
the B16F10 melanoma model, 5 × 105 dCas9-VP64-expressing cancer cells were
injected subcutaneously into the flank of C57BL/6J mice; 7, 10, 14 and 20 d after
transplantation, 5 × 1010–10 × 1010 GCs of AAV-g-MAEGI, AAV-vector or PBS
were intratumorally administered to tumor-bearing mice. For the pancreatic tumor
model, 2 × 106 Pan02-dCas9-VP64 cancer cells were injected subcutaneously
into the flank of C57BL/6J mice. Then, 5, 13, 21 and 35 d after transplantation,
5–10 × 1010 GCs of AAV-g-MAEGI, AAV-vector or PBS were intratumorally
administered to tumor-bearing mice. Tumors were measured every 3–4 d using
calipers and the sizes were calculated with the formula: volume = π/6xyz. Two-way
ANOVA was used to compare growth curves between treatment groups.

Tumorigenesis of E0771-SAM in C57BL/6J, Nude (Foxn1nu) or Rag1–/– mice.
E0771-SAM or E0771-vector tumor cells, 5 × 106, were injected into the orthotopic
mammary fat pad of syngeneic 5- to 8-week-old female C57BL/6J, Nude (Foxn1nu)
or Rag1–/– mice. Tumor sizes were measured every 3–4 d using calipers of the
three diameters, and sizes were calculated using the formula: volume = π/6xyz
(where x is tumor length, y is tumor width, and z is tumor depth). The statistical
significance of all tumor growth curves in the present study was assessed using
two-way analysis of variance (ANOVA), jointly considering the effect of treatment
and the passage of time on tumor growth. For CD4 and CD8 T cell depletion,
200 μg of anti-CD4 (GK1.5, BioXcell) and 200 μg of anti-CD8 (YTS 169.4) were
intraperitoneally injected into tumor-bearing C57BL/6J mice at dpi 7 and dpi 14.
The successful depletion of CD8 T cells was confirmed by isolating peripheral
blood mononuclear cells from mice at dpi 14 and 21, and analyzing the CD8+ T cell
population using flow cytometry.

Isolation of splenocytes and TILs. Syngeneic breast tumors were established by
orthotopically transplanting 2 × 106 E0771-dCas9-VP64 cells into the mammary fat
pad of 5- to 8-week-old female C57BL/6J mice. Tumor-bearing mice were randomly
assembled into different treatment groups and treated with various reagents where
applicable, as described in the captions. Mice were euthanized at 9, 19, 29 or 36 d
post-transplantation as indicated, and tumors and spleens were collected and kept
in ice-cold 2% FBS. For spleens, they were placed in ice-cold 2% FBS and mashed
through a 100-μm filter. Splenocytes were washed once with 2% FBS. Tumors
were minced into 1- to 3-mm size pieces using a scalper and then digested using
100 U ml–1 Collagenase IV for 30–60 min while stirring at 37 °C. Tumor suspensions
were filtered twice through a 100-μm cell strainer, and once through a 40-μm
cell strainer to remove large bulk masses. Red blood cells were lysed with 1 ml
ACK Lysis Buffer (Lonza) per spleen by incubating 2–5 min at room temperature,
which was followed by dilution with 10 ml 2% FBS and a pass through a 40-μm
filter. Splenocytes were resuspended in 2% FBS buffer, counted for flow cytometry
staining or RNA isolation. Single-cell suspensions of tumors were used for flow
cytometry staining, further FACS sorting or Ficoll purification to obtain TILs. For
Ficoll–Paque purification, single-cell suspensions at a density of ~107 cells ml–1 were
carefully layered on to Ficoll–Paque medium (GE Healthcare) and centrifuged at
400g for 30 min. Cells at the interface were carefully collected, and washed twice
with 2% FBS, counted and used for RNA isolation or flow cytometry staining.

ELISpot assay. IFN-γ ELISpot mouse kits (BD Biosciences) were used according
to the manufacturer’s instructions. Briefly, 96-well filtration plates were coated
overnight at 4 °C with IFN-γ-capturing monoclonal antibody; the plates were then
washed and blocked with RPMI-1640 medium containing 10% FBS for 2 h at room
temperature. Splenocytes and TIICs isolated from different treatment groups were
counted and resuspended in 10% FBS-supplemented RPMI-1640. Splenocytes and
TIICs were seeded into the 96-well filtration plate at concentrations of 1 × 106 cells
per well and 2.5 × 104 cells per well, respectively. After mitomycin treatment,
5 × 104 C57BL/6J fat pad-derived primary cells or E0771 tumor cells were added as
different stimulators to stimulate the IFN-γ secretion. The plates were cultured for
approximately 45 h at 37 °C and 5% CO2. The co-culture were stopped by soaking in
deionized water, and washing three times with PBS with Tween 20; the plates were
incubated with biotinylated detection antibody at room temperature for 2 h. Then,
plates were incubated with horseradish peroxidase (HRP)-conjugated streptavidin
at room temperature for 1 h after washing three times with PBS with Tween 20.
Spots were revealed using an AEC substrate reagent kit (BD Bioscience) at room
temperature, and counted using an Immunospot Reader (Cellular Technology). The
statistical significance was assessed using a two-tailed, unpaired, Welch’s t-test.
Generation of AAV-MAEGI. An AAV version of the CRISPRa vector (AAVCRISPRa vector, that is U6p-sgSapI-EF1a-MS2-p65-HSF1-sPA; Addgene, no.
129602), was generated by restriction cloning and Gibson assembly. The sgRNA
libraries of mSAM were cloned into the above CRISPRa plasmid by linearization
with SapI digestion and Gibson assembly. The purification and electroporation of
Gibson products into Endura electrocompetent cells were performed as previously
described51, with at least ×100 coverage of colonies represented per sgRNA. AAV
was produced by co-transfecting HEK-293FT cells with the above AAV plasmids
of CRISPRa vector or library (AAV-mSAM), AAV2, AAV9 or AAV-DJ serotype
plasmid and helper plasmid PDF6, to generate AAV-g-MAEGI. Briefly, 5.2 μg of
AAV-Vector, AAV-mSAM or other AAV-sglib plasmid, 8.7 μg of plasmid AAV9 or
AAV-DJ serotype, and 10.4 μg of pDF6 were mixed with PEI, at room temperature
for 10–15 min before adding them drop-wise into HEK-293FT cells in a 150mm dish at 80–90% confluency. Replicates collected from multiple dishes were
pooled to enhance production yield. Cells were collected 72 h post-transfection.
For AAV purification, chloroform (1:10 by volume) was added and the mixture
was vigorously shaken for 1 h at 37 °C. NaCl was added to a final concentration
of 1 M, and the mixture was shaken until dissolved and then pelleted at 20,000g
and 4 °C for 15 min. The aqueous layer was discarded while the chloroform layer
was transferred to another tube. PEG 8000 was added to 10% (w/v) and shaken
until dissolved. The mixture was incubated at 4 °C for 1 h and then spun at 20,000g
and 4 °C for 15 min. The supernatant was discarded and the pellet resuspended in
Dulbecco’s phosphate-buffered saline + MgCl2, treated with Benzonase (Sigma) and
incubated at 37 °C for 30 min. Chloroform (1:1 by volume) was then added, shaken
and spun down at 12,000g and 4 °C for 15 min. The aqueous layer was isolated
and passed through a 100kDa MWCO (Millipore). The concentrated solution was
washed with PBS and the filtration process repeated. Genomic copy number (GC)
of AAV was determined by real-time qPCR using custom Taqman assays (Thermo
Fisher Scientific) targeted to the engineered U6 promoter.

Flow cytometry. All antibodies for flow cytometry were purchased from Biolegend
or eBiosciences. Single-cell suspensions from tumors or spleens were prepared
using a gentleMACS tissue dissociation system. The panels of antibodies used
in the flow cytometry staining are as follows: panel 1: anti-CD45.2-APC/Cy7,
anti-CD3-PE, anti-CD4-FITC, anti-CD8a-APC; panel 2: anti-CD45-PerCP/
Cy5.5, anti-CD3-FITC, anti-CD4-PE/Cy7, or anti-CD8-APC/Cy7; or panel 3:
anti-CD45-APC/Cy7, anti-I-A/I-K-PerCP/Cy5.5, anti-CD11b-FITC, anti-CD11cPE/Dazzle594; anti-Ly6c-APC; or anti-F4/80-PE, anti-CD24-PE/Cy7. All flow
antibodies were used at 1:100 dilutions for staining unless otherwise noted. For
surface staining, cells were blocked with anti-Fc receptor anti-CD16/CD32, and
then stained with surface marker antibodies in a staining buffer of 2% FBS in PBS
on ice for 30 min. Samples were washed twice with 2% FBS in PBS before analysis.
For intracellular staining, eBioscience Intracellular Fixation & Permeabilization
Buffer Set was used to fix and permeabilize cells following the manufacturer’s
instructions. Briefly, after the staining of surface makers, cells were resuspended in
100 μl Fixation/Permeabilization working solution, and incubated on ice for 10 min
before washing with 1× Permeabilization buffer by centrifugation at 600g for 5 min.
Then the cell pellet was resuspended in 50 μl of 1× permeabilization buffer with
anti-Fc receptor anti-CD16/CD32, and incubated on ice for 10 min, before adding
50 μl of 2× intracellular staining antibodies and incubating on ice for 30 min. After
staining, cells were centrifuged at 600g for 5 min, and washed twice with staining
buffer before being analyzed or sorted on a BD FACSAria. The data were analyzed
using FlowJo software (v.9.9.4 or v.10.3). A previously reported strategy was used to
define the populations of monocytes, neutrophils, dendritic cells and macrophages
in tumors52. Antibodies used for flow cytometry are listed in Supplementary Table
1. Statistical significance was assessed using the two-tailed, Mann–Whitney test.
FACS isolation of CD45+ cells from tumors. Single tumor cell suspensions
were prepared using the gentleMACS system with the method described above.
Tumor cells were blocked using anti-Fc receptor anti-CD16/CD32. Live cells were
distinguished from dead cells in flow cytometry by staining with a LIVE/DEAD
Fixable Near-IR Dead Cell Stain Kit, following the manufacturer’s instructions.
Cells at a density of 107 ml–1 were stained with dimethylsulfoxide-dissolved live/
dead staining dye and PerCP/Cy5.5 or APC-conjugated CD45 antibody in
PBS + 2% FBS, and incubated on ice for 30 min. Stained cells were washed three
times before being analyzed and FACS isolated on a BD FACSAria. TIICs were
isolated by gating on PerCP/Cy7+APC/Cy7– or APC+APC/Cy7– populations.
Sorted TIICs were counted, and used for scRNA-seq and ELISpot analysis.
Immune cell profiling by scRNA-seq. FACS sorted cells were collected in
PBS + 2% FBS and concentrated by centrifugation at 400g for 5 min. Cell numbers
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and viabilities were assessed by trypan blue staining and analysis in Countess
II FL Automated Cell Counter (Thermo Fischer Scientific). The 10,000 CD45+
TIICs isolated from tumors were used for scRNA-seq library prep by following the
protocol from 10x Genomics.
ScRNA-seq data processing. Pan-immune cell, scRNA-seq data were preprocessed using both established pipelines and custom scripts. Briefly, raw
Illumina data files were processed by Cell Ranger 1.3 (10x Genomics)53, using
cellranger mkfastq to wrap Illumina’s bcl2fastq to correctly demultiplex sequencing
samples, and to convert barcode and read data to FASTQ files. Then, cellranger
count was used to take FASTQ files and perform alignment to the mouse genome
(mm10)54, filtering and UMI counting. Cells with fewer than 2,000 UMI counts
were subsequently filtered from analysis, leaving a final set of 7,863 cells for further
analysis. Next, imputation was performed using ALRA55, which is a conservative
strategy for distinguishing technical ‘dropout’ zeros from true biological zeros.
After log normalization, the 27,998 genes/features were additionally filtered using
a flat cutoff metric such that genes with variance < 0.1 were excluded, leaving
7,632 genes. Using the final normalized and processed dataset above, t-distributed
stochastic neighbor embedding (t-SNE) dimension reduction was performed56,57.
Individual data-points were colored, based on either the treatment condition for
each cell or unbiased k-means clustering performed on the normalized dataset.
Differential expression analyses between clusters and/or treatment conditions
were performed using a nonparametric, two-tailed, Mann–Whitney test, filtering
for genes with variance > 0.1 across the cell population of interest. A multiple
hypothesis correction was performed using the Benjamini–Hochberg method.
Differentially expressed genes were defined as having a Benjamini–Hochbergadjusted P < 0.001. A cutoff of 0 was used to determine whether cells expressed
a particular gene of interest. The statistical significance of differences in cell type
proportions between AAV-p-MAEGI and AAV-vector conditions was assessed
using a two-tailed, Fisher’s exact test. Gene ontology analysis was performed
using DAVID58.
RNA extraction, reverse transcription and qPCR. RNA in cells, splenocytes
and TILs was extracted using TRIzol Reagent (Invitrogen) by following standard
RNA extraction protocols. The first-strand complementary DNA of RNA was
synthesized using SuperScript IV Reverse Transcriptase (Invitrogen). After
normalizing the concentrations of cDNA with nuclease-free water, qPCR was
performed by adding designated Taqman probe of interested genes,
and glyceraldehyde 3-phosphate dehydrogenase was used as an internal
positive control.
Western blot. E0771, E0771-dCas9-VP64 and E0771-dCas9-VP64-MPH cells
in six-well plates were washed twice with ice-cold PBS before lysis with 1×
radioimmunoprecipitation assay buffer, which was kept on ice for 15 min. Cell
lysates were centrifuged at 12,000g for 15 min at 4 °C and protein-containing
supernatant was collected. Protein concentration was measured using a standard
Bradford assay (Bio-Rad) and 20 μg of protein in each sample was loaded on to a
sodium dodecylsulfate/polyacrylamide electrophoresis gel. After electrophoresis,
proteins separated in the gel were transferred on to nitrocellulose membranes. The
membranes were blocked at room temperature for 1 h using 5% skimmed milk in
Tris-buffered saline + Tween 20, followed by incubation with primary antibody
in 4 °C overnight. After washing three times with Tris-buffered saline + Tween
20, horseradish peroxidase-conjugated secondary antibody was added and
incubated at room temperature for 30–60 min. The chemiluminescent substrate
(Clarity Western ECL Substrate, Bio-Rad) was added on top of the blot membrane
according to the manufacturer’s instructions. The signals were captured using a
CCD camera-based imager (GE Healthcare).
AAV infectivity assay. AAVs carrying a GFP reporter (AAV-GFP) were used
to assess the infection rate of intratumoral AAV delivery. Orthotopic breast
tumors were established by transplanting 2 × 106 E0771-dCas9-VP64 cells into
the mammary fat pad of 5- to 8-week-old female C57BL/6J mice; 3 and 10 d after
transplantation, 1 × 1011 GCs of AAV-GFP were injected intratumorally into tumorbearing mice. Four days after intratumoral AAV injection, tumor cells, TIICs
(CD45+) and cells from nontumor organs were harvested. To analyze the persistent
expression of AAV-delivered transgene, 12 d after initial AAV injection (AAV-GFP
was injected at day 3 and day 10), tumor cells, TIICs (CD45+) were harvested.
Single tumor cell suspensions were prepared. A LIVE/DEAD Fixable Near-IR Dead
Cell Stain Kit was used to distinguish live cells from dead cells. Cells at a density of
107 ml–1 were stained with dimethylsulfoxide-dissolved live/dead staining dye and
PerCP/Cy5.5-conjugated CD45 antibody in PBS + 2% FBS, and incubated on ice
for 30 min. Stained cells were washed three times before being analyzed and FACS
isolated on a BD FACSAria.
Histology and immunohistochemistry. At matched time points, tumors from
different treatment group were collected and fixed in 10% neutral formalin
for 2–5 d. Tissues were transferred into 70% ethanol for long-term storage.
Hematoxylin and eosin staining or antibody staining was performed on 3- to 5-μm
tissue sections using standard procedures at the Yale Pathology Core Facility.
NATURE IMMUNOLOGY | www.nature.com/natureimmunology

TCR-seq. Mice in different treatment groups were euthanized at 30–40 d posttransplantation. Tumors and spleens were collected and kept in ice-cold 2% FBS
before use. Single-cell suspensions from tumors or spleens were prepared as
previously described. The RNA from collected splenocytes and TILs was extracted
using TRIzol and an Ambion RNA extraction kit. TCR library prep was performed
using the SMARTer Mouse TCR antibody Profiling Kit (Takara) according to the
manufacturer’s instructions.
TCR-seq data analysis. Raw fastq files from TCR-seq were processed to clonotypes
using MiXCR following the author’s recommendations59. Specifically, the mixcr
align function was first used to align to the V segment transcript, followed by
clonotype assembly using mixcr assemble and mixcr exportClones. Samples with
fewer than 1,000 UMI counts were removed from further analysis. Subsequently,
TCR-seq data were analyzed using the tcR package60 to determine clonal
proportions and occupied clonal homeostasis in each sample. Various metrics such
as Gini–Simpson and Chao1 indices were calculated.
Exome sequencing of E0771 and characterization of mutational spectrum.
E0771 cells and freshly dissected mammary fat pads from healthy, untreated 6- to
8-week-old female C57BL/6J mice were subjected to gDNA extraction following
standard protocols. A total of 2 μg of gDNA per sample was subjected to exome
capture using mouse exome probes (Roche) and then Illumina library preparation
following the manufacturer’s protocols. Exome-capture, paired-end fastq files
were mapped to the mm10 genome using Bowtie v.2.2.9 (ref. 61) and sorted using
Samtools62. VarScan v.2.3.9 (ref. 63) was then used in somatic mode to call indels
and SNPs that were specific to E0771 cells and not found in wild-type C57BL/6J
mammary fat-pad tissue. Germline calls were subsequently filtered out. The
remaining variants were collapsed to the gene level, and the number of indels or
SNPs for each gene was tabulated.
Generation of exome-guided AAV-p-MAEGI. Genes were ranked by the number
of somatic variants present in E0771 cells but not in healthy mammary fat pads.
Both intronic and exonic variants were included. A set of 1,116 top mutated genes
was chosen as differentially mutated genes in E0771. Up to three sgRNAs per gene
(three for most of the genes) targeting promoter regions were chosen. A CRISPRa
library consisting of 3,839 sgRNAs was designed for the E0771 top mutated gene
set (Addgene, no. 129601), pool synthesized (CustomArray) and cloned into the
AAV-CRISPRa vector described above. The production of library AAV was done as
described above, generating AAV-p-MAEGI for E0771.
Therapeutic testing of AAV-p-MAEGI in mice. Syngeneic TNBC were
established by orthotopic transplantation of 2 × 106 E0771-dCas9-VP64 cells
into the mammary fat pad of 5- to 8-week-old female C57BL/6J mice; 5, 12 and
18 d after tumor induction, 5–10 × 1010 GCs of AAV-p-MAEGI, AAV-vector
or PBS were intratumorally administered to tumor-bearing mice. For testing
of the abscopal effect, syngeneic TNBC cases were established by orthotopic
transplantation of 2 × 106 E0771 cells into an ipsilateral mammary fat pad, and
2.5 × 105 E0771 cells into the contralateral mammary fat pad; 4, 11, 18 and 24 d
after tumor induction, 5–10 × 1010 GCs of AAV-p-MAEGI or AAV-vector were
intratumorally administered to the ipsilateral tumor. Tumors were measured
every 3–4 d using calipers and their size was calculated using the formula:
volume = π/6x y z. Two-way ANOVA was used to compare growth curves between
treatment groups. Response to therapy was defined by a method similar to RECIST
1.1 criteria (CR, complete response, where endpoint tumor size = 0; nCR, nearcomplete response, where tumor size <50 mm3 for the last two measurements;
PR, partial response, where tumor sizes decreased for at least two consecutive
measurements; SD, stable disease, where tumor size is between 70% and ~100% of
initial tumor size at the first treatment; and PD, progressive disease, where tumor
size > initial tumor size at the first treatment).
A dual AAV system for in vitro and in vivo delivery of MAEGI. A dual AAVvector system of the CRISPRa (AAV-dCas9, that is, EFs-dSpCas9-spA (Addgene,
no. 129598) and AAV-CRISPRa vector, that is U6p-sgSapI-EF1a-MS2-p65-HSF1sPA (Addgene, no. 129602)) was generated by restriction cloning and Gibson
assembly. Individual sgRNA or sgRNA libraries were cloned into the AAVCRISPRa plasmid. The dCas9- or U6-sgRNA-EF1a-MS2-p65-HSF1-expressing
AAVs were produced using the method described above in Generation of AAVbased MAEGI. For in vitro and in vivo delivery, AAV-dCas9 and AAV-CRISPRa
were simultaneously added into cultured cells or co-injected into tumors at
a ratio of 1:1.
Therapeutic effects of dual AAV system-delivered p-MAEGI in mice. Syngeneic
TNBC cases were established by orthotopic transplantation of 2 × 106 E0771 cells
into the mammary fat pad of 5- to 8-week-old female C57BL/6J mice. Then, 4,
9 (11) and 18 d after tumor induction, 1–5 × 1010 GCs of AAV-dCas9, together
with same titers of AAV-p-MAEGI or AAV-vector, or PBS, were intratumorally
administered to tumor-bearing mice. Tumors were measured every 3–4 d using
calipers and their size was calculated using the formula: volume = π/6xyz. Two-way
ANOVA was used to compare growth curves between treatment groups.
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Statistical analysis. Data analysis was performed using GraphPad Prism v.7 and R
3.5. The unpaired, two-sided, Mann–Whitney test was used to compare two groups
unless indicated otherwise. Two-way ANOVA was used to compare multiple
groups in the tumor growth curves with two independent variables. P < 0.05 was
considered statistically significant.
Reporting Summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.

Data availability
Source data and statistics for non-next-generation sequencing experiments such as
tumor studies, flow cytometry, ELISpot and qPCR are provided in an Excel table
(see Supplementary Table 1). Processed genomic sequencing data are also provided
in an Excel table (see Supplementary Table 2). Original exome sequencing data are
available via the National Center for Biotechnology Information Sequence Read
Archive (PRJNA553203). Single-cell transcriptome sequencing data are available
via the Gene Expression Omnibus (GSE133983). Other data, reagents, methods,
computational codes and materials that support the findings of this research are
available from the corresponding author upon reasonable request.

Code availability
Custom codes used to support the findings of this research are available from the
corresponding author upon reasonable request.
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§ CHAPTER 4: DISSECTING GENETIC INTERACTIONS THROUGH
MULTIPLEXED CRISPR-CAS12A PERTURBATIONS

4.1: In vivo profiling of metastatic double knockouts through CRISPR–Cpf1 screens
Though certain mutations are recurrently identified across patients with a given cancer
type, different tumors will present with unique combinations of mutations that collectively
dictate the behavior of the cancer. When the effects of one mutation are modified by other
mutations, this phenomenon is termed a genetic interaction

39

. Hypothesizing that interactions

between tumor suppressors might synergistically drive metastasis, I set out to design a
methodology to efficiently investigate genetic interactions in vivo. I harnessed the multiplexing
capabilities of CRISPR-Cas12a to profile a library of cells carrying mutations in different pairs
of tumor suppressor genes, and assessed their metastatic capacity through a pooled screen 111.
This line of investigation was conceived together with my advisor Dr. Sidi Chen. My
primary role in this study was to design and execute the screening approach, carry out in vivo
mouse experiments and molecular biology studies, and analyze the resulting screen data. I also
prepared the manuscript text and figures together with Dr. Sidi Chen.
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In vivo profiling of metastatic double knockouts
through CRISPR–Cpf1 screens
Ryan D. Chow 1,2,3,4,9, Guangchuan Wang 1,2,3,9, Lupeng Ye1,2,3,9, Adan Codina1,2,3,5, Hyunu Ray Kim1,2,3,
Li Shen1,2,3, Matthew B. Dong1,2,3,4,6, Youssef Errami1,2,3 and Sidi Chen 1,2,3,4,5,6,7,8*
Systematic investigation of the genetic interactions that
influence metastatic potential has been challenging. Here we
developed massively parallel CRISPR–Cpf1/Cas12a crRNA
array profiling (MCAP), an approach for combinatorial interrogation of double knockouts in vivo. We designed an MCAP
library of 11,934arrays targeting 325pairwise combinations
of genes implicated in metastasis. By assessing the metastatic potential of the double knockouts in mice, we unveiled
a quantitative landscape of genetic interactions that drive
metastasis.
Metastasis, the major lethal factor of solid tumors, is a complex,
multi-step process1. A systems-level understanding of the genetic
interactions that influence metastatic potential is lacking, as libraryscale in vivo interrogation of double knockouts (DKOs) in mammalian species has proved challenging. The type V CRISPR system
Cpf1 (also known as Cas12a) has empowered simultaneous genome
editing at multiple loci2–4. Because Cpf1 does not require a transactivating CRISPR RNA (tracrRNA), multiplexed genome editing
can be achieved with a single crRNA array3,4. This characteristic
inspired us to develop Cpf1 as a system for interrogating genetic
interactions in vivo, with substantial advantages in library design,
readout and analysis compared to Cas9-based approaches.
We first established a CRISPR–Cpf1 lentiviral system for characterization of double knockouts in a cancer cell line (KPD)5,6
(Supplementary Fig. 1). To evaluate the cellular diversity that can
be accommodated in vivo, we cloned in a library of random 8-mers
and transplanted 4 × 106 8-mer-barcoded cells into nu/nu (n = 2) or
Rag1−/− mice (n = 4). Of the 65,536 possible 8-mers, we recovered an
average of 65,534.5 (99.99%) in nu/nu mice and 64,500.75 ± 940.58
(mean ± s.e.m.) (98.42%) in Rag1−/− mice 12 d post-transplant
(Supplementary Fig. 2).
We then sought to develop MCAP, an approach for highthroughput screening of DKOs. We focused on genes significantly mutated in a human metastasis cohort (MET500)7 and the
top hits from a single-knockout (SKO) metastasis screen in mice5
(Fig. 1a and Supplementary Table 1). We selected four CRISPR
RNAs (crRNAs) for each of the 26 metastasis driver candidates.
Compiling these 104 gene-targeting crRNAs and 52 non-targeting
control (NTC) crRNAs, we designed a metastasis-focused MCAP
library (MCAP-MET) composed of 1,326 NTC-NTC arrays,
5,408 SKO arrays and 5,200 DKO arrays, for a total of 11,934 dualcrRNA arrays (Supplementary Table 2). In the MCAP-MET library,

each gene pair is represented by 16 DKO constructs and each gene
is represented by 208 SKO constructs. Additionally, we appended
a random 10-mer barcode for clonal analyses. Deep sequencing
confirmed complete coverage of the library, and analysis of the
10-mer barcodes revealed the diversity of barcoded crRNA arrays
(BC arrays) (n = 774,295) (Supplementary Fig. 3a–d).
We generated lentiviral pools from the MCAP-MET plasmid library and infected Cpf1+ KPD cells (Fig. 1b). Seven and
fourteen days after transduction, we sequenced the crRNAs in
the cell pool, and found strong concordance with the plasmid
library (Supplementary Fig. 3e). In each cell pool we recovered
172,427 ± 2,591 (mean ± s.e.m.) unique BC arrays. To map the metastatic potential of the MCAP-MET library, we injected the cell pool
subcutaneously into nu/nu mice (4 × 106 cells per mouse, ×~350
coverage) (n = 10). At this coverage, each BC array is represented by
an average of ~23 cells following injection. After 6 weeks we collected
the primary tumors (n = 10) and lung lobes (n = 37), and performed
crRNA array sequencing. Using the BC array data, we assessed the
dynamics of selection in our metastasis model. We chose a 0.001%
cutoff by considering the distribution of BC array frequencies in
cell samples and quantified the number of ‘clones’ (approximated by
BC arrays) per sample, finding clear evidence of progressive selection as the cell pools formed primary tumors and lung metastases
(Supplementary Fig. 4). These results were consistent at a frequency
cutoff of ≥0.01% (Supplementary Fig. 5). Collectively, the clonelevel analyses illustrate the progressive selection pressures on cells
as they form primary tumors and metastasize to the lung.
We next considered the data in terms of the 11,934 dual-crRNA
arrays (Supplementary Fig. 6 and Supplementary Table 3). Using the
1,326 NTC-NTC arrays as an empirical null distribution, we identified crRNA arrays enriched at a false discovery rate (FDR) < 0.5%
in each sample (Supplementary Fig. 7a). We tabulated the percentage of arrays for a given genetic perturbation that were enriched
in at least one sample (Supplementary Fig. 7b,c). No single genes
had more than 40% of their SKO arrays enriched in lung metastases. In contrast, 62.5% of all arrays targeting the Nf2_Rb1 pair
were enriched in at least one lung metastasis, with 56.25% of arrays
enriched for Nf2_Pten and Nf2_Trim72 (Supplementary Fig. 7d–f).
We quantitatively determined the metastatic potential of the
various perturbations represented in the MCAP-MET library
(Supplementary Fig. 8a–c). To identify specific perturbations
exhibiting strong selection in vivo, we averaged the crRNA arrays
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Fig. 1 | In vivo profiling of metastatic double knockouts by MCAP. a, Schematic describing library design for MCAP of metastasis driver combinations.
b, Experimental design for combinatorial interrogation of metastasis drivers in vivo. c,d, Scatter plot of MCAP-MET single-knockout (n=26 genes) and
double-knockout (n=325 gene pairs) abundances in cell pools (n=6 cell replicates) versus primary tumors (n=10 mice) (c) or primary tumors versus
lung metastases (n=37 from ten mice) (d). Data shown in terms of average log2 RPM for the indicated sample type, after averaging of the constituent
crRNA arrays for each gene/gene pair. The linear regression over the entire library is shown (95% confidence interval shaded in). Significant outliers
(two-sided outlier test, adjusted P<0.05) are outlined and enlarged, with s.e.m. error bars. Adj., adjusted; av., average.

for each SKO or DKO condition on a sample-by-sample basis, then
aggregated the data by sample type. To pinpoint the perturbations
with the strongest selective advantage out of the entire MCAP-MET
library, we used all targeting genes/pairs for linear regression modeling. The top gene pairs favored in primary tumors relative to cell
pools (outlier test, adjusted P < 0.05) included Nf2_Trim72, Nf2_
Chd1, Nf2_Pten, Nf2_Arid1b, Nf2_Kdm6a and Nf2_Rb1 (Fig. 1c). A
similar set of gene pairs were enriched in lung metastases compared
to cell pools (Supplementary Fig. 8d). Comparing primary tumors
to lung metastases, Nf2_Trim72 and Nf2_Chd1 emerged as the top
metastasis-driving mutation pairs (Fig. 1d).
Our analyses suggested that certain gene pairs may be synergistic
in promoting metastasis. To identify such mutation combinations,
we first identified gene pairs that were significantly more abundant
than their respective single gene counterparts (two-sided Wilcoxon
rank sum test, adjusted P < 0.05). Because the effects of a mutation
combination may simply be additive rather than synergistic, we calculated a synergistic coefficient (SynCo = DKONM – SKON – SKOM)
for each gene pair (Fig. 2a and Supplementary Table 4). Collectively,
we found six DKOs that were significantly more abundant than the
corresponding SKOs and with a SynCo > 0: Nf2_Trim72, Chd1_Nf2,
Chd1_Kmt2d, Jak1_Kmt2c, Kmt2d_Pten and Nf1_Pten (Fig. 2b–d
and Supplementary Fig. 9). These data were summarized as a librarywide map of the selective advantage of each DKO relative to the
corresponding SKOs (Supplementary Fig. 10 and Supplementary
Table 5). Some of these synergistic interactions are recapitulated in
human cohorts (Supplementary Fig. 11 and Supplementary Table 6).
We then sought to validate the metastatic potential of the strongest gene pair identified in the screen, Nf2_Trim72. After cloning
in five different dual-crRNA arrays with combinations of Rosa26targeting crRNAs or the top-performing Nf2 and Trim72 crRNAs
from the screen (Rosa26 + Rosa26, Nf2 + Rosa26, Trim72 + Rosa26,
Nf2 + Trim72 or Trim72 + Nf2), we assessed mutation efficiency 7 d
after lentiviral transduction (n = 5 infection replicates each) and
confirmed that array configuration did not influence mutation efficiency (Fig. 3a and Supplementary Fig. 12a). To exclude the possibility that the Nf2_Trim72 gene pair may have undergone positive
selection in vitro before injection, we characterized the 5-ethynyl-

2’-deoxyuridine (EdU) incorporation of KPD cells expressing
Rosa26 + Rosa26, Nf2 + Rosa26, Trim72 + Rosa26 or Nf2 + Trim72
dual-crRNA arrays, and found no significant differences (n = 3 cell
replicates each) (Supplementary Fig. 12b,c).
To interrogate the metastatic potential of the Nf2_Trim72 gene
pair, we first performed in vitro Matrigel invasion assays (n = 3
independent experiments) and found that Nf2 + Trim72 infected
cells were more invasive than Rosa26 + Rosa26, Nf2 + Rosa26 or
Trim72 + Rosa26 infected cells (Supplementary Fig. 12d,e). We then
proceeded to validate the Nf2_Trim72 gene pair in vivo, transplanting 1.8 × 106 cells into nu/nu mice (n = 8 mice for each condition).
Primary tumors in the Nf2 + Trim72 group grew significantly larger
than Nf2 + Rosa26, Trim72 + Rosa26 or Rosa26 + Rosa26 tumors
(Fig. 3b). We followed the development of metastasis by luciferase
live imaging and, 28 d after the initial transplantation, we harvested
the primary tumors and lungs (Supplementary Fig. 13). Mice bearing Nf2 + Trim72 tumors had significantly more metastatic lung
nodules than mice bearing Nf2 + Rosa26, Trim72 + Rosa26 or
Rosa26 + Rosa26 tumors (Fig. 3c). Collectively, these data point to
specific mutation combinations with heightened metastatic potential
in vivo, and highlight the power of MCAP for high-throughput interrogation of genetic interactions in challenging biological systems.
Several high-throughput double perturbations have been performed in mammalian cells using RNA interference or CRISPR–
Cas9 technologies8–16. However, the dependence of Cas9 on a
tracrRNA predicates the need for multiple single-guide RNA
(sgRNA) cassettes for combinatorial knockouts, thus complicating library design, cloning, readout and analysis. In comparison, MCAP offers a streamlined approach for double or even
higher-order knockout/perturbation screens, with the potential
for sequential screens using invertible dual-crRNA arrays17. A
remaining challenge that limits the broader utility of MCAP is the
mutation efficiency of Cpf1, as this necessitates positive selection
screens using redundant library designs with several independent
constructs representing each perturbation. Of note, progress has
been made toward predicting crRNAs that can induce mutations
at higher efficiencies18,19, and Cpf1 itself has been engineered to
increase its activity and targeting range20.
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The MCAP method can be readily applied to different cell types,
biological processes and disease models and thus represents a tool
for mapping genetic interactions in mammalian species in vivo with
unparalleled simplicity and throughput.
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target sites of crPten and crNf1 were first amplified by PCR using the following
primers (5′–3′):

Additional information can be found in the associated Supplementary Protocol21,
as well as the Nature Research Reporting Summary.
Animal work statements and institutional approval. All experimental work
involving recombinant DNA was performed under the guidelines of the Yale
University Environment, Health and Safety Committee under an approved protocol
(No. Chen-rDNA-15-45). All animal work was performed under the guidelines
of Yale University Institutional Animal Care and Use Committee with approved
protocols (No. Chen-2015-20068 and Chen-2018-20068), and was consistent with
the Guide for Care and Use of Laboratory Animals, National Research Council,
1996 (Institutional Animal Welfare Assurance, No. A-3125-01). Six- to eight-weekold mice, both males and females, were used for MCAP screen experiments.
For subsequent validation experiments, only female mice were used.
Design of the MCAP-MET library. The top 23 annotated ‘tumor suppressors’
from the human MET500 cohort7 were compiled, and combined with three top
hits from a previous mouse metastasis screen (Nf2, Trim72 and Ube2g2)5 for a
final set of 26 genes. We then analyzed the complete exon sequences of these
26 genes to extract all possible Cpf1 spacers (that is, all 20-mers beginning with
the Cpf1 protospacer-adjacent motif (PAM), 5′-TTTV). Each of these 20-mers
was then reverse complemented and mapped to the entire mm10 reference
genome by Bowtie 1.1.2 (ref. 22), with settings -n 2 -l 18 -p 8 -a -y --best -e 90. After
filtering out all alignments that contained mismatches in the final three base pairs
(corresponding to the Cpf1 PAM) and disregarding any mismatches in the fourth
to last base pair, we quantified the number of genome-wide alignments for each
crRNA using all 0, 1 and 2 mismatch (mm) alignments. A total mismatch
score (MM score) was calculated for each crRNA using the following formula:
MM score = 0 mm × 1,000 + 1 mm × 50 + 2 mm × 1. We also counted the
number of consecutive thymidines in each crRNA, and used the following
formula: T score = 100/(max_consecutive_Thymidines) (ref. 2). We then
sorted all 20-nt crRNAs corresponding to each target gene by low MM score
and high T score. Finally, the top four crRNAs for each gene were chosen.
In the event of ties, crRNAs targeting constitutive exons and/or the first exon
were prioritized.
Fifty-two NTC crRNAs were randomly selected from a pool of random
20-mers that did not map to the mouse genome with up to two mismatches.
In combination with the 104 crRNAs targeting 26 genes, a total of 5,200 DKO,
5,408 SKO and 1,326 NTC-NTC arrays was designed for a total of 11,934 dualcrRNA arrays (MCAP-MET library). With a total pool of 26 genes, the number of
possible unique combinations of two different genes is 325. Each of these 325 gene
pairs was represented by 16 DKO arrays, whereas each single gene condition was
represented by 208 SKO arrays. For SKO crRNA arrays, we placed each genetargeting crRNA in the first position of the crRNA array and toggled the NTC
crRNAs through the second position. For each gene pair, the positioning of the
crRNAs representing each of the two genes was determined randomly. For each
oligo, we appended a degenerate 10-mer (10 × N, where N denotes a random
DNA nucleotide) following the U6 termination sequence to serve as a barcode for
downstream clonality analysis. After pooled oligo synthesis (CustomArray), we
used Gibson cloning to insert the MCAP-MET library into the BsmbI-linearized
crRNA expression vector (pLenti-U6-DR-crRNA-Puro-P2A-Firefly luciferase).
Cell lines. A non-small-cell lung cancer cell line5,6 (KPD cell line) was transduced
with pLenti-EFs-Cpf1-Blast to generate Cpf1-positive cells (KPD-Cpf1). All cell
lines were grown under standard conditions using DMEM containing 10% fetal
bovine serum (FBS) and 1% penicillin–streptomycin (pen/strep) in a 5% CO2
incubator.
Lentiviral library production. Briefly, envelope plasmid pMD2.G, packaging
plasmid psPAX2 and pLenti-MCAP-MET plasmid were added at a ratio of
1:1.5:2, and then polyethyleneimine was added and mixed well by vortexing. The
solution was left at room temperature for 10–20 min, and then the mixture was
added dropwise into 80–90% confluent HEK293FT cells and mixed well by gentle
agitation of the plates. Six hours post-transfection, fresh DMEM supplemented
with 10% FBS and 1% pen/strep was added to replace the transfection media.
Virus-containing supernatant was collected at 48 and 72 h post-transfection,
centrifuged at 1,500g for 10 min to remove the cell debris then aliquoted and
stored at −80 °C. Virus was titrated by KPD cell infection at a number of different
concentrations, followed by the addition of 3 μg ml–1 puromycin at 24 h postinfection to select the transduced cells. We determined viral titers by calculating
the ratios of surviving cells 48 or 72 h post-infection and the cell count at infection.
Nextera analysis of indels generated by Cpf1. crRNA arrays (crPten-crNf1 and
crNf1-crPten) were cloned into the pLenti-U6-DR-crRNA-Puro vector, and virus
was generated for transduction of KPD-Cpf1 cells.
Pten spacer = TGCATACGCTATAGCTGCTT
Nf1 spacer = TAAGCATAATGATGATGCCA
Six days after transduction and puromycin selection, genomic DNA was
harvested from the cells in culture. The surrounding genomic regions flanking the
NATURE METHODS | www.nature.com/naturemethods

Pten_F = ACTCACCAGTGTTTAACATGCAGGC
Pten_R = GGCAAGGTAGGTACGCATTTGCT
Nf1_F = AGCAGCTGTCCTGGCTGTTC
Nf1_R = CGTGCACCTCCCTTGTCAGG
Using Phusion Flash High Fidelity Master Mix (Thermo Fisher), the
thermocycling parameters for PCR were 98 °C for 2 min, 35 cycles of (98 °C for 1 s,
62 °C for 5 s, 72 °C for 15 s) and 72 °C for 2 min.
Nextera XT library preparation was then performed according to the
manufacturer’s protocol with minor modifications. Reads were mapped to the
mm10 mouse genome using BWA23, with the settings bwa mem -t 8 -w 200.
Indel variants were first processed with Samtools24 with the settings samtools
mpileup -B -q 15 -d 10000000000000, then input into VarScan v.2.3.9 (ref. 25) with
the settings pileup2indel --min-coverage 2 --min-reads2 2 --min-var-freq 0.00001.
Variants occurring within ±7 nt of the predicted crRNA cut sites were summed to
obtain total mutation frequencies.
Evaluation of in vivo library diversity in the absence of mutagenesis. We
synthesized a library of degenerate 8-mers and cloned these into the crRNA
expression vector. After lentiviral production, KPD cells were transduced with
the 8-mer lentiviral library and selected by puromycin; 4 × 106 KPD-8-mer cells
were subcutaneously injected in either Rag1−/− or nu/nu mice. Twelve days after
transplantation, mice were killed and tumors were isolated for genomic preparation
and readout.
MCAP in a mouse model of metastasis. Library transduction was performed
with three infection replicates at high coverage and low multiplicity of infection.
Briefly, according to viral titers, MCAP-MET lentiviruses were added to a total of
1 × 108 KPD-Cpf1 cells at a calculated multiplicity of infection of 0.2, and incubated
for 24 h before replacing the virus-containing media with 3 μg ml–1 puromycin
containing fresh media to select virus-transduced cells. Approximately 2.5 × 107
cells confer a ×~2,000 library coverage. MCAP-MET library-transduced cells
were cultured under the pressure of 3 μg ml–1 puromycin for 14 d before injection.
MCAP library-transduced KPD-Cpf1 cells were injected subcutaneously into the
right flank of nu/nu mice at 4 × 106 cells per flank (×~350 coverage per transplant).
Mouse tumor dissection. Mice were killed by carbon dioxide asphyxiation
followed by cervical dislocation. Tumors and lungs were manually dissected, fixed
in 10% formalin for 24–96 h and transferred into 70% ethanol. Tissues were flashfrozen with liquid nitrogen and ground in a 5-ml frosted polyethylene vial set
(No. 2240-PEF) in a 2010 GenoGrinder machine (SPEXSamplePrep).
Homogenized tissues were then used for DNA extraction.
Genomic DNA extraction. Frozen, ground tissue (200–800 mg) was resuspended
in 6 ml of NK Lysis Buffer (50 mM Tris, 50 mM EDTA, 1% SDS, pH 8.0)
supplemented with 30 μl of 20 mg ml–1 Proteinase K (Qiagen) in 15-ml conical
tubes, and incubated in a bath at 55 °C overnight. After all the tissues were lysed,
30 μl of 10 mg ml–1 RNase A (Qiagen) was added, mixed well and incubated at
37 °C for 30 min. Samples were chilled on ice and then 2 ml of pre-chilled 7.5 M
ammonium acetate (Sigma) was added to precipitate proteins. The samples were
inverted and vortexed for 15–30 s and then centrifuged at ≥4,000g for 10 min. The
supernatant was carefully decanted into a new 15-ml conical tube, followed by the
addition of 6 ml of 100% isopropanol (at a ratio of ~0.7), inverted 30–50 times and
centrifuged at ≥4,000g for 10 min. At this point, genomic DNA became visible
as a small white pellet. After the supernatant had been discarded, 6 ml of freshly
prepared 70% ethanol was added, mixed well and then centrifuged at ≥4,000g for
10 min. The supernatant was discarded by pouring, and remaining residue was
removed using a pipette. After air-drying for 10–30 min, DNA was resuspended by
the addition of 200–500 μl of nuclease-free H2O. Genomic DNA concentration was
measured using a Nanodrop (Thermo Scientific) and normalized to 1,000 ng μl–1
for the following readout PCR.
MCAP library readout. MCAP library readout was performed using a two-step
PCR approach. Briefly, in the first round of PCR, sufficient genomic DNA was used
as template to guarantee coverage of the library abundance and representation.
Each sample contained 12 μg of genomic DNA, split between six separate PCR
reactions. For the first PCR, the sgRNA-containing region was amplified using
primers specific to the MCAP vector using Phusion Flash High Fidelity Master
Mix (Thermo Fisher), with thermocycling parameters of 98 °C for 1 min, 15 cycles
of (98 °C for 1 s, 60 °C for 5 s, 72 °C for 15 s) and 72 °C for 1 min.
Fwd: AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG
Rev: CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTCTTTCCC
In the second PCR, first-round PCR products for each biological replicate were
pooled, then 2 μl of well-mixed first-round PCR products were used as the template
for amplification, with sample-tracking barcode primers having thermocycling
conditions set to 98 °C for 1 min, 15 cycles of (98 °C for 1 s, 60 °C for 5 s, 72 °C for
15 s) and 72 °C for 1 min. The second-round PCR products were quantified in 2%
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E-gel EX (Life Technologies) using E-Gel Low Range Quantitative DNA Ladder
(Thermo Fisher), then the same amounts of each barcoded sample were combined.
The pooled PCR products were purified using the QIAquick PCR Purification Kit
and further QIAquick Gel Extraction Kit from 2% E-gel EX. The purified pooled
library was quantified as above. Diluted libraries with 5–20% PhiX were sequenced
with the HiSeq 4000 system (Illumina), with 150-bp paired-end read length.
MCAP-MET plasmid library readout and analysis. Raw paired-end fastq
read files were first merged to single fastq files by PEAR26 with the settings
-y 8 G -j 8 -v 3. The merged fastq files were then filtered and de-multiplexed using
Cutadapt27, using two different sets of adaptors for extraction of crRNA array
sequences or the 10-mer barcode. For the crRNA array, we used the following
settings: cutadapt --discard-untrimmed -g tcttGTGGAAAGGACGAAACACCg,
followed by cutadapt --discard-untrimmed -a TGTAGATTTTTTT. The trimmed
sequences were then mapped to the MCAP-MET library using Bowtie22:
bowtie -v 3 -k 1 -m 1. For the 10-mer barcodes, we used the following Cutadapt
settings: cutadapt --discard-untrimmed -a aagcttggcgtGGATC, followed by
cutadapt --discard-untrimmed -g TACTAAGTGTAGATTTTTTT. The resultant
sequences were quantified to a reference of all possible 10-mer sequences. Reads
that successfully mapped to the MCAP-MET library and contained a valid barcode
were tabulated.

Design of dual-crRNA arrays for validation experiments. Dual-crRNA arrays
containing combinations of Rosa26-targeting crRNAs or the best-performing Nf2
and Trim72 crRNA were designed. The following spacer sequences were used:

Processing of MCAP-MET crRNA array abundance in cells and tumors. PEARmerged26 fastq files were filtered and de-multiplexed using Cutadapt27. To remove
extra sequences downstream (3′ end) of the crRNA array sequences, including
the DR and U6 terminator, we used the following settings: cutadapt --discarduntrimmed --e 0.1 -a aagcttggcgtGGATCCGATATCa -m 80. As the forward
PCR primers used to read out crRNA array representation were designed to
have a variety of barcodes to facilitate multiplexed sequencing, we then demultiplexed these filtered reads with the following settings: cutadapt -g file:fbc.
fasta --no-trim, where fbc.fasta contained the 12 possible barcode sequences
within the forward primers. Finally, to remove extraneous sequences upstream
(5′ end) of the crRNA array spacers, we first used the following settings:
cutadapt --discard-untrimmed --e 0.1 -g tcttGTGGAAAGGACGAAACACCg -m 80.
Then, we removed the 5′ DR as follows: cutadapt --discarduntrimmed -e 0.1 -g TAATTTCTACTAAGTGTAGAT -m 80. The filtered fastq reads
were then mapped to the MCAP-MET reference index. To do so, we first generated
a Bowtie index of the MCAP-MET library using the bowtie-build command in
Bowtie 1.1.2 (ref. 22). Using these bowtie indexes, we mapped the filtered fastq
read files using the following settings: bowtie -n 2 -k 1 -m 1 --best. These settings
ensured that only single-match reads would be retained for downstream analysis.
For data processing on the level of barcoded crRNAs, we used the same trimmed
fastq files as above but instead employed the barcoded crRNA plasmid library as
the reference index.

crRosa26.1: AGGCTATATTTCTGCTGTCT
crRosa26.2: TAGTTCAAAGCTTCTGACAG
crNf2: AAGGCCTCGATCTCCGTCTT
crTrim72: TGCCGTGCCTGCCTGATCCG
Insertion of NLS–green fluorescent protein (GFP) sequences into the crRNA
expression vector. The primary screen experiments were performed using
the U6 crRNA expression vector with an EF1-α short (EFS) promoter driving
expression of puromycin and firefly luciferase. For validation experiments, the
coding sequences for NLS-EGFP were inserted after puromycin-P2A-luciferase
in the crRNA expression vector by Gibson cloning, with a P2A sequence
separating the GFP.
Quantification of mutation frequency by T7E1. Seven days after lentiviral
transduction and puromycin selection, genomic DNA was extracted from the cells.
PCR amplification of the genomic regions flanking the Nf2 or Trim72 crRNAs was
performed using the following primers:
Nf2_F: CTCCTGAGGAAACTAGATGCCAACCT
Nf2_R: AAAGCTGTCTGTGGCAGGGTTATTTG
Trim72_F: GAGGAGAGGGCTGGGTATTTGAGAGA
Trim72_R: GCTGCCAAGCAAGGTAGGTAGCTATT
Using Phusion Flash High Fidelity Master Mix (Thermo Fisher), the
thermocycling parameters for PCR were 98 °C for 2 min, 35 cycles of (98 °C for 1 s,
60 °C for 5 s, 72 °C for 15 s) and 72 °C for 2 min.
The PCR amplicons were then used for T7E1 assays according to the
manufacturer’s protocol. Statistical significance was assessed by two-sided unpaired
Welch’s t-test.

Analysis of MCAP crRNA array library representation. Using the resultant
mapping output, we quantified the number of reads that had mapped to each
crRNA array within the library. We normalized the number of reads in each
sample by converting raw crRNA array counts to reads per million (RPM). The
RPM values were then subjected to log2 transformation for certain analyses.
Where applicable, linear regression lines and 95% confidence intervals were
calculated. For comparison of cells, primary tumors and lung metastases, crRNA
array abundances were averaged within sample groups and linear regression was
performed using the NTC-NTC arrays as a model for neutral selection. Significant
outliers were identified using the outlierTest function from the ‘car’ R package,
which calculates the studentized residuals of the linear regression and derives
the corresponding P values. The Benjamini–Hochberg procedure was then used
to adjust P values for multiple comparisons. For gene/gene pair analyses, the
corresponding SKO and DKO arrays were first averaged together, then aggregated
by sample type. Linear regression was performed using all SKO/DKO genotypes,
and outliers were identified as above.

EdU proliferation assay. To assess proliferation, we used the Click-iT EdU
Alexa Fluor 647 Flow Cytometry Assay Kit (Thermo Fisher, No. C10419). Cells
underwent incubation in culture with 10 μM EdU solution for 2 h, followed
by fixation, permeabilization and staining. Cells were then analyzed on a
BD FACSAria and the data were processed using FlowJo. Statistical significance
was assessed by two-sided unpaired Welch’s t-test.

Clone-level analysis of MCAP-MET samples. We analyzed the data at the clone
level using the barcoded crRNA abundances. We first converted the counts in each
sample to percentages of total reads. We then used two different frequency cutoffs
for considering 0.01% and ≥0.001%. Differences in the number of clones between
sample types were assessed by two-sided Wilcoxon rank sum test, and visualized
after log2 transform. Empirical cumulative distribution function was calculated after
combining all the clones in a given sample group; statistical differences in clone size
distributions were assessed by two-sided Kolmogorov–Smirnov test. The Shannon
diversity index was also calculated on each sample with the ‘vegan’ R package;
statistical differences were assessed by two-sided Wilcoxon rank sum test.
Enrichment analysis of MCAP-MET genotypes. To identify crRNA arrays
that were enriched in individual samples, we used the 1,326 NTC-NTC arrays
for modeling the empirical null distribution. Enriched crRNA arrays were
subsequently called at FDR < 0.5%. These results were aggregated to the single
gene/gene pair level, then tabulated across samples. Finally, we counted all
significant crRNA arrays associated with each genotype.

Identification of synergistic mutation combinations. We defined
the SynCo score for each gene pair with the following formula:
SynCo = DKONM – SKON – SKOM. The DKONM value is the median log2 RPM
abundance of all corresponding DKO crRNA arrays (that is, crN-crM), whereas
SKON and SKOM values are defined as the median log2 RPM abundance of all
corresponding SKO crRNA arrays. We calculated the SynCo of each gene pair
within the lung metastasis samples and further assessed whether the DKO
abundances were statistically significantly higher than the corresponding SKO
abundances, by two-sided Wilcoxon rank sum test. We defined synergistic
mutation combinations as gene pairs where (1) the SynCo score was >0 and (2)
the median differential abundances compared to the corresponding SKOs were
both >0.2, with an associated Benjamini–Hochberg adjusted P < 0.05 for both
comparisons. To generate a library-wide map of the relative selective advantages
for each gene pair versus single gene knockout, we used the aggregated gene-level
abundances in lung metastasis samples. We compared the abundance of each
DKO to its reference SKO, and visualized the data in a heat map. Each column
refers to the reference SKO, whereas each row denotes the modulatory effects of
the second KO.

Matrigel invasion assay. For in vitro assessment of invasive potential,
unsupplemented DMEM was first mixed with standard Matrigel (Corning,
No. 356234) on ice using pre-chilled pipette tips to a final concentration of
25% Matrigel. After placing FluoroBlok cell culture inserts with 8-μm pores
into a 24-well plate, we added 100 μl of the 25% Matrigel to each insert. The
inserts were incubated in the cell culture incubator for 1 h to solidify the
Matrigel. Cultured cells were then resuspended in unsupplemented DMEM at a
concentration of 0.5 × 106 cells ml–1, and 200 μl of the cell suspension was gently
added on top of the Matrigel layer. Finally, 600 μl of 10% FBS DMEM was
added to each well, underneath the inserts. Invasive cells were quantified using
an inverted microscope 24 h later on the GFP channel. Statistical significance
was assessed by two-sided unpaired Welch’s t-test.
Luciferase imaging for tracking metastasis. Mice were anesthetized by isoflurane
inhalation and imaged for metastasis using an IVIS machine (PerkinElmer) for
5 min following intraperitoneal injection of firefly d-luciferin potassium salt
(150 mg kg–1 body weight).
Quantification of primary tumors and lung metastases. Mice were
anesthetized by isoflurane inhalation, and tumor sizes were quantified
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every 2–3 d by calipers, using the formula volume (mm3) = π (6 × x × y × z)–1.
Statistical significance was assessed by two-way ANOVA, jointly considering
the effect of time and treatment condition. Mice were killed at 28 d
post-infection, and lungs were harvested for quantification of lung metastases.
Each lung lobe was separately visualized under a dissecting microscope.
Lung lobe metastases were quantified on bright-field images with real-time
confirmation by GFP expression. Statistical significance was assessed by twosided unpaired Welch’s t-test.

Data availability
MCAP data, sequences of oligos and library design are described in the Methods
section and Supplementary Tables. All vectors and libraries have been deposited
to Addgene and are available to the academic community. Cell lines and all data
supporting this work will be made available to the academic community upon
reasonable request to the corresponding author. Genomic sequencing data have
been deposited with NCBI SRA (PRJNA515306).

Code availability

Genomic comparisons of human primary tumors and metastases. Mutation
frequencies from the TCGA PanCancer dataset and the MET500 dataset were
filtered for the 26 genes represented in the MCAP-MET library. We determined
the statistical significance of Spearman correlation by calculating the t-statistic of
the correlation. Identification of gene pairs that were significantly co-mutated was
determined by hypergeometric test.

Key scripts used to process and analyze the data will be available to the academic
community upon reasonable request.
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4.2: Programmable sequential mutagenesis by inducible Cpf1 crRNA array inversion
Different patients present with unique combinations of mutations that interact in complex
ways, and the temporal order in which these various mutations are acquired can vary between
patients. Collectively, these issues severely obfuscate the interpretation of tumor genomes,
necessitating experimental modeling and characterization of the mutation combinations found in
patients. However, nearly all existing approaches to study mutation combinations involve
simultaneous knockouts of multiple genes, rather than stepwise perturbations. In order to study
tumor evolution as it naturally occurs in patients, methods for sequential mutagenesis are needed.
Towards to this end, I sought to combine Cre-inducible recombination cassettes with CRISPRCas12a gRNA arrays to enable programmable sequential mutagenesis 112.
This line of investigation was conceived together with my advisor Dr. Sidi Chen. My
primary role in this study was to design the technology, carry out cell culture experiments and
molecular biology studies, and analyze the resulting data. I also prepared the manuscript text and
figures together with Dr. Sidi Chen.
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I

n a large variety of biological and pathological processes,
genetic mutations or alterations are often acquired in a
sequential manner1–3. In evolution and speciation, the genomes of organisms acquire mutations constantly and are subjected to natural selection4. In genetically complex disorders such
as cancer, multi-step mutagenesis is often a major obstacle for
effective treatments. Cancers evolve through an ongoing process
of mutation–selection balance, where initial mutations are selected for, or against, in vivo, followed by subsequent acquisition of
additional mutations as the tumor grows5. Since the initial set of
oncogenic “driver” mutations is generally what starts and sustains
tumor growth, targeted molecular therapies are often chosen to
speciﬁcally attack such oncogenic dependencies5. However, the
selection pressures of treatment will favor secondary mutations
that confer drug resistance, leading to relapse6–8. Thus, the process of cancer evolution by sequential mutagenesis stymies these
therapies via continuous diversiﬁcation and adaptation to the
tumor microenvironment, eventually exhausting available treatment options5. Even with the advent of cancer immunotherapy,
where checkpoint blockade is increasingly being utilized in the
clinic, the acquisition of secondary mutations that abolish
T cell receptor (TCR)–antigen–major histocompatibility complex
recognition can still lead to immune escape and ultimately negate
the effect of immunotherapy9,10. Thus, the ability to perform
sequential and precise mutagenesis is critical for studying biological processes with multi-stage genetic events such as development and evolution, as well as the pathogenesis of complex
diseases such as cancer.
From a genetic engineering perspective, stepwise mutagenesis
or perturbation is a powerful technique for precise genetic
manipulation of cells and live organisms. Multiple methods have
been employed to achieve this end. In the pre-recombinant DNA
era, stepwise perturbation was often done by multiple rounds of
random mutagenesis using chemical or physical carcinogens
followed by artiﬁcial selection. The subsequent discovery and
application of recombinase systems such as Cre-loxP, Flp-FRT,
and φC31-att enabled inducible genetic events11. In these systems, the DNA recombinase (i.e., Cre) speciﬁcally recognizes its
target DNA sequence motif (i.e., loxP) and catalyzes recombination between two such target sites. Depending on the conﬁguration of the target sites, targeted recombinases can be utilized
for DNA excision, translocation, and/or inversion. However, the
ﬂoxed genomic loci underlying Cre-based systems must be preengineered on a gene-by-gene basis. This process of generating
new ﬂoxed alleles for each unique application is time and labor
intensive, further limiting the feasibility of multiplexed Cre
recombination.
More recently, precisely targeted and customizable mutagenesis was simpliﬁed by the discovery of RNA-guided endonucleases (RGNs) Cas912–14 and Cpf115,16 from clustered regularly
interspaced short palindromic repeats (CRISPR) systems. RGNs
can induce double-strand DNA breaks, subsequently generating
insertions and deletions at the target site. This process is precisely
targeted based on the sequences of CRISPR RNAs (crRNAs),
which complex with RGNs to enable and guide their nuclease
functions. Unlike with Cre recombination, CRISPR crRNAs can
be easily transferred to target cells through transfection or viral
vectors, thus obviating the need to pre-engineer the host genome
for each target gene.
In contrast to Cas9, the most widely utilized RGN to date,
Cpf1 is a single component RGN that does not depend on
trans-activating RNA and can autonomously process crRNA
arrays15–17. These features have made Cpf1 particularly attractive
for multiplexed mutagenesis. In addition to several studies
in mammalian systems, Cpf1-mediated mutagenesis and
transcriptional repression have now been successfully applied in
2
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plants18–20. Furthermore, chemical modiﬁcations on Cpf1 mRNA
and crRNAs have been identiﬁed that can improve cutting
efﬁciency21. It was recently demonstrated that Cpf1 can also
process crRNAs from mRNAs expressed by a Pol II promoter22,
further enabling ﬂexible transcriptional control.
Sequential mutagenesis using Cas9 was demonstrated in
ex vivo organoid cultures23. However, this approach required
sequentially introducing each sgRNA in culture, one at a time,
limiting its broader applicability. In particular, the sequential
introduction of different sgRNAs would be impractical for
library-scale screening or any in vivo experimental designs. To
our knowledge, conditional sequential mutagenesis using RGNs
has not yet been demonstrated. Here we describe a ﬂexible
sequential mutagenesis system through inducible inversion of a
single crRNA array (Cpf1-Flip) and demonstrate its simplicity in
stepwise multiplexed gene editing in mammalian cells for modeling sequential genetic events, such as in cancer. We further
apply Cpf1-Flip to model the acquisition of resistance mutations
to immunotherapy in a pooled mutagenesis setting, demonstrating the feasibility of Cpf1-Flip for conducting sequential
genetic studies. This system can be utilized for multi-step mutagenesis of any genes in the genome for interrogating complex
genetic events with temporal control.
Results
Construction of a Cpf1 sequential mutagenesis system. When
loxP sites are arranged such that they point towards each other,
Cre recombination leads to inversion of the intervening sequence.
However, this process leads to the complete regeneration of the
loxP sites, thereby allowing Cre to continually catalyze DNA
inversion. As continuous Cre-mediated inversion would be
counterproductive in many applications, mutant loxP sites have
been characterized that enable unidirectional Cre inversion24,25.
When the mutant loxP sites lox66 and lox71 are recombined, they
generate a wild-type loxP site and a double-mutant lox72. Cre has
a substantially lower afﬁnity for lox72, thus leading to mostly
irreversible inversion of the ﬂoxed DNA segment.
We designed a U6 expression cassette containing two inverted
BsmbI restriction sites, ﬂanked by a lox66 sequence and an
inverted lox71 sequence (Fig. 1a). In the same lentiviral vector,
an EFS promoter drives the expression of Lachnospiraceae
bacterium Cpf1 (LbCpf1, or Cpf1 for short)15 and a puromycin
resistance gene (EFS-Cpf1-Puro). After BsmbI restriction digest,
the vector linearizes and allows for insertion of a crRNA array.
To enable stepwise mutagenesis, we designed crRNA arrays
in which the ﬁrst crRNA is encoded on the sense strand, while
the second crRNA is inverted. We hereafter refer to this construct
as a crRNA FlipArray. Six consecutive thymidines (6xT) are
present in cis at the 3′ end of each crRNA, terminating U6
transcription. Each crRNA is preceded by the LbCpf1 direct
repeat (DR) sequence, which guides Cpf1 to process the crRNA
array16.
Cre-mediated recombination of the lox66 and lox71 mutant
loxP sites24,25 leads to inversion of the FlipArray, generating a
wild-type loxP and a double-mutant loxP, lox72. As the afﬁnity of
Cre recombinase for lox72 is substantially lower than for wildtype loxP, inversion of the FlipArray is mostly irreversible24,25.
After inversion, the two crRNAs trade places and the second
crRNA becomes expressed. Thus, in the absence of Cre, Cpf1
generates indels at the target site of the ﬁrst crRNA; after Cre
recombination, Cpf1 is directed to the target site of the second
crRNA. We hereafter term this approach Cpf1-Flip. In short, the
Cpf1–Flip system leverages CRISPR-Cpf1 mutagenesis and melds
it with the inversion capabilities of Cre/lox66/lox71 to enable
programmable two-step mutagenesis.
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Fig. 1 Cpf1–Flip–Cre-inducible sequential mutagenesis by a single crRNA FlipArray. a Schematic of vectors used in the study. The Cpf1-Flip construct
contains an EFS promoter driving expression of Cpf1 and puromycin resistance, and a U6 expression cassette containing two inverted BsmbI restriction
sites, ﬂanked by a lox66 sequence and an inverted lox71 sequence. After BsmbI digestion, a crRNA FlipArray is cloned in. The FlipArray inverts upon Cre
recombination, thereby switching the crRNA that is expressed. b Schematic of experimental design. Cells were ﬁrst infected with lentivirus containing
EFS-Cpf1-puro; U6-FlipArray. After 7 days, cells were then infected with lentivirus containing EFS-Cre to induce inversion of the FlipArray. Prior to Cre
recombination, only crNf1 is expressed; following Cre recombination, crPten becomes expressed. c Sequences of the FlipArray construct before and after
Cre recombination. Red boxes denote mutants from wild-type loxP. Prior to Cre, single mutant lox66 and lox71 sites are present. After Cre recombination, a
wild-type loxP site and a double mutant lox72 site are generated

Sequential mutagenesis in murine and human cells. To
demonstrate sequential editing of cancer genes, we ﬁrst applied
Cpf1-Flip to generate Nf1 and Pten mutations in a mammalian
lung cancer cell line (KPD)26. We cloned in a FlipArray containing a spacer targeting Nf1 (crNf1) and an inverted spacer
targeting Pten (crPten) (crNf1-crPten FlipArray, or NPF). We
infected the cells with lentivirus containing EFS-Cpf1-Puro; U6NPF (Fig. 1b). The pre-recombination construct was designed to
only express crRNA targeting the ﬁrst locus (Nf1) prior to the
introduction of Cre. After 6 days of puromycin selection (1 week
after the initial lentiviral transduction), we then infected the cells
with lentivirus containing an EFS promoter driving the expression of Cre (EFS-Cre). Cre-expressing cells undergo inversion of
the crRNA FlipArray, leading to sequential mutagenesis at the
second locus (Pten) (Fig. 1c).
To detect Cre-mediated inversion of the FlipArray, we isolated
genomic DNA from the NPF-expressing lung cancer cells before
infection with EFS-Cre and 10 days after infection. We designed
primers that would only generate a product if the FlipArray had
successfully inverted (Fig. 2a). We also designed primers speciﬁc
for the non-inverted FlipArray. These data demonstrated robust
FlipArray inversion (Fig. 2b). Speciﬁcally, by D10 following EFSCre, the FlipArray inversion frequency was 79.07 ± 8.23% (mean
± s.e.m.) (Fig. 2c). In order to monitor the induction of functional
FlipArray inversion at the transcript level, we also isolated total
NATURE COMMUNICATIONS | (2018)9:1903

RNA from the double-infected KPD cells at various timepoints.
After cDNA synthesis, we utilized inversion-speciﬁc primers to
detect inverted crRNA FlipArray transcripts (Fig. 2d). The
induction of inverted FlipArray transcripts steadily increased
through the course of the experiment, illuminating the kinetics of
Cre-mediated inversion of the FlipArray and its subsequent
transcription. The low-levels of inverted FlipArray transcripts at
baseline could be due to spontaneous inversion, or an artifact of
the primer design.
We sequenced the target sites of crNf1 and crPten to determine
whether the NPF construct had indeed created mutations in a
controlled stepwise manner. Uninfected controls did not have any
signiﬁcant variants at crNf1 (Supplementary Data 1) or crPten
target sites (Supplementary Data 2) (Fig. 2e, f, k). 7 days following
the ﬁrst lentiviral infection with EFS-Cpf1-Puro; U6-NPF, indels
were found at the crNf1 target site, but not the crPten site
(Fig. 2g, h, k). Since the second crRNA is not transcribed prior to
Cre recombination, this result afﬁrms that inversion of NPF has
not yet occurred at this time point. After another 10 days
following infection with EFS-Cre lentivirus (17 days following the
initial infection with EFS-Cpf1-Puro; U6-NPF), indels were found
at both crNf1 and crPten target sites at high frequencies
(Supplementary Data 3; Fig. 2i–k).
To further demonstrate the utility of Cpf1-Flip in diverse
biological systems, we designed a FlipArray targeting two human
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Fig. 2 Inducible sequential mutagenesis in murine cells through Cpf1-Flip. a Schematic for PCR-based detection of Cre-mediated inversion of the crRNA
FlipArray (targeting Nf1 and Pten). b PCR-based detection of non-inverted and inverted FlipArrays at D0 (n = 3) and D10 (n = 3) following Cre, along with
input control. c Quantiﬁcation of gel intensities in b, normalized to input and expressed as a percentage of total FlipArray abundance. d Detection and
quantiﬁcation of Cre-mediated inversion of the crRNA FlipArray at the RNA transcript level using RT-PCR (n = 2 infection replicates). The expression of the
inverted FlipArray was assessed at multiple timepoints following EFS-Cre infection using sequence-speciﬁc primers for the inverted FlipArray transcript as
normalized to the Cpf1 mRNA level. e, f Representative Illumina targeted amplicon sequencing of the crNf1 target site (e) and crPten target site (f) in
uninfected controls. g, h Representative Illumina targeted amplicon sequencing of the crNf1 target site (g) and crPten target site (h) 7 days after infection
with lentivirus containing EFS-Cpf1-puro; U6-NPF-FlipArray. Where relevant, the top 5 most frequent variants are shown, with the associated variant
frequencies in the boxes to the right. i, j Representative Illumina targeted amplicon sequencing of the crNf1 target site (i) and crPten target site (j) 17 days
after infection with lentivirus containing EFS-Cpf1-puro; U6-NPF-FlipArray and 10 days following EFS-Cre infection. Where relevant, the top ﬁve most
frequent variants are shown, with the associated variant frequencies in the boxes to the right. k Dot plot detailing the total variant frequencies at the crNf1
and crPten target sites in uninfected cells (red), 7 days after FlipArray transduction (−Cre) (green), and 17 days after FlipArray transduction (+Cre) (blue).
n = 2 cell replicates for uninfected group, n = 3 for other conditions. All error bars are mean ± s.e.m
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Fig. 3 Inducible sequential mutagenesis in human cells through Cpf1-Flip. a Schematic of a FlipArray targeting human DNMT1 and VEGFA. In the absence of
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crDNMT1 target site (d) and crVEGFA target site (e) in uninfected controls. f, g Representative Illumina targeted amplicon sequencing of the crDNMT1
target site (f) and crVEGFA target site (g) 7 days after infection with lentivirus containing EFS-Cpf1-puro; U6-DVF-FlipArray. Where relevant, the top ﬁve
most frequent variants are shown, with the associated variant frequencies in the orange box to the right. h, i Representative Illumina targeted amplicon
sequencing of the crDNMT1 target site (h) and crVEGFA target site (i) 21 days after infection with lentivirus containing EFS-Cpf1-puro; U6-DVF-FlipArray
and 14 days following EFS-Cre infection. The top ﬁve most frequent variants are shown, with the associated variant frequencies in the orange box to the
right. j, k Dot plot detailing the total variant frequencies at the crDNMT1 and crVEGFA target sites in uninfected cells, 7 days after FlipArray transduction
(−Cre), and 21 days after FlipArray transduction (+Cre). n = 2 cell replicates for uninfected and D7 condition, n = 6 for D21 condition. All error bars are
mean ± s.e.m

genes, DNMT1 and VEGFA. The crRNA in the ﬁrst position targets
DNMT1 (crDNMT1) while the second, inverted crRNA targets
VEGFA (crVEGFA) (crDNMT1-crVEGFA FlipArray, or DVF)
(Fig. 3a). Cre activation induces recombination of the lox66/lox71
sites, such that crVEGFA becomes expressed. We transduced
NATURE COMMUNICATIONS | (2018)9:1903

human HEK293T cells with EFS-Cpf1; U6-DVF lentivirus, followed
by puromycin selection. To assess the functionality of the
FlipArray, we then infected the cells with EFS-Cre lentivirus. Using
primers speciﬁc to the non-inverted or inverted DVF FlipArray, we
conﬁrmed that Cre administration drives efﬁcient inversion
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Fig. 4 Pooled sequential mutagenesis to model acquired resistance to immunotherapy. a Schematic of the experimental approach for pooled sequential
mutagenesis using Cpf1-Flip. Following restriction digest, a library of FlipArrays is cloned into the base vector. In each FlipArray, the ﬁrst crRNA targets a
tumor suppressor (Nf1), while the second crRNA targets a panel of putative immunomodulatory factors. Cre-mediated inversion induces expression of the
second crRNA. b Dot plot detailing the total variant frequencies at the crNf1 target site in uninfected cells, 14 days after FlipArray transduction (−Cre), and
28 days after FlipArray transduction (+Cre). c Dot plot detailing the total variant frequencies at the second crRNA target sites (Fasl, Ido1, Jak2, Lgals9, B2m,
and Cd274) in uninfected cells, 14 days after FlipArray transduction (−Cre), and 28 days after FlipArray transduction (+Cre). All error bars are mean ± s.e.
m (n = 3 cell replicates for all conditions).

(Fig. 3b). In this system, inversion efﬁciency was 85.42 ± 2.90% by
2 weeks following EFS-Cre (Fig. 3c).
Next, to determine whether the Cpf1-Flip system had enabled
sequential mutagenesis at the crDNMT1 and crVEGFA target
sites, we performed deep sequencing. As anticipated, uninfected
controls did not have signiﬁcant mutations at either site
(Supplementary Data 4, 5; Fig. 3d, e, j, k). Seven days after
transduction with EFS-Cpf1; U6-DVF lentivirus, signiﬁcant
indels were found at the crDNMT1 target site but not at the
crVEGFA target locus (Fig. 3f, g, j, k). The cells were then infected
with EFS-Cre to cause FlipArray inversion, leading to expression
of crVEGFA. 21 days after the initial transduction (14 days after
EFS-Cre administration), signiﬁcant indels were observed at both
crDNMT1 and crVEGFA target sites (Supplementary Data 6;
Fig. 3h–i). In these data, the DNMT1 cutting efﬁciency appeared
to be consistently lower at D21 than at D7. This is likely a
consequence of random sampling, as only a subset of the D7 cells
were subsequently taken forward for Cre infection. In addition, it
is possible that DNMT1 loss affects cell viability, given its crucial
role in maintaining DNA methylation27. The cutting efﬁciency at
crVEGFA was notably lower compared to crDNMT1. This
contrast may be due to lower efﬁciency of the crRNA itself, as
well as inefﬁciencies in FlipArray expression or subsequent
crRNA array processing. Taken together, these results demonstrate that Cpf1-Flip is a ﬂexible tool for sequential mutagenesis
based on the Cpf1:crRNA complex, temporally controlled by Cre
recombinase.
Modeling acquired resistance to immunotherapy with Cpf1Flip. We next sought to apply Cpf1-Flip to model acquired
resistance to immunotherapy in breast cancer cells (E0771 cell
line). We designed a small pool of FlipArrays in which the ﬁrst
crRNA targets Nf1 while the inverted second crRNA targets a
panel of immunomodulatory factors (Cd274, Ido1, B2m, Fasl,
Jak2, and Lgals9; referred to as TSG-Immune FlipArray library).
6
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These factors are thought to inﬂuence anti-tumor immunity and
have been implicated in acquired resistance to checkpoint inhibitors. After pooled lentiviral transduction of E0771 cells with the
TSG-Immune FlipArray library, we infected the cells with EFSCre lentivirus to induce FlipArray inversion (Fig. 4a). Upon Cremediated inversion, the second crRNA is expressed and triggers
the knockout of various immunomodulatory factors, thus
mimicking the sequential evolution of cancers in the face of
immunotherapeutic pressures.
Targeted amplicon sequencing conﬁrmed efﬁcient mutagenesis
of Nf1 (Fig. 4b), followed by mutagenesis of the immunomodulatory factors upon Cre-mediated FlipArray inversion (Fig. 4c)
(Supplementary Data 7, 8). Given the pooled nature of these
experiments, lower population-level cutting efﬁciencies are
anticipated at the second loci, as only a sixth of the total cell
population, on average, is infected with a given FlipArray. The
lack of consistent mutagenesis at the crB2m and crCd274 target
sites may be intrinsic to the crRNA sequences themselves, a result
of inefﬁcient Cre infection/recombination and FlipArray processing, or simply a consequence of biased representation within the
cell pool. Of note, we observed high cutting efﬁciencies at the Jak2
locus despite the pooled nature of the experiment. Since these
cells were processed completely in parallel as a minipool, the
observation that crJak2 and crLgals9 showed consistent mutagenesis points to intrinsic differences in crRNA targeting efﬁciencies
as the key factor underlying the lack of consistent cutting by
crB2m and crCd274. Collectively, these data demonstrate the
potential of Cpf1-Flip to facilitate sequential genetic screens—for
instance, to model the acquisition of resistance mutations to
cancer immunotherapy.
Discussion
We introduced Cpf1-Flip, an inducible sequential mutagenesis
system using invertible crRNA FlipArrays. As a proof-of-concept,
we demonstrated sequential mutagenesis in both mouse and
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human cells, while additionally performing pooled sequential
mutagenesis in a cancer cell line. These data revealed that the
cutting efﬁciency of the second target loci can be low with certain
crRNAs despite successful FlipArray inversion. The most likely
explanation for the discordance between FlipArray inversion and
subsequent mutagenesis of the second target locus is the differing
efﬁciencies of the crRNAs themselves. This is corroborated by the
variance observed across independent crRNAs in the pooled
TSG-Immune library (Fig. 4), where consistent cutting efﬁciencies were observed at the Jak2 and Lgals9 target sites, but not
at B2m or Cd274 sites. Moreover, cells with different crRNAs in a
pool can undergo random drift or selection, further diverting
their relative fractions and thereby indel frequencies. Nevertheless, the FlipArray library can be readout by barcoded PCR of
the speciﬁc crRNA cassette followed by high-throughput
sequencing. Thus, as with all CRISPR screens, pooled screen
studies using Cpf1-Flip would require multiple independent FlipArrays targeting each gene/gene pair to ensure fair representation in the mutant pool. In the future, the use of optimized
crRNA sequences28, improved FlipArray designs, and engineered
Cpf1 enzymes will improve the consistency and efﬁciency of
Cpf1-Flip.
By altering the composition and length of the crRNA arrays
within the FlipArray, one could readily engineer more complex
CRISPR perturbation programs. Designs with two or more
crRNAs within an invertible FlipArray at baseline would
empower stepwise double knockouts (2 + 2, or quadruple
knockouts as an end result) or higher dimensional sequential
mutagenesis. Of note, the use of modiﬁed Cre systems such as
CreER29, photoactivatable Cre30, and split-Cre31 would provide
even greater control of FlipArray inversion. Utilizing orthogonal
recombinases and recognition sites in the crRNA array would
allow for even more complex multi-step gene editing programs.
Through the use of tethered Cpf1 variants, FlipArrays could also
be potentially used for sequential and reversible gene activation32–34, repression35–37, or epigenetic modiﬁcation38–40 (Supplementary Fig. 1a). Given the scalability and ﬂexibility of
FlipArrays, conditional genetic studies for phenotypes that only
emerge upon sequential genetic events can be performed using
Cpf1-Flip either in culture or in vivo (Supplementary Fig. 1b).
Since new mutations are stochastically acquired by rare individual
cells within tumors41, Cpf1-Flip could therefore be relevant for
studying the dynamics of rare tumor subclones under varying
selection pressures, such as immunotherapy.
All such applications of Cpf1-Flip and its derivatives could
potentially be self-contained within a single viral vector, facilitating direct in vivo sequential genetic manipulations and functional studies.
Methods
FlipArray design and construction. The empty EFS-Cpf1-Puro; U6-FlipArray
vector was constructed by modiﬁcation of the pY109 lentiviral vector (Addgene
plasmid #84740)16. After BsmbI digestion (FastDigest Esp3I, ThermoScientiﬁc) to
linearize the U6 crRNA expression cassette, oligo cloning was performed to insert a
lox66 sequence, a DR, two BsmbI sites, and an inverted lox71. The empty vector
thus expresses LbCpf1 and puromycin resistance from an EFS promoter, while a
U6 promoter drives expression of a lox66/lox71 ﬂanked crRNA expression module
containing two BsmbI sites. BsmbI digestion and oligo cloning was then used to
insert FlipArrays into the empty vector. For a given pair of crRNAs, the following
oligo overhangs were used for cloning:
Oligo1 5′ overhang: TAGAT
Oligo1 3′ overhang: A
Oligo2 5′ overhang: GTTAT
Oligo2 3′ overhang: A
The main body of the FlipArray was structured as such:
5′-crRNA 1–6xT–6xA–Rev.Complement(crRNA 2)–Rev.Complement(DR)-3′
In this study, the following oligo sequences were used to target Nf1 and Pten:
crNf1 spacer: TAAGCATAATGATGATGCCA
NATURE COMMUNICATIONS | (2018)9:1903

crPten spacer: TGCATACGCTATAGCTGCTT
NPF oligo 1 (to clone into vector):
TAGATTAAGCATAATGATGATGCCATTTTTTAAAAAAAAGCAGCTATAGCGTATGCAATCTACACTTAGTAGAAATTAA
NPF oligo 2 (to clone into vector):
GTTATTAATTTCTACTAAGTGTAGATTGCATACGCTATAGCTGCTTTTTTTTAAAAAATGGCATCATCATTATGCTTAA
The following crRNA spacer sequences were also used, with analogous oligo
designs for cloning into the Cpf1-Flip vector:
crDNMT1: CTGATGGTCCATGTCTGTTA
crVEGFA: CTAGGAATATTGAAGGGGGC
crFasl: GTCCGGCCCTCTAGGCCCAC
crIdo1: CTACAGGGAATGCACAGATG
crJak2: ACATACATCGAGAAGAGTAA
crLgals9: TGCAGTACCAACACCGCGTA
crB2m: TGCACGCAGAAAGAAATAGC
crCd274: TAAAGCACGTACTCACCGAG
Lenti-Cre vector design and construction. The Lenti-Cre vector was designed to
express the Cre recombinase under a constitutive EFS promoter. The plasmid was
generated by PCR ampliﬁcation of Cre and EFS fragments followed by Gibson
assembly into a previous lentiviral vector backbone (lentiGuidePuro)42.
Cell culture and genomic DNA extraction. KPD cells26,43, E0771 cells (CH3
BioSystems), and HEK293T cells (ThermoFisher) were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Experiments were
conducted with at least two independent cellular replicates. For genomic DNA
extraction, ~500,000 cells were isolated. Cells were spun down at 500 × g for 5 min
and washed once with 1×PBS. After removing the supernatant, cell pellets were
resuspended in 500 μl QuickExtract DNA Extraction Solution (Epicentre). Cells
were then incubated at 65 °C for 20 min, followed by incubation at 85 °C for 5 min
to deactivate the enzymes.
Detection of FlipArray inversion by genomic DNA PCR. The following primers
were used to amplify the U6 cassette from genomic DNA:
RdF: GAGGGCCTATTTCCCATGATTCCTTCATATTT
RdR: ACAGTGCAGGGGAAAGAATAGTAGA
PCR conditions: 98 °C 2 min, 32 cycles of (98 °C 1 s, 62 °C 5 s, 72 °C 15 s), 72 °C
2 min, 4 °C hold.
Following Qiagen PCR puriﬁcation, 2 ng of the ﬁrst PCR were used for the
second inversion-speciﬁc or non-inverted-speciﬁc PCR. The following primers
were used for detection of non-inverted or inverted FlipArrays:
NPF_F: TCTTGTGGAAAGGACGAAACACCG
NPF_R: TGCATACGCTATAGCTGCTTTTTTTTAAAAAATGGCA
NPF_R_inv: TAAGCATAATGATGATGCCATTTTTTAAAAAAAAGCAG
DVF_F: TCTTGTGGAAAGGACGAAACACCG
DVF_R: GGGCTTTTTTAAAAAATAACAGACATGGACCATCAG
DVF_R_inv: CTGATGGTCCATGTCTGTTATTTTTTAAAAAAGCCC
PCR conditions: 98 °C 2 min, 14 cycles of (98 °C 1 s, 62°C 5 s, 72 °C 2 s), 72 °C
2 min, 4 °C hold. PCR reactions speciﬁc to non-inverted and inverted FlipArrays
were performed and analyzed simultaneously for each sample. Quantiﬁcation was
done on 2% E-gel using low-range quantitative ladder (ThermoFisher), and was
normalized to the ﬁrst PCR product. Full gel images are shown in Supplementary
Fig. 2a–c.
Quantiﬁcation of inverted FlipArray transcripts. KPD cells were cultured in
DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. For RNA
extraction, ~200,000 cells were isolated and spun down at 500 × g for 5 min. After a
PBS wash, cells were resuspended in 450 μl TRIzol. 100 μl of chloroform was then
added to each tube, followed by rigorous vortexing for 15 s and centrifuging at
12,000 × g for 10 min. The supernatant containing RNA was then puriﬁed using a
Qiagen RNeasy Kit following the RNA cleanup protocol. cDNA was generated by
reverse transcription with random hexamers. PCR detection of inverted crRNA
FlipArray transcripts was done using the following primers:
Inv_FlipArray_F: TGTAGATAGCGCTATAACTTCGTATAGC
Inv_FlipArray_R: AAGCAGCTATAGCGTATGCAATC
PCR conditions: 98 °C 2 min, 34 cycles of (98 °C 1 s, 56°C 5 s, 72°C 5 s), 72 °C
2 min, 4 °C hold.
As a normalization control, PCR detection of Cpf1 transcripts was done using
the following primers:
Cpf1_F: TTCTTTGGCGAGGGCAAGGAGACAA
Cpf1_R: GCACGCGCACCTCTGTATTGATCTT
PCR conditions: 98 °C 2 min, 40 cycles of (98 °C 1 s, 56 °C 5 s, 72 °C 20 s), 72 °C
2 min, 4 °C hold.
Quantiﬁcation of inverted FlipArray RNA abundance was done on 2% E-gel
using low-range quantitative ladder (ThermoFisher), and was normalized to Cpf1
mRNA transcript abundance.
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Detection of Cpf1 mutagenesis. The genomic regions ﬂanking the crRNA target
sites were ampliﬁed from genomic DNA using the following primers:
Nf1_F: GGGTCCGATTGCCAGTACCC
Nf1_R: AACGTGCACCTCCCTTGTCA
Pten_F: ACTCACCAGTGTTTAACATGCAGGC
Pten_R: GGCAAGGTAGGTACGCATTTGCT
DNMT1_F: CTGGGACTCAGGCGGGTCAC
DNMT1_R: CCTCACACAACAGCTTCATGTCAGC
VEGFA_F: CTCAGCTCCACAAACTTGGTGCC
VEGFA_R: AGCCCGCCGCAATGAAGG
Cd274_F: GAATGGTCCCCAAGACAAAGAAGAAGA
Cd274_R: ATTCCCAAAGGAGAACCTGTAATGAGC
Ido1_F: TTCATTGTTCTTCACCCCATGATTGGT
Ido1_R: CCCATGACTTTCCTAAGGAGTGTGAAA
B2m_F: TGTCAGGTGGAGTCTAGTGGTAGAAAA
B2m_R: ATTGGGCACAGTGACAGACTTCAATTA
Fasl_F: CGCCTGATTCTCCAACTCTAAAGAGAC
Fasl_R: GCAAAGAGAAGAGAACAGGAGAAAGGT
Jak2_F: AGATTCATAGCTGTCGTTCATCACTGG
Jak2_R: GTTAGTTCTCTTTCTGCTTCTCTGCCA
Lgals9_F: TTTGGCATCTTCACCAAGGTAGATTGT
Lgals9_R: TAAGCCTGGACTAAGTAAGTGAATGCC
PCR conditions: 98 °C 2 min, 32 cycles of (98 °C 1 s, 63 °C 5 s, 72 °C 20 s), 72 °C
2 min, 4 °C hold.
The genomic DNA from ~1000 cells was used for PCR with the NPF and DVF
FlipArrays. For the TSG-Immune FlipArray library experiments, genomic DNA
from ~6000 cells were used to account for the pooled nature of the experiment. The
resultant PCR products were used for Nextera library preparation following
manufacturer protocols. Reads were mapped to the mm10 or hg38 genome using
BWA-MEM44, with settings -t 8 -w 200. After identiﬁcation of indel variants using
the pileup2indel function in VarScan v2.3.9, a 1% variant frequency threshold was
to identify high conﬁdence variants for NPF and DVF experiments. A less stringent
0.2% variant frequency threshold was used for the TSG-Immune experiments due
to their pooled nature. All variant calls are detailed in Supplementary Data.
Sample size determination. No speciﬁc methods were used to predetermine
sample size.
Blinding statement. Investigators were blinded for sequencing data analysis with
generic sample IDs, but not blinded for PCR or RT-PCR.
Code availability. Custom scripts will be available to the academic community
upon reasonable request
Data availability. The FlipArray base vector has been submitted to Addgene (ID:
109349) and is available to the academic community. Cell lines, and additional data
will be available to the academic community upon reasonable request. The genomic
sequencing data sets generated during the current study are available in NCBI SRA
under accession SRP136201.
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§ CHAPTER 5: CONCLUSION AND FUTURE OUTLOOK
Direct in vivo CRISPR screens, such as those presented here in Chapter 2, offer a key
advantage in that they allow for detailed genetic investigations within the native context of the
host microenvironment. In these systems, the process of transformation and tumorigenesis occurs
in the cell types that are normally present in the target tissues, thus more faithfully modeling
cancers as they naturally develop in humans. Importantly, direct in vivo CRISPR screens are
highly adaptable and modular, as much of the reagents are supplied exogenously in the form of
viral vectors. In our studies, we adapted the same AAV-based approach to both mouse liver and
brain; using a complementary approach termed Tuba-seq, Winslow and colleagues have
performed autochthonous CRISPR screens in the murine lung to map the genetic factors
controlling lung adenocarcinoma development, progression, and therapeutic resistance 113–118.
In future work, it would of interest to assess in parallel the impact of cell-of-origin on the
phenotypes of diverse genetic perturbations. Simply by changing the promoter sequences in the
viral vectors that are used to deliver the CRISPR machinery, it should be possible to restrict Cas9
mutagenic activity to specific subpopulations of cells within a given tissue. By then comparing
the phenotypes of the same set of genetic perturbations but across different cell types, one could
perform detailed investigations on how the initial cell state influences the tumorigenic capacity
of different mutations. Along these lines, a recent study demonstrated that along the
differentiation path from neural crest cells, to melanoblasts, and finally to melanocytes, the latter
are uniquely resistant to malignant transformation by ectopic expression of the oncogene BRAF
119

. Applying a CRISPR screening approach to study multiple genetic perturbations in parallel

across different cell types or states could offer a wealth of detailed insights on the interactions
between oncogenes/tumor suppressors and cell of origin.
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Many of the works presented here also sought to understand the influence of genetic
factors on anti-tumor immunity. Although checkpoint inhibitors have shown remarkable clinical
efficacy across diverse cancer types, it has been estimated that over 80% of eligible patients do
not respond to treatment 120. Deciphering the mechanistic underpinnings of differential response
to immunotherapy is critical for identifying novel avenues for therapeutic intervention.
Accordingly, substantial efforts have been dedicated to genomic and transcriptomic profiling of
patients on immunotherapy, in the hopes of pinpointing features that differentiate responders
from non-responders

121

. But while genomic profiling has illuminated the molecular

characteristics of cancer immunotherapy with unprecedented resolution, it remains largely
unclear how we can effectively harness these insights to augment the efficacy of immunotherapy
for more patients.
The development of new experimental systems for functional cancer genomics may
prove particularly useful in expanding the patient population that will benefit from
immunotherapies. By enabling the identification of causal relationships between specific
mutations and a given phenotype (such as response to immunotherapy), CRISPR screening can
empower the prioritization of specific patient subpopulations that are most likely to benefit from
treatment, and can further nominate candidate pathways for pharmacologic targeting to
potentiate response to therapy.
Finally, the studies presented in Chapter 5 seek to address the problem of genetic
interactions, which lie at the heart of tumor evolution. By taking advantage of the multiplexing
capabilities of Cas12a, here we show that it is possible to interrogate multiple pairs of genetic
perturbations in parallel. Similar or analogous work by several other groups have also made
significant progress in this arena revealing the unpredictable complexities and phenotypes that
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can arise when multiple genetic perturbations are introduced simultaneously

122–130

. We further

perform a proof-of-principle study in modifying Cas12a for sequential (rather than simultaneous)
dual mutagenesis. As tumors have been demonstrated to acquire mutations both sequentially
across decades and simultaneously in “punctuated” bursts, future studies may seek to exploit the
flexibility of Cas12a systems to generate sophisticated multi-step, multi-perturbation models of
tumor evolution.
At present, the tumor sequencing reports that patients receive are often barren of
actionable insights and rife with uncertainty. Through our efforts towards mapping a functional
cancer genome atlas, we have taken another step towards realizing the full potential of precision
oncology. It is our hope that all patients will someday derive meaningful benefit from tumor
sequencing studies, illuminating personalized avenues for patients to live longer and better.
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